Aalbers, AGJ, 1681
Aarsvold, JN, 569(ab), 1370(ab)
Aas, M, 580(ab)
Abdel-Dayem, HM, 71(ab), 339(ab), 345(ab), 346(ab), 550(ab), 1171(ab)
Abe, A, 864(ab), 873(ab)
Abe, M, 721(ab)
Abe, S, 764(ab), 1315(ab)
Abe, Y, 993(ab)
Abi-Dargham, A, 51(ab), 52(ab), 54(ab), 379(ab)
Abidov, A, 351(ab), 353(ab), 356(ab)
Abletshauser, C, 506(ab)
Aboagye, EO, 97(ab)
Aboul-Enein, F, 353(ab)
Aboul-Enein, FA, 354(ab), 357(ab)
Abouzied, M, 566(ab)
Abouzied, MM, 82(ab)
Abraham, EH, 1454(ab)
Abul Huda, FI, 1071(ab)
Aburano, T, 1005(ab), 1418(ab)
Accorsi, R, 207(ab), 916(ab)
Acevedo, JC, 1181(ab)
Achaibou, F, 1143(ab)
Achong, DM, 1330(ab)
Acoy, D, 108(ab)
Acton, PD, 218(ab), 434(ab), 1624
Adachi, I, 801(ab), 809(ab)
Adachi, Y, 545(ab)
Adam, LE, 207(ab)
Adam, L-E, 1398
Adams, KH, 360(ab), 363(ab), 1046(ab)
Adar, E, 480(ab)
Adbel Dayem, H, 460(ab)
Adelstein, SJ, 1117(ab), 1125(ab), 1126(ab)
Adler, LP, 929(ab)
Aerts, J, 280(ab)
Affleck, DJ, 330(ab), 1470(ab)
Afriyie, M, 1333(ab)
Afriyie, MO, 246, 1282(ab), 1380(ab)
Agarwal, G, 431(ab)
Agarwal, SK, 143(ab)
Agdeppa, ED, 604(ab)
Agerstein, C, 1076(ab)
Ageyeva, L, 249(ab), 250(ab), 252(ab), 1111(ab)
Agostini, D, 717(ab)
Ágoston, P, 66
Aguade-Bruix, S, 12(ab)
Ahlberg, A, 180(ab)
Ahmed, R, 181(ab)
Ahn, B, 735(ab)
Ahn, BC, 1334(ab)
Ahn, SH, 403(ab), 1010(ab), 1521(ab)
Ahonen, AK, 946(ab)
Aide, N, 1143(ab)
Aigbirhio, FI, 492(ab), 1448(ab)
Aizawa, Y, 531, 1476
Ak, I 203
Akabani, G, 1259(ab)
Akagi, H, 801(ab), 809(ab)
Akaizawa, T, 440(ab)
Akaki, S, 1308(ab), 1341(ab)
Akalin, E, 482(ab)
Akhtar, A, 882(ab)
Akhurst, T, 46, 148(ab), 209(ab), 315(ab), 369(ab), 837(ab), 1072
Akin, EA, 1175(ab)
Akino, H, 181
Akioka, K, 131, 443
Akita, S, 780
Akiyama, H, 742(ab)
Al Younis, IH, 1394(ab)
Alak, MC, 1281(ab), 1304(ab)
Alauddin, M, 148(ab)
Alauddin, MM, 92(ab), 320(ab), 503(ab), 1072, 1075(ab), 1112(ab)
Alavi, A, 72, 74(ab), 102(ab), 107(ab), 136(ab), 140(ab), 267(ab), 285(ab), 321(ab), 450(ab), 456(ab), 458(ab), 463(ab), 466(ab), 468(ab), 487(ab), 552(ab), 564(ab), 583(ab), 871, 1066(ab), 1152(ab), 1155(ab), 1194(ab), 1202(ab), 1214(ab), 1238(ab), 1320(ab), 1339(ab), 1348(ab), 1355(ab), 1374(ab), 1377(ab), 1398(ab), 1410(ab)
Alazraki, N, 352(ab), 1414
Alazraki, NP, 569(ab), 1258(ab)
Albelda, SM, 1348(ab)
Alberini, J, 102(ab), 410(ab), 487(ab)
Alberini, JL, 1348(ab)
Albers, P, 581(ab)
Albert, MS, 232(ab), 880(ab)
Alexander, M, 394(ab)
Alexoff, D, 158(ab), 197(ab), 219(ab), 961(ab), 972(ab), 1331, 1570
Alexoff, DL, 380(ab)
Alhamwi, A, 938(ab)
Ali, H, 1465(ab)
Ali, M, 381(ab)
Aliaga, A, 709(ab)
Aliev, G, 1044
Allan, E, 1286(ab)
Allen, BJ, 1277(ab)
Allen, J, 1208(ab)
Allen, MS, 239(ab)
Almeida, F, 1285(ab)
Almeida, O, 784(ab)
Almeida, OD, 777(ab)
Almeida-Filho, OC, 338(ab)
Almo, KM, 268(ab)
Alnafisi, N, 466(ab), 1066(ab), 1152(ab)
Alonso, C, 301(ab)
Alonso, O, 882
Alpert, NM, 470, 711(ab), 836(ab), 1053(ab)
Al-Qahtani, MH, 1461(ab)
Alsharif, A, 1182(ab)
Alston, KL, 330(ab)
Al-Tikriti, M, 598(ab)
Al-Tikriti, MS, 163(ab), 978(ab)
Altimari, SM, 136(ab)
Altmann, A, 1096(ab), 1139(ab)
Altuna, D, 235(ab)
Alvarado, M, 1447(ab)
Ambrose, JA, 339(ab), 346(ab)
Ambrosio, MR, 474(ab)
Ameil, F, 1136(ab)
Amen, DG, 1395(ab)
Amirav, I, 487
Ammannati, F, 725
Amsterdam, JD, 55(ab)
Anand, K, 1327(ab)
Anderson, C, 863
Anderson, CJ, 331(ab), 494(ab), 495(ab), 1121(ab)
Anderson, DL, 968
Anderson, J, 358(ab)
Ando, A, 732(ab), 755(ab)
Andrée, B, 138(ab), 139(ab), 292
Andreaco, M, 36(ab)
Ang, K, 1088(ab)
Angel, J, 12(ab)
Angeletti, CA, 411(ab)
Angerstein, C, 447(ab)
Annat, G, 1063
Ansari, SM, 50(ab)
Anselmino, M, 591(ab)
Anthony, C, 438(ab)
Anthony, L, 124(ab)
Antich, P, 216(ab)
Antoch, G, 106(ab), 209(ab), 893(ab), 1133(ab), 1236(ab), 1339
Antonescu, C, 1385(ab)
Aoi, T, 896(ab)
Aoyama, T, 779(ab)
Apostolidis, C, 418(ab)
Arahata, Y, 993(ab)
Arai, H, 821(ab)
Arano, Y, 1498(ab)
Archer, CN, 39(ab)
Arena, S, 207
Arena, V, 1180(ab)
Argarval, AK, 1345(ab)
Arisaka, Y, 39, 141(ab), 1215(ab), 1337(ab)
Arnold, R, 1269(ab)
Arslan, G, 482(ab)
Arslandemir, C, 277(ab), 1207(ab), 1220(ab)
Artal, R, 1222(ab)
Asada, T, 304
Asenbaum, S, 405(ab)
Ashie, T, 518(ab)
Ashino, H, 531
Atasever, T, 1299(ab)
Audenaert, K, 458, 1426
Audonnet, S, 566
Aurengo, A, 991(ab)
Auricchio, A, 434(ab)
Austin, G, 1624
Awasthi, V, 1513(ab)
Awk, OD, 1353(ab)
Axelrod, D, 71(ab), 1171(ab)
Axworthy, DB, 1083(ab)
Ayalew, A, 451, 566
Ayalon, A, 453(ab)
Aykac, M, 33(ab), 930(ab), 931(ab), 932(ab)
Ayvaz, G, 1299(ab)
Azhdarinia, A, 435(ab), 1102(ab), 1471(ab), 1475(ab), 1478(ab)
Azinovic, I, 1256(ab)
Azure, MT, 445(ab)

Babaria, C, 587(ab)
Babich, J, 517(ab)
Babich, JW, 470
Babu, A, 726(ab)
Bacharach, SL, 365(ab), 565(ab), 1542
Bachem, MG, 257(ab)
Badawi, RD, 206(ab)
Bader, P, 131(ab)
Bading, JR, 92(ab), 437(ab), 1075(ab), 1097(ab)
Bae, SA, 599(ab), 1440(ab)
Bae, Y, 1166(ab)
Baehre, M, 1136(ab), 1472(ab)
Baek, HJ, 1217(ab)
Baghaei, H, 33(ab), 930(ab), 931(ab), 932(ab)
Bagnara, MC, 811
Bai, C, 375(ab)
Bai, J, 831(ab), 1079(ab), 1081(ab)
Baidoo, KE, 336(ab), 502(ab)
Baig, S, 1244(ab)
Bailey, J, 1286(ab), 1482(ab)
Bailey, K, 1502(ab)
Baird, WH, 897(ab)
Bajc, M, 640
Bajciova, V, 1071(ab)
Bajzik, G, 66
Bakale, G, 584(ab)
Baker, CSR, 1031
Baker, JR, 490(ab)
Bakker, WH, 120(ab), 121(ab), 123(ab)
Bakthula, R, 1225(ab)
Bal, CS, 143(ab), 287(ab), 454(ab), 1011(ab), 1327(ab)
Bal, G, 918(ab)
Bal, H, 820(ab), 918(ab)
Balanov, I, 487
Balatoni, J, 148(ab), 249(ab), 250(ab), 252(ab), 329(ab), 1072, 1111(ab)
Balbuena, RL, 1281(ab)
Balcer, LJ, 67(ab)
Baldessarini, R, 598(ab)
Baldwin, RM, 163(ab), 384(ab), 392(ab), 395(ab), 598(ab), 978(ab)
Ballani, NS, 1071(ab)
Ballinger, JR, 318, 1503(ab)
Balogh, L, 490(ab)
Balon, HR, 18(ab), 110(ab), 483(ab), 744(ab), 795(ab), 856
Balter, HS, 1126(le)
Baltes, N, 1191(ab)
Balteskard, L, 580(ab)
Balzarini, J, 1060(ab)
Bander, NH, 576(ab), 577(ab), 1190(ab)
Bandopadhyaya, GP, 479(ab)
Banerjee, S, 1129(ab), 1473(ab), 1474(ab)
Bang, SY, 364(ab)
Bansal, S, 1467(ab)
Bao, J, 38(ab), 927(ab)
Baquedano, P, 1384(ab)
Barai, S, 479(ab)
Barajas, MA, 155(ab)
Baranczuk, RJ, 1093(ab)
Baranowska-Kortylewicz, J, 957
Baranowski, J, 181(ab)
Baravelli, R, 474(ab)
Barbash, IM, 712(ab)
Barber, RW, 318
Barber, W, 944(ab)
Barber, WC, 215(ab)
Barbet, J, 579(ab)
Barentsz, JO, 1197(ab)
Bares, R, 131(ab), 391(ab), 401(ab), 635, 1056(ab), 1293(ab), 1366(ab)
Baresic, T, 344(ab)
Barkai, G, 1047(ab)
Barker, PB, 965(ab)
Barkigia, K, 1497(ab)
Bar-Meir, E, 484
Barnden, L, 908(ab)
Barnden, LR, 714(ab), 1259
Barnes, A, 986(ab)
Baron, J, 712(ab)
Baron, JC, 1448(ab)
Barone, R, 325(ab), 442(ab), 1267(ab), 1271(ab)
Barrett, HH, 175(ab), 933, 1104(ab), 1119(ab)
Barrio, JR, 1(ab), 7(ab), 89(ab), 155(ab), 157(ab), 422(ab), 604(ab)
Barron, BJ, 562(ab), 773(ab)
Barrow, S, 517(ab)
Barrow, SA, 854(ab), 952(ab)
Bar-Sever, Z, 129(ab)
Bar-Shalom, R, 114(ab), 117(ab), 290(ab), 922(ab), 1129, 1232(ab), 1295
Bartenstein, P, 389(ab), 543(ab), 970(ab), 992(ab), 1058(ab), 1148(ab), 1297(ab)
Barth, A, 309(ab), 313(ab)
Barth, R, 1094(ab)
Barthel, H, 97(ab), 1044(ab)
Barthel, P, 514(ab)
Bartholomeusz, FD, 968
Bartis, H, 1426(ab)
Bartolomei, M, 811
Basaglia, E, 76(ab)
Basaran, N, 203
Bassett, JD, 1280(ab)
Bateman, T, 815(ab), 912(ab)
Bateman, TM, 273, 811(ab)
Batista, NP, 338(ab)
Battelli, LA, 413
Baud, M, 285
Baudino, B, 1180(ab)
Bauer, M, 1029(ab)
Bauer, MJ, 1030(ab)

Bauhofer, A. 1296(ab)
Bauknecht, T. 1192(ab)
Baulieu, F. 221(ab), 1336(ab), 1388(ab)
Baulieu, JL. 221(ab), 1336(ab), 1388(ab)
Baumert, B. 118(ab)
Bax, JJ. 767, 795, 1634
Bayraktar, A. 62(ab)
Beason-Held, L. 1039(ab)
Beattie, B. 315(ab), 555(ab), 1122(ab)
Beattie, BJ. 369(ab), 837(ab)
Beauchemin, D. 1389(ab)
Becherer, A. 405(ab)
Beck Peccoz, P. 1326(ab)
Beck, J. 59(ab)
Becker, DV. 856
Becker, GA. 30(ab), 134(ab)
Becker, JA. 880(ab)
Becker, K. 242(ab), 243(ab), 279(ab), 1251(ab)
Becker, KF. 1086(ab)
Becker, W. 291(ab), 414(ab), 447(ab), 1076(ab)
Beckers, C. 138(ab), 139(ab)
Bednarczyk, E. 566(ab)
Beekman, FJ. 192(ab)
Begent, RH. 1244(ab)
Behe, M. 313(ab), 332(ab), 447(ab), 913(ab), 1076(ab)
Béhé, M. 126(ab), 406(ab), 467(ab), 1191(ab), 1269(ab)
Béhé, MP. 289(ab), 291(ab), 414(ab), 1189(ab)
Behr, TM. 62(ab), 65(ab), 126(ab), 289(ab), 291(ab), 313(ab), 332(ab), 406(ab), 414(ab), 447(ab), 467(ab), 913(ab), 918, 1076(ab), 1189(ab), 1191(ab), 1269(ab), 1296(ab), 1351(ab), 1354(ab)
Belakhlef, A. 1324, 1431(ab)
Belhocine, TZ. 426(ab)
Bellemann, ME. 439(le)
Beller, GA. 664
Belli, F. 745
Bello', M. 1180(ab)
Bellomini, MG. 591(ab)
Ben Ami, D. 480(ab)
Benada, A. 588(ab), 1408(ab)
Benada, AW. 142(ab)
Bénard, F. 262(ab), 704(ab), 709(ab), 833(ab), 1465(ab)
Ben-Arush, M. 1295
Benatar, NA. 29(ab)
Bendaly, EA. 401(ab)
Bender, D. 940, 1101(ab)
Bender, H. 1192(ab)
Benderbous, S. 221(ab)
Bendriem, B. 36(ab), 964(ab), 1268
Beneke, F. 1313(ab)
Benelhadj, S. 347(ab), 802(ab)
Bengel, F. 340(ab), 506(ab), 515(ab), 516(ab), 761(ab)
Bengel, FM. 514(ab)
Ben-Haim, M. 453(ab)
Ben-Haim, S. 585(ab), 778(ab), 791(ab), 1232(ab)
Benini, E. 499(ab)
Benjamin, C. 15(ab), 180(ab)
Benkelfat, C. 947(ab)
Bennett, PR. 215(ab)
Benoist, E. 1496(ab)
Bensinger, W. 1383
Bentourkia, M. 704(ab), 709(ab)
Bentzen, L. 940, 1101(ab)
Berawan, B. 19(ab)
Berenji, B. 92(ab)
Beresten, L. 252(ab)
Beresten, T. 249(ab), 250(ab)
Berezov, A. 487(ab)
Berg, G. 828
Bergamini, C. 904(ab)
Bergman, J. 1674
Bergmann, SR. 172(ab), 1707
Bergonni, S. 79, 745
Bergossi, L. 76(ab)
Bergsneider, M. 222(ab), 224(ab), 891(ab), 1000(ab), 1002(ab)
Bergström, KA. 946(ab)
Bergström, M. 889(ab), 1688
Berman, DS. 11(ab), 351(ab), 353(ab), 354(ab), 356(ab), 357(ab), 750(ab)
Bermudes, D. 251(ab)
Bernal Trujillo, P. 1429(ab)
Bernal, PT. 306(ab)
Bernante, P. 293(ab)
Bernard, B. 167(ab)
Bernard, BF. 1650
Bernard, HF. 442(ab), 444(ab), 446(ab)
Bernardo-Filho, M. 89
Bernarducci, MP. 1413(ab)
Bernaski, EJ. 339(ab)
Bernd, L. 510, 1153(ab)
Berndorff, D. 557(ab)
Berner, U. 1015(ab), 1295(ab)
Bernik, S. 71(ab), 1171(ab)
Bernstein, T. 400(ab)
Berridge, MS. 1044
Bertalanffy, H. 406(ab)
Berthier, V. 1063
Berthold, T. 890(ab)
Bertrand, A. 451, 566
Besch, OF. 298(ab)
Besnard, JC. 221(ab)
Besret, L. 921(ab)
Besseghir, N. 1179(ab)
Bessent, R. 1178(ab)
Bestetti, A. 355(ab)
Beu, M. 393(ab)
Bevilacqua, G. 500(ab)
Beyer, T. 38(ab), 40(ab), 205(ab), 209(ab), 893(ab), 937(ab), 1133(ab), 1236(ab)
Beylin, D. 929(ab)
Bharadwaj, P. 1415(ab)
Bhargava, KK. 246, 1333(ab), 1380(ab)
Bhargava, P. 583(ab), 1377(ab), 1386(ab)
Bhatia, RS. 1591
Bhattacharya, A. 1344(ab)
Bhogal, N. 828
Bianchi, F. 591(ab)
Bickel, EM. 445(ab)
Bieg, C. 1463(ab)
Biegon, A. 1447(ab)
Bielack, S. 128(ab), 1012
Bier, D. 366
Biermann, M. 1292(ab)
Biersack, HJ. 161(ab), 465(ab), 581(ab), 911(ab), 1150(ab), 1192(ab)
Biffi, M. 760(ab)
Bigio, E. 988(ab)
Bigner, DD. 1259(ab)
Bigott, H. 494(ab), 871(ab)
Bijster, M. 444(ab)
Bilgen, D. 33(ab)
Binns, D. 492
Birkenfeld, B. 306(ab)
Bischof Delaloye, A. 505(ab), 1179(ab), 1385(ab)
Bischoff, H. 409(ab)
Bishop, HA. 413
Bisi, G. 1180(ab)
Bissel, S. 976(ab)
Bitterman, H. 585(ab)
Bitzén, U. 640
Bitzer, M. 131(ab)
Bizais, Y. 586(ab), 1411(ab)
Bjelke, D. 1431(ab)
Blagosklonov, O. 285
Blake, GM. 338
Blanc, A. 374
Blankenberg, F. 2(ab), 22(ab), 259(ab), 396(ab), 702(ab)
Blankenberg, FG. 258(ab), 500(ab), 1359, 1392(ab)
Blasberg, R. 148(ab), 249(ab), 250(ab), 251(ab), 252(ab), 329(ab), 1111(ab)
Blasberg, RG. 1072
Blass, JP. 1052
Bläuenstein, P. 374
Blend, MJ. 1494(ab)
Blevis, I. 1168(ab)
Blevis, IM. 945(ab)
Blijham, GH. 1150
Block, S. 187(ab)
Blockx, P. 805(ab)
Blodgett, T. 209(ab)
Blodgett, TM. 1249(ab), 1250(ab)
Bloomfield, P. 840(ab)
Bloomfield, PM. 1031
Bluemke, DA. 1131(ab)
Blum, M. 1294(ab)
Blum, S. 724(ab)
Blum, T. 491(ab)
Blumenthal, R. 310(ab), 739(ab)
Boado, RJ. 948
Boan, JF. 155(ab)
Boaz, M. 1003(ab)
Bocher, M. 290(ab), 572(ab), 877(ab), 1032(ab)
Bockisch, A. 106(ab), 162(ab), 893(ab), 1133(ab), 1236(ab), 1339
Bodenstein, C. 436(ab), 1489(ab)
Boecker, H. 992(ab)
Boellaard, R. 362(ab), 892(ab), 926(ab)
Boening, G. 374(ab)
Boerman, O. 504(ab), 1128(le)
Boerman, OC. 558(ab), 918, 1085(ab), 1351(ab), 1354(ab), 1357(ab)
Boerner, AR. 1252(ab), 1488(ab)
Boers, M. 1304
Boersma, E. 795
Bofilias, I. 1298(ab)
Bohdiewicz, PJ. 1247(ab)
Bohnen, NI. 227(ab), 228(ab)
Bolch, WE. 97
Bolle, S. 426(ab)
Bolognese, L. 8
Bolwig, TG. 1046(ab)
Bolzati, C. 499(ab)
Bom, H. 735(ab)
Bom, HS. 756(ab), 1334(ab), 1367(ab), 1427(ab), 1437(ab)
Bomanji, JB. 1415(ab)
Bommer, M. 1059(ab)
Bonab, AA. 836(ab), 854(ab), 948(ab), 949(ab), 952(ab)
Bonfils, E. 550(ab)
Boni, G. 411(ab), 591(ab), 1182(ab)
Bonne, O. 1047(ab)
Bonnefoi, F. 227
Bonniaud, G. 928(ab)
Bonte, FJ. 988(ab)
Booker, JA. 740(ab)
Boon, P. 544(ab), 733
Boonyaprapa, S. 306(ab)
Bootsma, GP. 1212(ab)
Bora, NS. 1346(ab)
Borch, KW. 580(ab)
Borchardt, P. 555(ab)
Borgers, M. 556
Borges-Neto, S. 352(ab)
Börjesson, PK. 575(ab)
Bormans, G. 1517(ab)
Borner, AR. 1459(ab)
Bornmann, W. 1072
Borras, X. 799(ab)
Boschen, F. 911(ab)
Boschi, A. 166(ab), 499(ab)
Bossuyt, A. 87(ab), 1098(ab), 1145(ab), 1201, 1647
Bostaph, A. 408(ab)
Both, S. 1148(ab)
Botti, C. 745
Bottlaender, M. 215, 951(ab), 1425(ab), 1434(ab)
Boubaker, A. 1385(ab)
Boucek, J. 415(ab)
Bouilleret, V. 991
Bourguet, P. 889
Bourke, BN. 26(ab)
Boussion, N. 1419
Bouvard, G. 717(ab)
Bouvier, C. 122(ab)
Bowen, RL. 1244(ab)
Bowers, GD. 149(ab)
Bowers, SP. 590(ab)
Bowsher, J. 378(ab)
Bowsher, JE. 39(ab), 190(ab), 914(ab)
Boyle, MJ. 1185(ab)
Boz, A. 112(ab)
Bozkurt, A. 395(ab)
Braasch, DA. 948
Bradley, EL. 942(ab)
Bradley, LA. 1024(ab)
Bradley, Y. 408(ab), 1210(ab), 1405(ab)
Bradshaw, AW. 590(ab)
Bradshaw, PT. 1188(ab)
Bradt, BM. 1256(ab)
Brady, F. 97(ab)
Brandau, W. 162(ab), 1133(ab)
Brandt, S. 1290(ab)
Branzi, A. 760(ab)
Brasic, J. 394(ab)
Brasse, D. 38(ab), 40(ab), 205(ab), 937(ab)
Braumuller, H. 439(ab)
Braus, D. 1055(ab)
Brechbiel, M. 418(ab)
Brechbiel, MW. 554(ab), 560(ab), 1090(ab)
Brecheisen, MA. 1338(ab)
Breeman, WA. 167(ab), 444(ab), 446(ab)
Breeman, WAP. 1650, 1681
Breitz, H. 419(ab), 1264(ab)
Breitz, HB. 906(ab)
Brem, RF. 909
Bremner, JD. 53(ab)
Brenner, A. 310(ab)
Brenner, W. 135(ab), 298(ab), 835, 1036(ab), 1290(ab), 1361(ab), 1365(ab), 1585
Briat, A. 1511(ab)
Bridwell, RS. 1209(ab)
Brill, DR. 856
Brittinger, G. 414(ab)
Britton, KE. 301(ab), 1125(le)
Britz-Cunningham, S. 1144, 1213(ab)
Britz-Cunningham, SH. 1309(ab)
Brix, G. 439(le)
Brockmann, J. 165(ab)
Broft, A. 387(ab), 1054(ab)
Brooks, G. 1242(ab)
Brouwer, MH. 1212(ab)
Brouwers, AH. 1085(ab)
Brown, B. 1039(ab)
Brown, LM. 26(ab)
Brown, M. 47(ab), 1234(ab)
Brown, PH. 1603
Brown, PR. 144(ab)
Brownell, A. 397(ab), 859(ab)
Brownell, AL. 220(ab), 609(ab)
Bruce, A. 517(ab)
Bruckbauer, T. 36(ab)
Bruehlmeier, M. 374
Bruland, OB. 580(ab)
Bruno, O. 1281(ab)
Brunswick, DJ. 55(ab)
Bruskin, A. 1391
Bruyant, PP. 845(ab), 909(ab), 910(ab), 915(ab), 1343
Bruyndonckx, P. 212(ab)
Bryant, JL. 435(ab), 1088(ab), 1102(ab), 1471(ab), 1475(ab), 1478(ab)
Buchberger, R. 20(ab)
Buchert, R. 842(ab)

Buchheimer, N. 925(ab)
Buchholz, HG. 389(ab), 543(ab), 970(ab), 1055(ab), 1058(ab), 1148(ab)
Buchmann, I. 133(ab), 1263(ab)
Buchsbaum, D. 1082(ab)
Buck, A. 920(ab), 1235(ab), 1469, 1505(ab)
Buck, AK. 257(ab), 277(ab), 462(ab), 1059(ab), 1170(ab), 1207(ab), 1220(ab)
Budinger, TF. 1160(ab)
Budinsky, AC. 1254
Buechel, C. 992(ab)
Buehler, TC. 887(ab)
Buell, U. 187(ab), 1062(ab)
Bugaj, JE. 445(ab), 1650
Bugaj, JL. 123(ab)
Bui, C. 182(ab), 551(ab)
Buijs, F. 926(ab)
Buijs, WC. 575(ab)
Bülow, H. 28(ab), 340(ab), 761(ab)
Bumm, R. 1196(ab)
Bungcayao, K. 754(ab)
Bunker, SR. 1160(ab)
Bunko, H. 589, 1084
Buonamici, P. 8
Burbar, Z. 927(ab)
Burger, C. 510, 850(ab), 887(ab), 890(ab), 920(ab), 1469
Burker, M. 1512(ab)
Burnette, J. 352(ab)
Burns, AS. 1373(ab)
Burrell, SC. 264(ab)
Burrows, RC. 963(ab)
Burt, R. 1033(ab)
Buscema, M. 207
Buscombe, JR. 122(ab), 125(ab), 272(ab), 1149(ab), 1244(ab), 1268(ab), 1270(ab)
Bushnell, DL. 1223(ab)
Bustos, SR. 61
Butch, ER. 606(ab)
Butchko, GJ. 803(ab)
Butler, NJ. 1117(ab), 1125(ab)
Buursma, AR. 1107(ab)
Buvat, I. 45(ab), 834(ab), 835(ab), 849(ab), 1008(ab)
Buxton-Thomas, MS. 370(ab)
Byars, L. 927(ab)
Byun, SS. 1115(ab), 1116(ab), 1460(ab)

Cabaret, V. 1173(ab)
Cabrejas, RC. 301(ab)
Cadorette, J. 704(ab), 709(ab)
Cadwallader, KA. 652
Cafiero, F. 811
Cai, S. 46, 148(ab), 1072, 1122(ab)
Cai, W. 869(ab)
Cakir, N. 1299(ab)
Calame-Christe, M. 1699
Caldwell, JH. 513(ab), 858(ab)
Califano, J. 1255(ab)
Camacho, V. 799(ab), 1417(ab), 1419(ab)
Cameron, R. 412(ab), 413(ab), 1254(ab)
Camici, PG. 806, 1031
Camilleri, I. 1178(ab)
Camiré, M. 262(ab)
Camp, VM. 149(ab)
Campone, M. 428(ab)
Canales, K. 220(ab), 397(ab), 609(ab), 859(ab)
Candell-Riera, J. 12(ab)
Canellos, GP. 109(ab)
Canning, D. 1383(ab)
Canter, RJ. 74(ab)
Cantwell, MN. 1090
Cao, TM. 1255(ab)
Cao, Z. 941(ab)
Capizzi, R. 1255(ab)
Caplin, ME. 122(ab), 125(ab), 1149(ab), 1268(ab), 1270(ab)
Capuano, SV. 976(ab)
Carasig, D. 1025(ab)
Caravaglia, GM. 1169(ab)
Carcoforo, P. 76(ab)
Cardi, C. 819(ab)
Cardillo, T. 1484(ab)
Cardot, J-C. 285
Carey, AM. 164(ab)
Carey, MF. 247(ab)
Carlier, P. 442(ab)
Carlson, KA. 316(ab), 1458(ab), 1491(ab)
Carmi, R. 903(ab)
Carney, J. 40(ab), 205(ab), 937(ab)
Carney, JP. 38(ab)
Caroline, DF. 177(ab)
Carone, M. 1522(ab)
Carp, L. 805(ab)
Carpenter, M. 1082(ab)
Carpentier, P. 1173(ab)
Carr, RE. 316(ab)
Carrasquillo, JA. 365(ab), 565(ab), 1504(ab), 1525(ab)
Carrington, BM. 1286(ab)
Carrio, I. 799(ab), 1417(ab), 1419(ab)
Carson, JA. 565(ab)
Carson, JM. 365(ab)
Carson, RE. 198(ab), 843(ab), 960(ab), 969(ab)
Carter, EA. 1074(ab), 1335(ab), 1512(ab)
Carter, P. 380(ab)
Carter, W. 1258(ab)
Casadevall, A. 299(ab)
Casara, D. 293(ab), 1243(ab), 1279(ab)
Cascio, A. 1326(ab)
Case, J. 815(ab), 912(ab)
Case, JA. 811(ab)
Casey, KL. 860(ab)
Casey, M. 36(ab)
Casey, ME. 926(ab), 927(ab), 1398
Casperson, PR. 750(ab)
Cassady, D. 510(ab)
Cassem, EH. 1053(ab)
Castagna, M. 1182(ab)
Castaigne, A. 536
Castellani, M. 1326(ab)
Castellanos, FX. 1630
Castell-Conesa, J. 12(ab)
Castle, V. 132(ab), 1387(ab)
Castronovo, F. 1414
Catalano, M. 998(ab)
Cataldo, D. 280(ab)
Caveliers, V. 1201, 1647
Cavusoglu, Y. 793(ab), 812(ab)
Ceballos-Baumann, AO. 992(ab)
Ceravolo, R. 236(ab)
Cerfolio, RJ. 1216(ab)
Cerisano, G. 8
Cerqueira, M. 352(ab)
Cerrina, J. 410(ab)
Ceyssens, S. 255(ab)
Chacho, TK. 136(ab)
Chacko, T. 564(ab)
Chacko, TK. 140(ab), 456(ab), 458(ab), 1202(ab), 1214(ab), 1355(ab), 1374(ab), 1398(ab)
Chaikov, A. 945(ab)
Chakraborty, S. 1129(ab)
Chalam, GN. 813(ab)
Chalon, S. 221(ab), 596(ab)
Chaly, T. 201(ab), 202(ab), 986(ab), 1324
Champagne, J. 108(ab)
Chan, DC. 296(ab)
Chan, KM. 1190(ab)
Chan, MS. 304(ab)
Chan, VC. 1072(ab), 1174(ab)
Chander, S. 884(ab)
Chandrashekar, N. 287(ab), 1011(ab), 1327(ab)
Chang, CP. 263(ab), 461(ab)
Chang, CW. 160(ab), 459(ab), 955(ab), 1108(ab), 1193(ab)
Chang, EY. 196(ab)
Chang, H. 429(ab)
Chang, HD. 994(ab)
Chang, HT. 823(ab), 1161(ab)
Chang, JS. 1006, 1193(ab)
Chang, K. 559(ab), 579(ab), 1484(ab)
Chang, L. 1025(ab)
Chang, MC. 969(ab)
Chang, PF. 160(ab), 1108(ab)
Chang, T. 99(ab)
Chang, W. 1375(ab)
Chang, Y. 99(ab)
Channing, MA. 969(ab)
Chao, K. 567(ab)
Chap, L. 1253(ab)
Chapman, JD. 837, 1122(ab)
Chapman, WC. 83(ab)
Chappell, B. 861(ab)
Charlop, A. 500
Charlop, AW. 1100(ab)
Charnsangavej, C. 150(ab)
Charon, Y. 924(ab)
Charron, M. 207(ab), 916(ab), 1383(ab), 1386(ab), 1389(ab)
Chatal, JF. 428(ab), 579(ab), 1496(ab)
Chatterjee, R. 956(ab)
Chatterton, BE. 968
Chatziioannou, A. 89(ab)
Chatziioannou, AF. 212(ab)
Chaudhary, KS. 519
Chaudhuri, TK. 750(ab)
Cheema, A. 1289(ab)
Chefer, SI. 607(ab), 1433(ab), 1443(ab)
Chella, A. 411(ab)
Chen, C-J. 153
Chen, CY. 994(ab)
Chen, H. 777(ab), 784(ab)
Chen, J. 88(ab), 519(ab)
Chen, JC. 955(ab)
Chen, K. 359(ab), 529(ab)
Chen, M. 190(ab)
Chen, M-C. 153
Chen, MK. 336(ab)
Chen, P. 1254(ab), 1493(ab)
Chen, R-S. 153
Chen, S. 841(ab)
Chen, SL. 173(ab), 306(ab), 578(ab)
Chen, T. 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Chen, W. 225(ab), 1265(ab)
Chen, Y. 1122(ab), 1177(ab)
Chen, YI. 220(ab), 397(ab)
Cheon, GJ. 403(ab), 1010(ab), 1217(ab)
Cheong, SS. 737(ab)
Cherng, C-C. 56
Cherry, S. 973(ab)
Chessa, F. 1156(ab), 1159(ab), 1162(ab)
Cheze Le Rest, C. 1411(ab)
Chi, DY. 1460(ab)
Chi, Z. 841(ab)
Chiacchio, S. 1164(ab)
Chigurupati, S. 171(ab)
Chilvers, ER. 652, 1503(ab)
Chin, BB. 46(ab), 210(ab), 540, 785(ab), 878(ab)
Chin, FT. 159(ab)
Chinol, M. 1485(ab)
Chiron, C. 715
Chisin, R. 290(ab), 572(ab), 877(ab), 1008(ab), 1518(ab)
Chisin, RG. 1032(ab), 1047(ab)
Chiu, PF. 862(ab)
Cho, I. 729(ab)
Cho, J. 1094(ab)
Cho, SC. 302(ab)
Cho, SS. 838(ab)
Cho, YS. 403(ab), 1010(ab), 1521(ab)
Chodosh, J. 253
Choe, BY. 867(ab)
Choe, JG. 1492(ab)
Choe, YS. 101(ab), 240(ab), 919(ab), 1115(ab), 1116(ab), 1219(ab), 1369(ab), 1441(ab), 1460(ab)
Choi, BW. 1441(ab)
Choi, CH. 1010(ab)
Choi, CW. 403(ab), 1087(ab), 1105(ab), 1114(ab), 1144(ab), 1217(ab), 1353(ab), 1356(ab), 1424(ab), 1521(ab)
Choi, E. 840(ab), 855(ab), 933(ab)
Choi, JH. 1115(ab)
Choi, JY. 736(ab)
Choi, MY. 1018(ab)
Choi, S. 300(ab)
Choi, SC. 1144(ab)
Choi, SR. 218(ab), 600(ab), 1530(ab)
Choi, TH. 1353(ab)
Choi, Y. 101(ab), 240(ab), 919(ab), 1115(ab), 1116(ab), 1219(ab), 1369(ab), 1441(ab), 1460(ab)
Chong, G. 861(ab)
Chou, KL. 274(ab), 459(ab), 955(ab), 1193(ab)
Chou, Y-HW. 153
Chou, YT. 955(ab)
Choudhry, VP. 287(ab)
Choudhury, S. 479(ab)
Choudhury, SK. 143(ab)
Choukèr, M. 1045(ab)
Chouraqui, P. 712(ab)
Christian, B. 400(ab), 541(ab), 1522(ab)
Christian, BT. 203(ab), 382(ab)
Christian, C. 44(ab)
Christian, P. 1410
Christian, PE. 204(ab), 1545
Christodoulidou, J. 1163(ab), 1167(ab)
Chroustova, D. 110(ab), 483(ab)
Chu, KW. 1403(ab)
Chu, LS. 263(ab), 274(ab), 733(ab)
Chu, YK. 263(ab), 274(ab), 459(ab), 1350(ab)
Chugani, DC. 825(ab)
Chugani, HT. 825(ab)
Chun, K. 729(ab)
Chun, KJ. 1087(ab), 1105(ab), 1114(ab), 1144(ab), 1353(ab), 1356(ab), 1424(ab), 1521(ab)
Chun, KS. 1092(ab), 1521(ab)
Chun, Y. 3(ab), 508(ab), 509(ab)
Chung, CK. 542(ab), 982(ab), 1167
Chung, D. 305(ab)
Chung, J. 430(ab), 971(ab), 1022(ab), 1042(ab), 1095(ab), 1371(ab)
Chung, JK. 153(ab), 238(ab), 302(ab), 343(ab), 364(ab), 484(ab), 511(ab), 542(ab), 546(ab), 736(ab), 759(ab), 838(ab), 980(ab), 982(ab), 1018(ab), 1021(ab), 1141(ab), 1142(ab), 1476(ab), 1479(ab), 1527(ab)
Chung, J-K. 1167, 1188, 1432
Chung, JW. 153(ab)
Chung, SK. 827(ab), 867(ab), 1184(ab)
Chung, YA. 827(ab), 867(ab), 1184(ab)
Chyan, MK. 488(ab), 1487(ab)
Ciernik, IF. 118(ab)
Cinca, J. 799(ab)
Cinotti, L. 1063, 1419
Cirignano, L. 215(ab)
Cittanti, C. 166(ab), 344(ab)
Civelek, AC. 739(ab)
Civelek, C. 909
Clackdoyle, R. 918(ab)
Claessens, RAMJ. 330
Claringbold, PG. 415(ab)
Clark, JC. 212(ab), 1448(ab)
Clark, P. 210(ab)
Clarke, E. 1181
Clarke, M. 11N(6)
Clarke, SEM. 856
Classe, J. 73(ab)

Clausen, M, 842(ab)
Clauss, R, 1488(ab)
Claussen, CD, 1366(ab)
Cleij, MC, 1448(ab)
Cleji, MC, 97(ab)
Clements, JE, 965(ab)
Cline, HE, 369(ab), 837(ab)
Clough, D, 1242(ab)
Coaguila, C, 347(ab)
Cobben, DC, 278(ab)
Cochoff, S, 915(ab)
Cochoff, SM, 160
Coenan, H, 600(ab)
Coenen, HH, 366, 402(ab), 491(ab), 1459(ab)
Coffman, KT, 1481(ab)
Cohade, C, 10(ab), 48(ab), 49(ab), 78(ab), 113(ab), 116(ab), 427(ab), 548(ab), 885(ab), 1137, 1228(ab), 1237(ab), 1239(ab), 1241(ab), 1242(ab)
Cohen, I, 351(ab), 353(ab), 354(ab), 356(ab)
Cohen, IJ, 129(ab)
Cohen, O, 1321(ab)
Colamussi, P, 166(ab), 344(ab)
Colcher, D, 957
Coleman, M, 284(ab), 417(ab), 1018, 1257(ab)
Coleman, RE, 92, 1259(ab)
Colin, P, 347(ab), 765(ab), 810(ab)
Coll, C, 17(ab)
Collier, BD, 346
Collier, TL, 1707
Collignon, MA, 588(ab), 1408(ab)
Collingridge, DR, 97(ab)
Collins, AM, 754(ab)
Collins, DA, 1091(ab), 1168(ab)
Collins, JM, 93(ab), 94(ab), 1455(ab)
Colnot, DR, 575(ab)
Colombet-Lamau, C, 105(ab), 1143(ab)
Coman, IL, 881(ab), 901(ab)
Comerci, J, 1249(ab), 1250(ab)
Compton, J, 1048(ab)
Comtat, C, 1268, 1715
Cone, L, 177(ab), 589(ab)
Connett, JM, 1127(ab)
Connolly, LP, 1310
Connolly, SA, 1310
Conrad, B, 992(ab)
Conrad, GR, 561(ab), 563(ab)
Conrath, P, 374
Constantinescu, A, 216(ab)
Constantinou, M, 496(ab)
Contag, CH, 1392(ab)
Conti, M, 36(ab)
Conti, P, 148(ab)
Conti, PS, 92(ab), 267, 320(ab), 366(ab), 437(ab), 503(ab), 1072, 1075(ab), 1097(ab), 1112(ab)
Contoreggi, C, 1433(ab)
Cook, AC, 490(ab)
Cook, EF, 754(ab)
Cook, G, 1272(ab)
Cooper, J, 1289(ab)
Cooper, W, 235(ab)
Coover, L, 1169(ab)
Coover, LR, 575(le)
Corbett, JR, 182(ab), 273, 348(ab), 512(ab)
Corbitt, BD, 1024(ab)
Corcione, S, 76(ab)
Corey, DR, 948
Cornalba, G, 355(ab)
Cornel, JH, 795
Coronado, M, 566(ab)
Corone, C, 410(ab)
Correia, DJA, 470
Correte, L, 550(ab)
Corstens, F, 504(ab), 1128(le), 1351(ab)
Corstens, FH, 80(ab), 559(ab), 1085(ab), 1197(ab), 1212(ab), 1354(ab), 1357(ab)
Corstens, FHM, 15N(7), 918
Cortelazzi, D, 1326(ab)
Cosgrove, GR, 1053(ab)
Coss, R, 1128(ab)
Costa, DC, 1415(ab)
Cottoni, F, 1156(ab)
Cottu, P, 1162(ab)
Couch, W, 561(ab), 563(ab)
Couet, C, 1336(ab)
Coulon, C, 951(ab), 1227, 1425(ab)
Coutre, SE, 1255(ab)
Coutu, M, 704(ab)
Craig, W, 944(ab)
Crane, P, 327(ab)
Crazzolara, A, 610
Cremerius, U, 1062(ab)
Crémieux, A-C, 239
Cribier, A, 806(ab), 807(ab)
Cronin, M, 124(ab)
Cross, DJ, 860(ab), 872(ab), 989(ab)
Crotaz, GR, 1503(ab)
Croteau, E, 704(ab), 709(ab)
Crouzel, C, 1227
Crowe, EA, 328(ab), 1110
Cruz, J, 1346(ab)
Cuchiara, A, 871
Cullom, SJ, 273, 811(ab), 815(ab), 912(ab)
Culver-Schultz, C, 1274(ab)
Curet, O, 1434(ab)
Curtet, CM, 73(ab)
Cuthbertson, A, 392
Cutler, B, 387(ab)
Cutler, CS, 1083(ab), 1502(ab)
Cwikla, JB, 272(ab), 1149(ab)
Czech, NJ, 298(ab), 1036(ab), 1361(ab), 1365(ab)
Czerniecki, BJ, 74(ab)
Czernin, J, 36(ab), 188(ab), 225(ab), 253, 269(ab), 270(ab), 282(ab), 286(ab), 325, 412(ab), 413(ab), 422(ab), 752, 1029(ab), 1030(ab), 1234(ab), 1253(ab)

D'Agnolo, A, 1031(ab), 1457
Da Silva, AJ, 375(ab), 819(ab)
Da Silvia, AJ, 43(ab)
Dabasi, G, 66
Dacher, J-N, 27
Dadachova, E, 299(ab), 433(ab)
Dadparvar, S, 587(ab)
Dae, M, 551
Dae, MW, 174(ab)
Daenen, F, 833(ab)
Daftary, A, 237(ab)
Daghighian, F, 9(ab)
D'Agnolo, A, 111(ab), 268(ab), 296(ab), 407(ab), 1222(ab), 1376(ab)
Daher, E, 421
Dahlberg, ST, 6(ab), 27(ab)
Dahlbom, M, 21(ab), 47(ab), 188(ab), 422(ab), 425(ab), 781(ab), 870(ab), 1234(ab)
Daigle, J, 89(ab)
Dakhel, M, 71(ab), 339(ab), 345(ab), 346(ab), 460(ab), 550(ab), 1171(ab)
Daldrup-Link, HE, 127(ab)
Dam, HQ, 1311(ab), 1318(ab)
Dang, D, 738(ab)
Daniel, H, 85(ab)
Dann, EJ, 1295
Dannals, R, 394(ab)
Dannals, RF, 8(ab), 144(ab), 390(ab), 493(ab), 678, 1131(ab), 1454(ab), 1455(ab)
Daou, D, 347(ab), 350(ab), 765(ab), 788(ab), 802(ab), 810(ab), 889, 1352(ab)
Darcourt, J, 233(ab), 983
Darrah, D, 72(ab)
Dartevelle, P, 410(ab)
Das, BK, 431(ab), 1420(ab)
Das, SS, 1125(le)
Das, T, 1129(ab), 1473(ab), 1474(ab)
Dasan, B, 479(ab)
Dasse, P, 1336(ab)
Daube-Witherspoon, ME, 212(ab), 1398
David, N, 451
Davies, RK, 935(ab)
Davis, JM, 1294(ab)
Dawant, B, 50(ab)
De Backer, G, 731(ab), 768(ab)
De Barsy, C, 833(ab)
De Beco, V, 105(ab), 1143(ab)
De Bondt, P, 172(ab), 731(ab), 768(ab), 805(ab)
De Camps, J, 325(ab)
De Cicco, C, 75(ab)
De Cristofaro, MTR, 725
de Geus-Oei, LF, 80(ab), 1197(ab)
De Grandi, P, 1179(ab)
De Groot, T, 1060(ab)
De Herder, WW, 123(ab)
De Jong, HW, 192(ab)
De Jong, M, 123(ab), 167(ab), 442(ab), 444(ab), 446(ab)
de Jong, M, 617, 1650
de Klerk, JMH, 1150
De Knegt, RJ, 476(ab)
De La Rosa, R, 3(ab), 508(ab), 509(ab)
De Leonni Stanonik, M, 1034(ab)
De Lorenzo, A, 357(ab)
De Montpreville, V, 410(ab)
De Rimini, ML, 998(ab)
De Ron, P, 1145(ab)
De Sutter, J, 731(ab), 805(ab)
De Vos, FJ, 1262(ab)
De Vries, EF, 1107(ab)
De Waal, RM, 80(ab)
De Winter, F, 477(ab), 481(ab)
De Winter, O, 731(ab), 768(ab), 805(ab)
de Wit, M, 635
De Wolf-Peeters, C, 1060(ab)
De Wwinter, H, 481(ab)
Dean, RT, 445(ab)
Dearnaley, D, 1272(ab)
Debatin, J, 106(ab), 1133(ab)
Debatin, JF, 1236(ab), 1339
Debiose, DA, 1188(ab)
Debnath, ML, 605(ab), 1444(ab)
Decailliot, F, 1063
Degaonkar, M, 965(ab)
Degirmenci, B, 482(ab)
Degli Uberti, EC, 474(ab)
DeGrado, TR, 92
Degrossi, OJ, 1281(ab), 1304(ab)
Deguzman, A, 1175(ab)
Dei, S, 527(ab)
Dejesus, OT, 385(ab), 1464(ab)
Dekker, B, 256(ab)
Dekosky, ST, 227(ab), 228(ab)
Delaloye, JF, 1179(ab)
Delbeke, D, 83(ab), 1016(ab)
Delbot, T, 1284(ab)
Delforge, J, 215
Delgado, L, 882
Dell'agnello, G, 236(ab)
Deloar, HM, 896(ab)
Delong, P, 1348(ab)
Delpassand, E, 1151(ab)
Demers, G, 262(ab)
Demirkaya, O, 875(ab)
Demongeot, J, 1511(ab)
DeNardo, GL, 29N(9)
Denardo, GL, 312(ab), 334(ab), 420(ab), 1256(ab), 1261(ab)
DeNardo, SJ, 29N(9)
Denardo, SJ, 312(ab), 334(ab), 420(ab), 1256(ab), 1261(ab)
Dence, C, 1530
Deng, WP, 1108(ab)
DePuey, EG, 273
Depuey, EG, 727(ab), 796(ab)
Der, MG, 198(ab), 960(ab), 969(ab)
Derksen, BH, 1150
Derumeaux, G, 806(ab), 807(ab)
Desai, V, 392
Desantis, M, 1360(ab)
Desantis, R, 1485(ab)
Desarnaud, S, 1596
Desplaces, N, 1352(ab)
Desutter, J, 768(ab)
Deters, EC, 813(ab)
Dettori, G, 1162(ab)
Deutsch, G, 1024(ab)
Devillers, A, 579(ab)
Devlin, AL, 1186(ab), 1231(ab)
Devolder, AG, 1027(ab)
Devooght, J, 132(ab)
Devous, MD, 235(ab), 1023(ab), 1051(ab)
Dewaraja, Y, 1101
Dewaraja, YK, 882(ab)
Deweese, T, 427(ab)
Dewey, SL, 158(ab), 380(ab)
Dhawan, V, 201(ab), 202(ab), 986(ab), 1324, 1431(ab)
D'Hondt, E, 255(ab)
Di Bella, EV, 42(ab)
Di Carli, MF, 1144, 1213(ab)
Di Domenico, G, 212(ab)
Di Leo, C, 355(ab)
Diaz, AZ, 367(ab)
Dibella, EV, 820(ab), 918(ab)
DiBella, EVR, 421
Dichgans, M, 539(ab)
Dick, DW, 385(ab)
Dickstein, K, 585(ab)
Diedrich, J, 1269(ab)
Diehl, J, 990(ab)
Diehl, M, 1068(ab), 1295(ab)
Dieltein, M, 1283(ab)
Dierckx, R, 458, 481(ab), 544(ab), 733, 829(ab), 1426
Dierckx, RA, 477(ab), 592(ab), 731(ab), 768(ab), 805(ab), 1262(ab)
Dierickx, LO, 1145(ab)
Diestelhorst, S, 1273(ab)
Dietz, A, 260(ab)
Difilippo, FP, 940(ab)
DiFilippo, FP, 1398
Diggles, L, 273(ab)
Diggles, LE, 923(ab)
Diksic, M, 947(ab)
Dilone, A, 773(ab)
DiMeo, AJ, 1578
Dimitrakopoulou-Strauss, A, 79(ab), 91(ab), 510, 850(ab), 851(ab), 1153(ab)
Din, AS, 1069(ab), 1070(ab)
Dinanian, S, 810(ab)
Ding, Y, 388(ab)
Ding, YS, 56(ab), 197(ab), 317(ab), 386(ab), 398(ab), 961(ab), 1043(ab), 1452(ab)
Ding, Y-S, 1331
Dinkelborg, L, 557(ab)
Dinkelborg, LM, 400, 445(ab)
Disley, L, 256(ab)
Dittmann, H, 131(ab), 1293(ab)
Dittmar, C, 90(ab), 246(ab)
Divgi, C, 1429(ab), 1482
Dizendorf, E, 118(ab), 1240(ab)
Djomotschko, J, 467(ab)
Dlugos, D, 1389(ab)
Dobbeleir, AA, 800(ab)
Döbert, N, 1068(ab), 1295(ab)
Dobrocemsky, G, 183(ab)
Doebert, N, 1015(ab)
Dohmen, BM, 131(ab), 391(ab), 401(ab), 1056(ab)
Doi, M, 470(ab)
Doi, R, 173, 1203(ab)

Dollé, F, 1227
Dolle, F, 215, 951(ab), 1425(ab), 1434(ab)
Donahay, T, 551
Donati, S, 1164(ab)
Dondi, M, 904(ab)
Donohoe, KJ, 1072(ab), 1174(ab)
Dopichaj-Menge, U, 857(ab)
Dorion, D, 262(ab)
Dormehl, I, 1488(ab)
Dosik, A, 417(ab)
Dou, Y, 728(ab)
Doubrovin, M, 148(ab), 249(ab), 250(ab), 251(ab), 252(ab), 1072, 1111(ab)
Doubrovina, E, 1111(ab)
Dougherty, DD, 1053(ab)
Dougherty, JH, 1034(ab)
Douglas, JG, 1667
Douglas, K, 94(ab)
Douglas, KA, 93(ab)
Douglas, N, 1477(ab)
Doze, P, 1409(ab)
Draghici, S, 825(ab)
Dravet, F, 73(ab)
Drazil, L, 1146(ab)
Dresel, S, 1196(ab), 1313(ab), 1396(ab)
Drevets, WC, 1090
Driedger, AA, 178(ab), 181(ab)
Drieskens, O, 423(ab)
Drolet, D, 710(ab)
Dronne, F, 717(ab)
Drubach, LA, 1310
Drzezga, A, 230(ab), 231(ab), 990(ab), 1020(ab)
Du, Y, 193(ab)
Duan, J, 311(ab), 1245
Duarte, PS, 136(ab), 1398(ab)
Duatti, A, 166(ab), 499(ab)
Dubois-Randé, JL, 536
Dubovsky, EV, 762
Dudczak, R, 183(ab), 184(ab), 405(ab), 706(ab)
Dufour, RA, 816(ab)
Dulmet, E, 410(ab)
Dumont, F, 1132(ab)
Dunigan, K, 400(ab)
Dunkelmann, S, 1328(ab)
Dunlop, D, 310(ab)
Dunn, WL, 1430(ab)
Dunnwald, LK, 500, 1100(ab), 1158(ab)
Duong, DH, 15(ab)
Dupont, P, 1054, 1060(ab)
Dupuis, A, 1120(ab)
Durack, LD, 1383
Durak, B, 203
Durie, BG, 111(ab)
Durie, BGM, 1457
Dusing, R, 1093(ab)
Dusing, RW, 1338(ab)
Dutra, SCP, 89
Dutschka, K, 162(ab)
Duttaroy, A, 399(ab)
Duysinx, B, 280(ab)
Dwamena, BA, 813(ab)
Dworkin, H, 1225(ab), 1274(ab), 1276(ab)
Dworkin, HJ, 1247(ab)
Dynes, A, 370(ab)
Dzewas, B, 1251(ab)
Dziuk, K, 1207(ab), 1220(ab)

Eary, J, 1230(ab)
Eary, JF, 266(ab), 872(ab), 1383, 1526(ab)
Ebel, G, 913(ab)
Eberhardt, W, 106(ab)
Eberl, S, 831(ab)
Eberle, AN, 1699
Ebmeier, K, 21, 983
Ebmeir, K, 233(ab)
Echeruo, I, 881(ab), 901(ab)
Echt, EA, 1231(ab)
Eckelman, WC, 198(ab), 399(ab), 960(ab), 969(ab), 977(ab), 1118(ab), 1449(ab), 1501(ab), 1525(ab)
Eder, V, 1388(ab)
Edwards, D, 504(ab)
Edwards, DS, 1080(ab), 1495(ab)
Edwards, R, 1249(ab), 1250(ab)
Eerd, JV, 504(ab)
Eersels, J, 1048(ab)
Eftekhari, M, 1288(ab), 1323(ab)
Egelhof, T, 893(ab), 1339
Egerer, G, 418(ab)
Ehret, E, 562(ab), 773(ab)
Ehrlichmann, W, 1463(ab)
Eichhorn, W, 1297(ab)
Eidelberg, D, 201(ab), 202(ab), 986(ab), 1324, 1431(ab)
Eisenbarth, JA, 1524(ab)
Eisenberg, B, 1041(ab)
Eisenhut, M, 260(ab), 409(ab), 1096(ab), 1139(ab), 1515(ab), 1524(ab), 1528(ab)
Eisenmenger, A, 418(ab)
Eisner, RL, 5(ab), 728(ab)
Eissner, D, 1297(ab)
El Fakhri, G, 191(ab), 232(ab), 880(ab), 991(ab)
Elahi, D, 711(ab)
Elgazzar, AH, 346
Elhendy, A, 767, 795, 1634
Eliashiv, D, 1031(ab)
Elitok, E, 1049(ab)
Ell, PJ, 574(ab), 1048(ab), 1415(ab)
Ellars, C, 1080(ab), 1426(ab), 1495(ab)
Ellis, GK, 500, 1100(ab), 1158(ab)
Ellis, RJ, 1186(ab)
Ellison, D, 1368
Ellman, A, 306(ab)
Elmaleh, D, 9(ab), 397(ab), 609(ab)
Elman, I, 1624
Els, T, 1019(ab)
Elsinga, PH, 167, 278(ab), 1409(ab)
Elstrom, R, 285(ab)
El-Tamer, M, 1135(ab)
El-Zeftawy, H, 71(ab), 346(ab), 460(ab), 550(ab), 1171(ab)
Embree, MF, 1083(ab), 1502(ab)
Emmanouilides, C, 282(ab)
Emmerich, J, 1408(ab)
Emond, P, 596(ab)
Emons, G, 1189(ab)
Endo, H, 1457(ab)
Enezi, FH, 1071(ab)
Engel, A, 290(ab), 1129, 1232(ab)
Engeland, U, 913(ab)
Engelbach, J, 974(ab)
Engelbach, JA, 98(ab), 1127(ab), 1557
Engelhardt, EL, 837
Engenhart-Cabillic, R, 406(ab)
Enke, CA, 957
Enmon, RM, 555(ab)
Ensing, G, 703(ab)
Entok, E, 793(ab), 812(ab)
Epelbaum, R, 1295
Epstein, AL, 1265(ab)
Erba, P, 236(ab), 1164(ab)
Erdi, Y, 315(ab)
Erdi, YE, 567(ab), 876
Erickson, LC, 1491(ab)
Eriksson, L, 36(ab), 927(ab)
Erion, JL, 123(ab), 167(ab), 1650
Erlandsson, K, 1048(ab)
Ermert, J, 366, 491(ab)
Ernst, M, 1433(ab)
Erwin, WD, 25N(9), 817(ab), 906(ab), 1432(ab)
Escanyé, J-M, 451
Eschmann, M, 131(ab)
Eschmann, SM, 1293(ab), 1366(ab)
Eschner, W, 21
Esik, O, 66
Eskandar, Y, 1310(ab), 1324(ab), 1329(ab)
Eskola, O, 1674
Espenan, G, 124(ab)
Esposito, G, 540
Esquerre, JP, 221(ab)
Esteves, F, 1414(ab)
Estorch, M, 799(ab), 1417(ab), 1419(ab)
Eubank, W, 1230(ab)
Eubank, WB, 1158(ab)
Evans, D, 1039(ab)
Even-Sapir, E, 290(ab), 584, 603
Everaert, H, 1145(ab), 1201, 1647
Ewerbeck, V, 510, 1153(ab)
Ezhilarasan, R, 1305(ab)
Ezziddin, S, 465(ab), 1150(ab), 1192(ab)

Fabbri, M, 1400(ab)
Faber, TL, 12(ab), 519(ab), 525(ab)
Fabry, U, 1062(ab)
Fadel, E, 410(ab)
Fagioli, G, 904(ab)
Fagret, D, 1511(ab)
Fahey, FH, 925(ab)
Failing, S, 1486(ab)
Fairbank, C, 52(ab)
Faivre-Chauvet, A, 579(ab), 1496(ab)
Falchi, A, 1156(ab), 1159(ab), 1162(ab), 1206(ab)
Fallahi, B, 1323(ab)
Fallani, F, 760(ab)
Fan, H, 394(ab)
Fan, Y, 767(ab)
Fang, P, 601(ab)
Fang, W, 1399(ab), 1403(ab)
Fang, Y, 972(ab), 1570
Fang, YH, 361(ab)
Fanti, S, 760(ab), 904(ab), 1400(ab)
Faraggi, M, 628
Farboud, B, 1248(ab)
Farde, L, 292, 596(ab), 1445(ab)
Fard-Esfahani, A, 1288(ab), 1323(ab)
Farncombe, TH, 194(ab), 196(ab)
Farris, A, 1159(ab)
Farsad, M, 760(ab)
Farstad, B, 580(ab)
Fasth, K-J, 1688
Fatema, K, 742(ab)
Fatima, S, 306(ab), 342(ab)
Fatmi, S, 342(ab)
Fawwaz, R, 1132(ab), 1135(ab)
Feggi, LM, 76(ab), 474(ab)
Fei, X, 316(ab), 1458(ab), 1491(ab)
Feiglin, DH, 881(ab), 901(ab)
Feinberg, M, 712(ab)
Felder, C, 197(ab), 386(ab)
Felsberg, J, 402(ab)
Feng, B, 169(ab), 170(ab), 786
Feng, CF, 461(ab), 1350(ab)
Feng, D, 831(ab), 841(ab), 869(ab)
Feng, J, 874(ab), 907(ab)
Feng, Q, 136(ab), 140(ab), 267(ab), 321(ab), 450(ab), 564(ab), 1348(ab)
Fenton, J, 1286(ab)
Ferlitsch, A, 472(ab)
Fernandez, R, 370(ab)
Ferrari, R, 344(ab)
Ferraro, F, 935(ab)
Ferreira, N, 1268
Ferrer, L, 428(ab), 579(ab)
Ferrieri, R, 158(ab), 1331
Ferrieri, RA, 961(ab)
Fessler, JA, 882(ab)
Festa, A, 79
Feuardent, J, 45(ab), 834(ab), 835(ab)
Feuereisl, R, 744(ab), 795(ab)
Feustel, P, 1289(ab)
Ficaro, EP, 182(ab), 348(ab)
Fiche, M, 73(ab)
Fiessinger, JN, 1408(ab)
Fietz, T, 1528(ab)
Fife, RS, 316(ab)
Fig, LM, 813(ab), 816(ab)
Figer, A, 603
Figueiredo, AB, 338(ab)
Figueiredo, GL, 338(ab)
Filice, A, 166(ab), 344(ab)
Filmont, JE, 270(ab), 282(ab), 286(ab), 325
Filosofov, DV, 165(ab)
Fincker, F, 786(ab)
Fine, E, 787(ab)
Fink, U, 242(ab), 243(ab), 1251(ab)
Fink-Bennett, DM, 267
Finley, BR, 1248(ab)
Finn, R, 148(ab), 249(ab), 250(ab), 252(ab), 315(ab), 329(ab), 671, 1072, 1111(ab), 1122(ab)
Finn, RD, 555(ab)
Finta, L, 13(ab)
Fiore, JM, 417(ab), 1257(ab)
Fioretti, PM, 795
Fiorioli, M, 301(ab)
Fischer, M, 1191(ab)
Fischer, T, 292(ab), 1325(ab)
Fischman, A, 109(ab), 711(ab)
Fischman, AJ, 9(ab), 24(ab), 61(ab), 470, 836(ab), 854(ab), 948(ab), 949(ab), 952(ab), 1053(ab), 1074(ab), 1258(ab), 1335(ab), 1512(ab), 1514(ab)
Fischman, MW, 387(ab)
Fiset, P, 947(ab)
Fish, M, 11(ab)
Fish, SA, 463(ab), 1320(ab)
Fisher, D, 419(ab)
Fisher, RS, 589(ab)
Fisher, WS, 1007(ab)
Fishman, E, 1237(ab), 1242(ab)
Fissekis, JD, 92(ab), 320(ab)
Fitzsimmons, JM, 1138(ab)
Flamen, P, 423(ab), 1054
Flameng, W, 556
Flege, S, 128(ab), 1012
Fleisher, MA, 177(ab)
Fletcher, D, 1039(ab)
Fletcher, JG, 239(ab)
Fletcher, JW, 1033(ab), 1233(ab)
Floeth, F, 402(ab)
Flores, LG, 385(ab), 1464(ab)
Flotats, A, 799(ab), 1417(ab), 1419(ab)
Foerstl, H, 231(ab)
Fogelman, I, 338
Foidart, J, 138(ab), 139(ab)
Foletto, M, 1243(ab)
Folks, RD, 12(ab)
Foltin, R, 387(ab)
Fonarow, G, 21(ab), 781(ab)
Fong, K, 1392(ab)
Font, M, 155(ab)
Fontanelli, D, 236(ab)
Forero, A, 1264(ab)
Forget, P, 307(ab)
Forrer, F, 1266(ab)
Forssell-Aronsson, E, 828
Förster, G, 543(ab)
Förster, GJ, 1148(ab)
Forster, M, 176(ab)
Förstl, H, 990(ab), 1020(ab)
Forstrom, LA, 1430(ab)
Forte, LR, 333(ab)
Fortin, A, 262(ab)
Forutan, F, 393(ab)
Fossaa, SD, 580(ab)
Fourme, T, 347(ab), 765(ab), 802(ab), 810(ab)
Fowler, J, 197(ab), 219(ab), 1452(ab)
Fowler, JS, 56(ab), 211(ab), 317(ab), 386(ab), 388(ab), 961(ab), 972(ab), 1025(ab), 1043(ab), 1331, 1570
Fradet, G, 262(ab)
Fraga, G, 1419(ab)
Fraker, DL, 74(ab)
Franc, BL, 1392(ab)

Franca Neto, O, 725(ab)
Franceschetti, P, 474(ab)
Franceschi, D, 961(ab), 1331
Franceshi, D, 197(ab)
Franchi, R, 760(ab), 1400(ab)
Francis, RJ, 1244(ab)
Frank, JW, 1280(ab)
Franken, PR, 1201
Frankle, WG, 52(ab)
Franquiz, JM, 171(ab), 888(ab)
Franzius, C, 127(ab), 128(ab), 1012
Fraser, C, 198(ab), 969(ab)
Frattaruolo, M, 591(ab)
Frawley, J, 1038(ab)
Freedman, N, 365(ab), 565(ab), 1008(ab), 1032(ab), 1047(ab)
Freer, G, 500(ab)
Freimanis, RL, 929(ab)
Freimuth, P, 1513(ab)
Freitag, P, 1444
French, JN, 1255(ab)
Frenkel, A, 922(ab), 1129, 1295
Freudenberg, L, 162(ab), 209(ab)
Freudenberg, LS, 106(ab), 893(ab), 1133(ab), 1236(ab), 1339
Frey, E, 31(ab), 520(ab), 1101
Frey, EC, 193(ab), 195(ab), 213(ab), 432, 897(ab), 898(ab)
Frey, KA, 70(ab)
Friebe, M, 445(ab)
Friedberg, JW, 109(ab)
Friedland, RP, 1044
Friedman, JD, 351(ab), 353(ab), 354(ab), 356(ab), 357(ab)
Friello, P, 1433(ab)
Frijlink, HW, 1409(ab)
Fritsch, HW, 1191(ab)
Fritzberg, A, 1383
Frohlich, DE, 1091(ab)
Froidevaux, S, 1699
Froissart, M, 142(ab)
Front, A, 778(ab), 791(ab)
Frost, JJ, 8(ab), 1131(ab)
Frouin, V, 964(ab), 1715
Fu, X, 598(ab)
Fuchs, D, 484
Fujibayashi, Y, 532(ab), 705(ab), 822(ab), 968(ab), 1127(ab), 1218, 1490(ab), 1499(ab), 1557
Fujii, DK, 392
Fujii, H, 1245(ab)
Fujii, N, 497(ab)
Fujimoto, J, 471(ab)
Fujino, S, 779(ab), 789(ab)
Fujioka, S, 577
Fujita, M, 237(ab), 395(ab), 752(ab), 883(ab), 978(ab)
Fujita, S, 1028(ab)
Fujita, T, 1203(ab)
Fujiwara, H, 1510(ab)
Fujiwara, K, 1103(ab)
Fujiwara, M, 776(ab), 783(ab)
Fukuchi, K, 524(ab), 748(ab), 757, 995(ab), 996(ab), 1402(ab)
Fukuchi, M, 471(ab)
Fukuda, H, 244(ab), 440(ab), 962(ab), 1462(ab)
Fukuda, S, 261(ab)
Fukuda, Y, 1130(ab)
Fukui, A, 742(ab)
Fukumitsu, N, 1404(ab)
Fukunaga, H, 1201(ab)
Fukuoka, T, 950(ab)
Fukuyama, H, 229(ab), 975(ab)
Fukuzawa, S, 741(ab)
Fulin, Z, 404(ab)
Fuller, C, 407(ab), 1222(ab)
Fullerton, C, 52(ab)
Fulton, R, 869(ab)
Fumoleau, P, 428(ab)
Funabashi, N, 776(ab)
Fung, LT, 27(ab), 1416(ab)
Funk, S, 308(ab)
Furenlid, LR, 175(ab), 933, 1104(ab), 1119(ab)
Furl, N, 235(ab)
Furukawa, K, 533(ab)
Furumoto, S, 1462(ab)
Furuuchi, K, 487(ab)
Furuyama, H, 185(ab), 189(ab), 772(ab), 782(ab), 1381(ab)
Fuse, K, 531
Fuseau, C, 951(ab), 1227
Futami, S, 1028(ab)
Futatsubashi, M, 1140(ab)

Gabriel, J, 502(ab)
Gacinovic, S, 1415(ab)
Gage, HD, 925(ab)
Gagnon, A, 13(ab), 15(ab), 180(ab)
Gagnon, D, 526(ab)
Gaidouk, MI, 1325(ab)
Gaitini, D, 114(ab), 1129, 1232(ab), 1295
Galavoni-Tjuvajev, J, 329(ab)
Gali, H, 333(ab)
Galimberti, V, 75(ab)
Gallardo, HF, 329(ab)
Gallion, H, 1249(ab), 1250(ab)
Galt, J, 815(ab), 912(ab)
Galt, JR, 519(ab), 758(ab), 1370(ab)
Gambhir, S, 146(ab)
Gambhir, SS, 1(ab), 7(ab), 155(ab), 247(ab), 248(ab), 253, 752, 1106(ab), 1110(ab), 1113(ab)
Gandini, D, 1182(ab)
Gangwar, PK, 1260(ab)
Gao, DW, 174(ab)
Gao, ZY, 321(ab)
Garbay, JR, 924(ab)
Garcia-Garayoa, E, 374
Garcia Del Rio, H, 1281(ab), 1304(ab)
Garcia, A, 1438(ab)
Garcia, E, 815(ab), 912(ab)
Garcia, EV, 12(ab), 273, 519(ab), 525(ab)
Gardin, I, 792(ab)
Garg, PK, 598(ab)
Garg, S, 598(ab)
Gargiulo, T, 1180(ab)
Garmestani, K, 1525(ab)
Garrigue, MA, 1336(ab)
Garth, H, 1175
Garza, V, 398(ab), 961(ab), 1331
Gaskill, M, 1225(ab), 1247(ab)
Gasthaus, K, 900(ab), 1435(ab)
Gasto, C, 1050(ab)
Gates, V, 1276(ab)
Gates, VL, 1274(ab)
Gatica, H, 17(ab)
Gatley, J, 1452(ab)
Gatley, SJ, 56(ab), 197(ab), 386(ab), 1331
Gatti, G, 77(ab)
Gaura, V, 964(ab)
Gauthier, ME, 704(ab), 709(ab)
Gavaruzzi, G, 1400(ab)
Gaw Gonzalo, IT, 1026(ab)
Gayed, I, 1151(ab), 1187(ab)
Geaghan, SM, 1359
Gebuza, B, 13(ab)
Geist, CL, 1029(ab), 1030(ab)
Gelbard, I, 54(ab)
Gelernter, J, 384(ab)
Gelfand, MJ, 11N(9)
Gelovani Tjuvajev, J, 148(ab), 249(ab), 250(ab), 252(ab), 1111(ab)
Gelovani, J, 251(ab)
Gemayl, C, 180(ab)
Gemmel, F, 477(ab), 481(ab)
Gennari, A, 1164(ab)
Gennert, MA, 909(ab), 910(ab)
George, P, 1434(ab)
Geraghty, S, 308(ab)
Gerasimov, M, 398(ab)
Gerasimov, MR, 158(ab), 380(ab)
Gerbaudo, VH, 1144, 1213(ab), 1309(ab)
Gerber, BL, 556
Gerl, J, 1136(ab)
Gerlach, JR, 351(ab)
Germanier, AG, 61
Germano, G, 351(ab), 353(ab), 354(ab), 356(ab), 357(ab)
Gerstner, A, 62(ab), 65(ab)
Gerszten, K, 1249(ab), 1250(ab)
Gerundini, P, 1326(ab)
Gerzon, I, 1001(ab)
Gestin, JF, 1496(ab)
Getka, E, 1039(ab)
Gewirtz, H, 9(ab), 24(ab)
Geworski, L, 570(ab), 635, 1172(ab)
Gharehpapagh, E, 137(ab)
Gharzeddine, L, 788(ab)
Ghazarossian, V, 2(ab), 22(ab), 702(ab)
Ghesani, M, 1407(ab)
Ghezzi, C, 1511(ab)
Ghossein, R, 1482
Gianoukakis, AG, 1289(ab)
Giard, S, 1173(ab)
Gifford, A, 388(ab), 1452(ab)
Gifford, HC, 194(ab), 846(ab)
Giganti, M, 166(ab), 344(ab)
Gil, R, 52(ab)
Gildehaus, F, 1396(ab)
Gildersleeve, DL, 512(ab), 1446(ab)
Gill, PS, 437(ab)
Gilland, DR, 190(ab)
Gilland, K, 31(ab)
Gilland, KL, 432
Gillies, JM, 1482(ab)
Gillooley, J, 550(ab)
Ginanneschi, M, 1485(ab)
Ginovart, N, 1438(ab)
Giovacchini, G, 969(ab)
Giovannini, AA, 61
Gipponi, M, 811
Gips, S, 585(ab), 778(ab), 791(ab)
Gironet, N, 1388(ab)
Giusti, M, 1180(ab)
Glaser, T, 1056(ab)
Glass, DM, 519
Glass, EC, 1414
Glass, J, 1452(ab)
Glatting, G, 96(ab), 277(ab), 876(ab)
Gleason, SS, 942(ab)
Glenn, TC, 222(ab), 224(ab), 1000(ab), 1002(ab)
Glick, SJ, 846(ab)
Glick-Wilson, BE, 316(ab), 1458(ab), 1491(ab)
Glover, DK, 664, 942(ab)
Gnanasekeram, H, 4(ab), 23(ab)
Göbel, H, 1036(ab)
Godbersen, GS, 298(ab)
Godbole, MM, 431(ab)
Goecke, K, 467(ab)
Goellner, JR, 455(ab)
Goerges, R, 1133(ab)
Goerres, G, 887(ab)
Goerres, GW, 890(ab), 1147(ab), 1235(ab), 1469
Goethals, I, 458, 592(ab), 1426
Gogami, A, 1490(ab)
Goins, B, 1137(ab)
Göke, B, 1191(ab)
Gold, DV, 1484(ab)
Gold, L, 1238(ab)
Goldenberg, DM, 310(ab), 556(ab), 558(ab), 559(ab), 579(ab), 693, 1484(ab)
Goldfarb, CR, 469(ab)
Goldsmith, SJ, 284(ab), 417(ab), 576(ab), 577(ab), 1018, 1190(ab), 1257(ab)
Goldstein, DS, 420(ab), 1256(ab), 1261(ab)
Gomez, L, 1181(ab)
Gomeza, J, 399(ab)
Gomori, JM, 1032(ab)
Gonen, M, 46
Gonzalez Trotter, DE, 369(ab), 837(ab)
Gonzalez, KD, 923(ab)
González, P, 882
Gonzalez, P, 17(ab)
Goodbody, A, 517(ab)
Goode, AR, 942(ab)
Goodenough, DJ, 464(ab)
Goodman, MM, 149(ab), 151(ab), 597(ab)
Goodman, S, 909
Goodman, SL, 322(ab)
Goodwill, T, 132(ab)
Googins, S, 1525(ab)
Gopal, AK, 1526(ab)
Gopinath, G, 1268(ab)
Gordon, EM, 1112(ab)
Gorenberg, M, 484, 487
Gorey, JG, 979(ab)
Goris, M, 419(ab), 720(ab)
Goris, ML, 507(ab), 798(ab), 1255(ab)
Gorman, CA, 455(ab)
Gorman, JM, 52(ab)
Gorodin, P, 4(ab)
Goshen, E, 453(ab), 1321(ab)
Gosink, HJ, 1472(ab)
Gostomzyk, J, 1052(ab)
Gotjen, D, 390(ab)
Goto, R, 962(ab)
Gotthard, M, 1269(ab)
Gotthardt, M, 62(ab), 65(ab), 126(ab), 289(ab), 291(ab), 313(ab), 332(ab), 406(ab), 414(ab), 467(ab), 1191(ab), 1296(ab)
Gottschalk, C, 237(ab)
Gould, R, 339(ab)
Govindan, SV, 556(ab)
Goyenechea, M, 784(ab)
Graeber, G, 549(ab), 1229(ab)
Graf, R, 90(ab), 246(ab)
Graf, S, 183(ab), 184(ab)
Graham, K, 1528(ab)
Graham, MM, 283(ab), 449(ab), 1157, 1223(ab)
Graham-Coco, W, 517(ab)
Grahek, D, 81(ab), 105(ab), 130(ab), 928(ab), 1143(ab)
Graichen, S, 1295(ab)
Gralow, JR, 500, 1100(ab), 1157(ab), 1158(ab)
Grandy, D, 972(ab)
Grandy, DK, 1570
Granegger, S, 472(ab)
Graneto, MJ, 117
Grant, S, 1414(ab), 1422(ab)
Grant, SF, 569(ab)
Gratz, S, 62(ab), 65(ab), 126(ab), 289(ab), 291(ab), 406(ab), 414(ab), 467(ab), 918, 1269(ab), 1351(ab), 1354(ab)
Gratzl, O, 1444
Gray, H, 1178(ab)
Gray, M, 786(ab)
Greeley, M, 1507(ab)
Green, A, 1532(ab)
Green, AJ, 1244(ab)
Green, AM, 11(ab), 15(ab), 255(ab)
Green, G, 739(ab)
Green, MA, 1481(ab)
Greenberg, JH, 601(ab)
Greene, C, 569(ab)
Greene, M, 487(ab)
Greenspan, B, 738(ab)
Greenwald, B, 1199(ab)
Greer, K, 34(ab), 378(ab)
Greer, PJ, 844(ab), 1090
Gregoire, M, 921(ab)
Grégoire, M-C, 1715
Greiner-Bechert, L, 295(ab)
Gremillion, T, 926(ab), 927(ab)
Grewal, RK, 587(ab)
Grierson, JR, 95(ab), 254(ab), 1210

Gries, W, 161(ab)
Grieshaber, MK, 400
Griffiths, GL, 556(ab), 558(ab)
Grigsby, PW, 100(ab)
Grimmer, T, 990(ab), 1020(ab)
Groch, MW, 817(ab), 1432(ab)
Groch, PJ, 1432(ab)
Groen, HJM, 167
Grohé, C, 1150(ab)
Grön, G, 1052(ab)
Gropler, RJ, 510(ab), 1530, 1557
Groshar, D , 312
Groshar, D, 368(ab), 484, 487
Gross, M, 406(ab)
Gross, MD, 813(ab), 816(ab)
Grosso, M, 411(ab), 1164(ab), 1182(ab)
Groth, P, 1328(ab)
Gruber, D, 857(ab)
Gruender, G, 1055(ab), 1058(ab)
Gruenwald, F, 1015(ab)
Gruenwald, U, 86(ab)
Gruesser, S, 1055(ab)
Gründer, G, 389(ab), 543(ab), 970(ab)
Grünwald, F, 465(ab), 1068(ab), 1295(ab)
Gschwend, JE, 200
Gu, XY, 578(ab)
Guan, L, 285(ab), 1339(ab)
Guan, YH, 1406(ab)
Guendisch, D, 608(ab)
Guenther, I, 1227
Guérin, C, 1063
Guhlke, S, 161(ab), 581(ab), 608(ab), 1192(ab)
Guilarte, T, 234(ab), 965(ab)
Guillo, P, 586(ab)
Guilloteau, D, 221(ab), 596(ab), 1336(ab)
Gülbas, Z, 203
Gulec, SA, 438(ab)
Gull, H, 738(ab)
Gullberg, GT, 169(ab), 170(ab), 372(ab), 522(ab), 786, 918(ab)
Gulyas, B, 596(ab), 1445(ab)
Gungor, F, 112(ab)
Gunn, RN, 292
Guo, F, 808(ab)
Guo, H, 359(ab)
Guo, J, 589(ab)
Guo, N, 379(ab), 381(ab), 602(ab), 953(ab)
Gupta, AK, 1260(ab)
Gupta, N, 549(ab), 1063(ab), 1229(ab)
Gupta, NC, 413
Gupta, NK, 1255(ab)
Gupta, S, 246, 384, 485(ab), 1084(ab), 1278(ab), 1333(ab), 1508(ab)
Gupta, V, 479(ab)
Guralnik, L, 114(ab), 117(ab), 1129
Gutman, F, 792(ab), 806(ab), 807(ab)
Gutman, M, 584, 603
Guy, LG, 704(ab)

Ha, HJ, 319(ab)
Haas, R, 418(ab)
Habbema, JDF, 330
Haber, R, 1329(ab)
Haber, SB, 126(le)
Haberkorn, U, 260(ab), 409(ab), 418(ab), 439(le), 1096(ab), 1139(ab), 1515(ab), 1524(ab), 1528(ab)
Habert, MO, 991(ab)
Hachamovitch, R, 352(ab), 354(ab), 356(ab), 357(ab), 754(ab)
Hack, S, 417(ab), 1257(ab)
Hackett, E, 381(ab), 1054(ab), 1440(ab)
Hada, T, 471(ab)
Haddad, P, 1288(ab)
Haddad, RI, 264(ab)
Hadley, DM, 476
Haertter, S, 1058(ab)
Hafeli, U, 1486(ab)
Hagen, PJ, 1317
Haghighi, K, 1127(le)
Hahn, J, 292(ab), 1283(ab), 1322(ab)
Hahn, K, 59(ab), 200(ab), 539(ab), 828(ab), 1045(ab), 1196(ab), 1302(ab), 1313(ab), 1396(ab)
Haidar, M, 350(ab), 788(ab), 802(ab), 1352(ab)
Haim, N, 1295
Haindl, W, 1038(ab)
Haldemann, A, 610
Halkar, R, 1414(ab)
Halkar, RK, 569(ab), 590(ab), 728(ab), 758(ab), 1370(ab)
Hall, FL, 1112(ab)
Hall, NC, 424(ab)
Halldin, C, 292, 596(ab), 1445(ab)
Hallett, M, 969(ab)
Halter, G, 277(ab)
Ham, H, 33
Ham, HR, 851
Hamacher, K, 402(ab), 1459(ab)
Hamacher, KA, 577(ab), 1190(ab)
Hamann, C, 59(ab), 200(ab), 828(ab), 1045(ab)
Hamann, SM, 1361(ab)
Hambye, A, 800(ab)
Hamill, J, 36(ab)
Hamlin, DK, 488(ab), 489(ab), 1487(ab)
Hammes, RJ, 154(ab)
Hampel, H, 230(ab)
Hamscho, N, 1068(ab), 1295(ab)
Han, DJ, 1006
Han, ES, 1504(ab)
Han, SH, 1150
Hanif, M, 1407(ab)
Hankins, J, 419(ab)
Hanrahan, S, 1447(ab)
Hanrath, P, 187(ab)
Hansen, ES, 1046(ab)
Hansen, HJ, 556(ab), 559(ab), 1484(ab)
Hanson, SR, 710(ab)
Hantraye, P, 921(ab)
Hany, TF, 137(ab), 547(ab), 890(ab), 1235(ab), 1240(ab), 1469
Hapdey, S, 45(ab), 834(ab), 835(ab)
Hara, T, 187, 276(ab), 421(ab)
Haraden, BM, 1530
Haraguchi, K, 1218, 1490(ab)
Harapanhalli, RS, 1126(ab)
Hardikar, AS, 881(ab), 901(ab)
Harding, K, 1181
Hardoff, R, 129(ab)
Harf, A, 1596
Harkness, BA, 925(ab)
Harno, K, 832(ab)
Haroon, H, 441(ab)
Harrington, KJ, 519
Harris, TD, 504(ab), 1080(ab)
Harris, TS, 235(ab), 988(ab), 1023(ab), 1051(ab)
Harrison, S, 180(ab)
Hartikainen, J, 1
Hartmann Siantar, CL, 312(ab)
Hartmann, IJC, 1317
Hartner, W, 25(ab)
Hartung, D, 4(ab), 23(ab)
Hartung, M, 90(ab), 246(ab)
Harwood, SJ, 295(ab)
Hasanreisoglu, B, 1299(ab)
Hasegawa, BH, 35(ab), 174(ab), 215(ab), 944(ab)
Hasegawa, S, 14(ab), 762(ab), 1201(ab)
Hasegawa, Y, 596, 995(ab), 996(ab)
Haselrig, T, 1029(ab), 1030(ab)
Hashikawa, K, 229(ab), 536(ab), 818(ab)
Hashimoto, A, 763(ab)
Hashimoto, K, 1130(ab), 1498(ab)
Hashimoto, M, 734(ab)
Hashizume, T, 596
Hashmonai, M, 945(ab)
Haslinger, B, 992(ab)
Hassan, N, 451
Hasselbalch, S, 1046(ab)
Hasselbalch, SG, 853(ab)
Hassoun, W, 227, 921(ab)
Hastings, DL, 441(ab), 1286(ab)
Hata, T, 771(ab), 999
Hatano, K, 497(ab), 993(ab)
Hatazawa, J, 534(ab), 839(ab), 1006(ab)
Hatton, BN, 1370(ab)
Hatton, RL, 908(ab)
Hattori, N, 222(ab), 224(ab), 1000(ab), 1002(ab)
Haubner, R, 322(ab), 436(ab), 439(ab), 1489(ab)
Haugen, B, 1307(ab)
Hausmann, O, 1444
Haut, M, 954(ab)
Havlik, E, 1489
Hawkins, RA, 1160(ab), 1227(ab)
Hawman, E, 1186(ab)
Hay, ID, 294(ab), 455(ab)
Hayahsi, T, 865(ab)
Hayano, J, 780
Hayashi, A, 1218, 1490(ab), 1611
Hayashi, K, 15, 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Hayashi, T, 223(ab), 995(ab), 996(ab)
Hayashida, K, 223(ab), 748(ab), 757, 852(ab), 865(ab), 995(ab), 996(ab), 1402(ab)
Hayes, SW, 351(ab), 353(ab), 354(ab), 356(ab), 357(ab)
Hayles, S, 92(ab)
Haynam, A, 1094(ab)
Haynam, AA, 1208(ab)
Haynor, DR, 1230(ab)
Hays, MT, 210
Hazra, DK, 1260(ab)
He, J, 485(ab), 501(ab), 1084(ab), 1508(ab), 1529(ab)
He, X, 31(ab)
He, ZX, 582(ab), 745(ab), 808(ab), 1399(ab)
Heeger, SW, 418(ab)
Heerschap, A, 1197(ab)
Hegerl, U, 1045(ab)
Heiba, S, 71(ab), 460(ab), 550(ab), 1171(ab)
Heiba, SI, 339(ab), 345(ab), 346(ab)
Heichel, T, 510, 1153(ab)
Heidelberg, TH, 890(ab)
Heikman, P, 946(ab)
Heindel, W, 127(ab)
Heinz, A, 389(ab), 391(ab), 1055(ab)
Heinze, A, 1036(ab)
Heinze-Kuhn, K, 1036(ab)
Heiss, WD, 90(ab), 246(ab), 927(ab)
Heiss, W-D, 21
Helal, BO, 1284(ab)
Heller, EN, 421, 724(ab)
Heller, G, 180(ab)
Heller, GV, 273
Helmeke, HJ, 432(ab)
Hendel, R, 352(ab)
Hendel, RC, 11(ab), 273
Henderson, R, 769(ab)
Hendler, A, 1254(ab), 1358(ab)
Henriksen, G, 580(ab)
Henze, E, 135(ab), 298(ab), 1036(ab), 1290(ab), 1361(ab), 1365(ab)
Henze, M, 260(ab), 409(ab), 528(ab), 1524(ab)
Heo, YJ, 756(ab), 1334(ab), 1367(ab), 1427(ab), 1437(ab)
Herbst, B, 332(ab)
Herholz, K, 21
Hermann, D, 389(ab), 391(ab), 1055(ab)
Hermanska, J, 714(le)
Hermoni, N, 1232(ab)
Hermony, N, 1295
Hernandez Pampaloni, M, 3(ab), 508(ab), 509(ab)
Hernandez, G, 3(ab), 508(ab), 509(ab)
Hernandez, MA, 1419(ab)
Heron, DE, 1249(ab), 1250(ab)
Herrero, P, 510(ab), 871(ab), 1530, 1557
Herscovitch, P, 960(ab), 969(ab)
Hershkop, M, 1254(ab), 1358(ab)
Hertel, AH, 19(ab)
Herwig, U, 1049(ab)
Herz, M, 86(ab), 318(ab)
Hess, S, 580(ab)
Hesse, S, 1044(ab)
Hesse, T, 515(ab)
Hesseltine, SM, 469(ab)
Hetzel, M, 277(ab), 1207(ab), 1220(ab)
Hey, P, 1482(ab)
Hichwa, RD, 36(ab), 1523(ab)
Hickeson, M, 136(ab), 140(ab), 468(ab), 564(ab), 871, 1155(ab), 1214(ab), 1320(ab), 1383(ab), 1410(ab)
Hickey, KT, 1707
Hicks, RJ, 492
Hiemke, C, 1058(ab)
Hiemstra, CA, 1681
Higashi, K, 39, 141(ab), 1215(ab), 1337(ab)
Higashi, T, 173, 658, 1090(ab), 1198(ab), 1203(ab), 1204(ab), 1218(ab), 1221(ab), 1312(ab)
Higashino, H, 470(ab), 743(ab)
Higuchi, C, 142(ab)
Higuchi, I, 1201(ab)
Higuchi, T, 349(ab), 589, 708(ab), 716(ab), 1452
Hildinger, M, 434(ab)
Hilger, CS, 557(ab)
Hill, P, 739(ab)
Hill, TC, 1072(ab)
Hiller, A, 1514(ab)
Hillier, S, 1512(ab)
Hilson, AJ, 122(ab), 125(ab), 272(ab), 1149(ab), 1244(ab), 1268(ab), 1270(ab)
Hilton, J, 144(ab), 390(ab), 394(ab), 493(ab), 678, 1455(ab)
Hiltunen, J, 596(ab), 946(ab)
Himmelman, J, 828
Hines, H, 375(ab), 1398
Hinkle, G, 1094(ab)
Hinkle, GH, 1208(ab)
Hinnen, F, 1227
Hirai, J, 779(ab)
Hirai, M, 732(ab), 755(ab)
Hiraki, Y, 1308(ab), 1341(ab)
Hirano, T, 341(ab), 577
Hiraoka, M, 1218(ab)
Hirayama, A, 774(ab)
Hirobe, S, 1611
Hirokawa, Y, 1476
Hirono, O, 742(ab)
Hirsch, E, 991
Hisada, K, 775(ab), 789(ab)
Hisley, C, 371(ab)
Hittinger, L, 536
Hitzel, A, 27, 792(ab), 806(ab), 807(ab)
Hlisces, R, 1439(ab)
Hnatowich, DJ, 335(ab), 384, 485(ab), 486(ab), 501(ab), 1084(ab), 1508(ab), 1529(ab)
Ho, AD, 418(ab)
Ho, C, 84(ab), 841(ab)
Ho, CL, 304(ab)
Ho, N, 1126(ab)
Ho, P, 327(ab)
Hodis, H, 509(ab)
Hoeffken, H, 62(ab), 65(ab), 126(ab), 406(ab), 467(ab), 1269(ab), 1296(ab)

Hoekstra, CJ, 1304
Hoekstra, HJ, 278(ab)
Hoekstra, OS, 1304, 1317
Höffken, H, 289(ab), 291(ab)
Hoffman, EJ, 870(ab)
Hoffman, T, 152(ab), 1502(ab)
Hoffman, TJ, 333(ab), 1138(ab), 1507(ab)
Hofmann, M, 1488(ab)
Hofmann, MM, 1252(ab)
Höft, S, 1585
Hogenkamp, HP, 1091(ab)
Hogg, A, 492
Hoh, CK, 72(ab), 188(ab), 425(ab), 475(ab), 1227(ab), 1469(ab)
Hokin, K, 1005(ab)
Holbrook, S, 11N(2)
Holdsworth, CH, 191(ab)
Holle, L-H, 1175
Hollett, PD, 1591
Holm, S, 1046(ab)
Holschneider, CH, 103(ab), 104(ab)
Holt, DP, 605(ab), 976(ab), 1444(ab)
Holz, JB, 1191(ab)
Homs, C, 1375(ab)
Honda, N, 527(ab), 1200(ab), 1401(ab)
Hondo, M, 1200(ab)
Honer, M, 212(ab)
Hong, J, 99(ab)
Hong, JP, 1353(ab)
Hong, SW, 403(ab), 1010(ab), 1087(ab), 1105(ab), 1114(ab), 1144(ab), 1217(ab), 1353(ab), 1356(ab), 1424(ab), 1521(ab)
Honma, H, 261(ab)
Hopper, A, 12(ab)
Hoppert, T, 19(ab)
Horger, M, 1366(ab)
Hori, K, 440(ab)
Hori, M, 536(ab), 818(ab), 997(ab)
Horikoshi, M, 705(ab)
Horiuchi, KS, 1130(ab)
Horti, AG, 395(ab), 607(ab), 1433(ab), 1443(ab)
Horton, JA, 1007(ab)
Hosaka, K, 966(ab), 1035(ab)
Hoshizaki, H, 749(ab), 753(ab)
Hosoi, S, 721(ab), 723(ab), 1211(ab)
Hosokawa, M, 88(ab)
Hosokawa, R, 752(ab)
Hosono, M, 527(ab), 1200(ab), 1401(ab)
Hosotani, R, 173
Hospers, GA, 1107(ab)
Hou, YK, 598(ab)
Houle, S, 1438(ab)
Houston, T, 186(ab)
Houzard, C, 889, 1419
Hovanessian, L, 1176(ab)
Hovda, D, 1000(ab)
Hovda, DA, 222(ab), 224(ab), 1002(ab)
Howarth, DM, 740(ab)
Howe, J, 449(ab)
Howell, R, 1128(ab)
Howell, RW, 33N(1)
Howman-Giles, R, 305(ab)
Hsaio, MC, 1057(ab)
Hsu, C, 879(ab)
Hsu, H, 1078(ab)
Hsu, PI, 1340(ab)
Hsueh, S, 99(ab)
Hsueh, W, 3(ab), 508(ab), 509(ab)
Hu, D, 469(ab)
Hu, J, 26(ab)
Hu, M, 1493(ab)
Hu, P, 1265(ab)
Hua, FC, 1406(ab)
Huang, CL, 862(ab)
Huang, G, 16(ab), 707(ab)
Huang, GF, 605(ab), 1444(ab)
Huang, H-WC, 253
Huang, SC, 89(ab), 222(ab), 224(ab), 604(ab), 770(ab), 891(ab), 1000(ab), 1002(ab)
Huang, WS, 994(ab), 1332(ab)
Huang, W-S, 56
Huang, Y, 54(ab), 168(ab), 379(ab), 381(ab), 387(ab), 599(ab), 602(ab), 953(ab), 956(ab), 1054(ab), 1440(ab)
Huang, Z, 1456(ab), 1520(ab)
Hubbs, AF, 413
Huber, J, 212(ab)
Huber, K, 184(ab)
Huber, R, 322(ab), 1086(ab)
Hubner, KF, 424(ab), 1034(ab)
Huesman, RH, 522(ab), 523(ab), 530(ab)
Huiqing, Z, 404(ab)
Hulse, P, 1286(ab)
Humeres, P, 17(ab)
Humm, J, 315(ab), 1122(ab)
Humm, JL, 369(ab), 671, 837(ab), 876
Hummel, S, 1667
Humplik, BI, 1317(ab)
Hung, JC, 928, 1430(ab), 1495, 1531(ab)
Hur, MG, 1092(ab)
Hur, MK, 1521(ab)
Hurwitz, GA, 178(ab), 181(ab)
Hurwitz, RA, 803(ab)
Husain, M, 1051(ab)
Hussey, D, 1438(ab)
Hussey, DH, 1188(ab)
Hustinx, R, 138(ab), 139(ab), 280(ab), 833(ab)
Hutchins, GD, 214(ab), 316(ab), 868(ab), 1458(ab), 1491(ab)
Hutson, RK, 1034(ab)
Hutton, B, 305(ab)
Hutton, BF, 908(ab)
Huyghe, D, 1517(ab)
Huyghe, I, 805(ab)
Hwang, AB, 35(ab)
Hwang, BT, 733(ab)
Hwang, CH, 546(ab)
Hwang, DR, 52(ab), 54(ab), 168(ab), 379(ab), 381(ab), 387(ab), 400(ab), 599(ab), 602(ab), 953(ab), 956(ab), 1054(ab), 1440(ab)
Hwang, E-H, 589
Hwang, JJ, 1436(ab)
Hwang, JM, 1018(ab)
Hwang, KH, 1064(ab), 1316(ab)
Hwang, Y, 1707
Hyde, NC, 574(ab)
Hyder, W, 342(ab)

Iacampo, S, 704(ab)
Iannone, P, 1099(ab)
Ibaragi, M, 534(ab)
Ibaraki, M, 839(ab)
Ibrahim, T, 28(ab)
Ichihara, T, 1286
Ichikawa, S, 1279
Ichise, M, 395(ab), 843(ab)
Ide, M, 1245(ab)
Ido, T, 244(ab), 1017(ab), 1462(ab)
Idy-Peretti, I, 347(ab), 350(ab), 765(ab), 802(ab), 810(ab)
Iglesis, R, 1181(ab)
Iguchi, T, 1341(ab)
Ihara, M, 863(ab)
Iida, A, 780
Iida, H, 223(ab), 497(ab), 524(ab), 722(ab), 840(ab), 852(ab), 855(ab), 865(ab), 866(ab), 883(ab), 896(ab), 933(ab), 995(ab), 996(ab)
Iida, Y, 950(ab), 975(ab), 1312(ab), 1510(ab)
Ikeda, M, 1315(ab)
Ikeda, S, 721(ab)
Ikezoe, J, 470(ab), 721(ab), 723(ab), 1211(ab), 1368(ab), 1616
Ilagan, R, 247(ab)
Im, KC, 919(ab)
Imabayashi, E, 304
Imaizumi, M, 536(ab), 818(ab), 997(ab)
Imamura, M, 173, 1203(ab), 1204(ab)
Imondi, AR, 1208(ab)
Imuro, Y, 746(ab)
Inabnet, WB, 1310(ab), 1324(ab), 1329(ab)
Inagaki, M, 741(ab)
Inagaki, T, 1005(ab)
Inaoka, Y, 902(ab)
Inbar, M, 603
Ind, PI, 496(ab)
Inglis, BA, 97
Ingmire, K, 1426(ab)
Ingram, F, 758(ab)
Innis, RB, 163(ab), 237(ab), 384(ab), 392(ab), 395(ab), 598(ab), 843(ab), 883(ab), 978(ab)
Ino, H, 15
Inoue, G, 229(ab)
Inoue, H, 967(ab)
Inoue, K, 962(ab)
Inoue, M, 715(ab), 1476
Inoue, T, 1342(ab), 1457(ab), 1471(ab)
Inoue, Y, 751(ab)
Intenzo, CM, 1311(ab), 1318(ab)
Intra, M, 75(ab)
Inubushi, M, 1(ab), 7(ab), 718(ab), 757
Iosilevsky, G, 922(ab), 945(ab)
Ippolito, V, 998(ab)
Irie, A, 1165(ab)
Irie, S, 1005(ab)
Ishida, H, 1611
Ishida, Y, 524(ab), 748(ab), 757, 865(ab), 1028(ab), 1402(ab), 1453(ab)
Ishigaki, T, 1315(ab)
Ishii, K, 238(ab), 958(ab), 966(ab), 985(ab), 987(ab), 1027(ab), 1035(ab), 1611
Ishikawa, I, 141(ab)
Ishikawa, Y, 1418(ab)
Ishimori, T, 173, 658, 1090(ab), 1198(ab), 1203(ab), 1204(ab), 1218(ab), 1221(ab), 1312(ab)
Ishiwata, A, 989(ab)
Ishiwata, K, 958(ab), 987(ab), 1027(ab)
Ishizu, K, 229(ab), 863(ab), 975(ab), 1198(ab)
Isobe, N, 749(ab), 753(ab)
Isobe, S, 732(ab), 755(ab)
Israel, O, 114(ab), 117(ab), 290(ab), 945(ab), 1129, 1232(ab), 1295
Issa, M, 1414(ab)
Iterbeke, K, 374
Ito, H, 534(ab), 839(ab), 962(ab), 1004(ab), 1006(ab)
Ito, I, 797(ab)
Ito, K, 497(ab), 852(ab), 866(ab), 993(ab), 1204(ab)
Ito, M, 1457(ab)
Ito, T, 743(ab)
Ito, Y, 185(ab), 189(ab), 337(ab), 772(ab), 782(ab), 1381(ab)
Itoh, H, 804(ab)
Itoh, M, 1017(ab)
Itti, E, 273(ab), 1026(ab), 1596
Itti, L, 1026(ab)
Ivančević, V, 635
Ivancevic, V, 857(ab)
Ivanova, A, 1111(ab)
Iverson, BC, 928, 1531(ab)
Ivkic, M, 1183(ab)
Iwado, Y, 185(ab), 772(ab), 782(ab), 1381(ab)
Iwai, K, 993(ab)
Iwaisako, T, 950(ab)
Iwanczyk, JS, 35(ab), 569(ab), 870(ab), 923(ab), 943(ab)
Iwano, S, 1315(ab)
Iwasa, M, 545(ab)
Iwasaka, T, 746(ab)
Iwasaki, A, 1464
Iwasaki, T, 780(ab)
Iwata, K, 35(ab), 215(ab), 944(ab)
Iwata, M, 518(ab), 1312(ab)
Iwata, R, 109, 1462(ab)
Iyer, M, 247(ab), 1113(ab)
Iyer, R, 1187(ab)
Izawa, H, 732(ab)
Izbicki, G, 234
Izumo, M, 1089(ab)

Jäckel, B, 1382(ab)
Jackson, A, 441(ab)
Jackson, AB, 1373(ab)
Jackson, MA, 1519(ab)
Jacobs, AH, 90(ab), 246(ab)
Jacobs, F, 1426
Jacobs, M, 400(ab)
Jacobs, MP, 1727
Jacobsen, LK, 384(ab)
Jacobson, AF, 1205(ab)
Jacobson, MS, 1519(ab)
Jadvar, H, 92(ab), 366(ab), 769(ab), 1097(ab), 1176(ab), 1410
Jagadeesan, B, 143(ab)
Jager, P, 265(ab)
Jager, PL, 278(ab), 1207, 1409(ab)
Jagoda, EM, 399(ab), 977(ab), 1118(ab)
Jagt, P, 926(ab)
Jahan, S, 422(ab)
Jahn, M, 134(ab)
Jaime, A, 1364(ab)
Jain, D, 4(ab), 1333(ab)
Jamar, F, 120(ab), 121(ab), 325(ab), 442(ab), 1267(ab)
Jana, S, 71(ab), 1171(ab)
Jang, HJ, 101(ab), 240(ab), 1219(ab), 1369(ab)
Jang, MJ, 511(ab), 542(ab), 838(ab)
Jang, S, 107(ab), 552(ab), 1152(ab), 1238(ab)
Janicek, MJ, 1258(ab)
Janier, M, 1063
Jansen, PL, 476(ab)
Janssens, W, 418(ab)
Jansson, S, 828
Jaramillo, D, 1310
Jares, M, 18(ab)
Jarkas, N, 597(ab)
Jarkewicz, G, 915(ab)
Jartti, T, 773
Jaszczak, R, 34(ab), 378(ab)
Jaszczak, RJ, 39(ab), 190(ab), 914(ab)
Javaid, A, 790(ab)
Javellana, T, 1273(ab)
Javier, M, 186(ab)
Jayne, M, 388(ab)
Jayson, G, 441(ab)
Jebavy, P, 744(ab), 795(ab)
Jeloka, TK, 1420(ab)
Jenkins, BG, 220(ab)
Jennings, D, 68(ab)
Jensen, EA, 239(ab)
Jentzen, W, 162(ab), 1339
Jentzen, WJ, 1133(ab)
Jeon, TJ, 473(ab), 1067(ab)
Jeong, H, 1371(ab)
Jeong, HJ, 484(ab), 511(ab), 1142(ab)
Jeong, H-J, 1432
Jeong, HK, 886(ab)
Jeong, J, 430(ab), 971(ab), 1095(ab)
Jeong, JM, 153(ab), 1142(ab), 1429(ab), 1432, 1476(ab), 1479(ab), 1527(ab)
Jeong, M, 1017(ab)
Jeong, MH, 756(ab)
Jerusalem, G, 280(ab)
Jhiang, S, 1094(ab)
Ji, SD, 1399(ab)
Jia, F, 1083(ab)
Jiang, C, 1265(ab)

Jigalin, A, 900(ab)
Jimbo, M, 935(ab)
Jimenez, X, 3(ab), 508(ab), 509(ab)
Jin, J, 429(ab)
Jindal, SK, 1073(ab)
Jinnouchi, S, 1028(ab)
Jirsa, L, 714(le)
Joas, LA, 154(ab)
Joe, A, 581(ab)
Jofre, J, 17(ab)
Joh, CW, 730(ab), 1064(ab), 1316(ab), 1372(ab), 1428(ab)
John, CS, 1647
Johnson, KA, 232(ab), 880(ab)
Johnson, LL, 551
Johnson, M, 1187(ab)
Johnson, TK, 1307(ab)
Johnston, C, 31N(6), 36N(7), 39N(8)
Johnström, P, 492(ab)
Jokisch, DW, 97
Jollivet, C, 1388(ab)
Jones, AG, 406
Jones, DA, 1345(ab)
Jones, DW, 979(ab)
Jones, HA, 652
Jones, K, 232(ab), 880(ab)
Jones, L, 974(ab)
Jones, LA, 98(ab)
Jones, WF, 927(ab)
Jong-dae, L, 705(ab)
Jongbloed, G, 892(ab)
Jonson, B, 640
Jönsson, B-A, 1657
Jönsson, L, 1657
Joos, C, 87(ab), 1098(ab)
Jordan, M, 718(ab)
Jordan, R, 95(ab)
Joseph, B, 1333(ab)
Joseph, K, 1191(ab)
Joseph, U, 562(ab), 773(ab)
Jouan, V, 566
Juengling, FD, 277(ab), 462(ab), 1019(ab), 1049(ab), 1052(ab)
Juergens, H, 127(ab), 128(ab)
Juh, RH, 827(ab), 867(ab)
Juhasz, C, 825(ab)
Juillière, Y, 451
Julka, PK, 1011(ab)
Julyan, PJ, 441(ab), 1286(ab)
Jung, H, 886(ab), 1095(ab)
Jung, HW, 1432
Jung, WH, 1144(ab)
Jung, WS, 1087(ab), 1105(ab), 1114(ab), 1356(ab), 1424(ab)
Jung, YW, 1446(ab)
Jungclas, H, 1191(ab)
Jürgens, H, 1012
Jurisson, SS, 1083(ab), 1507(ab)
Juweid, ME, 283(ab), 449(ab), 1507

Kaarstad, K, 940, 1101(ab)
Kabasakal, L, 882
Kachi, T, 993(ab)
Kadrmas, DJ, 32(ab), 42(ab), 204(ab), 372(ab), 1545
Kagan, M, 1426(ab)
Kagana, O, 114(ab)
Kagaya, Y, 109
Kaji, T, 199(ab), 533(ab), 848(ab), 967(ab), 1040(ab), 1319(ab), 1331(ab)
Kalapparambath, TP, 632
Kalbacher, H, 1252(ab), 1488(ab)
Kalff, V, 492, 714(ab), 1259
Kalinyak, JE, 1285(ab)
Kam, BL, 123(ab)
Kamagata, S, 1611
Kambara, N, 752(ab)
Kamel, E, 547(ab), 1469
Kaminek, M, 18(ab), 744(ab), 795(ab)
Kaminska, A, 715
Kaminski, MS, 354
Kampen, WU, 135(ab), 298(ab), 1036(ab), 1290(ab), 1361(ab), 1365(ab)
Kamran, M, 727(ab), 796(ab)
Kanamaru, H, 181
Kanamaru, R, 244(ab)
Kanayama, S, 774(ab), 775(ab), 789(ab)
Kanazawa, S, 1308(ab), 1341(ab)
Kandimalla, J, 1333(ab)
Kanegawa, N, 1510(ab)
Kanekiyo, S, 985(ab)
Kaneko, K, 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Kaner, B, 482(ab)
Kaneta, T, 109
Kang, D, 1022(ab), 1042(ab)
Kang, E, 546(ab), 838(ab), 980(ab), 1018(ab), 1021(ab)
Kang, H, 546(ab), 980(ab), 1021(ab)
Kang, J, 430(ab), 971(ab), 1095(ab)
Kang, SB, 1141(ab), 1142(ab)
Kang, WJ, 343(ab), 759(ab)
Kanmatsuse, K, 734(ab)
Kannampilly, J, 1378(ab)
Kanno, I, 534(ab), 839(ab), 1006(ab)
Kanno, T, 1140(ab)
Kanoi, T, 701(ab)
Kao, C, 874(ab)
Kao, CK, 1501(ab)
Kao, P, 99(ab)
Kao, SY, 1193(ab)
Kao, T, 361(ab), 531(ab)
Kap, P, 307(ab)
Kaplan, E, 584
Kaplan, HJ, 1346(ab)
Kappes, R, 1375(ab)
Karabiyikoglu, M, 396(ab)
Karacay, H, 559(ab), 1484(ab)
Karadogan, I, 112(ab)
Karam, M, 1289(ab)
Karanikas, G, 405(ab)
Karasik, A, 1321(ab)
Karayalcin, B, 112(ab)
Karcher, G, 451, 566
Karczewski, D, 881(ab), 901(ab)
Kareinen, A, 1
Karlan, BY, 103(ab), 104(ab)
Karp, JS, 41(ab), 207(ab), 212(ab), 1398
Karwath, P, 161(ab), 608(ab)
Kasagi, K, 1312(ab)
Kasai, T, 727(ab), 796(ab)
Kasama, S, 1279
Kasamatsu, S, 1499(ab)
Kashimada, A, 1200(ab), 1401(ab)
Kashiwagi, T, 471(ab)
Kashyap, R, 287(ab)
Kasner, DL, 441(le)
Kasperbauer, JL, 294(ab)
Kasperek, A, 1482(ab)
Kassaee, A, 1238(ab)
Kassis, AI, 406, 1117(ab), 1125(ab), 1126(ab)
Kassubek, J, 1019(ab)
Kastis, GA, 175(ab), 933, 1104(ab), 1119(ab)
Kataoka, K, 701(ab), 752(ab)
Katayama, Y, 987(ab), 1027(ab)
Kato, C, 245(ab)
Kato, K, 950(ab), 1315(ab), 1476
Kato, T, 275(ab), 852(ab), 866(ab), 993(ab), 1061(ab), 1195(ab)
Kato, Y, 241(ab)
Katoch-Rouse, R, 1443(ab)
Katoh, A, 304
Katoh, C, 185(ab), 189(ab), 199(ab), 261(ab), 288(ab), 337(ab), 533(ab), 772(ab), 782(ab), 821(ab), 826(ab), 848(ab), 1040(ab), 1195(ab), 1306(ab), 1314(ab), 1319(ab), 1381(ab)
Katoh, S, 1319(ab)
Katsikis, PD, 1359
Katsumi, Y, 229(ab)
Katti, KV, 1507(ab)
Katuda, T, 596
Katzenellenbogen, JA, 1461(ab)
Kaufer, DI, 227(ab), 228(ab)
Kaufmann, CC, 1189(ab)
Kaufmann, R, 1015(ab)
Kauppinen, TA, 832(ab), 946(ab)
Kawaguchi, Y, 478(ab), 1379(ab)
Kawai, Y, 814(ab)
Kawakami, H, 743(ab)
Kawamoto, S, 554(ab)
Kawamura, K, 958(ab), 987(ab)
Kawano, M, 1343(ab)
Kawase, T, 1124(ab)
Kawashima, A, 1084
Kawashima, H, 950(ab)
Kawasuji, M, 589
Kawasumi, Y, 497(ab), 993(ab)
Kaya, GC, 345(ab), 346(ab)
Kaye, O, 138(ab), 139(ab)
Ke, CY, 1481(ab)
Ke, S, 150(ab)
Keane, MJ, 413
Keech, F, 12N(9)
Keen, H, 256(ab)
Keene, P, 1254(ab)
Kegeles, L, 51(ab)
Kegeles, LS, 956(ab), 1054(ab), 1440(ab)
Kegley, B, 488(ab)
Keidar, Z, 114(ab), 117(ab), 290(ab), 922(ab), 1129, 1232(ab)
Keiding, S, 439(le), 940, 1101(ab)
Keller, A, 1417(ab)
Kellinghaus, C, 983(ab)
Kelly, MJ, 714(ab), 1259
Kelsch, DN, 940(ab)
Kemerink, G, 255(ab)
Kennedy, A, 371(ab), 1275(ab)
Kennedy, C, 1039(ab)
Kennedy, MD, 1481(ab)
Kepe, V, 604(ab)
Kern, P, 462(ab)
Kerrou, K, 81(ab), 105(ab), 130(ab), 1143(ab)
Kerwin, RW, 1048(ab)
Keshary, N, 1327(ab)
Keshstgar, MR, 574(ab)
Kessler, H, 322(ab)
Kessler, M, 553(ab)
Kessler, ML, 119(ab)
Kessler, RM, 50(ab)
Ketring, A, 1502(ab)
Ketring, AR, 1083(ab)
Khalkhali, I, 126(le), 273(ab), 923(ab)
Khan, J, 468(ab), 564(ab), 1155(ab), 1320(ab), 1383(ab), 1410(ab)
Khan, MK, 490(ab)
Khanna-Hazra, P, 1260(ab)
Khatibi, B, 269(ab)
Khaw, B, 25(ab)
Khaw, BA, 703(ab)
Khawli, L, 1265(ab)
Khazaeli, M, 1082(ab)
Khazaeli, MB, 311(ab), 1245, 1264(ab)
Khenissi, L, 1054(ab)
Khorsand, A, 184(ab)
Kieffer, D, 255(ab), 1517(ab)
Kieffer, DM, 1532(ab)
Kienzle, G, 156(ab)
Kieper, DA, 909
Kies, P, 794(ab)
Kiesewetter, DO, 399(ab), 1118(ab), 1501(ab)
Kiesewetter, KO, 977(ab)
Kijewski, MF, 232(ab), 880(ab)
Kijima, H, 241(ab)
Kikuchi, T, 1368(ab), 1457(ab), 1616
Kikukawa, K, 939(ab)
Kilbourn, MR, 70(ab), 606(ab)
Kilcoyne, R, 308(ab)
Killiany, R, 232(ab), 880(ab)
Kilts, CD, 151(ab)
Kim, BI, 1144(ab)
Kim, BN, 302(ab)
Kim, BT, 101(ab), 240(ab), 919(ab), 1115(ab), 1116(ab), 1219(ab), 1369(ab), 1441(ab), 1460(ab)
Kim, BY, 963(ab)
Kim, CG, 435(ab), 1475(ab)
Kim, CK, 777(ab), 784(ab), 1310(ab), 1324(ab), 1329(ab)
Kim, CY, 1432
Kim, D, 971(ab)
Kim, DG, 1432
Kim, E, 150(ab), 324(ab), 1151(ab)
Kim, EE, 435(ab), 1088(ab), 1102(ab), 1109(ab), 1471(ab), 1475(ab), 1478(ab)
Kim, EH, 1105(ab), 1114(ab), 1356(ab), 1424(ab)
Kim, EN, 827(ab), 1184(ab)
Kim, GE, 537(ab)
Kim, H, 109(ab)
Kim, HC, 1064(ab)
Kim, HJ, 886(ab)
Kim, HS, 1064(ab), 1353(ab)
Kim, I, 1166(ab)
Kim, J, 495(ab), 871(ab), 1022(ab), 1042(ab)
Kim, JH, 69(ab), 1397(ab), 1397(ab)
Kim, JS, 364(ab), 537(ab), 546(ab), 1006, 1421(ab)
Kim, JW, 1141(ab)
Kim, JY, 98(ab), 331(ab), 494(ab), 756(ab), 974(ab), 1127(ab), 1367(ab), 1427(ab), 1437(ab)
Kim, K, 852(ab), 866(ab), 971(ab), 1095(ab)
Kim, KB, 343(ab), 759(ab)
Kim, KM, 223(ab), 524(ab), 865(ab), 883(ab), 933(ab)
Kim, KS, 473(ab)
Kim, M, 971(ab), 1492(ab)
Kim, MH, 1141(ab)
Kim, MJ, 1397(ab)
Kim, NH, 1492(ab)
Kim, S, 226(ab), 253, 735(ab), 1166(ab), 1310(ab), 1324(ab), 1329(ab)
Kim, SE, 101(ab), 240(ab), 919(ab), 1115(ab), 1116(ab), 1219(ab), 1369(ab), 1441(ab), 1460(ab)
Kim, SH, 827(ab), 867(ab), 1184(ab)
Kim, SK, 593(ab), 896
Kim, SM, 756(ab), 1006, 1311(ab), 1318(ab), 1334(ab), 1367(ab), 1427(ab), 1437(ab)
Kim, ST, 537(ab)
Kim, SW, 1092(ab), 1521(ab)
Kim, Y, 1166(ab)
Kim, YH, 101(ab), 240(ab), 1219(ab), 1369(ab)
Kim, YJ, 153(ab), 1476(ab), 1479(ab), 1527(ab)
Kim, YK, 238(ab), 302(ab), 343(ab), 364(ab), 542(ab), 736(ab), 759(ab), 982(ab), 1018(ab), 1142(ab), 1167, 1432
Kim, YR, 1441(ab)
Kimes, AS, 395(ab), 607(ab), 1433(ab), 1443(ab)
Kimura, G, 780
Kimura, Y, 958(ab), 987(ab), 1027(ab)
Kinahan, PE, 884(ab), 1230(ab), 1268
Kinast, O, 706(ab)
Kinda, A, 905(ab)
King, I, 251(ab)
King, MA, 6(ab), 27(ab), 194(ab), 845(ab), 909(ab), 910(ab), 915(ab), 1416(ab)
King, P, 380(ab)
Kinno, Y, 1342(ab)
Kinnunen, J, 832(ab)

Kinuya, S, 349(ab), 716(ab), 1079(ab), 1081(ab), 1084, 1089(ab)
Kirichian, AM, 1125(ab)
Kirkwood, ID, 968
Kirschling, TE, 154(ab)
Kirton, A, 1438
Kishi, H, 187, 421(ab), 902(ab)
Kishibe, Y, 535(ab), 771(ab), 999
Kisrieva-Ware, Z, 510(ab)
Kissel, T, 1096(ab), 1139(ab)
Kitabatake, A, 189(ab), 337(ab), 772(ab), 782(ab)
Kitagawa, K, 341(ab), 536(ab), 818(ab), 997(ab), 1286
Kitahar, K, 568(ab)
Kitai, T, 341(ab)
Kitamura, K, 902(ab)
Kitamura, S, 987(ab), 989(ab), 1027(ab)
Kitano, H, 863(ab)
Kitaura, Y, 809(ab)
Kitayama, M, 774(ab)
Kitayama, N, 304
Kitsos, T, 305(ab)
Kitsukawa, S, 783(ab)
Kittel, D, 1325(ab)
Kittner, C, 1328(ab)
Kiyono, Y, 1510(ab)
Kiyosawa, M, 1027(ab)
Kjaer, A, 140
Klauss, H, 406(ab)
Klein, C, 340(ab)
Klein, GJ, 523(ab)
Klein, JL, 12(ab)
Klein, M, 572(ab)
Klein, S, 1055(ab)
Klemm, E, 465(ab), 581(ab)
Kletter, K, 183(ab), 184(ab), 405(ab), 706(ab)
Klipper, R, 1137(ab)
Kloiber, R, 1438
Kloos, R, 1094(ab)
Kluge, G, 1076(ab)
Kluge, R, 176(ab)
Klunk, WE, 605(ab), 1444(ab)
Knapp, W, 1252(ab)
Knapp, WH, 432(ab), 1488(ab)
Kneilling, M, 439(ab)
Knell, V, 1244(ab)
Knesaurek, K, 777(ab), 1310(ab)
Knesewitsch, P, 1302(ab)
Knight, LC, 502(ab), 589(ab)
Knight, N, 11N(4), 40N(8)
Knoess, C, 90(ab), 246(ab), 927(ab)
Knoop, BO, 635
Knox, S, 419(ab)
Knudsen, GM, 360(ab), 363(ab), 853(ab), 1046(ab)
Knust, EJ, 162(ab)
Knust, J, 1133(ab)
Ko, RW, 1390(ab), 1393(ab)
Ko, Y, 1150(ab)
Kobayashi, H, 554(ab), 658, 1090(ab), 1315(ab)
Kobayashi, J, 1040(ab)
Kobayashi, K, 1381(ab)
Kobayashi, M, 88(ab)
Kobayashi, S, 1027(ab)
Kobayashi, T, 958(ab)
Koch, A, 1328(ab)
Koch, W, 200(ab), 539(ab), 828(ab), 1302(ab)
Kochan, P, 589(ab)
Kochhar, R, 1344(ab)
Koda, J, 1227(ab)
Kodama, M, 531, 1476
Kodama, Y, 141(ab), 1215(ab), 1337(ab)
Koecher, M, 19(ab)
Koehne, G, 329(ab)
Koeppe, RA, 70(ab), 227(ab), 228(ab)
Koga, H, 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Kogan, K, 290(ab)
Kohanim, S, 435(ab), 1102(ab), 1109(ab), 1471(ab), 1475(ab), 1478(ab)
Kohlmyer, S, 44(ab), 1137, 1398
Kohlmyer, SG, 204(ab)
Kohno, Y, 568(ab)
Kohya, T, 189(ab), 337(ab), 772(ab), 782(ab)
Kojima, A, 905(ab)
Kojouharov, I, 1136(ab)
Kolasinska, AD, 272(ab)
Kolb, DC, 1016(ab)
Kolb, PD, 1210
Kolb, PE, 95(ab)
Kolbert, KS, 309(ab), 313(ab), 323(ab), 555(ab)
Kolesnikov-Gauthier, H, 1173(ab)
Kolindou, A, 592(ab)
Koller, E, 706(ab)
Kolodgie, FD, 4(ab), 23(ab)
Kolodny, GM, 1072(ab)
Kolsky, KL, 498(ab), 1497(ab), 1513(ab)
Komaba, Y, 1027(ab)
Komori, T, 801(ab), 809(ab), 1016(ab)
Komuro, I, 776(ab), 783(ab)
Kondas, D, 1225(ab), 1247(ab)
Konijnenberg, M, 325(ab), 1271(ab)
Konishi, J, 173, 179(ab), 554(ab), 658, 701(ab), 722(ab), 752(ab), 863(ab), 950(ab), 975(ab), 1090(ab), 1198(ab), 1203(ab), 1204(ab), 1218(ab), 1221(ab), 1312(ab), 1498(ab)
Konishi, S, 1084, 1343(ab)
Konishi, T, 576(ab), 577(ab), 1190(ab)
Konstan, M, 584(ab)
Kontaxakis, G, 851(ab)
Konuk, O, 1299(ab)
Kooij, P, 325(ab), 1271(ab)
Kooij, PP, 123(ab)
Koomagi, R, 91(ab)
Kopelman, D, 945(ab)
Koral, KF, 882(ab)
Korde, A, 598(ab)
Koren, AO, 395(ab), 607(ab), 1433(ab)
Kormann, O, 725(ab)
Korolov, NA, 165(ab)
Kosaka, K, 276(ab)
Kosaka, N, 187, 421(ab)
Koshida, K, 1084
Kostakoglu, L, 284(ab), 417(ab), 576(ab), 577(ab), 1018, 1190(ab), 1257(ab)
Kosuda, S, 568(ab)
Kothari, P, 576(ab), 577(ab)
Kotzerke, J, 200, 462(ab), 1170(ab)
Koulibaly, M, 233(ab), 983
Kouno, Y, 1341(ab)
Koutcher, JA, 323(ab), 555(ab)
Kovacs, A, 1557
Kovacs, Z, 494(ab)
Kowoll, L, 760(ab)
Koyama, S, 957(ab)
Koyama, Y, 743(ab)
Kozikowski, A, 397(ab), 609(ab)
Kozikowski, AP, 493(ab)
Koziorowski, J, 671
Kozlowski, J, 863
Kraeber-Bodere, F, 579(ab)
Kraitchman, DL, 46(ab), 210(ab), 540, 785(ab)
Kramer, EL, 1294(ab)
Krasna, M, 1199(ab)
Kraus, G, 400(ab)
Krause, J, 1396(ab)
Krause, KH, 1396(ab)
Krauss, L, 1365(ab)
Krausz, Y, 290(ab)
Krawczynska, E, 352(ab)
Krawczynska, EG, 758(ab)
Krenning, E, 617, 1271(ab)
Krenning, EP, 120(ab), 121(ab), 123(ab), 167(ab), 325(ab), 442(ab), 444(ab), 446(ab), 1267(ab), 1650, 1681
Kridelka, F, 426(ab)
Krijnen, P, 330
Krikoriar, G, 1624
Krishnamurthi, G, 214(ab)
Krishnamurthy, GT, 901, 1603
Krishnamurthy, S, 901
Kritzman, JN, 182(ab), 348(ab)
Kroger, LA, 1256(ab)
Krohn, KA, 95(ab), 266(ab), 367(ab), 872(ab), 963(ab), 1012(ab), 1157, 1157(ab), 1230(ab), 1526(ab), 1667
Krol, A, 881(ab), 901(ab)
Kroll, S, 354, 417(ab), 1257(ab)
Kropp, J, 1439(ab)
Kross, B, 37(ab)
Krössin, T, 1382(ab)
Kruitwagen, CLJJ, 1150
Krynyckyi, BR, 777(ab), 784(ab), 1310(ab), 1324(ab), 1329(ab)
Krystal, JH, 392(ab)
Kubo, A, 1124(ab)
Kubo, N, 821(ab), 826(ab)
Kubo, S, 179(ab), 722(ab)
Kubota, I, 715(ab), 742(ab)
Kubota, K, 244(ab), 440(ab), 1462(ab)
Kuchel, T, 968
Kudo, K, 276(ab)
Kudomi, N, 223(ab), 524(ab), 865(ab), 933(ab)
Kuehn, KU, 911(ab)
Kuehn, T, 1170(ab)
Kuge, Y, 88(ab), 185(ab), 189(ab), 199(ab), 245(ab), 258(ab), 259(ab), 261(ab), 275(ab), 288(ab), 337(ab), 533(ab), 772(ab), 782(ab), 848(ab), 967(ab), 1040(ab), 1061(ab), 1195(ab), 1306(ab), 1314(ab), 1319(ab), 1331(ab), 1381(ab), 1453(ab)
Kuginuki, M, 141(ab)
Kuhnast, B, 322(ab), 436(ab), 1489(ab)
Kuikka, J, 1
Kuji, I, 383(ab), 1018
Kukis, DL, 334(ab)
Kula, NS, 598(ab)
Kulkarni, PV, 216(ab)
Kulmala, J, 1674
Kumakura, H, 1279
Kumakura, Y, 864(ab), 873(ab), 947(ab)
Kumamoto, K, 1234
Kumar, A, 287(ab), 454(ab), 1011(ab), 1327(ab)
Kumar, H, 1378(ab)
Kumar, P, 1123(ab), 1305(ab), 1463(ab), 1466(ab)
Kumar, R, 71(ab), 143(ab), 479(ab), 894(ab)
Kumar, S, 1344(ab)
Kundra, V, 406
Kung, H, 600(ab), 603(ab), 1442(ab), 1451(ab), 1530(ab)
Kung, HF, 67(ab), 218(ab), 434(ab)
Kunkel, M, 1148(ab)
Kunze, K, 900(ab)
Kupinski, MA, 933
Kurabayashi, M, 1279
Kureshi, S, 342(ab)
Kurian, V, 1433(ab)
Kurizaki, T, 957
Kuroda, K, 533(ab)
Kurokawa, K, 780
Kurosawa, H, 1234
Kurtaran, A, 706(ab)
Kurz, A, 231(ab), 990(ab), 1020(ab)
Kusano, S, 568(ab)
Kusic, Z, 1183(ab)
Kuten, A, 1129
Kuwabara, H, 954(ab), 999(ab)
Kuwabara, Y, 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Kuwert, T, 145
Kuyvenhoven, JD, 33, 851
Kvols, L, 120(ab), 121(ab), 1267(ab)
Kwack, HS, 403(ab), 1010(ab)
Kwark, C, 867(ab)
Kwekkeboom, D, 1271(ab)
Kwekkeboom, DJ, 123(ab), 325(ab), 1650
Kwon, J, 1022(ab), 1042(ab)
Kyme, AZ, 908(ab)
Kymes, SM, 726(ab)
Kyotani, S, 757
Kyriakou, Y, 824(ab)
Kyuma, M, 763(ab)

Laakso, M, 1
Labar, D, 442(ab)
Labombardi, V, 460(ab)
Lacan, G, 973(ab)
Lacic, M, 30(ab), 1183(ab)
Lacomblez, L, 991(ab)
Lacorte, L, 564(ab), 1152(ab)
Lafontaine, I, 262(ab)
Laforest, R, 212(ab), 974(ab), 1127(ab), 1557
Lahoutte, T, 87(ab), 1098(ab), 1145(ab), 1201, 1647
Lai, C, 99(ab)
Lai, KH, 1340(ab)
Lajeunesse, S, 15(ab), 180(ab)
Laki, D, 1518(ab)
Lalani, E-N, 519
Lalush, DS, 1578
Lam, KS, 334(ab)
Lam, PT, 1115
LaManna, JC, 1044
Lamargese, I, 180(ab)
Lamborn, KR, 334(ab), 1256(ab)
Lamki, LM, 562(ab), 773(ab)
Lammertsma, AA, 362(ab), 892(ab), 926(ab), 1041, 1304
Lamonica, D, 566(ab)
Lamonica, DM, 267
Lampe, Y, 1049(ab)
Lampl, Y, 1001(ab), 1003(ab)
Lan, S, 1121(ab)
Landin, R, 1258(ab)
Landmann, M, 876(ab)
Landman-Parker, J, 130(ab)
Landsman, DZ, 1294(ab)
Lang, L, 960(ab), 1449(ab)
Lang, LX, 198(ab)
Lang, O, 18(ab), 110(ab), 483(ab), 744(ab), 795(ab)
Lange, N, 863
Lange, P, 1382(ab)
Lange-Asschenfeld, C, 543(ab)
Langen, KJ, 402(ab), 1459(ab)
Langleben, DD, 1624
Långström, B, 1688
Laniece, P, 227
Laniece, P, 921(ab)
Lanser, ME, 61(ab)
Lanza, RC, 916(ab)
Laperle, K, 1094(ab)
Lardinois, D, 547(ab)
Larsen, RH, 580(ab)
Larson, S, 1013(ab)
Larson, SM, 46, 115(ab), 309(ab), 315(ab), 329(ab), 555(ab), 567(ab), 876, 1065(ab), 1122(ab), 1482
Lartizien, C, 884(ab), 1268, 1434(ab)
Laruelle, M, 51(ab), 52(ab), 54(ab), 168(ab), 379(ab), 381(ab), 384(ab), 387(ab), 599(ab), 602(ab), 953(ab), 956(ab), 1054(ab), 1440(ab)
Lasso, J, 888(ab)
Lastoria, S, 916
Lau, YH, 305(ab)
Lauer, B, 761(ab)
Launay, O, 1352(ab)

Launes, J, 946(ab)
Lavenne, F, 1063
Laverman, P, 1357(ab)
Law, MP, 1031
Lawhorn-Crews, J, 94(ab)
Lawler, LP, 46(ab)
Lawrance, J, 441(ab), 1286(ab)
Lawton, TJ, 500
Laycock, S, 556
Lazaris, D, 1163(ab)
Lazewatsky, J, 327(ab), 1426(ab)
Lazzeri, E, 236(ab), 591(ab), 1164(ab)
Le Bars, D, 1063
Le Cloirec, J, 889
Le duc-Pennec, A, 586(ab)
Le Guludec, D, 239, 347(ab), 350(ab), 703(ab), 713(ab), 765(ab), 788(ab), 802(ab), 810(ab), 889, 1352(ab)
Le Rest, C, 586(ab)
Le, K, 247(ab)
Leach, S, 954(ab)
Leahy, MF, 415(ab)
Leal, J, 78(ab), 548(ab), 885(ab)
Leamon, CP, 1477(ab)
Lear, JL, 308(ab), 376(ab), 521(ab)
Lebech, A-M, 140
Lebedev, NA, 165(ab)
Lebtahi, R, 347(ab), 350(ab), 788(ab), 802(ab), 889, 1352(ab)
Leclerc, G, 704(ab)
Lecomte, R, 704(ab), 709(ab)
Leduc-Pennec, A, 1352(ab)
Lee, BB, 1369(ab)
Lee, BC, 1460(ab)
Lee, BI, 364(ab)
Lee, C, 541(ab)
Lee, CH, 403(ab), 1010(ab)
Lee, D, 430(ab), 971(ab), 1022(ab), 1042(ab), 1095(ab)
Lee, DC, 1132(ab)
Lee, DS, 153(ab), 238(ab), 302(ab), 343(ab), 364(ab), 484(ab), 511(ab), 542(ab), 546(ab), 736(ab), 759(ab), 838(ab), 980(ab), 982(ab), 1018(ab), 1021(ab), 1142(ab), 1167, 1371(ab), 1432, 1476(ab), 1479(ab), 1527(ab)
Lee, ES, 1353(ab)
Lee, H, 429(ab), 867(ab)
Lee, HJ, 948
Lee, HK, 300(ab), 319(ab), 537(ab), 1006, 1421(ab)
Lee, HP, 1141(ab)
Lee, HY, 511(ab), 736(ab)
Lee, J, 735(ab), 972(ab), 1022(ab), 1042(ab), 1334(ab), 1342(ab), 1441(ab)
Lee, JD, 69(ab), 473(ab), 886(ab), 1067(ab), 1390(ab), 1391(ab), 1393(ab), 1397(ab)
Lee, JH, 101(ab), 537(ab)
Lee, J-H, 1570
Lee, JI, 838(ab)
Lee, JS, 238(ab), 302(ab), 364(ab), 542(ab), 546(ab), 838(ab), 919(ab), 982(ab), 1018(ab)
Lee, K, 735(ab), 769(ab)
Lee, KH, 101(ab), 240(ab), 919(ab), 1115(ab), 1116(ab), 1144(ab), 1219(ab), 1369(ab), 1441(ab), 1460(ab)
Lee, KS, 979(ab), 1219(ab)
Lee, KU, 838(ab)
Lee, M, 50(ab), 430(ab), 971(ab), 1022(ab), 1041(ab), 1042(ab), 1095(ab), 1371(ab)
Lee, MC, 153(ab), 238(ab), 302(ab), 343(ab), 364(ab), 484(ab), 511(ab), 542(ab), 546(ab), 736(ab), 759(ab), 838(ab), 980(ab), 982(ab), 1018(ab), 1021(ab), 1141(ab), 1142(ab), 1167, 1432, 1476(ab), 1479(ab), 1527(ab)
Lee, MH, 730(ab), 1064(ab), 1316(ab), 1372(ab), 1428(ab)
Lee, MS, 300(ab)
Lee, RJ, 174(ab)
Lee, SC, 1340(ab)
Lee, SG, 542(ab), 982(ab)
Lee, SJ, 1105(ab), 1114(ab), 1356(ab)
Lee, SK, 980(ab), 1167
Lee, SS, 756(ab)
Lee, SY, 1441(ab)
Lee, TS, 1087(ab), 1105(ab), 1114(ab), 1353(ab), 1356(ab)
Lee, U, 69(ab)
Lee, WC, 862(ab)
Lee, WW, 429(ab), 1421(ab)
Lee, Y, 430(ab), 971(ab), 1095(ab)
Lee, YJ, 484(ab), 542(ab), 838(ab), 1479(ab)
Lee, YS, 153(ab), 1476(ab), 1479(ab), 1527(ab)
Lee, Z, 584(ab)
Leenders, KL, 1444
Leeper, D, 1128(ab)
Legrand, H, 1470(ab)
Lehikoinen, P, 773
Lehner, B, 1153(ab)
Lehtiö, K, 1674
Lehto, S, 1
Leigh, BR, 1258(ab)
Leitha, T, 571(ab), 573(ab)
Lemaire, C, 280(ab)
Lemen, L, 124(ab)
Lenox, M, 926(ab), 927(ab)
Leo, R, 1326(ab)
Leon, A, 1181(ab)
Leonard, JP, 284(ab), 417(ab), 1018, 1257(ab)
Leor, J, 712(ab)
Leperse, V, 1284(ab)
Leppo, J, 6(ab)
Lerch, H, 900(ab), 1435(ab)
Lerman, H, 584, 603
Lerman-Sagie, T, 303(ab)
Leroy Ladurie, F, 410(ab)
Lessel, J, 769(ab)
Lester, H, 1032(ab), 1047(ab)
Leuchtweis, A, 230(ab)
Lever, JR, 1138(ab)
Leverger, G, 130(ab)
Leviel, V, 227, 921(ab)
Levitt, D, 441(ab)
Levy, WC, 513(ab)
Lewellen, B, 872(ab)
Lewellen, TK, 1157, 1230(ab)
Lewis, AD, 1083(ab)
Lewis, DH, 1041(ab)
Lewis, JS, 331(ab), 871(ab), 1121(ab), 1127(ab), 1557
Lewis, MR, 1083(ab)
Lewis, PJ, 540(ab)
Lewis, X, 248(ab)
Leyton, M, 947(ab)
Li, C, 150(ab)
Li, FJ, 443(ab)
Li, H, 33(ab), 930(ab), 931(ab), 932(ab)
Li, M, 706(ab), 1221(ab)
Li, MH, 1427(ab), 1437(ab)
Li, R, 50(ab)
Li, S, 706(ab)
Li, T, 1265(ab)
Li, WP, 331(ab), 1121(ab)
Li, X, 377(ab)
Li, XF, 1079(ab), 1081(ab)
Li, Y, 1486(ab)
Li, Z, 366(ab), 513(ab), 858(ab), 1452(ab), 1497(ab)
Liang, JZ, 377(ab)
Liang, Y, 214(ab)
Liao, SQ, 459(ab), 461(ab), 733(ab)
Liao, WH, 224(ab), 891(ab), 1002(ab)
Liao, YP, 89(ab)
Liard, A, 27
Libutti, SK, 365(ab), 565(ab)
Licata, CA, 1034(ab)
Licho, R, 61(ab), 64(ab), 538(ab), 915(ab)
Liebowitz, M, 54(ab)
Liehn, J-C, 715
Lien, CH, 733(ab)
Liepe, K, 1439(ab)
Liewald, F, 277(ab)
Lim, EH, 327(ab)
Lim, S, 1105(ab), 1356(ab)
Lim, SJ, 1087(ab), 1105(ab), 1114(ab), 1356(ab), 1424(ab)
Lim, SM, 403(ab), 1010(ab), 1087(ab), 1114(ab), 1144(ab), 1217(ab), 1353(ab), 1424(ab), 1521(ab)
Lim, ST, 1334(ab)
Lima-Filho, MO, 338(ab)
Lin, B, 1480(ab)
Lin, E, 1307(ab)
Lin, H, 1339(ab)
Lin, HC, 1311(ab), 1318(ab)
Lin, HD, 847(ab)
Lin, JH, 767(ab)
Lin, KJ, 1057(ab), 1436(ab)
Lin, KP, 847(ab)
Lin, KS, 336(ab), 502(ab)
Lin, MH, 994(ab)
Lin, MT, 955(ab)
Lin, Q, 882(ab)
Lin, WJ, 1108(ab)
Lin, XT, 1406(ab)
Lin, YY, 981(ab)
Lindencrona, U, 828
Line, BL, 206(ab)
Line, BR, 371(ab), 1199(ab), 1275(ab), 1413(ab)
Ling, C, 1122(ab)
Ling, CC, 671, 876
Link, B, 283(ab)
Link, JM, 513(ab), 858(ab), 1120(ab), 1157, 1157(ab)
Linke, R, 539(ab)
Links, JM, 44(ab), 895(ab), 1137
Lionnet, M, 1063
Liow, J, 358(ab)
Lipowska, M, 1422(ab)
Lippold, R, 1297(ab)
Lipson, E, 881(ab), 901(ab)
Liptrot, M, 360(ab)
Lister-James, J, 445(ab)
Littman, BH, 470
Liu, C, 486(ab), 501(ab), 1084(ab), 1508(ab), 1529(ab)
Liu, CY, 1057(ab)
Liu, F, 564(ab)
Liu, G, 384, 485(ab), 501(ab), 1084(ab), 1508(ab), 1529(ab)
Liu, H, 1007(ab), 1024(ab), 1078(ab), 1216(ab), 1373(ab)
Liu, HG, 1216(ab)
Liu, J, 604(ab), 1128(ab)
Liu, N, 335(ab), 384, 485(ab), 486(ab), 1084(ab), 1508(ab), 1529(ab)
Liu, Q, 487(ab)
Liu, RS, 160(ab), 263(ab), 274(ab), 361(ab), 459(ab), 461(ab), 531(ab), 733(ab), 823(ab), 847(ab), 862(ab), 955(ab), 981(ab), 994(ab), 1108(ab), 1161(ab), 1193(ab), 1340(ab), 1350(ab)
Liu, S, 1080(ab), 1495(ab)
Liu, X, 255(ab), 316(ab), 1101, 1458(ab), 1491(ab), 1657
Liu, XJ, 582(ab), 719(ab), 745(ab), 808(ab), 1399(ab), 1403(ab)
Liu, Y, 33(ab), 930(ab), 931(ab), 932(ab)
Liu, Y-H, 421, 1115
Liu, YZ, 1403(ab)
Liu, Z, 175(ab), 933, 1104(ab), 1119(ab)
Livieratos, L, 806
Livingston, RB, 500, 1100(ab), 1157(ab), 1158(ab)
Livni, E, 609(ab), 836(ab), 948(ab), 949(ab)
Livshitz, G, 584, 603
Ljungberg, M, 972, 1101, 1657
Llamas-Olier, A, 882
Lleong, E, 392
Lo, ES, 379(ab)
Lobuglio, AF, 311(ab)
LoBuglio, AF, 1245
Lobuglio, AF, 1264(ab)
Loc'h, C, 215
Locascio, F, 754(ab)
Lochmann, M, 543(ab)
Loddenkemper, T, 983(ab)
Lodge, MA, 206(ab), 371(ab), 1275(ab)
Logan, J, 56(ab), 158(ab), 197(ab), 219(ab), 380(ab), 386(ab), 388(ab), 961(ab), 972(ab), 1025(ab), 1331, 1570
Lohmann, B, 1296(ab)
Loiseau, P, 703(ab), 713(ab)
Lomas, DA, 1503(ab)
Lombardo, I, 52(ab), 54(ab)
Lomena, F, 1050(ab)
London, ED, 395(ab), 1433(ab)
Longaker, MT, 1392(ab)
Longari, V, 1326(ab)
Lopresti, B, 227(ab), 228(ab)
Lopresti, BJ, 976(ab)
Lorberboym, M, 303(ab), 480(ab), 1001(ab), 1003(ab)
Lorenz, E, 374(ab)
Lorette, G, 1388(ab)
Louie, AY, 503(ab)
Loussouarn, A, 1496(ab)
Louvrou, A, 1163(ab), 1167(ab)
Love, C, 297(ab), 457(ab), 1359(ab), 1363(ab), 1380(ab)
Low, PS, 1481(ab)
Lowe, G, 206(ab)
Lowe, J, 206(ab)
Lowe, VJ, 239(ab), 294(ab), 1014(ab), 1028, 1430(ab)
Lu, C, 57(ab), 58(ab), 63(ab), 66(ab)
Lu, C-S, 153
Lu, H, 377(ab)
Lu, J, 879(ab)
Lu, L, 1688
Lubberink, M, 889(ab), 1391
Lubin, E, 364
Lücking, CH, 1019(ab)
Lüdemann, P, 983(ab)
Luder, AS, 487
Ludwig, G, 725(ab)
Ludwig, V, 725(ab)
Luetolf, UM, 118(ab)
Luhn, M, 1328(ab)
Luini, A, 77(ab)
Luk, P, 38(ab), 927(ab)
Lull, R, 1285(ab)
Lund, R, 29(ab)
Lundqvist, H, 1391
Lundqvist, R, 1038(ab)
Luo, J, 71(ab), 1171(ab)
Luo, L, 1456(ab)
Luo, YX, 251(ab)
Lupetti, A, 1126(le)
Lurie, Y, 585(ab)
Luthra, SK, 97(ab), 496(ab)
Luu, AN, 336(ab)
Luxen, A, 280(ab), 973(ab)
Lynch, DR, 67(ab)
Lyons, S, 256(ab)

Ma, J, 413
Ma, S, 99(ab)
Ma, Y, 198(ab), 201(ab), 202(ab), 960(ab), 969(ab), 986(ab), 1324, 1431(ab)
Maas, NF, 67(ab)
Mabuchi, H, 15

Mabuchi, M. 772(ab), 782(ab), 821(ab), 826(ab), 1381(ab)
Macapilac, H. 1151(ab)
Macapinlac, H. 1187(ab)
Macapinlac, HA. 46, 108(ab), 876, 1109(ab), 1478(ab)
MacDonald, L. 870(ab)
MacDonald, LR. 35(ab), 569(ab), 923(ab), 943(ab)
Macey, DJ. 1245
Macgregor, RR. 961(ab)
MacGregor, RR. 1331
Mach, RH. 925(ab)
Machac, J. 777(ab), 784(ab), 1310(ab), 1324(ab), 1329(ab)
Machet, L. 1388(ab)
Machida, K. 527(ab), 1200(ab), 1401(ab)
Machtay, M. 107(ab), 552(ab)
Machulla, HJ. 30(ab), 134(ab), 156(ab), 391(ab), 401(ab), 1056(ab), 1123(ab), 1463(ab)
Maciel, BC. 338(ab)
Mäcke, HR. 409(ab)
Maclaughlin, E. 593(ab)
Madakasira, PV. 541(ab)
Madar, I. 234
Maddahi, J. 352(ab), 795
Madeddu Jr, G. 1156(ab), 1206(ab)
Madeddu, G. 1156(ab), 1159(ab), 1162(ab), 1206(ab)
Madhavi, T. 479(ab)
Madras, BK. 61(ab), 854(ab), 948(ab), 949(ab), 952(ab)
Maecke, HR. 610, 1252(ab), 1266(ab), 1488(ab), 1502(ab)
Maeda, H. 939(ab), 1286
Maeda, M. 1140(ab)
Maetani, Y. 1204(ab)
Magalotti, C. 77(ab)
Magata, Y. 863(ab)
Maguire, RP. 1444
Mahall, C. 65(ab)
Mahoney, DW. 928, 1531(ab)
Mahren, B. 1505(ab)
Maillot, F. 1336(ab)
Maini, A. 143(ab), 234(ab), 394(ab), 493(ab), 965(ab)
Maini, CL. 79, 745
Majewski, S. 37(ab), 373(ab), 909, 942(ab)
Maki, K. 1308(ab)
Makino, K. 341(ab), 1286
Makrigiorgos, GM. 1117(ab)
Maksud, P. 991(ab)
Makuuchi, H. 241(ab)
Malaise, MG. 138(ab), 139(ab)
Malek, F. 18(ab), 795(ab)
Malhi, H. 246, 1333(ab)
Malhotra, A. 143(ab), 287(ab), 479(ab), 894(ab)
Malhotra, G. 146(ab)
Malison, RT. 384(ab)
Mallett, ME. 11(ab)
Mallidi, P. 1063(ab)
Malminiemi, K. 773
Malveaux, EJ. 149(ab), 151(ab)
Malveaux, G. 597(ab)
Mamede, M. 179(ab), 658, 722(ab), 975(ab), 1090(ab), 1218(ab), 1221(ab)
Mamede, MH. 173, 1198(ab), 1203(ab), 1204(ab)
Mamoudy, P. 1352(ab)
Manca, G. 236(ab), 411(ab), 1182(ab)
Manco-Johnson, M. 308(ab)
Mandel, SJ. 72, 463(ab), 466(ab), 468(ab), 1320(ab)
Manfras, B. 462(ab)
Mang'era, K. 384, 1529(ab)
Mangner, TJ. 93(ab), 94(ab), 401(ab)
Manjeshwar, RM. 369(ab), 837(ab)
Manka-Waluch, A. 581(ab)
Mankoff, DA. 500, 1012(ab), 1100(ab), 1120(ab), 1157(ab), 1158(ab), 1667
Mankowski, JL. 965(ab)
Mann, EA. 64(ab)
Mann, K. 389(ab), 391(ab), 543(ab), 1055(ab)
Mannting, F. 406
Manrique, A. 27, 792(ab), 806(ab), 807(ab)
Mansour, CS. 5(ab), 728(ab)
Mantil, J. 203(ab), 382(ab), 541(ab), 1522(ab)
Mantil, JC. 400(ab)
Manuel, M. 103(ab), 104(ab)
Maragh, M. 1275(ab)
Maragh, MR. 1199(ab)
Marcellis, M. 138(ab)
Marcellis, S. 139(ab)
Marchais, S. 1445(ab)
Marchevsky, A. 407(ab)
Marcos, T. 1050(ab)
Marcus, CS. 267, 1241, 1273(ab)
Marek, K. 60(ab), 68(ab)
Marengo, M. 904(ab)
Margouleff, C. 1324, 1431(ab)
Mari, C. 2(ab), 22(ab), 396(ab), 702(ab), 720(ab)
Mariani, G. 411(ab), 500(ab), 591(ab), 811, 983, 1164(ab), 1182(ab)
Marie, P-Y. 451, 566
Marin-Neto, JA. 338(ab)
Marino, PS. 496(ab)
Markert, O. 938(ab)
Markert, U. 1136(ab)
Markova, J. 110(ab)
Marongiu, P. 1206(ab)
Marosi, C. 405(ab)
Maroy, R. 964(ab)
Marquet, RL. 1681
Marres, HA. 575(ab)
Marsden, PK. 29(ab)
Marsee, D. 1094(ab)
Marseille, DM. 226(ab), 1029(ab)
Marshall, JF. 1467(ab)
Marshall, L. 785(ab), 878(ab), 885(ab), 1239(ab), 1241(ab), 1242(ab)
Marshall, LT. 44(ab), 48(ab), 1137
Marsland, B. 1482(ab)
Marsteller, D. 158(ab), 219(ab), 380(ab)
Martarello, L. 149(ab), 151(ab)
Martel, G. 703(ab), 713(ab)
Martel, MK. 119(ab), 553(ab)
Marti, JM. 155(ab)
Martin, D. 936(ab)
Martin, F. 1050(ab)
Martin, J. 52(ab)
Martin, SJ. 1524(ab)
Martindale, A. 415(ab)
Martinez, D. 51(ab), 54(ab), 387(ab), 602(ab), 1029(ab), 1030(ab), 1054(ab)
Martini, S. 725
Maruoka, N. 532(ab), 968(ab)
Maruyama, A. 762(ab)
Maruyama, K. 14(ab), 762(ab)
Marwin, SE. 297(ab), 457(ab), 1363(ab)
Marx, K. 1322(ab)
Marx, KK. 292(ab)
Marzec, UM. 710(ab)
Marzi, M. 1485(ab)
Marzilli, LG. 1422(ab)
Masala, MV. 1156(ab)
Masatoshi, M. 1103(ab)
Mason, A. 969(ab)
Mason, G. 392(ab)
Mason, R. 216(ab)
Masood, R. 437(ab)
Masood, Y. 180(ab)
Massague, J. 249(ab)
Massardo, T. 17(ab), 882
Massengale, JC. 1175(ab)
Massoudi, S. 1290(ab), 1361(ab)
Mast, P. 918
Mastrippolito, R. 227, 921(ab)
Masud, M. 1103(ab)
Masuda, K. 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Matei, C. 323(ab), 555(ab)
Mateos, JJ. 1050(ab)
Matheja, P. 983(ab)
Mather, SJ. 1368
Mathews, WB. 144(ab), 390(ab), 678, 1454(ab)
Mathias, CJ. 1481(ab)
Mathis, CA. 227(ab), 228(ab), 605(ab), 844(ab), 976(ab), 1090, 1444(ab)
Matoba, M. 1337(ab)
Matochik, JA. 1433(ab), 1443(ab)
Matouskova, E. 483(ab)
Matsuda, H. 304
Matsuda, K. 593(ab)
Matsudaira, M. 775(ab)
Matsui, M. 1035(ab)
Matsui, S. 774(ab)
Matsuki, T. 518(ab)
Matsumoto, K. 217(ab), 1198(ab), 1312(ab)
Matsumoto, M. 536(ab), 734(ab), 818(ab), 905(ab)
Matsumoto, N. 734(ab)
Matsumura, K. 341(ab), 545(ab)
Matsumura, Y. 1291(ab)
Matsunari, I. 514(ab), 589, 774(ab), 775(ab), 779(ab), 789(ab), 803
Matsuno, K. 958(ab)
Matsuoka, H. 743(ab)
Matsuoka, N. 957(ab)
Matsuyama, S. 1245(ab)
Mattar, SG. 590(ab)
Mattes, D. 1230(ab)
Mattes, MJ. 560(ab)
Matthew, KJ. 1294(ab)
Matthews, DC. 1526(ab)
Matthies, A. 465(ab), 581(ab), 871
Mattmuller, S. 1522(ab)
Matuschek, C. 257(ab)
Mauceri, C. 1144, 1213(ab)
Mauch, P. 109(ab)
Maughan, RL. 107(ab), 552(ab), 1238(ab)
Mauguière, F. 1419
Maune, S. 1585
Maurer, A. 273
Maurer, AH. 11N(6), 16N(2), 177(ab), 589(ab)
Maurer, M. 455(ab)
Mausner, L. 498(ab)
Mausner, LF. 1497(ab), 1513(ab)
Mawalawi, O. 1054(ab)
Mawlawi, O. 51(ab), 54(ab), 108(ab), 387(ab)
Mayberg, HS. 1053(ab)
Maynard, K. 39N(4)
Maza, S. 570(ab), 1172(ab)
Mazumdar, S. 1090
Mazuru, D. 1083(ab)
Mazuru, DG. 333(ab), 1138(ab)
Mazza, SM. 413
Mazzarol, G. 75(ab), 811
McArthur, JC. 234(ab)
McBride, B. 710(ab)
McBride, W. 89(ab)
McBride, WJ. 558(ab), 559(ab), 1484(ab)
McCallum, RW. 1338(ab)
McCann, UD. 678
McCarron, J. 1445(ab)
McCarthy, DW. 1499(ab)
McCarthy, KE. 124(ab), 1185(ab)
McCarthy, T. 315(ab)
McCarthy, TJ. 98(ab), 117, 1346(ab)
McColl, R. 216(ab)
McCollum, AD. 264(ab)
McConathy, J. 149(ab), 151(ab), 597(ab)
McCook, B. 884(ab)
McCook, BM. 1249(ab), 1250(ab)
McCready, VR. 1272(ab)
McCusker, C. 1335(ab), 1512(ab)
McDonald, LJ. 1412(ab), 1591
McDonogh, JE. 552(ab)
McDougall, IR. 1287(ab), 1300(ab), 1301(ab), 1303(ab)
McElroy, DP. 870(ab)
McEwan, AJB. 87
McGhie, IA. 811(ab)
McGill, CC. 180(ab)
McGill, J. 510(ab)
McGinley, M. 1358(ab)
McIver, B. 294(ab), 455(ab)
McKenna, M. 441(le)
McKenna, R. 407(ab), 1222(ab)
McKenzie, AF. 492
McKusick, KA. 27N(7)
McKuster, K. 1074(ab)
McLaughlin, PW. 1188(ab)
McMillin, C. 1093(ab)
McMillin, CH. 1338(ab)
McNamara, D. 130(ab)
McNamee, L. 1146(ab)
Mcnitt-Gray, M. 47(ab), 1234(ab)
Meade, TJ. 503(ab)
Medina, LA. 1137(ab)
Meding, J. 400
Medvedec, M. 714(le)
Meegalla, S. 1530(ab)
Meeran, K. 1280(ab)
Mehilli, J. 28(ab)
Mehta, L. 1186(ab), 1231(ab)
Meier, DA. 856
Meignan, M. 1596
Meignan, MA. 648
Meikle, SR. 942(ab)
Meimarakis, G. 1196(ab)
Meininger, V. 991(ab)
Meinken, GE. 1497(ab), 1513(ab)
Meisner, J. 787(ab)
Mekel, M. 1295
Melcher, C. 36(ab)
Melder, I. 1070(ab)
Mele, D. 344(ab)
Melega, W. 973(ab)
Melfi, FM. 411(ab)
Melin, JA. 556, 621
Melissinou, M. 1163(ab), 1167(ab)
Meller, B. 1136(ab), 1472(ab)
Meltzer, CC. 228(ab), 884(ab), 1249(ab), 1250(ab)
Meltzer, HY. 50(ab)
Meltzer, PC. 948(ab), 952(ab)
Mena, E. 799(ab), 1417(ab), 1419(ab)
Mena, I. 1181(ab)
Ménard, J-F. 27
Menard, L. 924(ab)
Menconi, GF. 411(ab)
Menda, Y. 283(ab), 449(ab), 1223(ab)
Méndez, J. 475(ab)
Mendizabal, M. 392
Menon, PSN. 1327(ab)
Mentis, M. 986(ab)
Menu, P. 566
Menzel, C. 1015(ab), 1068(ab), 1295(ab)
Meoli, DF. 26(ab)
Mercer, N. 974(ab)
Mercer, NM. 98(ab)
Merdler, A. 778(ab), 791(ab)
Meredith, R. 419(ab)
Meredith, RF. 311(ab), 1245, 1264(ab)
Merhige, ME. 186(ab)
Merlet, P. 215, 536
Merlo, A. 1444
Mertens, J. 87(ab), 1098(ab), 1201
Mertes, P-M. 566
Mesangeau, D. 215
Mesina, CT. 362(ab), 892(ab)

Mester, J. 842(ab)
Meta, J. 325, 752
Metz, C. 190(ab)
Metzler, S. 34(ab), 378(ab)
Metzler, SD. 914(ab), 1259(ab)
Meulemans, A. 239, 703(ab), 713(ab)
Meyer, AF. 811(ab)
Meyer, CR. 1184
Meyer, G. 588(ab), 1408(ab)
Meyer, GJ. 432(ab)
Meyer, JH. 1438(ab)
Meyer, MA. 1224(ab)
Miao, Y. 152(ab)
Michalas, S. 1163(ab), 1167(ab)
Michel, C. 36(ab), 927(ab)
Michel, JB. 703(ab)
Michel, RB. 560(ab)
Michigishi, T. 1079(ab), 1081(ab), 1084, 1089(ab), 1343(ab)
Mick, R. 74(ab)
Micolajczyk, K. 850(ab)
Middlekauff, H. 770(ab)
Mielke, R. 21
Mier, W. 1515(ab), 1528(ab)
Migneco, O. 233(ab), 983
Mignon, M. 889
Mikhail, M. 180(ab)
Miliziano, J. 408(ab), 1210(ab), 1405(ab)
Miller, D. 239(ab), 726(ab)
Miller, JH. 593(ab), 896
Miller, K. 1029(ab)
Miller, KD. 316(ab), 1458(ab), 1491(ab)
Miller, KJ. 1030(ab)
Miller, TR. 100(ab)
Mills, C. 71(ab), 1171(ab)
Milner, R. 1488(ab)
Min, J. 1113(ab)
Minaker, K. 711(ab)
Minami, C. 1273(ab)
Minamihaba, O. 742(ab)
Minato, K. 217(ab)
Minematsu, K. 967(ab)
Minn, H. 1674
Minnerop, M. 608(ab)
Minoshima, S. 70(ab), 860(ab), 872(ab), 989(ab), 1012(ab)
Minowada, S. 421(ab)
Mintz, Y. 453(ab)
Mintzer, RA. 569(ab)
Miralbell, R. 1417(ab)
Mirick, GR. 334(ab), 1256(ab)
Mirzaitehrane, M. 339(ab)
Misaki, T. 1312(ab)
Mishani, E. 1032(ab), 1518(ab)
Mishina, M. 987(ab), 1027(ab)
Mishkin, F. 1273(ab)
Mishkin, FS. 273(ab), 923(ab), 1026(ab)
Mishra, SK. 431(ab)
Missimer, J. 1444
Mitani, K. 987(ab)
Mitchell, G. 1038(ab)
Mitrou, P. 1068(ab)
Mitsui, M. 734(ab)
Mittal, BR. 1073(ab), 1344(ab)
Miura, S. 839(ab)
Miyabe, H. 780
Miyabe, K. 1464
Miyagawa, M. 721(ab), 723(ab), 1211(ab)
Miyajima, S. 1476
Miyake, M. 1017(ab)
Miyake, Y. 223(ab), 497(ab), 865(ab), 1453(ab)
Miyamoto, T. 715(ab), 742(ab)
Miyatake, K. 748(ab)
Mizuno, S. 864(ab), 873(ab)
Mlikotic, A. 1273(ab)
Moadel, R. 787(ab)
Mochizuki, T. 258(ab), 259(ab), 470(ab), 721(ab), 723(ab), 1061(ab), 1211(ab), 1368(ab), 1616
Mock, BH. 316(ab), 1458(ab), 1491(ab)
Modarress-Mossalla, MM. 1288(ab)
Modelesky, T. 3(ab), 508(ab), 509(ab)
Moerlein, SM. 974(ab)
Mohammed, A. 1528(ab)
Mohannadi, SH. 1071(ab)
Mohsenifar, Z. 1222(ab)
Moka, D. 292(ab), 1283(ab), 1322(ab)
Moldenhauer, G. 418(ab)
Molea, N. 1164(ab)
Molinet, R. 1086(ab)
Momose, T. 751(ab), 864(ab), 873(ab)
Monbaron, D. 505(ab)
Monden, T. 1291(ab), 1379(ab)
Monetti, N. 760(ab), 1400(ab)
Monterosso, JR. 1624
Montie, JE. 1188(ab)
Montilla, JL. 1209(ab)
Montravers, F. 81(ab), 105(ab), 130(ab), 1143(ab)
Moon, BS. 1092(ab), 1521(ab)
Moon, DH. 319(ab), 429(ab), 537(ab), 1006, 1421(ab)
Moon, JW. 1067(ab)
Moonis, M. 538(ab)
Moore, A. 496(ab)
Moore, CJ. 856(ab)
Moore, DS. 1373(ab)
Moore, RY. 227(ab), 228(ab)
Moore, SC. 191(ab), 880(ab)
Moosmayer, D. 557(ab)
Mor, M. 585(ab), 791(ab), 1129, 1232(ab)
Morag, Y. 129(ab)
Morales, JA. 1222(ab)
Morandeau, L. 1496(ab)
Moreau, P. 280(ab)
Moresco, L. 811
Moretti, E. 499(ab)
Morgan, M. 1094(ab)
Mori, E. 1035(ab)
Mori, H. 383(ab)
Mori, T. 966(ab), 1035(ab)
Mori, Y. 1404(ab)
Morini, F. 591(ab)
Morita, K. 518(ab), 1319(ab)
Morita, Y. 821(ab), 826(ab)
Moriwaki, H. 995(ab), 996(ab)
Morlote, M. 339(ab)
Morris, M. 315(ab)
Morrison, M. 392
Morrow, TJ. 860(ab)
Mortelmans, L. 255(ab), 423(ab), 1054, 1060(ab)
Mortimer, PS. 318
Morton, KA. 1134(ab), 1500(ab)
Moser, E. 1019(ab)
Moses, WW. 934(ab)
Motomura, N. 905(ab), 939(ab)
Mottl, H. 1071(ab)
Mottolese, M. 745
Mountz, JD. 1078(ab)
Mountz, JM. 1007(ab), 1024(ab), 1078(ab), 1216(ab), 1373(ab)
Moura, EG. 89
Mourtzikos, K. 371(ab), 1199(ab), 1275(ab), 1413(ab)
Moussavian, B. 456(ab), 564(ab)
Moutray, K. 815(ab), 912(ab)
Moyers, C. 36(ab)
Mozley, PD. 55(ab), 67(ab)
Mrkobrada, M. 1493(ab)
Mruck, S. 145
Msds Study Group. 1292(ab)
Mubashar, M. 519
Muehlensiepen, H. 1459(ab)
Muehllehner, G. 41(ab), 212(ab), 1398
Mueller, BA. 1168(ab)
Mueller, H. 135(ab)
Mueller, J. 1172(ab)
Mueller, S. 209(ab), 1133(ab)
Mueller, SP. 106(ab), 893(ab), 1236(ab)
Mueller-Brand, J. 610, 1266(ab)
Mueller-Gaertner, HW. 393(ab)
Mueller-Schauenburg, W. 1366(ab)
Muhle, C. 1585
Mukai, T. 229(ab), 701(ab), 722(ab), 863(ab), 975(ab), 1198(ab), 1203(ab), 1498(ab)
Mukherjee, A. 1278(ab)
Mukherjee, J. 203(ab), 382(ab), 541(ab), 1522(ab)
Mukherjee, S. 1216(ab)
Mukhin, AG. 395(ab), 607(ab), 1433(ab), 1443(ab)
Mulatero, C. 441(ab)
Mulder, NH. 1107(ab)
Mulder, P. 717(ab)
Mulholland, GK. 159(ab), 1450(ab)
Mullan, BP. 239(ab), 294(ab), 455(ab), 1430(ab)
Mullani, N. 562(ab), 773(ab)
Muller, J. 9(ab), 24(ab)
Müller, U. 1044(ab)
Mullett, D. 1063(ab), 1229(ab)
Mullin, P. 1031(ab)
Mun, EF. 309(ab)
Mundle, G. 391(ab)
Munk, OL. 439(le), 940, 1101(ab)
Munz, D. 570(ab), 1172(ab)
Munz, DL. 635, 857(ab), 1037(ab), 1317(ab), 1382(ab)
Mura, M. 1400(ab)
Mura, MS. 1156(ab)
Murakami, M. 577
Murakami, T. 1211(ab)
Murakami, Y. 959(ab)
Murali, D. 385(ab), 1464(ab)
Murali, R. 487(ab)
Muralidharan, KC. 1071(ab)
Muramoto, S. 181
Murase, K. 470(ab), 818(ab)
Murata, H. 253(ab)
Murata, O. 1401(ab)
Murata, T. 968(ab)
Murphey-Corb, M. 976(ab)
Murphy, D. 1048(ab)
Murphy, E. 1280(ab), 1285(ab)
Murphy, J. 308(ab)
Murray, DR. 569(ab)
Murray, JA. 239(ab)
Murri, L. 236(ab)
Murthy, R. 1275(ab)
Musachio, J. 394(ab)
Musachio, JL. 493(ab)
Mussi, A. 411(ab)
Mut, F. 882
Muto, P. 916, 998(ab)
Mutschler, J. 1263(ab)
Muzi, M. 266(ab), 367(ab), 1012(ab), 1120(ab), 1157
Muzic, RF. 940(ab)
Muzik, O. 93(ab), 94(ab), 401(ab), 825(ab)
Myerson, R. 871(ab)
Myslivecek, M. 18(ab), 744(ab), 795(ab)

Nabi, H. 566(ab)
Nabi, HA. 82(ab), 267
Nabid, A. 262(ab)
Naeher, I. 1191(ab)
Nagabhushan, N. 1415(ab)
Nagahasi, T. 261(ab)
Nagai, R. 751(ab)
Nagamachi, S. 1028(ab)
Nagano-Saito, A. 993(ab)
Nagaoka, S. 1342(ab)
Nagaraja, H. 1094(ab)
Nagata, Y. 1218(ab)
Nagaya, N. 757
Nagle, CE. 11N(1), 267
Någren, K. 773
Nagren, K. 609(ab)
Nahmias, C. 36(ab)
Nair, V. 1378(ab)
Nakache, R. 584
Nakada, K. 88(ab), 199(ab), 245(ab), 261(ab), 275(ab), 288(ab), 1061(ab), 1195(ab), 1306(ab), 1314(ab), 1319(ab), 1331(ab)
Nakagami, Y. 1457(ab)
Nakagawa, K. 776(ab), 783(ab)
Nakagawa, M. 962(ab), 984(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Nakagawa, Y. 783(ab)
Nakai, K. 1245(ab)
Nakajima, K. 15, 349(ab), 589, 708(ab), 716(ab), 775(ab), 789(ab), 1343(ab)
Nakamoto, Y. 10(ab), 44(ab), 46(ab), 48(ab), 116(ab), 173, 210(ab), 658, 785(ab), 856(ab), 885(ab), 1137, 1198(ab), 1203(ab), 1218(ab), 1312(ab), 1454(ab), 1455(ab)
Nakamura, A. 993(ab)
Nakamura, F. 1040(ab), 1140(ab)
Nakamura, K. 1124(ab)
Nakamura, S. 746(ab)
Nakamura, T. 801(ab), 809(ab), 852(ab), 866(ab)
Nakanishi, N. 757
Nakano, A. 705(ab)
Nakano, H. 1027(ab)
Nakano, S. 304, 1315(ab)
Nakata, S. 1368(ab), 1616
Nakata, T. 518(ab), 763(ab)
Nakatani, D. 762(ab)
Nakayama, Y. 1315(ab)
Nakazawa, M. 531
Nakhoda, KZ. 136(ab), 463(ab), 466(ab), 1214(ab)
Nakopoulou, L. 1163(ab), 1167(ab)
Nakouzi, A. 299(ab)
Namavari, M. 1(ab), 7(ab), 157(ab)
Nambu, Y. 39
Namer, IJ. 991
Namkoong, SE. 1184(ab)
Nanasato, M. 732(ab), 755(ab)
Naninato, P. 77(ab)
Nanni, C. 1400(ab)
Nanninga, D. 1107(ab)
Nanus, DM. 1190(ab)
Narabayashi, I. 801(ab), 809(ab)
Narang, A. 1305(ab)
Narayan, S. 119(ab), 553(ab)
Narayanan, MV. 6(ab), 194(ab), 909(ab), 910(ab)
Narayanan, T. 203(ab)
Narayanan, TK. 382(ab), 1522(ab)
Narendran, R. 381(ab), 602(ab), 956(ab), 1440(ab)
Narita, H. 780
Narula, J. 2(ab), 4(ab), 22(ab), 23(ab), 702(ab)
Narula, N. 4(ab), 23(ab)
Narula, Z. 2(ab), 22(ab), 702(ab)
Narvaiza, I. 155(ab)
Nathan, M. 239(ab)
Nathan, MA. 1014(ab)
Natsume, T. 939(ab)
Nauta, J. 265(ab)
Navarro, M. 417(ab)
Navarro, V. 1050(ab)
Nazneen, L. 703(ab), 713(ab)
Negoita, C. 529(ab)
Nehmeh, SA. 876
Nekarda, H. 279(ab)
Nekolla, S. 21(ab), 183(ab), 184(ab), 514(ab), 781(ab)
Nekolla, SG. 28(ab), 340(ab), 506(ab), 515(ab), 516(ab), 761(ab), 775(ab), 789(ab)

Nelson, AD, 1186(ab), 1231(ab)
Nelson, J, 124(ab), 1185(ab)
Nemeroff, CB, 151(ab)
Nemoto, E, 999(ab)
Neri, G, 20(ab)
Neubauer, SE, 1181(ab)
Neuberg, D, 109(ab)
Neumaier, B, 96(ab), 200, 277(ab)
Neverve, J, 506(ab)
Nevrotski, T, 1383(ab)
Newberg, A, 1194(ab)
Newcorn, J, 56(ab)
Newhouse, MT, 487
Newport, DF, 38(ab)
Newsome, D, 754(ab)
Ng, K, 99(ab)
Ngai, WT, 235(ab)
Ngo, K, 602(ab), 956(ab), 1054(ab)
Nguyen, H, 773(ab)
Nguyen, S, 1596
Nibbering, PH, 1126(le)
Nicholas, RS, 318
Nichols, KJ, 172(ab)
Nichols, N, 815(ab)
Nicholson, RL, 196(ab)
Nickles, RJ, 385(ab), 1464(ab)
Nicol, B, 1336(ab)
Niereneberg, AA, 1053(ab)
Nies, C, 1296(ab)
Nijran, KS, 370(ab)
Nikfardjam, M, 184(ab)
Nikkinen, P, 946(ab)
Nikolov, G, 480(ab)
Nikula, T, 418(ab), 1086(ab)
Nil-A trial group, 68(ab)
Nilsson, M, 828
Nilsson, SF, 580(ab)
Nimmagadda, S, 94(ab)
Nir, B, 303(ab)
Nisar, N, 144(ab)
Nishii, R, 1028(ab)
Nishimura, K, 1200(ab)
Nishimura, S, 957(ab), 959(ab)
Nishimura, T, 14(ab), 762(ab), 818(ab), 1201(ab), 1234, 1453(ab)
Nishino, M, 1315(ab)
Nishio, S, 1130(ab)
Nishiyama, Y, 478(ab), 1165(ab), 1291(ab), 1379(ab), 1464
Nishizaki, M, 1616
Nishizawa, S, 705(ab), 822(ab)
Nitzsche, EU, 610, 1266(ab)
Nobili, F, 233(ab), 983
Noda, A, 957(ab), 959(ab)
Noda, S, 1056(ab)
Noguera, EC, 1364(ab)
Noguti, A, 596
Nohara, R, 701(ab), 752(ab)
Nollert, J, 260(ab)
Nonokawa, M, 732(ab), 755(ab)
Norbury, R, 1048(ab)
Noriyasu, K, 185(ab), 189(ab), 337(ab), 772(ab), 782(ab), 1381(ab)
Norman, JA, 330(ab)
Norris, CM, 264(ab)
Norys, C, 1052(ab)
Notghi, A, 1181
Nott, JM, 868(ab)
Novgorodov, AF, 165(ab)
Novotny, C, 706(ab)
Nowak, B, 187(ab), 1062(ab)
Noz, ME, 1294(ab)
Nozaki, N, 742(ab)
Nuñez, R, 46
Nuessle, K, 1207(ab), 1220(ab)
Nunez, RF, 1069(ab), 1070(ab), 1282(ab)
Nuri, M, 549(ab)
Nutt, R, 36(ab), 40(ab), 927(ab)
Nuvoli, S, 1159(ab), 1162(ab)
Nuyts, J, 188(ab), 425(ab), 1054, 1304
Nybo, MR, 154(ab)
Nyström, E, 828
Oakes, TR, 385(ab)
Obata, A, 1499(ab)
Obata, T, 1089(ab)
Oberg, AL, 455(ab)
Objois, M, 1336(ab)
Ochi, H, 131, 443
Ochiai, K, 1200(ab)
Ochoa, B, 1502(ab)
O'Connor, MK, 1168(ab)
Oda, K, 987(ab), 1027(ab)
Odagawa, Y, 1381(ab)
Odaka, K, 776(ab), 783(ab)
Odano, I, 951(ab)
O'Doherty, MJ, 29(ab), 1467(ab)
Odonnell, MJ, 159(ab)
O'Donnell, RT, 312(ab), 334(ab), 420(ab), 1261(ab)
O'Donoghue, JA, 671
O'Dorisio, T, 124(ab)
Oe, K, 779(ab)
Oei, H-Y, 330
Oertel, WH, 62(ab), 65(ab)
Oertzen, JV, 911(ab)
Oesterreich, G, 366
Ofluoglu, S, 183(ab), 184(ab), 1489
Ofner, F, 1262(ab)
Ogawa, K, 1498(ab)
Ogawa, M, 223(ab), 497(ab), 933(ab)
Ogi, S, 1404(ab)
Ogoshi, K, 241(ab)
Oguchi, M, 39, 141(ab), 1337(ab)
Ogura, Y, 801(ab), 809(ab)
Oh, C, 1475(ab)
Oh, EJ, 1492(ab)
Oh, H, 1095(ab)
Oh, JB, 980(ab)
Oh, SH, 546(ab)
Oh, SJ, 300(ab), 319(ab)
Ohbayashi, Y, 1464
Ohkawa, M, 478(ab), 1165(ab), 1291(ab), 1379(ab), 1464
Ohnishi, T, 304
Ohno, H, 1200(ab)
Ohno, Y, 568(ab), 1611
Ohta, S, 341(ab)
Ohtawa, N, 1200(ab)
Ohte, N, 780
Ohtomo, K, 751(ab), 864(ab), 873(ab)
Ohyama, M, 958(ab), 987(ab), 1027(ab)
Oikawa, H, 244(ab)
Oikonen, V, 1674
Oishi, S, 497(ab)
Ojha, B, 1216(ab)
Oka, H, 223(ab), 524(ab)
Oka, N, 865(ab)
Oka, T, 1342(ab), 1457(ab)
Okada, A, 742(ab)
Okada, H, 872(ab), 1140(ab)
Okada, K, 181
Okada, M, 755(ab)
Okada, T, 1200(ab), 1401(ab)
Okamoto, S, 1286
Okarvi, SM, 1483(ab), 1509(ab)
Okazaki, K, 1204(ab)
Okazaki, S, 957
Okazawa, H, 535(ab), 771(ab), 999
O'Keefe, GJ, 861(ab)
Okizaki, A, 1418(ab)
Oksman, Y, 1321(ab)
Oku, N, 536(ab), 818(ab), 997(ab)
Oku, S, 864(ab), 873(ab)
Okumura, W, 780(ab)
Okumura, Y, 1308(ab)
Okura, K, 705(ab)
Okuyama, C, 1234
Okuyama, M, 742(ab)
Oldfield, GS, 740(ab)
O'Leary, J, 1185(ab)
Oliverio, JG, 186(ab)
Olivier, P, 451, 566
Olmos, RAV, 1414
Olson, JJ, 149(ab)
Olsson, B, 640
Olsson, H, 292
O'Malley, JP, 1007(ab), 1373(ab)
Omata, N, 532(ab), 968(ab)
Omichi, M, 1200(ab), 1401(ab)
Omura, M, 1457(ab)
Ongseng, F, 469(ab)
Ono, H, 734(ab)
Ono, M, 1447(ab)
Ono, S, 764(ab)
Onthank, D, 327(ab)
Onthank, DC, 1080(ab)
Ooba, M, 752(ab)
Oono, M, 1342(ab)
Oosterwijk, E, 558(ab), 1085(ab)
O'Phelan, K, 222(ab), 1002(ab)
Orange, DT, 145(ab)
O'Reilly, R, 1111(ab)
O'Reilly, RJ, 329(ab)
Orellana, P, 306(ab), 1384(ab)
O'Rourke, RA, 750(ab)
Ortega, ML, 1050(ab)
Osada, H, 1200(ab), 1401(ab)
Osaki, Y, 536(ab), 818(ab)
Oshima, S, 749(ab), 753(ab)
Osieka, R, 1062(ab)
Osman, I, 46
Osman, M, 44(ab), 48(ab), 49(ab), 78(ab), 113(ab), 878(ab), 885(ab), 1137, 1239(ab), 1241(ab)
Osman, MM, 116(ab), 548(ab), 1228(ab), 1237(ab), 1242(ab)
Osman, S, 97(ab)
Osorio, M, 1429(ab)
Ostrowsky, K, 1419
O'Sullivan, F, 1012(ab), 1157
O'Sullivan, J, 1272(ab)
Ota, K, 141(ab)
Otsuka, M, 1362(ab)
Ott, K, 243(ab), 279(ab), 1251(ab)
Ottaviani, M, 951(ab), 1425(ab)
Otto, D, 1252(ab)
Ouadi, A, 1496(ab)
Ouchi, Y, 1140(ab)
Overgaard, J, 1101(ab)
Owen, C, 397(ab)
Owen, N, 152(ab), 1502(ab)
Owen, NK, 333(ab), 1083(ab), 1138(ab)
Owens, N, 1507(ab)
Owonikoko, T, 678
Owonikoko, TK, 144(ab), 390(ab)
Oxilia-Estigarribia, M, 21(ab), 781(ab)
Oya, S, 600(ab)
Oyama, N, 98(ab), 181
Oyanagi, C, 229(ab)
Oyen, R, 423(ab)
Oyen, W, 504(ab), 1128(le), 1351(ab)
Oyen, WJ, 80(ab), 575(ab), 1085(ab), 1197(ab), 1212(ab), 1354(ab)
Oyen, WJG, 918
Oz, OK, 216(ab)
Oza, A, 1254(ab)
Ozaki, K, 1109(ab)
Ozawa, S, 741(ab)
Ozawa, Y, 1342(ab)
Ozdogan, O, 482(ab)

Padhy, AK, 306(ab), 882, 1429(ab)
Padma, MV, 400(ab)
Padma, S, 147(ab), 1378(ab), 1423(ab)
Paeng, J, 1371(ab)
Paeng, JC, 153(ab), 343(ab), 511(ab), 759(ab), 1142(ab)
Paganelli, G, 75(ab), 77(ab), 811, 1485(ab)
Pagetta, C, 293(ab), 1279(ab)
Paglianiti, I, 236(ab), 1164(ab)
Paik, CH, 1504(ab), 1525(ab)
Paik, JY, 1115(ab), 1116(ab), 1460(ab)
Paillard, M, 142(ab)
Pain, F, 227
Pain, L, 921(ab)
Pain, SJ, 318
Painuily, NK, 1260(ab)
Pajunen, P, 1
Pak, CK, 25(ab)
Pak, KY, 1104(ab)
Palestro, CJ, 246, 295(ab), 297(ab), 457(ab), 632, 1069(ab), 1070(ab), 1255(ab), 1282(ab), 1333(ab), 1359(ab), 1363(ab), 1380(ab)
Palladino, L, 1180(ab)
Palm, S, 555(ab)
Palmedo, H, 465(ab), 526, 581(ab), 1150(ab)
Palmer, J, 640
Palumbo, B, 1254
Palumbo, R, 1254
Pan, X, 874(ab), 907(ab)
Panareo, S, 166(ab), 344(ab)
Pandey, AK, 894(ab)
Pandey, RM, 1327(ab)
Pandey, U, 1278(ab)
Panganamamula, KV, 589(ab)
Pant, GS, 894(ab)
Papadaki, E, 1167(ab)
Papadopoulos, T, 145
Papagiannopoulou, D, 1507(ab)
Papantoniou, V, 1163(ab), 1167(ab)
Papathanassiou, D, 715
Papenfuss, AT, 861(ab)
Papi, S, 1485(ab)
Papisov, MI, 1514(ab)
Pappas, N, 386(ab), 388(ab), 961(ab), 1025(ab), 1331
Paracchi, A, 1326(ab)
Parameswaran, RV, 757(ab)
Pardridge, WM, 948
Parent, F, 350(ab)
Parisi, J, 754(ab)
Park, C, 1253(ab)
Park, CH, 730(ab), 1064(ab), 1316(ab), 1428(ab)
Park, GH, 1492(ab)
Park, H-M, 77
Park, JH, 153(ab), 1092(ab), 1217(ab)
Park, JM, 101(ab), 240(ab), 1219(ab), 1369(ab)
Park, KB, 1428(ab)
Park, KH, 473(ab)
Park, LS, 1504(ab), 1525(ab)
Park, MH, 1105(ab), 1114(ab), 1356(ab)
Park, NH, 1141(ab)
Park, SK, 1006
Park, SY, 429(ab)
Park, YH, 827(ab), 1184(ab)
Parker, JA, 1072(ab), 1410
Parker, MA, 1477(ab)
Park-Holohan, S-J, 338
Parkinsons' Study Group, 60(ab)
Parkman, HP, 589(ab)
Parmar, JS, 1503(ab)
Parnell, J, 1359(ab)
Parnham, KB, 935(ab)
Pasqualoni, R, 79, 745
Passeri, A, 725
Passos, MCF, 89
Patel, P, 427(ab), 878(ab)
Pathak, H, 1260(ab)
Patt, BE, 35(ab), 569(ab), 870(ab), 923(ab), 943(ab)
Patt, JT, 1468(ab)
Patt, M, 1466(ab), 1468(ab)
Patterson, RE, 5(ab), 728(ab)
Patton, DD, 25N(7), 25N(3), 30N(1), 281(br), 933
Patton, PW, 97
Pattyn, P, 592(ab)
Paul, AK, 14(ab), 1201(ab)
Pauleit, D, 402(ab)
Paulmurugan, R, 1106(ab)
Paulson, PE, 860(ab)
Paulus, MJ, 942(ab)
Pauwels, EKG, 1126(le)

Pauwels, EKJ, 203
Pauwels, S, 120(ab), 121(ab), 325(ab), 442(ab), 1267(ab), 1271(ab)
Pavia, J, 1050(ab)
Pavlopoulos, S, 851(ab)
Pavlova, OA, 607(ab), 1433(ab), 1443(ab)
Payne, JK, 235(ab)
Payoux, P, 221(ab)
Pazin-Filho, A, 338(ab)
Pazzi, P, 474(ab)
Pecking, A, 410(ab)
Peeters, CF, 80(ab)
Péglion, J-L, 1227
Pegram, M, 1253(ab)
Peifer, JW, 12(ab)
Peker, C, 239, 703(ab), 713(ab)
Peker, O, 482(ab)
Pelizzo, MR, 293(ab), 1279(ab)
Pellegrina, D, 500(ab)
Pellegrino, D, 1182(ab)
Pelosi, E, 1180(ab)
Peng, NJ, 823(ab), 1161(ab), 1340(ab)
Penglis, S, 968
Pennec, A, 1411(ab)
Pennell, DJ, 806
Penney, B, 874(ab)
Penney, BC, 907(ab)
Pentlow, KS, 309(ab), 315(ab), 1122(ab), 1482
Penuelas, I, 155(ab)
Périault, C, 715
Percoco, G, 344(ab)
Pereira Neto, C, 725(ab)
Perez de Sá, V, 640
Perez, A, 387(ab)
Pereztol-Valdez, O, 12(ab)
Perlmutter, JS, 974(ab)
Perna, AJ, 186(ab)
Perone, R, 550(ab)
Perry, G, 1044
Peruzzi, P, 715
Peschel, C, 281(ab), 416(ab)
Peschke, P, 1096(ab), 1139(ab)
Petegnief, Y, 81(ab), 105(ab), 928(ab), 1143(ab)
Peter, J, 528(ab)
Peters, AM, 318, 519, 652
Peters, C, 387(ab)
Peterson, CD, 1727
Peterson, LE, 266(ab)
Peterson, LM, 367(ab), 1157(ab)
Petra, PH, 1157(ab)
Petrakis, I, 392(ab)
Petric, A, 604(ab)
Petrich, T, 432(ab)
Petrilli, G, 79, 745
Petrov, A, 4(ab), 23(ab)
Petruzella, FD, 664
Pettinato, C, 760(ab), 904(ab), 1400(ab)
Petzold, J, 824(ab)
Peyrot, MF, 390(ab)
Pezzino, V, 207
Pfahlberg, A, 145
Pfannenberg, AC, 1366(ab)
Pham, HL, 1273(ab)
Pham, V, 602(ab)
Phaneuf, DC, 15(ab)
Phelps, ME, 13N(2), 47(ab), 89(ab), 188(ab), 222(ab), 224(ab), 225(ab), 226(ab), 253, 269(ab), 270(ab), 282(ab), 286(ab), 325, 412(ab), 413(ab), 422(ab), 425(ab), 752, 1000(ab), 1002(ab), 1029(ab), 1030(ab), 1234(ab), 1253(ab)
Philippe, J, 1262(ab)
Philippi, H, 85(ab), 86(ab), 318(ab)
Phillips, EH, 268(ab)
Phillips, WT, 1137(ab)
Phom, H, 287(ab), 1011(ab), 1327(ab)
Piao, R, 536(ab), 997(ab)
Piccolo, S, 916, 998(ab)
Pichler, BJ, 212(ab), 374(ab), 439(ab)
Pichova, R, 18(ab), 110(ab), 483(ab), 744(ab), 795(ab)
Picozzi, V, 419(ab)
Pieper, B, 34(ab), 378(ab)
Pieper, BC, 914(ab)
Piepsz, A, 33, 851
Piert, M, 30(ab), 134(ab), 1123(ab)
Pieterman, RM, 167
Pietilä, M, 773
Pietrzyk, U, 1435(ab)
Piffanelli, A, 166(ab), 344(ab), 499(ab)
Piggot, K, 1270(ab)
Pike, J, 251(ab)
Pike, V, 1445(ab)
Pike, VW, 292
Pilati, P, 1243(ab)
Pillai, MRA, 1129(ab), 1278(ab), 1473(ab), 1474(ab)
Pillai, V, 201(ab), 202(ab), 1324
Pillarsetty, N, 1507(ab)
Pinborg, LH, 1046(ab)
Pindzola, R, 999(ab)
Pingitore, R, 1182(ab)
Pinkus, E, 100(ab)
Pinot, L, 227, 921(ab)
Pinquier, J, 1434(ab)
Pinson, CW, 83(ab)
Pintya, AO, 338(ab)
Pio, B, 1253(ab)
Piotto, A, 1279(ab)
Pirich, C, 183(ab), 184(ab), 1489
Pissarek, M, 366
Pisu, N, 1206(ab)
Pither, R, 392
Pitman, AG, 714(ab), 1259
Pitre, S, 924(ab)
Pivovaroff, MJ, 944(ab)
Plössl, K, 1530(ab)
Placke, M, 1208(ab)
Plascjak, PS, 1525(ab)
Platts, A, 1270(ab)
Plenevaux, A, 973(ab)
Pless, M, 610
Plisson, C, 151(ab)
Plossl, K, 218(ab), 434(ab)
Podoloff, D, 1414
Podoloff, DA, 108(ab), 150(ab), 324(ab), 435(ab), 1088(ab), 1102(ab), 1109(ab), 1151(ab), 1187(ab), 1471(ab), 1475(ab), 1478(ab)
Poepperl, G, 59(ab), 539(ab), 1045(ab)
Poffijn, B, 477(ab), 481(ab)
Pogarell, O, 59(ab), 1045(ab)
Pohjonen, H, 832(ab)
Pointurier, I, 765(ab), 1284(ab)
Poldermans, D, 767, 795, 1634
Pollock, BH, 1188(ab)
Pollum, H, 467(ab)
Pomper, MG, 234(ab), 493(ab), 965(ab), 1455(ab)
Ponde, DE, 98(ab)
Ponomarev, I, 249(ab)
Ponomarev, V, 250(ab), 252(ab), 1111(ab)
Pons, F, 1050(ab)
Ponzo, F, 102(ab), 450(ab), 552(ab), 1202(ab), 1383(ab), 1389(ab), 1398(ab)
Poole, JE, 513(ab)
Poole, KG, 496(ab)
Poole, RA, 758(ab)
Popov, V, 37(ab)
Porcu, A, 1162(ab)
Portnoy, O, 1624
Posner, MR, 264(ab)
Post, AM, 1359
Postema, EJ, 575(ab)
Postgård, P, 828
Potharaju, SP, 424(ab)
Pötter, E, 432(ab)
Pottier, JM, 1388(ab)
Pötzi, C, 405(ab)
Pourabdollah, S, 825(ab)
Powell, CC, 455(ab)
Powers, A, 124(ab)
Powers, B, 220(ab)
Powers, R, 397(ab), 609(ab)
Pozderac, R, 1094(ab)
Pozza, E, 76(ab)
Pradat, PF, 991(ab)
Pradhan, PK, 431(ab), 1420(ab)
Prakash, AM, 346(ab)
Prandini, N, 76(ab), 474(ab)
Pratali, R, 1164(ab)
Pratt, J, 376(ab), 521(ab)
Press, OW, 1526(ab)
Preston, DF, 1093(ab), 1338(ab)
Pretorius, PH, 6(ab), 27(ab), 64(ab), 1416(ab)
Price, BH, 1053(ab)
Price, DT, 92
Price, JC, 844(ab), 1090
Price, JP, 940(ab)
Price, PM, 97(ab)
Prieto, J, 155(ab)
Prince, JL, 895(ab)
Prins, MH, 1317
Prior, JO, 505(ab), 1385(ab)
Prisco, G, 75(ab)
Pruim, J, 167, 265(ab), 476(ab)
Pruneri, G, 77(ab)
Prunier, C, 221(ab)
Prvulovich, E, 574(ab)
Pugliese, PV, 1380(ab)
Pujol, J-F, 227
Pullan, S, 392
Punt, CJ, 1197(ab)
Pupi, A, 8, 233(ab), 725, 983
Purushotham, AD, 318

Qazil, M, 1063(ab)
Qi, J, 530(ab)
Qi, YJ, 213(ab)
Qian, C, 155(ab)
Qian, Z, 1185(ab)
Qin, W, 448(ab)
Qu, Z, 556(ab)
Quaife, RF, 348(ab)
Que, TH, 167
Quinn, J, 488(ab), 489(ab), 1487(ab)
Quinn, T, 152(ab)
Quinones, M, 3(ab), 508(ab), 509(ab)
Qureshy, A, 440(ab)

Rabau, M, 603
Rabito, CA, 470
Radan, L, 585(ab)
Radau, PE, 181(ab), 200(ab), 828(ab)
Radü, EW, 1444
Rafecas, M, 374(ab)
Raffel, DM, 512(ab), 1446(ab)
Raffelt, K, 292(ab), 1283(ab), 1322(ab)
Raghuraman, K, 1507(ab)
Rahul, C, 147(ab)
Rai, KR, 1255(ab)
Raizer, J, 1013(ab)
Rajappan, K, 806
Rajendran, J, 1230(ab)
Rajendran, JG, 266(ab), 367(ab), 1383, 1526(ab)
Rajon, DA, 97
Raman, S, 1276(ab)
Ramanna, L, 769(ab)
Ramasamy, R, 1707
Ramaswamy, M, 1227(ab)
Ramos, CF, 89
Rao, DV, 33N(1)
Rao, J, 325, 752, 1248(ab)
Rao, PS, 448(ab), 1128(ab), 1347(ab)
Raphael, CG, 1175(ab)
Rapoport, SI, 969(ab)
Rasey, JS, 1210
Rasgon, N, 1029(ab)
Rasgon, NL, 1030(ab)
Ratanaproeska, A, 1387(ab)
Ratib, O, 1234(ab)
Rattat, D, 257(ab), 1505(ab)
Rau, FC, 85(ab), 86(ab), 318(ab)
Rauch, SL, 1053(ab)
Rauseo, P, 144(ab), 493(ab)
Rauseo, PA, 1454(ab)
Ravasi, L, 399(ab), 977(ab), 1118(ab)
Ravert, HT, 8(ab), 144(ab), 390(ab), 678, 1131(ab), 1454(ab), 1455(ab)
Ravi Shankar, U, 882
Ravi, P, 1423(ab)
Ravid, A, 584
Ravin, PD, 61(ab), 64(ab)
Ray, P, 248(ab)
Raylman, RR, 37(ab), 373(ab)
Rea, S, 79
Rebenstock, A, 107(ab)
Reddy, JA, 1477(ab)
Redondo, F, 17(ab)
Reed, J, 38(ab)
Reed, JH, 927(ab)
Refaely, Y, 1199(ab)
Refosco, F, 499(ab)
Regalbuto, C, 207
Regan, D, 354
Regelink, G, 265(ab)
Rehm, K, 358(ab)
Reichart, B, 515(ab), 516(ab)
Reichel, G, 1123(ab)
Reichert, DE, 495(ab), 1516(ab)
Reichmann, K, 911(ab)
Reidel, G, 281(ab), 416(ab)
Reifenberger, G, 402(ab)
Reilhac, A, 1715
Reilly, RM, 1254(ab), 1493(ab)
Reiman, E, 359(ab), 529(ab)
Reiman, RE, 92
Reimold, M, 391(ab), 1056(ab)
Reinhardt, M, 465(ab)
Reinhardt, MJ, 581(ab), 1150(ab)
Reischl, G, 156(ab), 1463(ab)
Reisinger, I, 1382(ab)
Remaud, P, 1496(ab)
Remy, P, 964(ab)
Ren, KA, 451(ab)
Ren, X, 707(ab)
Renaut, R, 359(ab), 529(ab)
Renda, JJ, 1078(ab)
Rennen, H, 504(ab), 1128(le)
Rennen, HJ, 1351(ab), 1354(ab), 1357(ab)
Rennen, HJJM, 918
Repa, I, 66
Resche, I, 73(ab), 428(ab), 579(ab)
Reschini, E, 1326(ab)
Reske, SN, 96(ab), 257(ab), 277(ab), 462(ab), 876(ab), 1049(ab), 1052(ab), 1059(ab), 1170(ab), 1207(ab), 1220(ab), 1263(ab), 1505(ab)
Reske, SS, 133(ab)
Reutelingsperger, CP, 1357(ab)
Reuter, S, 462(ab)
Reutter, BW, 523(ab)
Reynolds, C, 38(ab)
Rezaie, A, 1323(ab)
Reznik, A, 945(ab)
Rhiem, K, 1192(ab)
Rhim, CC, 1184(ab)
Rhodes, CG, 496(ab), 1031
Rhodes, DJ, 1168(ab)
Ribbens, C, 138(ab), 139(ab)
Ribbert, H, 1505(ab)
Ribeiro, MJ, 964(ab)
Ricard, M, 924(ab), 1425(ab), 1434(ab)
Ricaurte, GA, 678
Rice, HM, 83(ab)
Richard, J-C, 1063
Richardson, L, 787(ab)
Richerzhagen, N, 927(ab)
Richman, C, 420(ab), 1261(ab)
Richman, CM, 312(ab)

Richter, E, 1136(ab), 1472(ab)
Richter, JA, 155(ab)
Richter, M, 1037(ab)
Richter, R, 90(ab), 246(ab)
Richter, WS, 1382(ab)
Ridlehuber, HW, 1624
Riedel, E, 46
Rigel, J, 1438
Rigo, P, 138(ab), 139(ab)
Rijpkema, M, 1197(ab)
Rikimaru, H, 1103(ab)
Rimoldi, O, 1031
Ringelstein, EB, 983(ab)
Rini, JN, 1069(ab), 1070(ab), 1282(ab)
Rink, T, 1175
Rinn, KJ, 1100(ab)
Rinne, D, 1015(ab)
Risa, B, 714(ab), 1259
Rizzieri, D, 1259(ab)
Robbins, RJ, 1482
Robert, F, 311(ab), 1245
Robert, P, 233(ab)
Robert, PH, 983
Roberts, AD, 385(ab), 1464(ab)
Roberts, DW, 540(ab)
Robeson, W, 1431(ab)
Robin, F, 1596
Robinson, S, 1080(ab), 1426(ab)
Rocca, P, 75(ab)
Rockson, SG, 720(ab)
Roddy, R, 927(ab)
Rodriguez, G, 233(ab), 983
Roecken, M, 439(ab)
Roedel, R, 911(ab)
Roelandt, JRTC, 767, 795
Roelants, VA, 621
Roelcke, U, 1444
Roesch, F, 389(ab), 1055(ab), 1058(ab)
Roesch, P, 819(ab)
Rogers, B, 1082(ab)
Rogers, J, 1229(ab), 1229(ab)
Rogers, S, 47(ab), 1234(ab)
Roh, J, 971(ab)
Roland, PS, 1023(ab)
Romanini, A, 811, 1182(ab)
Romano, J, 502(ab)
Rondain, JE, 306(ab)
Rong, T, 451(ab)
Roodenburg, J, 265(ab)
Roos, JC, 330, 575(ab)
Roos, K, 718(ab)
Rosa, F, 1196(ab)
Rosario, E, 1526(ab)
Rösch, F, 165(ab), 970(ab)
Rose, C, 281(ab)
Rosenzweig, KE, 876
Ross, EL, 1368
Ross, GL, 1178(ab)
Ross, R, 718(ab)
Rossi, CR, 1243(ab)
Rossi, M, 591(ab)
Rosso, J, 1596
Rostomilly, R, 1667
Rotenberg, G, 453(ab), 1321(ab)
Rothmund, M, 1296(ab)
Rottenberg, D, 358(ab)
Roullet, JB, 1134(ab), 1500(ab)
Roumenov, D, 1425(ab), 1434(ab)
Rousseau, C, 73(ab), 428(ab), 579(ab)
Rouze, N, 214(ab)
Royal, HD, 856
Ruan, CG, 1399(ab)
Ruan, S, 329(ab), 671, 1122(ab)
Rubello, D, 293(ab), 1243(ab), 1279(ab)
Rubin, J, 239(ab)
Rubin, NT, 470
Rubin, RH, 470
Rubins, DJ, 973(ab)
Rubinstein, R, 290(ab), 1008(ab), 1032(ab)
Rubio-Aliaga, I, 85(ab)
Rudat, V, 260(ab)
Rudi, J, 79(ab)
Ruers, TJ, 80(ab), 1197(ab)
Ruiz, J, 505(ab)
Ruiz, M, 664
Rule, KA, 1034(ab)
Rumi, MG, 1326(ab)
Runge, R, 1439(ab)
Rusckowski, M, 335(ab), 384, 485(ab), 486(ab), 501(ab), 1084(ab), 1508(ab), 1529(ab)
Rush, AJ, 1051(ab)
Russell, CD, 762
Russell, J, 671
Russell, R, 433(ab)
Russo, G, 998(ab)
Rust, TC, 32(ab)
Ruszkiewicz, J, 976(ab), 1090
Ryou, H, 935(ab)
Ryu, J, 300(ab)
Ryu, JS, 300(ab), 319(ab), 429(ab), 1421(ab)
Ryu, J-S, 1006
Ryu, SY, 1144(ab)
Ryu, YH, 69(ab), 473(ab), 1067(ab), 1390(ab), 1391(ab), 1393(ab), 1397(ab)
Ryvlin, P, 1419
Rzepka, AE, 1186(ab)

Sabatino, G, 1485(ab)
Sabba, N, 499(ab)
Sabbah, A, 285
Sabel, M, 402(ab)
Sabri, O, 176(ab), 824(ab), 1044(ab), 1466(ab)
Sachleben, RA, 4(ab)
Sachs, J, 117(ab), 290(ab)
Sacktor, N, 234(ab)
Sadato, N, 181
Saddadi, F, 452(ab)
Sadeh, M, 1001(ab), 1003(ab)
Sadelain, M, 329(ab)
Saeed, MA, 342(ab)
Saeed, S, 1273(ab)
Safavy, A, 1082(ab)
Saga, T, 173, 554(ab), 658, 779(ab), 1090(ab), 1198(ab), 1203(ab), 1204(ab), 1218(ab), 1221(ab), 1312(ab)
Saghari, M, 1288(ab), 1323(ab)
Saginoya, T, 244(ab), 1017(ab)
Sagou, M, 865(ab)
Saha, MS, 942(ab)
Sahijdak, W, 553(ab)
Said, S, 400(ab)
Saito, K, 1005(ab), 1286
Saito, M, 1342(ab)
Saito, S, 440(ab)
Saji, H, 229(ab), 701(ab), 863(ab), 950(ab), 975(ab), 1130(ab), 1498(ab), 1510(ab)
Sakamoto, E, 933(ab)
Sakamoto, I, 1211(ab)
Sakamoto, K, 470(ab)
Sakamoto, M, 1103(ab)
Sakamoto, S, 217(ab), 304, 966(ab)
Sakane, N, 1234
Sakayori, O, 989(ab)
Sakhuja, V, 1073(ab)
Sakrauski, A, 439(ab)
Sakuma, H, 341(ab)
Sakuma, T, 39
Salberg, G, 580(ab)
Saleh-Mghir, A, 239
Salem, R, 1274(ab), 1276(ab)
Salgado, RB, 881(ab)
Salgado, RS, 901(ab)
Salman, K, 1066(ab), 1214(ab)
Sam, J, 107(ab)
Sam, JW, 136(ab), 1152(ab)
Sampalis, FS, 271(ab)
Sampalis, JS, 271(ab)
Samuel, G, 1129(ab), 1473(ab), 1474(ab)
Samuelsson, L, 1688
Sancho, G, 1417(ab)
Sandberg, K, 144(ab)
Sanders, M, 56(ab)
Sanderson, SD, 957
Sandler, MP, 1016(ab), 1258(ab)
Sandrock, D, 570(ab), 857(ab), 1172(ab), 1317(ab)
Sankaran, S, 432
Sansom, L, 968
Santana, C, 525(ab)
Santana, CA, 12(ab)
Santos, MM, 351(ab), 353(ab)
Santos, PA, 191(ab)
Saouaf, R, 1135(ab)
Sapoznikov, D, 1047(ab)
Sarda, L, 239, 788(ab)
Sarda-Mantel, L, 703(ab), 713(ab)
Sarikaya, I, 1013(ab)
Sarkar, SD, 632, 787(ab)
Sarma, H, 1278(ab)
Sarma, HD, 1129(ab), 1473(ab), 1474(ab)
Sartor, J, 161(ab)
Sasaki, M, 238(ab), 966(ab), 984(ab), 1035(ab), 1154(ab), 1212.5(ab), 1226(ab), 1246(ab)
Sasaki, T, 987(ab), 1027(ab)
Sasaki, Y, 253(ab)
Sasano, T, 1103(ab)
Sashin, D, 999(ab)
Sassaman, MB, 1501(ab)
Sasso, D, 1506(ab)
Sassolas, G, 889
Sato, J, 1418(ab)
Sato, K, 1688
Sato, M, 1218, 1490(ab)
Sato, N, 658, 840(ab), 855(ab), 1504(ab)
Sato, S, 1308(ab), 1341(ab), 1343(ab)
Sato, T, 764(ab)
Sato, Y, 440(ab), 734(ab)
Satoh, K, 478(ab), 1165(ab), 1291(ab), 1379(ab), 1464
Satter, M, 400(ab)
Sattler, B, 824(ab)
Satyamurthy, N, 1(ab), 7(ab), 89(ab), 155(ab), 157(ab), 422(ab), 604(ab), 1253(ab)
Sauter, E, 448(ab)
Savenkova, L, 602(ab)
Savolainen, S, 832(ab)
Savy, L, 1270(ab)
Sayed, MG, 1238(ab)
Sayeram, S, 195(ab)
Sayre, J, 21(ab), 781(ab)
Scarano, D, 417(ab), 1257(ab)
Schaap, J, 1094(ab)
Schaefer, JE, 1056(ab)
Schaefer, WM, 187(ab)
Schaefers, K, 938(ab)
Schaefers, M, 938(ab)
Schäfers, KP, 1031
Schafers, M, 794(ab)
Schaible, R, 1150(ab)
Schaper, K, 358(ab)
Scharnhorst, J, 266(ab), 1667
Schauer, T, 1515(ab), 1528(ab)
Schaum, E, 1361(ab)
Schauwecker, DS, 925
Schechter, N, 1088(ab)
Scheffel, U, 394(ab), 493(ab), 678, 1454(ab), 1455(ab)
Scheidhauer, K, 21, 233(ab), 281(ab), 416(ab)
Schelbert, H, 1(ab), 3(ab), 508(ab), 509(ab)
Schelbert, HR, 7(ab), 718(ab), 770(ab), 781(ab), 15N(12)
Scheld, H, 794(ab)
Schell, CP, 27(ab), 1416(ab)
Schelper, LF, 1136(ab)
Scher, H, 315(ab)
Scher, HI, 46
Schiavina, M, 1400(ab)
Schicha, H, 21, 292(ab), 1283(ab), 1322(ab), 1325(ab)
Schiepel, N, 515(ab), 516(ab)
Schiepers, C, 47(ab), 188(ab), 270(ab), 282(ab), 286(ab), 412(ab), 413(ab), 425(ab), 752, 1234(ab)
Schiffer, W, 158(ab)
Schiffer, WK, 380(ab)
Schillaci, O, 1162(ab), 1206(ab)
Schilling Von, C, 281(ab), 416(ab)
Schilsky, M, 1333(ab)
Schilsky, ML, 246
Schilz, J, 824(ab)
Schinkel, AFL, 767
Schipper, ML, 62(ab), 65(ab), 126(ab), 289(ab), 291(ab), 313(ab), 406(ab), 414(ab), 467(ab), 1269(ab), 1296(ab)
Schirp, U, 1266(ab)
Schirrmeister, H, 257(ab), 277(ab), 462(ab), 1059(ab), 1170(ab), 1207(ab), 1220(ab)
Schirru, A, 1159(ab)
Schleiff, P, 413
Schleyer, PJ, 861(ab)
Schlieck, A, 62(ab), 65(ab), 126(ab), 406(ab), 467(ab), 1269(ab), 1296(ab)
Schlyer, D, 1331
Schlyer, DJ, 197(ab), 211(ab), 961(ab)
Schmaljohann, J, 581(ab), 608(ab)
Schmalor, W, 332(ab)
Schmand, M, 36(ab)
Schmid, DT, 1147(ab)
Schmid, E, 1086(ab)
Schmid, RA, 1313(ab)
Schmid, S, 1147(ab)
Schmidt, AM, 1132(ab)
Schmidt, B, 281(ab), 416(ab)
Schmidt, G, 514(ab)
Schmidt, M, 21
Schmidt, MA, 123(ab)
Schmieder, S, 1459(ab)
Schmitz, A, 321(ab)
Schneider, H, 889(ab)
Schneider, R, 1122(ab)
Schneider, RF, 837
Schnell, O, 506(ab)
Schober, O, 127(ab), 128(ab), 794(ab), 938(ab), 983(ab), 1012, 1292(ab)
Schoder, H, 115(ab), 567(ab), 876, 1013(ab), 1065(ab)
Scholz-Ahrens, KE, 135(ab)
Schomäcker, K, 1325(ab)
Schomaecker, K, 292(ab)
Schönfeldt, C, 1049(ab)
Schoon, E, 307(ab)
Schoonjans, JM, 909
Schopphoff, H, 21
Schottelius, M, 330(ab)
Schoultz, BW, 580(ab)
Schraml, F, 1039(ab)
Schramm, NU, 913(ab)
Schreckenberger, M, 389(ab), 543(ab), 1148(ab), 1297(ab)
Schreiber, K, 28(ab)
Schrezenmeir, J, 135(ab)
Schroth, H-J, 1175
Schubert, EK, 500, 1100(ab), 1157(ab), 1158(ab)
Schubiger, PA, 374
Schuemichen, C, 1328(ab)
Schuhmacher, C, 1086(ab)
Schuhmacher, J, 409(ab)
Schuler, G, 761(ab)
Schulteis, G, 72(ab)
Schultheiss, S, 96(ab)
Schultz, J, 1083(ab)
Schultz, K, 56(ab)
Schulz, A, 133(ab)
Schumacher, K, 132(ab), 1387(ab)

Schumacher, T, 610, 1266(ab)
Schumann, G, 391(ab)
Schurrat, T, 467(ab), 913(ab)
Schuster, DP, 863
Schuster, SJ, 285(ab)
Schwaiger, M, 28(ab), 85(ab), 86(ab), 230(ab), 231(ab), 242(ab), 243(ab), 279(ab), 281(ab), 318(ab), 322(ab), 340(ab), 374(ab), 416(ab), 436(ab), 439(ab), 506(ab), 514(ab), 515(ab), 516(ab), 761(ab), 990(ab), 992(ab), 1020(ab), 1086(ab), 1123(ab), 1251(ab), 1489(ab)
Schwameis, E, 1489
Schwartz, DL, 266(ab), 367(ab), 1230(ab)
Schwartz, JL, 95(ab), 254(ab), 1210
Schwartz, R, 1181(ab)
Schwarz, K, 281(ab), 416(ab)
Schweeger, I, 1489
Schwimmer, J, 253
Schwitter, MR, 890(ab)
Sciacca, RR, 1707
Sciagrà, R, 8
Sciamarella, MG, 353(ab)
Sciammarella, MG, 351(ab), 354(ab), 357(ab)
Sciuk, J, 127(ab), 128(ab), 1012
Sciuto, R, 79, 745
Scopinaro, F, 1206(ab)
Scott, AM, 861(ab)
Scotto di Luzio, A, 725
Seeholzer, SH, 837
Seese, A, 176(ab), 824(ab)
Segars, W, 31(ab), 208(ab)
Segars, WP, 43(ab), 195(ab), 519(ab)
Segil, C, 1376(ab)
Segil, CM, 1376(ab)
Sehbai, A, 1063(ab)
Seibyl, JP, 60(ab), 68(ab), 237(ab), 384(ab), 392(ab), 395(ab), 598(ab), 936(ab)
Seidel, J, 212(ab)
Seidenschwang, S, 1086(ab)
Seidl, C, 1086(ab)
Seifert, B, 1469
Seigel, B, 71(ab), 1171(ab)
Seimbille, YE, 1465(ab)
Seitz, U, 96(ab)
Seki, H, 39, 1215(ab)
Seki, R, 747(ab)
Sekiya, M, 721(ab)
Seliounine, S, 216(ab)
Sellers, D, 365(ab), 565(ab)
Seltzer, M, 425(ab)
Seltzer, MA, 422(ab), 752
Semah, F, 991
Semmler, W, 400, 528(ab)
Senda, M, 217(ab), 966(ab), 1004(ab), 1027(ab)
Seneca, N, 395(ab)
Senekowitsch-Schmidtke, R, 85(ab), 86(ab), 318(ab), 322(ab), 436(ab), 439(ab), 1086(ab)
Senocak, O, 482(ab)
Senthilnathan, MS, 1420(ab)
Seo, I, 1375(ab)
Seok, J, 1166(ab)
Seong, S, 1371(ab)
Serganova, I, 249(ab), 250(ab), 252(ab)
Sergeeva, T, 770(ab)
Serra-Grima, JR, 799(ab)
Seshadri, N, 146(ab)
Sestini, S, 8, 725
Sfakianaki, E, 145(ab)
Sfakianakis, GN, 145(ab)
Sgouros, G, 309(ab), 313(ab), 323(ab), 555(ab)
Shabtai, M, 453(ab)
Shaffer, P, 125(le)
Shah, AA, 727(ab), 796(ab)
Shah, AB, 186(ab)
Shah, AM, 739(ab)
Shah, AP, 97
Shah, F, 496(ab)
Shah, KS, 215(ab)
Shaha, A, 1482
Shahinian, A, 320(ab), 503(ab), 1112(ab)
Shahinian, AH, 1075(ab)
Shahzad, A, 172(ab)
Shalev, A, 1047(ab)
Shankar, LK, 72
Shankar, S, 1470(ab)
Shao, L, 43(ab), 375(ab), 819(ab)
Shao, X, 606(ab)
Shapiro, B, 813(ab)
Sharabi, A, 550(ab)
Sharkey, RM, 310(ab), 559(ab), 579(ab), 1484(ab)
Sharma, PD, 894(ab)
Sharma, R, 1225(ab)
Sharma, RK, 1420(ab)
Sharma, S, 1347(ab)
Sharp, T, 871(ab)
Sharp, TL, 98(ab), 1530, 1557
Shaver, KM, 13(ab)
Shavrin, A, 252(ab)
Shaw, L, 750(ab)
Shaw, LJ, 352(ab)
Shaw, SM, 56
Shea, C, 380(ab), 961(ab), 1331
Shehab, D, 346
Shei, HR, 459(ab), 461(ab), 1350(ab)
Sheikh, A, 309(ab)
Shelbert, H, 21(ab)
Shelton, SE, 385(ab)
Shelton, V, 186(ab)
Shemmari, S, 1071(ab)
Shen, C, 257(ab), 1505(ab)
Shen, DH, 1094(ab)
Shen, R, 808(ab)
Shen, S, 311(ab), 312(ab), 419(ab), 906(ab), 1245, 1261(ab), 1264(ab)
Shen, SS, 420(ab)
Shen, Y, 487(ab)
Sheriff, AU, 117
Sherry, AD, 494(ab)
Shi, B, 203(ab), 382(ab), 1522(ab)
Shi, CQ, 421
Shi, HC, 173(ab), 578(ab)
Shi, J, 1044
Shi, QW, 451(ab)
Shi, RF, 582(ab), 719(ab), 745(ab), 808(ab), 1399(ab), 1403(ab)
Shiba, K, 383(ab)
Shibakawa, M, 1453(ab)
Shidahara, M, 852(ab), 865(ab), 866(ab), 933(ab)
Shields, A, 327(ab)
Shields, AF, 93(ab), 94(ab), 401(ab)
Shiga, T, 199(ab), 533(ab), 848(ab), 967(ab), 1040(ab), 1195(ab), 1314(ab)
Shih, CY, 733(ab)
Shim, YM, 240(ab)
Shim, YW, 1390(ab), 1391(ab)
Shima, K, 1234
Shimada, H, 241(ab)
Shimada, K, 741(ab)
Shimadzu, H, 1453(ab)
Shimamoto, K, 518(ab), 763(ab)
Shimazaki, M, 518(ab)
Shimizu, H, 705(ab)
Shimizu, M, 15
Shimoji, K, 399(ab), 977(ab), 1118(ab)
Shimomura, H, 801(ab), 809(ab)
Shimosegawa, E, 839(ab)
Shin, J, 430(ab), 971(ab), 1095(ab)
Shin, JH, 484(ab)
Shin, MJ, 1006
Shin, SH, 1356(ab)
Shin, YJ, 1390(ab), 1391(ab), 1393(ab)
Shinohara, H, 902(ab)
Shirai, N, 131, 443
Shirakawa, K, 554(ab)
Shirakawa, S, 939(ab)
Shirbiny, A, 1375(ab)
Shishido, T, 742(ab)
Shiue, CY, 160(ab), 321(ab), 601(ab), 1348(ab)
Shiue, GG, 601(ab), 1348(ab)
Shizukuishi, K, 1342(ab), 1457(ab)
Shlag-Eizenberg, D, 585(ab)
Shoaib, T, 1178(ab)
Shoghi-Jadid, K, 604(ab)
Shohtsu, A, 1245(ab)
Shokouhi, S, 211(ab)
Shoner, SC, 1120(ab)
Shoshan, Y, 1008(ab), 1032(ab)
Shoyeb, AH, 172(ab)
Shrem, Y, 903(ab)
Shreve, P, 551(ab)
Shreve, PD, 1099(ab)
Shuen, CM, 994(ab)
Shuke, N, 1005(ab), 1084, 1418(ab)
Shulkin, B, 1387(ab)
Shulkin, BL, 132(ab)
Siddiqui, P, 1289(ab)
Siderowf, AD, 67(ab)
Sieb, JP, 59(ab)
Sieckman, GL, 333(ab)
Siedlak, SL, 1044
Siegal, T, 1008(ab), 1032(ab)
Siegel, AH, 540(ab)
Siegel, AM, 540(ab)
Siegel, J, 310(ab)
Siegel, JA, 326(ab), 328(ab), 354, 1110, 1241
Siegel, S, 212(ab)
Sierralta, P, 17(ab)
Siessmeier, T, 389(ab), 543(ab), 970(ab), 1055(ab), 1058(ab), 1148(ab)
Siever, L, 51(ab)
Sievers, RE, 174(ab)
Siewert, JR, 242(ab), 243(ab), 279(ab), 1251(ab)
Sigman, S, 728(ab)
Silagan, N, 268(ab)
Silbergeld, DL, 1667
Silberstein, E, 327(ab)
Silberstein, EB, 856
Silva, PJ, 1080(ab)
Silverman, D, 269(ab)
Silverman, DH, 225(ab), 226(ab), 282(ab), 325, 752, 1029(ab), 1030(ab), 1253(ab)
Silverman, DHS, 253
Simcic, V, 1398
Simkins, R, 541(ab)
Simoes, MV, 338(ab), 514(ab)
Simonneau, G, 350(ab)
Simpson, CP, 149(ab)
Simpson, HB, 54(ab)
Simpson, NE, 149(ab)
Simpson, NR, 1707
Simula, S, 1
Singh, A, 594(ab), 595(ab), 738(ab)
Singh, AK, 1349(ab)
Singh, B, 1073(ab), 1305(ab), 1344(ab)
Singh, LN, 1017(ab)
Singh, V, 1073(ab)
Singh, VP, 1011(ab)
Sinha, A, 1065(ab)
Sinha, AM, 187(ab)
Sinha, N, 1482
Sinha, P, 561(ab), 563(ab)
Sinkovics, I, 66
Sinnett, D, 519
Sinusas, AJ, 26(ab), 421, 1115
Sinzinger, H, 472(ab), 1254, 1489
Sit, A, 1249(ab), 1250(ab)
Sitbon, O, 350(ab)
Sitek, A, 169(ab), 170(ab), 522(ab), 786
Sitko, J, 89(ab)
Sitter, H, 1296(ab)
Sjögreen, K, 972, 1101
Skalski, J, 885(ab), 1184
Skuza, KA, 1127(le)
Slama, M, 347(ab), 765(ab), 802(ab), 810(ab)
Slart, RH, 1409(ab)
Slavine, N, 216(ab)
Sledge, GW, 316(ab), 1458(ab), 1491(ab)
Slegers, G, 1262(ab)
Slifstein, M, 52(ab), 54(ab), 381(ab), 953(ab)
Slimani, L, 1511(ab)
Sloan, AE, 401(ab)
Slobodin, G, 312
Slomka, PJ, 178(ab), 181(ab)
Slooff, MJ, 476(ab)
Slooter, GD, 1681
Small, GW, 226(ab), 253, 604(ab)
Smelser, H, 489(ab)
Smestad, S, 1039(ab)
Smit, EF, 1304
Smith, C, 120(ab), 121(ab), 325(ab), 1267(ab), 1271(ab)
Smith, CD, 590(ab)
Smith, CJ, 1507(ab)
Smith, E, 936(ab)
Smith, GT, 424(ab), 1034(ab)
Smith, KF, 1294(ab)
Smith, MA, 29(ab), 1044
Smith, MF, 373(ab), 942(ab)
Smith, N, 256(ab), 1482(ab)
Smith, R, 1168(ab)
Smith-Jones, P, 576(ab), 1190(ab)
Smyrk, TC, 239(ab)
Snary, D, 1368
Snow, GB, 575(ab)
Snyder, SE, 606(ab)
Sobhani, I, 889
Sodee, DB, 584(ab), 1186(ab)
Soede, AC, 558(ab)
Sogabe, I, 470(ab)
Soghomonian, S, 249(ab), 250(ab), 251(ab), 252(ab)
Sohn, HS, 827(ab), 1184(ab)
Sohn, J, 1346(ab)
Sojkova, J, 540(ab)
Sokol, S, 67(ab)
Sokolov, R, 296(ab)
Solal, M, 924(ab)
Solanki, C, 1503(ab)
Solanki, KK, 301(ab)
Solanto, M, 56(ab)
Soliani, G, 76(ab)
Solinas, ME, 1159(ab), 1162(ab), 1206(ab)
Solinas, P, 1206(ab)
Solito, B, 591(ab)
Som, S, 1038(ab)
Somanesan, S, 1429(ab)
Somer, EJ, 29(ab)
Somura, F, 732(ab)
Soncini, E, 964(ab)
Song, A, 334(ab)
Song, H, 735(ab)
Song, HC, 756(ab), 1334(ab), 1367(ab), 1427(ab), 1437(ab)
Song, HM, 1392(ab)
Song, TY, 919(ab)
Song, X, 520(ab)
Song, YS, 1141(ab)
Songy, B, 786(ab)
Soni, RA, 1176(ab)
Sopov, V, 368(ab), 484
Soret, M, 45(ab), 834(ab), 835(ab)
Sorger, D, 1466(ab), 1468(ab)
Sorita, T, 1089(ab)
Soroa, VE, 301(ab)
Sosa, A, 1375(ab)
Sossi, V, 1398
Soti, Z, 135(ab)
Soufer, R, 421
Soutar, D, 1178(ab)
Souvatzoglou, M, 1163(ab), 1167(ab)

Sovago, J. 596(ab), 1445(ab)
Spaepen, K. 1060(ab)
Spana, G. 1128(ab)
Spanaki, MV. 198(ab)
Spangler, TA. 264(ab)
Spanu, A. 1156(ab), 1159(ab), 1162(ab), 1206(ab)
Spanu, L. 1156(ab)
Sparber, M. 133(ab)
Sparks, RB. 310(ab), 314(ab), 324(ab), 326(ab), 328(ab), 1110, 1241
Spence, AM. 367(ab), 963(ab), 1012(ab), 1157, 1667
Spencer, F. 6(ab)
Sperling, LS. 758(ab)
Spetsieris, P. 201(ab), 202(ab), 1324
Spetsieris, PG. 986(ab)
Spicer, JA. 1093(ab)
Spies, SM. 164(ab)
Spieth, ME. 441(le)
Spinks, T. 212(ab)
Spinks, TJ. 1031
Spitz, FR. 74(ab)
Spitzer, M. 1049(ab), 1052(ab)
Sprenger, E. 1585
Springer, K. 1513(ab)
Squatrito, S. 207
Squire, O. 315(ab)
Squire, OD. 876
Srinivasan, A. 123(ab), 1650
Srinivasan, M. 510(ab)
Srivastava, DN. 143(ab)
Srivastava, S. 498(ab)
Srivastava, SC. 1497(ab), 1513(ab)
Stabin, M. 38N(7), 210, 310(ab)
Stabin, MG. 326(ab), 906(ab)
Stachowiak, A. 150(ab)
Stachowiak, AM. 906(ab)
Stahl, A. 243(ab), 1251(ab)
Stahl, F. 761(ab)
Stahlschmidt, A. 134(ab)
Staley, JK. 163(ab), 384(ab), 392(ab)
Stamatakis, EA. 476
Stamp, GW. 519
Standl, E. 506(ab)
Stanec, M. 1183(ab)
Stanec, Z. 1183(ab)
Stastny, JJ. 1494(ab)
Stattaus, J. 106(ab), 1236(ab), 1339
Staudenherz, A. 571(ab), 573(ab)
Stearns, CW. 204(ab), 1398
Steel, CJ. 496(ab)
Stegger, L. 794(ab), 938(ab)
Stegmann, T. 19(ab)
Stehle, G. 575(ab)
Stein, R. 556(ab)
Steinbach, G. 1263(ab)
Steinbach, J. 1468(ab)
Steinert, HC. 118(ab), 547(ab), 887(ab), 1235(ab)
Steinmetz, AP. 129(ab)
Steinmetz, N. 11(ab), 1357(ab), 1532(ab)
Steinmetz, ND. 15(ab), 255(ab)
Stekhova, SA. 1157(ab)
Stellbrink, C. 187(ab)
Stelzer, KJ. 1667
Stengler-Wenzke, K. 1044(ab)
Stenhova, H. 483(ab)
Stepanov, P. 929(ab)
Stephens, AW. 710(ab)
Stephens, C. 150(ab)
Stern, R. 584(ab)
Sterzinger, JJ. 154(ab)
Stevenson, GD. 175(ab), 933, 1104(ab), 1119(ab)
Steventon, RS. 813(ab)
Stier Junior, A. 725(ab)
St-Jacques, P. 704(ab)
Stobbe, CC. 837
Stochino, MB. 1159(ab)
Stockbridge, H. 1041(ab)
Stoddart, HA. 936(ab)
Stoddart, HF. 936(ab)
Stoeber, B. 86(ab)
Stoeckli, SJ. 1147(ab)
Stokkel, MPM. 203, 1317
Stoll, SP. 211(ab)
Stollfuss, J. 279(ab)
Stolz, J-F. 451
Stone, KL. 214(ab), 316(ab), 1458(ab), 1491(ab)
Storp, C. 1020(ab)
Stout, D. 89(ab)
Stout, DB. 422(ab)
Strand, S-E. 972, 1101, 1657
Stratton, JR. 513(ab), 858(ab)
Strauss, HW. 2(ab), 22(ab), 23(ab), 258(ab), 259(ab), 396(ab), 500(ab), 702(ab), 708(ab), 811, 1164(ab), 1359, 1624
Strauss, L. 79(ab), 850(ab)
Strauss, LG. 91(ab), 510, 851(ab), 1153(ab)
Streeter, JR. 728(ab)
Stremmel, C. 145
Stroobants, S. 1054, 1060(ab)
Stroobants, SG. 1304
Strother, S. 358(ab)
Stubbs, J. 517(ab)
Studenov, A. 317(ab), 398(ab)
Stueben, G. 893(ab)
Stumpe, KD. 137(ab)
Styblo, TM. 569(ab)
Stypmann, J. 794(ab)
Su, WJ. 1350(ab)
Su, Z. 487(ab)
Succi Leonelli, E. 344(ab)
Sud, K. 1073(ab)
Sudo, Y. 381(ab), 599(ab), 953(ab), 956(ab)
Sugarbaker, DJ. 1144, 1213(ab)
Sugawara, Y. 1368(ab), 1616
Sugimoto, K. 535(ab), 771(ab), 999
Sugimura, K. 1035(ab)
Sugioka, J. 741(ab)
Sugiura, T. 746(ab)
Suh, TS. 867(ab)
Sulman, C. 1173(ab)
Sumanovski, L. 1699
Sumiya, H. 383(ab), 1452
Summersides, G. 968
Sun, CM. 981(ab)
Sun, H. 93(ab), 94(ab)
Sun, HB. 316(ab)
Sun, JG. 304(ab)
Sun, X. 494(ab)
Sundaram, PS. 147(ab), 1378(ab), 1423(ab)
Sundaram, SK. 365(ab), 565(ab), 1542
Sundaresan, G. 1(ab), 7(ab)
Sundram, FX. 1429(ab)
Sureshbabu, W. 1187(ab)
Suriano, S. 236(ab), 591(ab)
Surowiec, A. 1136(ab)
Surti, KS. 1194(ab)
Surti, S. 41(ab)
Sutcliffe-Goulden, JL. 1467(ab)
Sutton, R. 1377
Suurmeijer, AJ. 278(ab)
Suwa, M. 809(ab)
Suzuki, K. 141(ab), 783(ab)
Suzuki, S. 1005(ab)
Suzuki, T. 276(ab), 780(ab), 1124(ab), 1245(ab), 1279
Suzuki, Y. 181, 241(ab), 1245(ab)
Svarer, C. 360(ab), 363(ab), 853(ab), 1046(ab)
Swanson, JM. 56(ab)
Swanson, SM. 1494(ab)
Swanston, N. 108(ab)
Swerdloff, RS. 1026(ab)
Swingle, C. 590(ab)
Sy, W. 1375(ab)
Syed, I. 1415(ab)
Syed, R. 1415(ab)
Syed, S. 1074(ab), 1335(ab), 1512(ab)
Syrkin, G. 232(ab), 880(ab)
Syrota, A. 215, 1284(ab), 1425(ab)
Syvänne, M. 1
Szabo, M. 405(ab)
Szabo, Z. 144(ab), 390(ab), 678
Szajek, LP. 1501(ab), 1525(ab)
Szakáll, S. Jr., 66
Szuba, A. 720(ab)
Szulc, M. 754(ab)
Szwerc, M. 549(ab), 1229(ab)

Tabler, H. 1297(ab)
Tachibana, H. 764(ab)
Tadamura, E. 179(ab), 722(ab), 752(ab), 1198(ab)
Tadokoro, M. 1315(ab)
Tafani, M. 221(ab)
Tagaya, M. 967(ab)
Tagliabue, L. 355(ab)
Tai, YC. 212(ab)
Taillefer, R. 11(ab), 13(ab), 15(ab), 180(ab)
Taintor, N. 219(ab), 972(ab)
Taintor, NB. 1570
Tait, J. 2(ab), 22(ab), 396(ab), 702(ab)
Tait, JF. 258(ab), 259(ab), 500(ab), 706(ab), 1359
Tajima, T. 241(ab)
Takada, N. 288(ab)
Takada, Y. 755(ab)
Takahashi, H. 244(ab), 288(ab), 715(ab)
Takahashi, J. 995(ab), 996(ab)
Takahashi, K. 742(ab), 839(ab)
Takahashi, M. 527(ab), 535(ab), 771(ab), 902(ab), 999, 1401(ab)
Takahashi, N. 1337(ab), 1457(ab)
Takahashi, S. 109
Takahashi, T. 531, 763(ab), 1200(ab), 1401(ab), 1476
Takahashi, W. 1245(ab)
Takahashi, Y. 470(ab), 1342(ab)
Takai, Y. 109
Takaki, A. 577
Takamatsu, H. 957(ab), 959(ab)
Takami, A. 783(ab)
Takano, M. 518(ab)
Takasawa, M. 536(ab), 818(ab), 997(ab)
Takashima, K. 1462(ab)
Takashima, S. 1337(ab)
Takayama, Y. 1279
Takazawa, K. 1452
Takeda, K. 341(ab), 545(ab), 939(ab), 1286
Takeda, Y. 1040(ab), 1308(ab)
Takehana, K. 664, 746(ab)
Takehara, K. 1343(ab)
Takei, M. 783(ab)
Takei, T. 245(ab), 261(ab), 275(ab), 288(ab), 1061(ab), 1195(ab), 1306(ab), 1314(ab), 1319(ab), 1331(ab)
Takeichi, Y. 732(ab)
Takeishi, Y. 715(ab), 742(ab), 764(ab)
Takekoshi, N. 774(ab), 775(ab), 779(ab), 789(ab)
Takekuma, M. 1140(ab)
Takeuchi, K. 131, 443
Takeuchi, M. 471(ab)
Taki, J. 15, 349(ab), 589, 708(ab), 716(ab), 775(ab), 789(ab), 803, 1452
Taki, S. 39, 141(ab), 1215(ab), 1337(ab)
Takvorian, T. 109(ab)
Talbot, JN. 81(ab), 105(ab), 130(ab), 928(ab), 1143(ab)
Talbot, PS. 381(ab), 602(ab), 956(ab), 1440(ab)
Talley, JJ. 117
Tamagnan, G. 163(ab), 395(ab), 598(ab), 978(ab)
Tamakai, N. 1040(ab)
Tamaki, N. 88(ab), 179(ab), 185(ab), 189(ab), 199(ab), 245(ab), 258(ab), 259(ab), 261(ab), 275(ab), 288(ab), 337(ab), 518(ab), 533(ab), 722(ab), 772(ab), 782(ab), 821(ab), 826(ab), 848(ab), 967(ab), 1061(ab), 1195(ab), 1306(ab), 1314(ab), 1319(ab), 1331(ab), 1381(ab), 1453(ab)
Tamir, A. 778(ab)
Tamizu, A. 1308(ab)
Tamura, S. 1028(ab)
Tan, PS. 740(ab)
Tan, S. 1150
Tanabe, N. 531, 1476
Tanada, S. 253(ab), 783(ab)
Tanaka, F. 1221(ab)
Tanaka, H. 1218, 1490(ab)
Tang, FY. 437(ab)
Tang, G. 1456(ab), 1520(ab)
Tang, T. 441(ab)
Tang, X. 1456(ab), 1520(ab)
Tanganelli, L. 1182(ab)
Tani, S. 734(ab)
Taniguchi, K. 749(ab), 753(ab)
Taniguchi, M. 141(ab), 1215(ab), 1337(ab)
Tann, M. 1033(ab)
Tann, MA. 1233(ab)
Tanner, H. 1699
Tansey, LW. 1088(ab)
Tao, ZH. 719(ab)
Tapolsky, G. 1486(ab)
Tarkiainen, J. 596(ab), 1445(ab)
Tarolo, G. 355(ab)
Tarutani, K. 217(ab)
Tasci, C. 482(ab)
Tateno, M. 751(ab)
Tatsch, K. 59(ab), 200(ab), 539(ab), 828(ab), 1045(ab), 1196(ab), 1302(ab), 1396(ab)
Tatsumi, M. 10(ab), 48(ab), 856(ab), 1201(ab), 1455(ab)
Tawakol, A. 9(ab), 24(ab)
Taylor, A. 1414(ab), 1422(ab)
Taylor, AT, Jr., 762
Taylor, JM. 1188(ab)
Tazawa, S. 531, 715(ab), 1476
Tchermiantchouk, O. 296(ab)
Tchermiantchouk, O. 407(ab), 1222(ab)
Teipel, S. 230(ab)
Telang, F. 1025(ab)
Tembl, A. 799(ab), 1417(ab), 1419(ab)
Tempero, MA. 957
Tenaey, CR. 917(ab)
Teräs, M. 773
Teragaki, M. 131, 443
Terai, H. 15
Teramoto, N. 223(ab), 933(ab)
Terao, T. 470(ab)
Teratani, T. 536(ab), 997(ab)
Teule, GJJ. 1317
Tewson, TJ. 1157(ab)
Textor, J. 1150(ab)
Thadani, VM. 540(ab)
Thakur, ML. 15N(7), 448(ab), 1128(ab), 1347(ab)
Thaler, H. 1072
Thambar, S. 551
Thames, HD. 1188(ab)
Thanos, P. 219(ab), 972(ab)
Thanos, PK. 1570
Thede-Reynolds, K. 1523(ab)
Thelen, MH. 131(ab), 1293(ab)
Theml, T. 231(ab)
Theodore, LJ. 1083(ab)
Theodore, WH. 198(ab)
Theodoropulos, S. 1506(ab)
Thi Minh Chau, T. 1429(ab)
Thie, JA. 527(ab), 830(ab), 1034(ab)
Thierens, H. 1262(ab)
Thimm, M. 231(ab)

Thireou, T, 851(ab)
Thomas, CT, 1188(ab)
Thomas, EJ, 287(ab), 479(ab), 1011(ab), 1327(ab)
Thomas, FD, 881(ab), 901(ab)
Thomas, J, 1060(ab)
Thomas, SR, 210
Thompson, CJ, 937(ab)
Thorson, LM, 1430(ab)
Thostenson, C, 1526(ab)
Thrall, JH, 1258(ab)
Thulliez, C, 717(ab)
Tian, X, 448(ab)
Tian, YQ, 745(ab), 808(ab)
Tibbals, J, 1270(ab)
Tiebosch, A, 265(ab)
Timmerman, R, 1033(ab)
Timuralp, B, 793(ab), 812(ab)
Tindall-Cox, CS, 1523(ab)
Ting, G, 57(ab), 58(ab), 63(ab), 66(ab), 153, 1057(ab), 1108(ab), 1436(ab)
Tisato, F, 499(ab)
Tishler, RB, 264(ab)
Tjoe, M, 769(ab)
Tjuvajev, JG, 1072
Tobey, EA, 235(ab), 1023(ab)
Toczek, M, 969(ab)
Toczek, MT, 198(ab)
Todd-Pokropek, A, 1410
Todoh, S, 288(ab)
Togashi, K, 554(ab)
Tognoni, G, 236(ab)
Tokareva, E, 517(ab)
Tolmachev, V, 1391
Tolvanen, T, 1674
Tomas, MB, 297(ab), 457(ab), 1069(ab), 1070(ab), 1282(ab), 1363(ab)
Tomemori, T, 776(ab)
Tomita, K, 1452
Tomiyama, N, 1211(ab)
Tomiyoshi, K, 1457(ab)
Tompkins, R, 711(ab)
Tompkins, RG, 470, 1074(ab), 1335(ab)
Tonami, H, 39, 141(ab), 1215(ab), 1337(ab)
Tonami, N, 349(ab), 383(ab), 589, 708(ab), 716(ab), 775(ab), 789(ab), 803, 1079(ab), 1081(ab), 1084, 1089(ab), 1343(ab), 1452
Tondeur, M, 33
Toniato, A, 293(ab), 1279(ab)
Toohey, RE, 328(ab), 1110
Torigoe, S, 1457(ab)
Torizuka, T, 1140(ab)
Tornai, MP, 39(ab)
Torok, F, 884(ab)
Toulouse, KA, 928, 1531(ab)
Tourwé, D, 374
Townsend, DW, 38(ab), 40(ab), 205(ab), 937(ab), 1249(ab), 1250(ab)
Toyama, H, 843(ab), 939(ab), 985(ab), 1027(ab)
Toyama, T, 747(ab), 749(ab), 753(ab), 780(ab), 797(ab), 1279
Toyoda, H, 179(ab), 722(ab)
Toyohara, J, 1218, 1490(ab)
Toyokuni, T, 155(ab)
Traasdahl, E, 580(ab)
Tralins, KS, 1667
Traub, T, 183(ab)
Traughber, B, 1454(ab)
Traughber, BJ, 48(ab), 856(ab), 1455(ab)
Travagli, JP, 924(ab)
Travaini, L, 75(ab)
Travin, MI, 11(ab)
Travis, M, 1048(ab)
Traylor, J, 1093(ab)
Trébossen, R, 1268
Trebossen, R, 215, 964(ab), 1284(ab), 1434(ab)
Trevena, IC, 12N(3)
Treves, ST, 1144, 1213(ab), 1309(ab), 1310
Treyer, V, 1240(ab)
Trichel, A, 976(ab)
Trifiro, G, 75(ab)
Tripathi, M, 287(ab), 1011(ab), 1327(ab)
Triulzi, A, 355(ab)
Trón, L, 66
Tronco, GG, 1069(ab), 1070(ab), 1282(ab), 1359(ab)
Truong, C, 225(ab)
Truong, D, 770(ab)
Truong, P, 1445(ab)
Tsai, C, 99(ab), 99(ab)
Tsay, DG, 823(ab), 1161(ab), 1340(ab)
Tseng, J, 500, 1100(ab)
Tsopelas, C, 1377
Tsuchida, D, 1404(ab)
Tsuchihashi, K, 763(ab)
Tsuchiya, H, 1452
Tsui, B, 31(ab), 520(ab)
Tsui, BM, 43(ab), 193(ab), 195(ab), 208(ab), 213(ab), 519(ab), 897(ab), 898(ab)
Tsui, BMW, 432, 1555
Tsuji, S, 383(ab)
Tsuji, T, 771(ab), 999
Tsujitani, M, 109
Tsukada, H, 957(ab), 958(ab)
Tsukamoto, E, 88(ab), 185(ab), 199(ab), 245(ab), 258(ab), 259(ab), 261(ab), 275(ab), 288(ab), 821(ab), 826(ab), 1040(ab), 1061(ab), 1195(ab), 1306(ab), 1314(ab), 1319(ab), 1331(ab)
Tsukamoto, M, 199(ab), 533(ab), 848(ab), 1040(ab)
Tsutida, T, 705(ab)
Tsuyuguchi, N, 1009(ab)
Tsyganov, E, 216(ab)
Tubau, J, 769(ab)
Tuli, MM, 1071(ab)
Turgeon, H, 1054(ab)
Turner, JH, 415(ab)
Turzo, A, 586(ab), 1411(ab)
Tuttle, RM, 1482
Twisk, JWR, 1304
Tzen, K, 57(ab), 58(ab), 66(ab), 99(ab)
Tzen, KY, 1057(ab), 1436(ab)
Tzen, K-Y, 153
Tzen, T, 63(ab)

Uccelli, L, 166(ab), 499(ab)
Uchida, S, 1342(ab)
Uchiyama, A, 985(ab)
Uchiyama, M, 1404(ab)
Uddin, M, 652
Ueberfuhr, P, 515(ab), 516(ab)
Ueda, M, 975(ab), 1130(ab)
Ueda, T, 705(ab), 1616
Ueda, Y, 39, 1215(ab)
Uemura, K, 985(ab)
Uffelman, W, 14N(3), 29N(10), 30N(11), 25N(2), 30N(7), 33N(9), 34N(6), 32N(1), 36N(5), 40N(4), 24N(12)
Ugur, A, 112(ab)
Uman, S, 296(ab)
Umeda, T, 801(ab), 809(ab)
Unadkat, JD, 1120(ab)
Unal, M, 1299(ab)
Undar, L, 112(ab)
Ungureanu-Longrois, D, 566
Uno, K, 776(ab)
Urano, M, 1122(ab)
Uren, R, 305(ab)
Uribe, J, 33(ab), 930(ab), 931(ab), 932(ab)
Ursea, B, 576(ab), 577(ab)
Ushijima, Y, 1234
Ushio, Y, 577
Usui, N, 1200(ab)
Usui, Y, 1401(ab)
Utunomiya, K, 801(ab), 809(ab)
Uyttendaele, D, 477(ab)
Uyttendaele, F, 481(ab)
Uzui, H, 705(ab)

Vaalburg, W, 167, 265(ab), 278(ab), 476(ab), 1107(ab), 1409(ab)
Vaart van der, AW, 892(ab)
Vabuliene, E, 436(ab)
Vaidyanathan, G, 330(ab), 1470(ab)
Vaillant, L, 1388(ab)
Valent, P, 706(ab)
Valenti, MP, 991
Valentin, L, 921(ab), 924(ab)
Valentine, A, 1270(ab)
Valette, H, 1227, 1425(ab), 1434(ab)
Valk, PE, 325, 752, 1248(ab)
Valkema, R, 120(ab), 121(ab), 325(ab), 1267(ab)
Vallabhajosula, S, 284(ab), 417(ab), 576(ab), 577(ab), 1190(ab), 1257(ab)
Vallis, K, 1254(ab), 1493(ab)
Valotassiou, V, 1163(ab), 1167(ab)
Van Amelsvoort, T, 1048(ab)
Van Crombrugge, P, 477(ab)
Van de Wiele, C, 477(ab), 481(ab), 592(ab), 731(ab), 768(ab), 805(ab)
Van De Wiele, C, 1426
Van Den Abbeele, AD, 109(ab), 264(ab)
Van Den Berg, R, 444(ab)
Van Den Bossche, B, 592(ab)
van Den Heuvel, OA, 362(ab)
Van der Laan, BF, 278(ab)
Van der Walt, N, 1488(ab)
Van der Wansem, K, 167(ab)
Van der Wilt, GJ, 1212(ab)
van Dijk, A, 1150
van Domburg, RT, 767
Van Dongen, GA, 575(ab)
Van Dort, ME, 1446(ab)
Van Dyck, CH, 384(ab), 392(ab), 395(ab)
Van Eerd, JE, 1085(ab)
van Eijck, CHJ, 1681
Van Every, B, 714(ab), 1259
Van Gameren, A, 167(ab), 444(ab), 446(ab)
Van Harskamp, E, 444(ab)
Van Heerden, B, 458
Van Heeringen, C, 1426
Van Heertum, RL, 51(ab), 52(ab), 54(ab), 387(ab), 1054(ab), 1132(ab), 1135(ab)
Van Herle, A, 1029(ab)
Van Herle, AJ, 1030(ab)
Van Herle, K, 1029(ab), 1030(ab)
van het Schip, AD, 1150
van Jaarsveld, BC, 330
Van Kroonenburgh, M, 307(ab)
Van Laarhoven, H, 1197(ab)
Van Laere, K, 733
Van Laere, KJ, 458, 544(ab), 829(ab)
Van Lier, JE, 1465(ab)
Van Poppel, H, 423(ab)
Van Poppel, R, 1107(ab)
van Putten, JWG, 167
Van Rijk, PP, 192(ab)
van Rijk, PP, 1150
Van Schaijk, FG, 558(ab)
Van Waarde, A, 1409(ab)
Van Wyhe, J, 1210(ab)
Vandenberghe, P, 1060(ab)
Vandenberghe, S, 172(ab)
Vandenbulcke, K, 1262(ab)
Vander Borght, TM, 621
Vanderghinste, D, 1517(ab)
Vanderheyden, J, 1504(ab)
Vanderheyden, JL, 255(ab), 1357(ab), 1532(ab)
Vandermeiren, R, 800(ab)
Vandierendonck, A, 1426
Vanecho, D, 1275(ab)
Vankan, Y, 423(ab)
Vannier, MW, 1366
Vanninen, E, 1
Vanoverschelde, J-LJ, 556, 621
Vanseymortier, L, 1173(ab)
Vansteenkiste, J, 1304
Vaquero, JJ, 212(ab)
Vardareli, E, 793(ab), 812(ab)
Vardereli, E, 203
Vargas, HI, 923(ab)
Varma, VM, 464(ab)
Varrone, A, 883(ab)
Vashist, A, 724(ab)
Vaska, P, 211(ab), 219(ab), 1570
Vaufrey, F, 921(ab)
Vaupel, DB, 395(ab), 1433(ab), 1443(ab)
Vaylet, C, 1352(ab)
Vazquez-Sequeiros, E, 239(ab)
Velasquez, C, 1384(ab)
Veliz, J, 1364(ab)
Veltman, DJ, 362(ab)
Venencia, CD, 61
Venisnik, KM, 1110(ab)
Venkatesh, M, 1129(ab), 1278(ab), 1473(ab), 1474(ab)
Venook, A, 1227(ab)
Vento, A, 77(ab)
Vera, DR, 72(ab), 475(ab), 1469(ab)
Véra, P, 27, 715, 792(ab), 806(ab), 807(ab)
Verbeke, K, 1517(ab)
Verbeke, KA, 255(ab), 1532(ab)
Verbruggen, A, 1517(ab)
Verbruggen, AM, 255(ab), 1532(ab)
Vercouillie, J, 596(ab)
Verdenet, J, 285
Verduyckt, T, 1517(ab)
Veress, AI, 170(ab)
Verhagen, AF, 1212(ab)
Verhoef, G, 1060(ab)
Verhoeff, NP, 392(ab)
Vermeir, G, 1426
Vernaleken, I, 970(ab)
Vernaleken, IB, 1058(ab)
Vernon, C, 1383
Veronesi, U, 75(ab)
Verreault, J, 262(ab)
Versijpt, J, 458, 733, 829(ab)
Vervaet, A, 800(ab)
Vesalainen, R, 773
Vespa, PM, 222(ab), 1002(ab)
Vesper, J, 992(ab)
Vessella, RL, 488(ab), 489(ab), 1487(ab)
Vetzel, M, 1477(ab)
Vezina, WC, 181(ab)
Vici, P, 745
Victoria, A, 724(ab)
Vider, J, 250(ab)
Viergever, MA, 192(ab)
Vigneri, R, 207
Viitanen, L, 1
Vijaykumar, D, 1461(ab)
Vilain, D, 347(ab), 350(ab), 810(ab)
Vilain, MO, 1173(ab)
Villa, G, 811
Villeirs, G, 592(ab)
Villemagne Sr, PM, 8(ab), 1131(ab)
Villemagne, VL, 844(ab), 1090, 1389(ab)
Villemain, D, 1511(ab)
Virgolini, I, 122(ab), 706(ab), 1270(ab)
Virmani, R, 4(ab), 23(ab)
Visser, TJ, 167(ab), 1650
Visvikis, D, 574(ab), 1048(ab)
Vitali, P, 983
Viti, M, 1164(ab)
Vitola, JV, 725(ab)
Vitola, Z, 725(ab)
Vivek, T, 479(ab)

Vlahov, IR, 1477(ab)
Vleugels, S, 1054
Vogelaers, D, 477(ab), 481(ab)
Vogg, AT, 96(ab)
Voipio-Pulkki, L-M, 773
Volenberg, I, 246
Volkert, WA, 333(ab)
Volkow, N, 197(ab)
Volkow, ND, 56(ab), 211(ab), 317(ab), 386(ab), 388(ab), 961(ab), 972(ab), 1025(ab), 1043(ab), 1331, 1570
Vollmar, S, 927(ab)
Volterrani, D, 236(ab), 411(ab), 500(ab), 1164(ab), 1182(ab)
Von der Heide, M, 277(ab)
Von Mallek, D, 1150(ab)
Von Schulthess, G, 137(ab)
Von Schulthess, GK, 118(ab), 547(ab), 887(ab), 890(ab), 1147(ab), 1235(ab), 1240(ab)
von Schulthess, GK, 1469
Vonck, K, 544(ab), 733
Vonthein, R, 1293(ab)
Voordeckers, M, 1145(ab)
Vosberg, H, 393(ab)
Vose, J, 419(ab)
Votaw, JR, 151(ab), 597(ab)
Vranjesevic, D, 269(ab), 270(ab), 325
Vrigneaud, JM, 703(ab), 713(ab)
Vu, T, 1151(ab)
Vuillez, JP, 579(ab)
Vuong, BK, 969(ab)
Vuong, H, 888(ab)
Vyas, R, 1506(ab)
Vydrin, S, 935(ab)

Wachsberger, P, 1128(ab)
Wackers, FJ, 13(ab)
Wackers, FJTh, 421, 1115
Wada, H, 109, 1221(ab)
Wada, M, 173
Wada, Y, 968(ab)
Waddington, W, 1048(ab)
Waddington, WA, 574(ab)
Wagner, A, 571(ab), 573(ab)
Wagner, HN, 336(ab)
Wagner, HN, Jr., 11N(8), 18N(12), 267
Wagner, M, 96(ab)
Wagner, T, 1472(ab)
Wagner, W, 1148(ab)
Wagner-Bohn, A, 127(ab)
Wagner-Utermann, U, 1524(ab)
Wahed, MII, 531
Wahl, R, 785(ab)
Wahl, RL, 10(ab), 44(ab), 46(ab), 48(ab), 49(ab), 78(ab), 113(ab), 116(ab), 210(ab), 354, 427(ab), 548(ab), 856(ab), 878(ab), 885(ab), 1137, 1184, 1188(ab), 1228(ab), 1237(ab), 1239(ab), 1241(ab), 1242(ab), 1454(ab), 1455(ab)
Wainer, N, 945(ab)
Wajnblum, D, 1518(ab)
Wakabayashi, T, 763(ab)
Wakasugi, H, 554(ab)
Wakasugi, S, 596
Waldherr, C, 610, 1266(ab)
Waldman, SA, 392
Waldmann, TA, 554(ab)
Waldrop, S, 1414(ab)
Wallace, AM, 72(ab), 475(ab), 1469(ab)
Wallace, S, 150(ab)
Wallace, WE, 413
Wallack, M, 71(ab), 1171(ab)
Wallis, JW, 1410
Walls, ZF, 891(ab)
Walrand, S, 325(ab), 1267(ab), 1271(ab)
Walter, H, 1049(ab), 1052(ab)
Wampach, H, 715
Wand, GS, 390(ab)
Wang, CH, 766(ab)
Wang, DY, 1403(ab)
Wang, F, 769(ab)
Wang, G, 976(ab)
Wang, GJ, 56(ab), 197(ab), 386(ab), 388(ab), 961(ab), 1025(ab)
Wang, G-J, 1331
Wang, HE, 160(ab), 1108(ab)
Wang, J, 443(ab), 1077(ab), 1493(ab)
Wang, JK, 361(ab), 531(ab), 862(ab)
Wang, LG, 443(ab)
Wang, M, 1456(ab)
Wang, Q, 582(ab), 1528(ab)
Wang, RF, 767(ab), 847(ab)
Wang, S, 92
Wang, SW, 582(ab)
Wang, TS, 1132(ab), 1135(ab)
Wang, W, 193(ab), 520(ab)
Wang, XM, 1403(ab)
Wang, Y, 33(ab), 605(ab), 897(ab), 898(ab), 930(ab), 931(ab), 932(ab), 1444(ab), 1520(ab)
Wang, ZJ, 1346(ab)
Wanivenhaus, A, 1489
Ware, RE, 492
Wareham, DW, 1125(le)
Warren, SM, 1392(ab)
Wartski, M, 410(ab)
Warwick, J, 458, 829(ab)
Washimi, Y, 993(ab)
Watabe, H, 524(ab), 840(ab), 852(ab), 855(ab), 865(ab), 866(ab), 883(ab), 896(ab), 933(ab), 995(ab), 996(ab)
Watanabe, G, 589
Watanabe, K, 531, 721(ab), 1476
Watanabe, N, 253(ab), 1084
Watanabe, W, 1401(ab)
Watanabe, Y, 545(ab)
Watemberg, N, 303(ab)
Waterhouse, RN, 1132(ab)
Waters, DJ, 1481(ab)
Waters, SL, 496(ab)
Watkins, GL, 1523(ab)
Watkinson, AJ, 1270(ab)
Watson, A, 256(ab)
Watson, C, 927(ab)
Watson, CC, 40(ab)
Watson, DD, 664
Watson, EE, 210
Watson, T, 323(ab)
Watson, TA, 1138(ab)
Watzlowik, P, 279(ab)
Waxman, A, 1031(ab), 1258(ab)
Waxman, AD, 103(ab), 104(ab), 111(ab), 268(ab), 296(ab), 407(ab), 1222(ab), 1376(ab), 1457
Way, B, 973(ab)
Weber, B, 920(ab)
Weber, DK, 4(ab), 23(ab)
Weber, S, 212(ab)
Weber, WA, 85(ab), 242(ab), 243(ab), 279(ab), 322(ab), 436(ab), 439(ab), 1196(ab), 1251(ab), 1489(ab)
Weckesser, M, 983(ab)
Weder, W, 547(ab)
Wegener, WA, 295(ab)
Wei, HX, 808(ab)
Weigel, RJ, 1300(ab), 1301(ab)
Weiland, FL, 11(ab)
Weinberg, IN, 929(ab)
Weinberger, DR, 979(ab)
Weiner, M, 988(ab)
Weiner, R, 1506(ab)
Weinhold, P, 1099(ab)
Weininger, J, 877(ab)
Weinreich, R, 1444
Weisenberger, A, 37(ab)
Weisenberger, AG, 373(ab), 942(ab)
Weiss, AP, 1053(ab)
Weiss, K, 1489
Weiss, L, 234
Weiss, MF, 1313(ab)
Weitemeyer, L, 983(ab)
Weitzner, B, 1472(ab)
Welch, M, 315(ab)
Welch, MJ, 98(ab), 117, 494(ab), 495(ab), 871(ab), 974(ab), 1127(ab), 1346(ab), 1461(ab), 1499(ab), 1557
Welling, MM, 1126(le)
Wells, RG, 196(ab)
Welsh, P, 330(ab), 1470(ab)
Welsh, RE, 942(ab)
Wen, CY, 766(ab)
Wen, J, 377(ab)
Wen, LF, 831(ab)
Wen, WT, 766(ab)
Wen, X, 150(ab)
Wendt, RE, 906(ab)
Weng, L, 1065(ab)
Weng, Y, 57(ab)
Wermke, M, 1020(ab)
Wermke, MD, 230(ab)
Wesch, H, 418(ab)
Wess, J, 399(ab)
Wester, H, 330(ab)
Wester, HJ, 86(ab), 318(ab), 322(ab), 1489(ab)
Westlin, J-E, 1391
Westphal, JR, 80(ab)
Wey, S, 57(ab), 58(ab), 63(ab), 66(ab)
Wey, S-P, 153
Wey, SP, 1057(ab), 1436(ab)
Whatley, M, 365(ab), 565(ab)
White, C, 988(ab)
White, CA, 1258(ab)
White, JF, 652
White, P, 541(ab)
Whitener, D, 152(ab)
Whybrow, PC, 1029(ab), 1030(ab)
Wiberg, D, 828
Wickstrom, E, 448(ab)
Widström, C, 1391
Wiebe, LI, 1123(ab), 1463(ab), 1466(ab)
Wied, MU, 1269(ab)
Wiedel, J, 308(ab)
Wieder, H, 242(ab), 279(ab)
Wieland, DM, 512(ab)
Wienhard, K, 90(ab), 246(ab), 927(ab)
Wiens, LW, 1210
Wiersema, M, 239(ab)
Wikström, H, 1445(ab)
Wilbur, D, 1487(ab)
Wilbur, DS, 488(ab), 489(ab)
Wildberger, JE, 1062(ab)
Wiley, CA, 976(ab)
Wilhelm, M, 794(ab)
Wilk, M, 877(ab), 903(ab)
Wilke, F, 842(ab)
Wilkinson, RW, 1368
Willemsen, AT, 278(ab)
Willemsen, ATM, 167
Willems-Foidart, J, 426(ab)
Willendrup, P, 363(ab), 853(ab)
Williams, B, 1094(ab)
Williams, BR, 728(ab)
Williams, BS, 1208(ab)
Williams, CM, 103(ab), 104(ab), 111(ab), 268(ab), 296(ab), 407(ab), 1222(ab), 1376(ab), 1457
Williams, DO, 551
Williams, G, 256(ab)
Williams, MB, 942(ab)
Williams, RC, 929(ab)
Williamson, PD, 540(ab)
Wilson, AA, 678, 1438(ab)
Wilson, DW, 175(ab), 933, 1104(ab), 1119(ab)
Wilson, JM, 434(ab)
Wilson, JTL, 476
Wilson, M, 27N(7)
Winkeler, A, 90(ab), 246(ab)
Winkle, WL, 316(ab)
Winter, J, 1432(ab)
Winter, RW, 1500(ab)
Winzer, K, 1172(ab)
Wioland, M, 130(ab)
Wiseman, GA, 267, 283(ab), 455(ab), 1028
Wiseman, RW, 963(ab)
Wisniewski, G, 936(ab)
Wisniewski, S, 976(ab)
Witt, T, 1033(ab)
Wodarsky, C, 161(ab)
Wojcik, R, 37(ab)
Wolf, BA, 321(ab)
Wolf, I, 281(ab), 416(ab)
Wolfe, HR, 392
Wolff, J, 1438
Wolfram, RM, 1254
Wollenweber, SD, 204(ab)
Wolohan, P, 1516(ab)
Woltering, EA, 438(ab)
Woltering, G, 124(ab)
Won, KS, 737(ab)
Wong, C, 56(ab), 388(ab)
Wong, CO, 1225(ab), 1247(ab), 1276(ab)
Wong, DF, 234(ab), 394(ab), 493(ab), 965(ab), 970(ab), 1058(ab)
Wong, F, 1151(ab)
Wong, FC, 314(ab), 324(ab), 328(ab), 1110
Wong, KJ, 1504(ab), 1525(ab)
Wong, KP, 831(ab)
Wong, V, 304(ab)
Wong, W, 33(ab), 931(ab), 932(ab)
Wong, WH, 930(ab)
Wong, WL, 206(ab)
Woo, JH, 300(ab)
Woo, KS, 1087(ab), 1105(ab), 1114(ab), 1356(ab), 1424(ab)
Woo, SK, 919(ab)
Woods, K, 456(ab)
Woody, CL, 211(ab)
Woolfenden, JM, 175(ab), 1104(ab), 1119(ab)
Wooten, WW, 575(le)
Wörmann, B, 414(ab), 1189(ab)
Wormstall, H, 1056(ab)
Wrase, J, 389(ab), 391(ab), 1055(ab)
Wu, A, 248(ab)
Wu, G, 182(ab), 551(ab)
Wu, H, 510, 1456(ab)
Wu, HM, 222(ab), 224(ab), 1000(ab), 1002(ab)
Wu, JC, 1(ab), 7(ab)
Wu, L, 247(ab)
Wu, LC, 361(ab), 531(ab), 733(ab), 847(ab), 862(ab)
Wu, MC, 35(ab), 174(ab)
Wu, Q, 150(ab), 1078(ab)
Wu, SY, 1332(ab)
Wu, Y, 960(ab)
Wuellner, U, 608(ab)
Wunderlich, A, 1049(ab)
Wyper, DJ, 476
Wyse, EP, 61

Xiangtong, L, 404(ab)
Xing, T, 33(ab), 930(ab), 931(ab), 932(ab)
Xiuli, M, 14(ab)
Xu, L, 844(ab), 1090
Xu, LC, 1477(ab)
Xu, S, 323(ab), 555(ab)
Xu, Y, 961(ab), 1331
Xu, Z, 1265(ab)
Xue, LY, 1117(ab), 1125(ab)

Yahara, Y, 341(ab)
Yajima, K, 780, 959(ab)
Yamada, S, 109, 337(ab)
Yamada, T, 993(ab)
Yamagishi, H, 131, 443
Yamaguchi, H, 764(ab)
Yamaguchi, K, 244(ab), 1017(ab), 1103(ab)
Yamaguchi, M, 15
Yamaki, N, 939(ab)

Yamamoto, AJ, 72
Yamamoto, F, 245(ab), 261(ab), 275(ab), 288(ab), 1061(ab), 1195(ab), 1306(ab), 1314(ab), 1331(ab)
Yamamoto, I, 39, 141(ab), 1215(ab), 1337(ab)
Yamamoto, K, 181
Yamamoto, S, 217(ab), 933(ab)
Yamamoto, T, 902(ab)
Yamamoto, Y, 478(ab), 1165(ab), 1291(ab), 1379(ab), 1464
Yamane, Y, 109
Yamashita, T, 1337(ab)
Yamauchi, A, 1165(ab)
Yamauchi, H, 535(ab)
Yamauchi, K, 518(ab)
Yamauchi, S, 742(ab)
Yamazaki, T, 244(ab), 962(ab)
Yanagihara, K, 1221(ab)
Yang Ko, FC, 286(ab)
Yang, D, 324(ab)
Yang, DJ, 435(ab), 1088(ab), 1102(ab), 1109(ab), 1471(ab), 1475(ab), 1478(ab)
Yang, MF, 582(ab)
Yang, SD, 1092(ab), 1521(ab)
Yang, W, 1094(ab)
Yang, Z, 1480(ab)
Yang, ZF, 1481(ab)
Yano, M, 470(ab)
Yao, Z, 334(ab)
Yap, C, 282(ab), 286(ab), 412(ab), 413(ab)
Yap, CS, 752
Yap, JT, 38(ab), 40(ab), 205(ab), 937(ab), 1249(ab), 1250(ab)
Yap, WY, 1338(ab)
Yarnall, S, 929(ab)
Yasuda, S, 241(ab), 1245(ab)
Yasumura, Y, 748(ab)
Yatin, M, 1512(ab)
Ye, D, 1127(ab)
Ye, XX, 1436(ab)
Yefremov, N, 114(ab), 117(ab), 1232(ab)
Yeh, MH, 823(ab)
Yeh, SH, 263(ab), 274(ab), 459(ab), 461(ab), 1193(ab)
Yeldell, D, 310(ab)
Yen, SH, 263(ab)
Yen, T, 57(ab), 58(ab), 63(ab), 66(ab), 99(ab)
Yen, TC, 1057(ab)
Yen, T-C, 153
Yen, TZ, 1436(ab)
Yenari, M, 396(ab)
Yendiki, A, 882(ab)
Yeni, P, 1352(ab)
Yeo, J, 1371(ab)
Yeo, JS, 343(ab), 484(ab), 542(ab), 736(ab), 759(ab), 1479(ab)
Yetkin, I, 1299(ab)
Yeung, DW, 84(ab), 304(ab)
Yeung, H, 1013(ab)
Yeung, HW, 115(ab), 567(ab), 1065(ab)
Yeung, HWD, 46
Yildiz, A, 112(ab)
Yin, M, 1514(ab)
Yoda, S, 734(ab)
Yoder, B, 213(ab)
Yokoi, T, 902(ab), 951(ab)
Yokota, C, 967(ab)
Yokota, M, 732(ab), 755(ab)
Yokoyama, I, 751(ab)
Yokoyama, K, 1079(ab), 1081(ab), 1084, 1089(ab)
Yonas, H, 999(ab)
Yonehara, T, 577
Yonekura, K, 751(ab)
Yonekura, Y, 181, 532(ab), 705(ab), 822(ab), 968(ab), 1218, 1490(ab)
Yoneyama, T, 775(ab), 789(ab)
Yoo, J, 495(ab), 1371(ab)
Yoon, CJ, 153(ab)
Yoon, CS, 1391(ab), 1397(ab)
Yoon, EJ, 1492(ab)
Yoon, HM, 1018(ab)
Yoon, JK, 101(ab), 240(ab), 1219(ab), 1369(ab)
Yoon, SN, 1372(ab), 1428(ab)
Yoon, TR, 1367(ab)
Yoshida, H, 229(ab)
Yoshida, K, 776(ab), 783(ab)
Yoshida, T, 1234
Yoshikawa, E, 1140(ab)
Yoshikawa, J, 131, 443
Yoshikawa, T, 536(ab), 818(ab), 997(ab)
Yoshimura, Y, 1218, 1490(ab)
Yoshinaga, K, 185(ab), 189(ab), 337(ab), 772(ab), 782(ab), 1381(ab)
Yoshioka, T, 244(ab)
Yoshiyama, M, 131, 443
Youn, T, 1022(ab), 1042(ab)
Young, JW, 927(ab)
Young, L, 888(ab)
Young, LH, 421
Young, S, 145(ab)
Young, SN, 947(ab)
Younsi, N, 81(ab), 105(ab), 130(ab), 1143(ab)
Yu, CL, 770(ab), 847(ab)
Yu, D, 435(ab), 1088(ab), 1102(ab), 1109(ab), 1471(ab), 1475(ab), 1478(ab)
Yu, J, 1486(ab)
Yu, JQ, 587(ab)
Yu, KH, 1092(ab)
Yu, LL, 1265(ab)
Yu, M, 397(ab), 609(ab)
Yu, M-D, 56
Yu, S, 1504(ab)
Yu, WP, 149(ab)
Yu, X, 366(ab), 1097(ab)
Yuan, A, 312(ab), 420(ab), 1261(ab)
Yuki, M, 109
Yukihiro, M, 435(ab), 1102(ab), 1471(ab), 1475(ab)
Yun, M, 473(ab), 886(ab), 1067(ab), 1152(ab)
Yun, MK, 319(ab)
Yune, MJ, 69(ab), 1390(ab), 1391(ab)
Yurkovetskiy, A, 1514(ab)
Yutani, K, 471(ab)
Yu-Wen, C, 899(ab)
Yuzefovich, B, 877(ab)
Yuzefovich, I, 368(ab), 903(ab)

Zaffino-Nevrotski, T, 1389(ab)
Zaini, M, 358(ab)
Zakko, S, 1102(ab)
Zalutsky, MR, 330(ab), 1259(ab), 1470(ab)
Zammarchi, G, 500(ab)
Zanco, P, 20(ab)
Zander, A, 570(ab)
Zanzonico, P, 315(ab), 1122(ab), 1429(ab)
Zanzonico, PB, 329(ab), 555(ab), 1665
Zaruba, P, 571(ab), 573(ab)
Zaudig, M, 1045(ab)
Zavarzin, V, 929(ab)
Zavattini, G, 212(ab)
Zavosky, LA, 1370(ab)
Zea-Ponce, Y, 51(ab)
Zehetgruber, H, 1489
Zeng, GL, 526(ab)
Zerva, C, 1163(ab), 1167(ab)
Zervos, G, 517(ab)
Zettinig, G, 183(ab), 405(ab), 571(ab), 573(ab)
Zhang, CL, 767(ab)
Zhang, HG, 1078(ab)
Zhang, J, 493(ab), 1083(ab)
Zhang, JL, 247(ab)
Zhang, L, 979(ab), 1520(ab)
Zhang, S, 485(ab), 1084(ab), 1508(ab)
Zhang, X, 173(ab)
Zhang, XL, 719(ab), 745(ab)
Zhang, Y, 91(ab)
Zhang, YM, 486(ab), 501(ab), 1508(ab), 1529(ab)
Zhang, Z, 719(ab), 784(ab), 1310(ab)
Zhao, C, 1418(ab), 1480(ab)
Zhao, J, 1406(ab)
Zhao, S, 88(ab), 245(ab), 258(ab), 259(ab), 275(ab), 1061(ab), 1306(ab)
Zhao, XD, 195(ab)
Zhao, Z, 375(ab), 819(ab)
Zheng, M, 1526(ab)
Zheng, QH, 316(ab), 1458(ab), 1491(ab)
Zhernosekov, KP, 165(ab)
Zhou, Y, 234(ab), 359(ab), 394(ab), 493(ab), 965(ab), 970(ab), 1058(ab)
Zhu, H, 882
Zhu, HJ, 507(ab), 798(ab)
Zhu, M, 767(ab)
Zhu, W, 197(ab), 448(ab), 961(ab), 1331
Zhu, Y-M, 160
Zhu, Z, 168(ab), 208(ab), 599(ab), 602(ab), 1440(ab)
Zhuang, HM, 102(ab), 136(ab), 140(ab), 267(ab), 285(ab), 321(ab), 450(ab), 456(ab), 458(ab), 463(ab), 466(ab), 468(ab), 487(ab), 564(ab), 583(ab), 1155(ab), 1202(ab), 1214(ab), 1320(ab), 1348(ab), 1355(ab), 1374(ab), 1377(ab), 1383(ab), 1398(ab), 1410(ab)
Ziegler, S, 1123(ab)
Ziegler, SI, 322(ab), 374(ab), 436(ab), 439(le), 515(ab)
Zier, S, 725(ab)
Ziessman, HA, 35N(5), 1345(ab)
Ziffer, J, 171(ab)
Ziffer, JA, 888(ab)
Zimmer, AM, 164(ab)
Zimmer, L, 227, 921(ab)
Zimmerman, RE, 232(ab), 880(ab)
Zimmermann, F, 242(ab), 279(ab)
Zimmermann, W, 1368
Zimny, M, 1062(ab)
Zimny, S, 307(ab)
Zin, D, 480(ab)
Zink, MC, 965(ab)
Ziock, K, 944(ab)
Zito, MJ, 13(ab)
Zittel, TT, 134(ab)
Zneny, LM, 251(ab)
Zoboli, S, 904(ab)
Zoe, H, 1018
Zoghbi, S, 421
Zoghbi, SS, 163(ab), 237(ab), 392(ab), 395(ab), 978(ab)
Zonnenberg, BA, 1150
Zor, E, 793(ab), 812(ab)
Zubal, G, 532(ab), 822(ab)
Zubeldia, J, 566(ab)
Zubeldia, JM, 82(ab)
Zucchi, V, 1182(ab)
Zuckerman, E, 312
Zuckier, LS, 433(ab), 1127(le)
Zuo, CT, 1406(ab)
Zwas, ST, 453(ab), 1321(ab)
Zweit, J, 256(ab), 441(ab), 1286(ab), 1482(ab)

A

A549 cells
metabolic validation of FLT, 95(ab)
proliferation, FLT as measure of thymidine kinase activity, 1210
Abdominal cancer, FDG PET, attenuation correction in, beginner PET oncologist, 1198(ab)
Abdominal organs, mismatch, PET-CT image registration, 48(ab)
Abscess, imaging agent, ^{99m}Tc complexes, 1353(ab)
Accessory spleen, after splenectomy, chronic idiopathic thrombocytopenic purpura, 287(ab)
Acetazolamide
brain SPECT, during temporary balloon occlusion test and after carotid occlusion, 1616
cerebral perfusion reserve, oxygen extraction fraction and, 996(ab)
delayed effects, chronic cerebrovascular ischemic disease, SPECT triple ^{99m}Tc ECD, 577
^{99m}Tc ECD SPECT, cerebrovascular disease revascularization, 998(ab)
Acetazolamide challenge
cerebral blood flow and volume changes, PET, 535(ab)
misery perfusion detected by, PET, 536(ab)
stress brain perfusion SPECT, cerebral metabolism after endarterectomy, 537(ab)
Acetylcholine, level effects, binding of a SPECT nicotinic acetylcholine receptor tracer, 978(ab)
Acetylcholinesterase
cerebral activity
after donepezil therapy in Alzheimer's disease, 228(ab)
in Parkinson's and Alzheimer's disease, 227(ab)
mapping, ^{18}F-labeled N-benzylpiperidine benzisoxazole for, 1441(ab)
radiotracers for, Alzheimer's disease, 606(ab)
Acetylcholinesterase inhibitors, treatment in Alzheimer's disease, brain perfusion follow-up, 983
Acetylcholine transporter, vesicular, SPECT and PET benzovesamicol tracers, 1450(ab)
Acute coronary syndrome, matrix metalloproteinase expression, in atherosclerotic plaques, 4(ab)
Addiction
computer games, adolescents, brain imaging of, 1393(ab)
cue-induced activation of fMRI, orbitofrontal cortex, 1055(ab)
expectation effects, behavioral responses to methylphenidate, 386(ab)
treatment, specific binding of ^{11}C GVC, 398(ab)
Adenocarcinoma, *see also* specific type or site
lung, FDG PET small animal system, 216(ab)
radioimmunotherapy in, potentiation with C5a agonist, 957
Adenosine triphosphate
dipyridamole administration and, myocardial blood flow during, 179(ab)
pharmacological stress agent
isometric handgrip exercise effects, caffeine intake and, 722(ab)
prediction of ischemia in left ventricular hypertrophy, 724(ab)
safety profile, 721(ab)
SPECT, 723(ab)
Adenovirus, transfer of sodium iodide symporter, thyroid cancer, 429(ab)
Adhesive capsulitis, ^{99m}Tc HIG, correlative study with bone scintigraphy, 482(ab)
Adipocytes, dosimetry models of trabecular skeleton, 97
β-Adrenergic receptors
cardiac, quantification, 215
density, CAD and LV dysfunction, 513(ab)
Aerosols, β-agonist distribution, respiratory syncytial virus bronchiolitis, infants, 487
Affinity enhancement system, radioimmunotherapy of cancer, 1496(ab)
Aging
cerebral blood flow and, during P_ACO_2 changes, PET measurement, 534(ab)
cerebral blood flow and glucose metabolism, FK960 effects, monkey, 957(ab)
cerebral glucose metabolism and, partial volume effect, 238(ab)
changes in distribution of ^{123}I iomazenil, brain SPECT, 237(ab)
^{11}C SA4503 binding to sigma$_1$ receptors, aged monkey brain, 958(ab)
gender and, effects on large normal SPECT rCBF database, 235(ab)
idiopathic Parkinson's disease and, ^{99m}Tc TRODAT-1 SPECT, 57(ab)
prognostic value of ^{99m}Tc Myoview SPECT scan and, 352(ab)
pulmonary permeability and, ^{99m}Tc DTPA inhalation imaging, 582(ab)
uptake of FDG in bone marrow and, 1066(ab)
volumetric bone mineral density measurements and, 307(ab)
Agranulocytosis, infection imaging in, 918, 925
AIDS
dementia, benzodiazepine receptors in, PET, 234(ab)
DMAC in, FDG PET imaging of, 460(ab)
simian immunodeficiency virus, brain metabolism in, PET, 965(ab)
Alcohol
acutely detoxified patients, cortical GABA function in, SPECT, 392(ab)
craving for, mu-opiate receptor availability and genotype effects, 391(ab)
effects on serotonin transporters, limbic system, 390(ab)
Aldosterone, cardiac sympathetic nerve activity and, congestive heart failure, 1279
Alpha-particle emitters
At-211 labeled molecules, assessment of stability, 1487(ab)
irradiation in apoptosis induction, chronic lymphocytic leukemia, 1262(ab)
radionuclides, therapy for cancer, 1277(ab)
Alzheimer's disease
abeta-plaque imaging, novel stilbenes for, 1442(ab)
abeta-plaques as imaging agents, benzofuran derivatives, 1451(ab)
acetylcholinesterase and glucose metabolic changes, after donepezil therapy, 228(ab)
acetylcholinesterase mapping, ^{18}F-labeled N-benzylpiperidine benzisoxazole for, 1441(ab)
amyloid β protein, in vivo labeling of, 1044, 1052
cerebral cortex, atrophy and function correlation, FDG PET, 985(ab)
cerebral metabolic deficits, FDG PET study, 231(ab)
cerebral metabolic reactivity in, FDG imaging, 230(ab)
cholinesterase inhibitor therapy in, rCBF SPECT in prediction of response, 236(ab)
detection by cerebral SPECT, mild cognitive impairment patients, 989(ab)
diagnosis, UCLA PET in, 20N(2)
differential diagnosis of dementia, SPECT in, 988(ab)
early and late onset, PET, 41N(9)
early symptoms of dementia, evaluation by PET, 253
effects of estrogen on serotonin receptors, SPECT, 1048(ab)
extent of glucose metabolism reductions, false discovery rate for correction, 838(ab)
FDDNP *versus* torsionally modified analogs, PET molecular imaging probes, 604(ab)
^{18}F Tht, for amyloid assessment, 605(ab)
^{123}I/^{125}I IMPY as abeta-plaque imaging agent, 603(ab)
imaging in, 39N(9)
M2 selectivity, internalization and, 977(ab)
mild, selective attention and anosognosia in, FDG PET, 1034(ab)
morphologic and functional changes, SPECT and MRI, 304
nicotinic cholinergic receptors
cognitive enhancement in, 394(ab)
evaluation by SPECT, 229(ab)
Parkinson's disease and, PET comparison, 227(ab)
posterior cingulate cortex, hypoperfusion in, 3D stereotactic surface projection, 984(ab)
preclinical, reconstruction and corrections effects on discrimination tasks, 880(ab)
preclinical prediction, SPECT perfusion measures, 232(ab)
radioligand to assess amyloid in, 1444(ab)
radiotracers for acetylcholinesterase, ^{18}F FEPP and FEPMA, 606(ab)
sigma$_1$ receptors in, PET with ^{11}C SA4503, 987(ab)
spatially normalized PET and SPECT, direct comparison, 21
SPECT diagnosis, SPM for, 233(ab)
treatment with acetylcholinesterase inhibitors, brain perfusion follow-up during, 983
American Chemical Society (ACS), Fowler, Joanna honored, 11N(5)
American Society of Nuclear Cardiology (ASNC), Society of Nuclear Medicine and, joint position statement, 273
Amino acids
accumulation, inflammatory tissue, FDG comparison, 87(ab)
biodistribution, oncologic imaging outside the brain, 1098(ab)
cerebral metabolism, PET for, 405(ab)
^{18}F labeled, direct radiofluorination, 1521(ab)
^{18}F-labeled tracers, uptake in tumor cells, lymphocytes, macrophages, and xenotransplanted tumors, 318(ab)
myocardial transport, protein synthesis rate and, 711(ab)
PET, delineation in cerebral gliomas, 402(ab)
preload, increased tumor uptake of 3-IMT, 1201, 1207
transporter subtypes, tumor and inflammatory cells, RT PCR, 85(ab)
uptake mechanisms, ^{18}F FET, tumor and inflammatory cells, 86(ab)
uptake profiles, tumor imaging, 149(ab)
Amphetamines
binding of ^{18}F fallypride, striatal and extrastriatal regions, baboon, 381(ab)
dopamine release induced by, ^{18}F fallypride displacement in thalamus and, 382(ab)
sequential $H_2{}^{15}O$ PET studies before and after, baboon, 1090
Amyloid β protein, cerebral, labeling using intranasal basic fibroblast growth factor, 1044, 1052
Amyotrophic lateral sclerosis, physiopathology, cerebral SPECT, voxel-based, 991(ab)
Anatomic standardization, clinical brain SPECT data based on, ROC comparison of methods, 458
Anesthesia, inhaled isoflurane, effects on liquid gastric emptying, pigs, 968
Angina pectoris
before acute myocardial infarction, infarct size relations, 16(ab)
spastic, reverse redistribution of ^{99m}Tc sestamibi, 764(ab)
Angiogenesis
FGF-induced, in CAD, myocardial exercise SPECT for evaluation, 19(ab)
imaging with ^{99m}Tc EC-endostatin, 435(ab)
^{111}In-labeled $\alpha_v\beta_3$ ligand, imaging solid tumors, 327(ab)
myocardial, radiolabeled targeted marker of, ischemic rat model, 26(ab)
Angioplasty, *see also* Percutaneous transluminal coronary angioplasty (PTCA)
large balloon angio catheter, ^{166}Ho DTPA dose calculation in, 1428(ab)
Angiotensin-converting enzyme (ACE) inhibitor
^{123}I BMIPP dynamic SPECT, congestive heart failure, 742(ab)
renal artery stenosis, impaired renal function and, 143(ab)
renal blood flow, heart failure patients, 770(ab)
Angiotensin receptor, radioligand binding, ^{11}C L159 PET imaging, 144(ab)

nnexin V
iodination of, imaging of apoptosis, 671
radiolabeled, imaging cell death with, rheumatoid arthritis, 1359, 1366
nosognosia, selective attention and, in mild Alzheimer's disease, FDG PET, 1034(ab)
nterior cingulate cortex, methylphenidate discontinuation effects, prepubescent boys with ADHD, 1624, 1630
ntiangiogenic therapy, with thalidomide, radioimmunotherapy and, cognitive effects, human cancer xenografts, 1084
ntiarrhythmic agents, left ventricular function and, chronic heart failure patients under exercise, 755(ab)
ntibiotics, effects on combined labeled leukocyte/marrow imaging, joint infection, 297(ab)
ntibody fragments
streptavidin, tumor targeting, mouse model, 489(ab)
^{99m}Tc-labeled, tumor imaging, 557(ab)
nticancer agents, diagnostic imaging and, strong market outlook, 31N(3)
nti-carcinoembryonic antigen (CEA)
pretargeting, radioimmunotherapy patients, 579(ab)
pretargeting system for ^{90}Y delivery, 559(ab)
ntidementia drug, FK960, cerebral blood flow and glucose metabolism with, aging monkeys, 957(ab)
ntimicrobial peptides, ^{99m}Tc-labeled, bacterial and *Candida albicans* infections, 1125(le)
ntineoplastic agents, continuous monitoring of systemic leakage, isolated limb perfusion, 1243(ab)
ntipsychotic drugs
atypical, occupancy of dopamine D2 receptors by, 50(ab)
changes in brain chemistry with, PET, 380(ab)
mechanism of extrapyramidal side effects, brain dopaminergic neurotransmission, 950(ab)
ntisense DNA
^{111}In labeled
EGF-induced gene expression, breast cancer, 1493(ab)
targeting human N-myc gene, 1492(ab)
Tat enhanced cell uptake, target cells, 486(ab)
ntisense oligonucleotide, ^{111}In-labeled N-myc phosphorothioate, neuroblastoma cells, 253(ab)
-Antitrypsin, monomer and polymers, method of radiolabelling, 1503(ab)
ntitubercular treatment, skeletal tuberculosis, ^{99m}Tc MDP bone scintigraphy in, 479(ab)
nxiety, brain imaging of, PET, 53(ab)
poptosis
annexin V treatment, in atherosclerosis, 22(ab)
in atheroma identification, FDG *versus* ^{99m}Tc annexin V, 2(ab)
continuous low dose rate beta irradiation therapy, Burkitt's lymphoma cell line, 1424(ab)
cranial suture, imaging with ^{99m}Tc annexin V, rat model, 1392(ab)
detection, ^{124}I annexin V, 256(ab)
drug treatment-induced, ^{111}In pegylated annexin V uptake, MDA-MB468 tumors, 150(ab)
hepatic, prolonged fasting and refeeding effects, radiolabeled annexin V, 1335(ab)
imaging of, radiolabeled annexin V, rheumatoid arthritis, 1359, 1366
iodination of annexin V for imaging of, 671
lung carcinoma cell line, inhibition by survivin-specific triplex forming oligonucleotides, 257(ab)
macrophages, annexin V noninvasive targeting, 23(ab)
oncotic myocardial necrosis and, antimyosin and glucaric acid imaging, 25(ab)
PET imaging, ^{11}C annexin V for, 1457(ab)
tumor response, after single-dose chemotherapy with ^{99m}Tc annexin V, 259(ab)
ppendicitis, acute, ^{99m}Tc HMPAO and, children, 48N(11)
rbutamine, stress perfusion imaging, critical coronary artery stenoses, dogs, 664
romatic amino acid decarboxylase, activity, MAO inhibitor downregulation of, monkey, 385(ab)
rrhythmias, ^{123}I MIBG evaluation, SPECT, 760(ab)
Arteriovenous shunt, multipurpose system, for animal studies, 920(ab)
Arthroplasty, hip
heterotopic ossification, 346
increased uptake of FDG PET at tip, 1374(ab)
long-lasting non-specific FDG uptake, 140(ab)
Artifacts
arm positioning effects, rest/stress SPECT myocardial perfusion imaging, 1560(ab)
bladder-filling, pelvic images, dynamic SPECT, 196(ab)
focal tracer uptake, dual-modality PET/CT scans, 1339
metallic object, FDG PET-CT, 1239(ab)
motion, myocardial perfusion SPECT images, 173(ab)
PET/CT, inaccurate localization of lesions, 116(ab)
poststress motionlike, dual-head gamma camera for ^{201}Tl myocardial SPECT, 285
respiratory and diaphragmatic motion, with and without attenuation correction, myocardial SPECT, 1259
respiratory motion
combined PET/CT systems, 209(ab)
differences in FDG uptake in PET/CT, 210(ab)
FDG PET, lung, 208(ab)
PET emission images, CT attenuation correction in, 1228(ab)
supraclavicular muscle FDG uptake, evaluation with PET/CT, 113(ab)
S-Arylcysteine, ^{18}F-labeled, reaction with cysteine, 1468(ab)
Asialoglycoprotein receptor scintigraphy, mean transit time, functional image and, in hepatocyte function, 1611
Astatine-211
alpha-particle emitting, radioiodine and, glycated octreotide labeled with, 330(ab)
biotin derivatives, in pretargeting, 488(ab)
simple compounds, stability of, 1487(ab)
uptake in sodium iodide symporter, cancer cell lines, 432(ab)
Asthma, lung deposition studies in, radiosynthesis of ^{18}F FP, 496(ab)
Atherosclerosis
annexin V treatment, 22(ab)
FDG uptake, thoracic aorta, risk factors for CAD, 784(ab)
identification of plaques, ^{99m}Tc annexin V *versus* FDG, 2(ab)
lesions, intravascular characterization with FDG and beta probe, 9(ab)
molecular imaging of, targeting of endothelin receptors, 400
myocardial flow reserve, simvastatin and pravastatin effects, 751(ab)
plaque identification, radiolabeled monocyte chemotactic protein-1 *versus* annexin V, 702(ab)
plaques
matrix metalloproteinase expression and, 4(ab)
noninvasive characterization with FDG, 24(ab)
subclinical, endothelial dysfunction associated with, insulin-resistant patients, 509(ab)
Atherothrombosis, apoptotic macrophages, noninvasive targeting with annexin V, 23(ab)
Atrial fibrillation, myocardial SPECT in, 351(ab)
Attention deficit hyperactivity disorder (ADHD)
cerebral blood flow
methylphenidate discontinuation effects, boys, 1624, 1630
methylphenidate-induced changes, children, 302(ab)
intellectual stress test, brain SPECT during, children, 303(ab)
L-enantiomer of methylphenidate, ^{11}C PET, 1043(ab)
^{99m}Tc TRODAT-1 study, nicotine effects on dopamine transporter, 1396(ab)
neuroimaging
before and after methylphenidate, children, 1394(ab)
subtyping with high-resolution HMPAO, 1395(ab)
never-medicated, dopamine transporters and D2 receptors in, 56(ab)
Attenuation correction
combined PET/CT systems
incidental findings on non-contrast CT portion, 1237(ab)
quantitative tracer uptake, 44(ab)
CT, planar activity quantification, application to ^{131}I, 972
CT-based
combined PET/CT scanner, respiration level effects, 887(ab)
low-dose CT scans for, 375(ab)
ProstaScint guided brachytherapy, 1186(ab)
diaphragmatic respiratory motion effects, myocardial SPECT, 1259
differences in FDG uptake, respiratory motion artifacts and, 210(ab)
effects on lesion detection, ^{67}Ga citrate SPECT, 368(ab)
emission and transmission scan time, PET, 886(ab)
emission-transmission scan mismatch, image registration method for correction of, 362(ab)
FDG PET
diagnosis, abdominal and pelvic tumors, 1198(ab)
metastatic thyroid cancer, 1314(ab)
improved compensation method with emission data, ^{201}Tl SPECT, 905(ab)
inferior wall artifact in, cardiac MIBI SPECT, 714(ab)
lesion detectability and, FDG PET of thyroid cancer, 1284(ab)
maps statistics, effects on myocardial SPECT, 904(ab)
multispeak SPECT, with CT data, 903(ab)
in myocardial perfusion SPECT, joint position statement of ASNC and SNM, 273
for myocardial SPECT, 939(ab)
myocardial SPECT, hybrid SPECT/CT system, 171(ab)
narrow beam, ^{166}Ho images, 906(ab)
nonuniform, myocardial SPECT in CAD, 176(ab)
partial reconstruction and, brain SPECT, 908(ab)
PET
radiographic contrast effects, hybrid PET/CT device, 888(ab)
tumor-to-background activity ratios, 834(ab)
whole-body images, reducing loss of image quality, 1054
PET/CT, oral CT contrast agents in, 205(ab)
respiratory motion effects, FDG uptake in PET, 785(ab)
ROC evaluation of, ^{99m}Tc myocardial perfusion imaging, 6(ab)
SPECT, CT-based scatter correction and, phantom study, 902(ab)
transmission scanning for, PET/CT comparison, 1137
Auditory cortex, functional connectivity in primary regions, deafness, FDG PET, 546(ab)
Auger electrons
^{111}In-labeled N-myc phosphorothioate antisense oligonucleotide, neuroblastoma cells, 253(ab)
radiolabeled somatostatin analogs, anti-angiogenic and anti-tumor effects, 438(ab)
Australia New Zealand Society of Nuclear Medicine (ANZSNM), 2002 annual meeting, 39N(4)
Autism, tongue acupuncture treatment in, monitoring with FDG PET, 304(ab)
Autoimmune anterior uveitis, experimental, MicroPET I in, 1346(ab)
Autonomic nervous system, function, exercise training in chronic heart failure and, 773
Autoradiography
^{125}I MIBG, endomyocardial laser channels, 551
dynamic FDG, automated spatial registration, rat brain, 532(ab)
ischemic but viable myocardium, imaging with ^{18}F FRP170, 109

B

Balloon occlusion, temporary test, brain SPECT to evaluate tolerance and hemodynamic changes, 1616
Benzodiazepine receptors
binding, essential tremor patients, 70(ab)
^{11}C FMZ PET, 863(ab)
ischemic disease patients, 533(ab)
^{123}I IMZ distribution, focal cerebral ischemia, 967(ab)
noninvasive quantification, ^{11}C flumazenil PET, 199(ab)
Benzodiazepines, PET/EEG simultaneous recording, thalamic metabolism and cortical alpha rhythm, 543(ab)
Bile duct cancer, extrahepatic, CT and FDG PET comparison, 1195(ab)

Bile flow, hepatic, transit pattern and, in gallbladder lumen, 901
Bioconjugates, hydrophilic polyacetals, for macromolecular radiopharmaceuticals, 1514(ab)
Biodistribution, ^{123}I ADAM, conventional tissue dissection and whole body autoradiography, 1436(ab)
Biodistribution, neurotensin(8–13) pseudopeptide, radiolabeled with ^{99m}Tc, 374
Biomolecular structures, synchrotron x-rays, 42N(6)
Biopsy, fine-needle aspiration cytology, sentinel lymph node, head and neck cancer, 1585
Bioreducible marker, 2-nitroimidazole derivatives of cyclam, for tumor hypoxia, 837
Bioterrorism research, HHS initiatives, 35N(1)
Biotin analogs, astatinated derivatives, in pretargeting, 488(ab)
Bismuth-213, rituximab and, treatment of B-lineage NHL, 418(ab)
Bladder cancer, FDG PET staging of, 423(ab)
Blindness, early onset, $GABA_A$ receptor in visual cortex, PET, 1027(ab)
β-Blockers, left ventricular remodeling and myocardial metabolism, after infarction, 780
Blood-brain barrier
SPECT imaging, acute stroke patients, 1003(ab)
targeted antisense radiopharmaceuticals, Huntington's disease, 948
Blood-pool imaging
2D planar *versus* 3D SPECT, ejection fractions, 1626(ab)
gated
automated *versus* MUGA-C, 1628(ab)
automatic software for processing of left ventricular function, 802(ab)
Fourier phase and amplitude analysis, 810(ab)
left ventricular function with idiopathic dilated cardiomyopathy, 807(ab)
reproducibility of right and left ventricular Fourier phase analysis, ventriculography, 801(ab)
right ventricular function, 806(ab)
right ventricular function and volume analysis, 1558(ab)
gated SPECT
automatic evaluation of right ventricular ejection fraction, 349(ab)
biventricular dynamic physical phantom, 172(ab)
left and right ventricular ejection fraction, 349(ab)
versus myocardial perfusion imaging, left ventricular ejection fraction, 347(ab)
new fully automatic algorithm for, 348(ab)
intraventricular dyssynchrony, in dilated cardiomyopathy, 809(ab)
Blood-pool scintigraphy, whole-body, congenital venous and lymphovenous malformations, 1369(ab)
Blood sampling
arterial, multipurpose shunt system for animal studies, 920(ab)
beta microprobe for measuring radioactivity, PET scanning of small animals, 211(ab)
continuous system, GSO detector assembly for, 933(ab)
FDG PET quantitation without, input function for, 361(ab)
Bolton-Hunter chemistry, iodination of annexin V, Imaging of apoptosis, 671
Bombesin
^{99m}Tc-labeled analogs, for tumor imaging, 336(ab)
^{111}In-labeled DTPA or DOTA, receptor-targeted scintigraphy and radionuclide therapy, 1650
Bone, radionuclide studies
^{18}F fluoride, in postmenopausal women, 338
^{99m}Tc MDP in postmenopausal women, 338
Bone densitometry, volumetric mineral measurements, aging effects, 307(ab)
Bone formation, heterotopic ossification, 346
Bone imaging, ^{64}Cu microPET, 494(ab)
Bone lesions, malignant and benign, ^{18}F FDG PET differentiation of, 510
Bone marrow
cellularity, dosimetry models of trabecular skeleton, 97
detection of metastases, ^{99m}Tc MIBI and HMDP for, 596
infiltration, detection with FDG PET, 1067(ab)
maximum tolerable radiation dose, peptide-receptor radiotherapy, 325(ab)
non-marrow-targeting ^{90}Y-antibody, prediction of myelotoxicity, 1245
red, patient-specific dosimetry, 326(ab)
spleen and, FDG uptake, correlation with hematologic parameters, 1070(ab)
uptake of FDG, correlation with age, 1066(ab)
Bone metabolism
defined disorders, ^{18}F fluoride PET, 135(ab)
FDG PET, 134(ab)
Bone metastases
^{99m}Tc MIBI and HMDP for detection of, 596
cancerous, differentiation, pH-sensitive ^{99m}Tc DOTA, 1130(ab)
versus degenerative changes, FDG PET, 1247(ab)
FDG PET and bone scans in, 1151(ab)
FDG PET whole-body evaluation, 1152(ab)
^{18}F fluoride PET diagnosis, 1150(ab)
in gastrointestinal tract malignancy, bone scintigraphy for, 1205(ab)
prostate cancer
cisplatin effects on ^{89}Sr therapy, 79, 87
radionuclide study with ^{186}Re etidronate, 1150
from prostate cancer, ^{186}Re HEDP therapy, 1272(ab)
radionuclide therapy of, patients with advanced breast and prostate cancer, 580(ab)
^{153}Re HEDP in treatment of, from prostate cancer, 581(ab)
Bone mineral density, values measured by DEXA, diagnostic radionuclide studies, 1370(ab)
Bone pain, palliation
prior bisphosphonate infusion, skeletal uptake of ^{153}Sm EDTMP, 1273(ab)
^{186}Re-labeled bisphosphonate for, 1498(ab)
Bone scans
FDG PET, after fractures and surgical intervention, 136(ab)
^{99m}Tc alendronate, in place of other bisphosphonates, 1364(ab)
^{99m}Tc HMDP, painful knee replacements, 1363(ab)
^{99m}Tc MDP
mechanism of extraosseous accumulation, 1362(ab)
sternal fractures after air bag deployment, 1360(ab)
serial pinhole, time for muscle-pedicle bone graft, 1367(ab)
three-phase, patients with low back pain, 1361(ab)
Bone scintigraphy
asymptomatic femoral neck abnormal uptake on, 484
heterotopic ossification, 346
on-line pediatric atlas, 32N(12)
Bone tumors
benign and malignant, uptake degree of ^{99m}Tc MIBI, 1372(ab)
differentiation from soft tissue, ^{201}Tl scintigraphy, radionuclide angiography and planar imaging, 1379(ab)
malignant and benign, FDG PET discriminant analysis, 1153(ab)
malignant primary, FDG comparison with conventional imaging, 127(ab)
^{201}Tl and three-phase bone scintigraphy, comparative study, 478(ab)
^{201}Tl scintigraphy for, 1368(ab)
Book review, *Permissible Dose:* A History of Radiation Protection in the Twentieth Century, 281
Brachytherapy, ProstaScint guided, CT-based attenuation reconstruction, 1186(ab)
Brain
^{11}C WAY and ^{11}C DWAY PET, neuropsychiatric disorders, 292
circular-orbit cone-beam SPECT, observer study, 1578
damage, PET identification of, 41N(7)
functional imaging, evaluation of early dementia, 253
SPECT, computer-aided intrapatient comparison, 715
Brain imaging, *see also* specific imaging technique
addiction of computer games, adolescents, 1393(ab)
application of anisotropic smoothing, FDG PET in trauma, 891(ab)
automatic spatial registration, dynamic FDG autoradiography, 532(ab)
chronic dopamine depletion, binding of PET D1 receptor radiotracers and, rat, 379(ab)
combined PET/CT systems, neuroshield with, 937(ab)
comparison of modalities, expert clinical judgment and brain tumor recurrence, 1033(ab)
detection of SERT, fluorinated ADAM derivative as imaging agent, 600(ab)
dual-isotope, two independent activation tasks, 822(ab)
extent of glucose metabolism reductions, elderly depression of early Alzheimer's disease, 838(ab)
FDG PET
brain function and blood flow changes in back pain, 1376(ab)
cerebral lesions incidentally detected, 1016(ab)
at Yoga practice, 1017(ab)
Klinefelter syndrome, men, inverse hemispheric dominance in, 1026(ab)
measurement of serotonin transporter, obsessive-compulsive disorder, 54(ab)
motion correction for PET, optical motion tracking system and listmode acquisition, 840(ab)
nicotinic receptors, inhibition of cytochrome P-450 effects, 607(ab)
nociception, statistical autoradiographic mapping of, 860(ab)
observer variation in interpretation, 1041(ab)
PET, neural correlates of fear conditioning, 53(ab)
PET/EEG simultaneous recording, under placebo and lorazepam, 543(ab)
postischemic inflammation, ^{99m}Tc MCP-1 and annexin V, 396(ab)
PTSD, peripheral arousal during guided traumatic imagery in, PET, 1047(ab)
quantitative analysis with ^{11}C WAY 100635, serotonin receptors in schizophrenia, 52(ab)
retention of ^{99m}Tc ECD, metabolic alterations in, rat, 166(ab)
ROI analysis, 363(ab)
semantic processing and cognitive demand, interaction, 1022(ab)
uptake of radiolabeled acid metabolites, modeling, monkey, 960(ab)
Brain injury, traumatic
glucose metabolic changes, FDG PET, 224(ab)
reduction in gray matter glucose phosphorylation after, 1000(ab)
SPECT analysis methods, ROC comparison of, 458
Brain phantom, accuracy of image fusion, localization frame, 867(ab)
Brain tumors
clinical diagnosis, ^{11}C Met PET, 1009(ab)
factor analysis, ^{11}C choline PET, 1008(ab)
malignant, ^{111}In DTPA-D-Glu1-minigastrin in viability of, 406(ab)
malignant, intratumoral injection, PET imaging of drug distribution after, 1444
metastatic, whole-body FDG PET usefulness in, 1432
pediatric, evaluation with ^{99m}Tc MIBI SPECT, 1438
primary and metastatic, ^{18}F FLT PET for assessment, 401(ab)
radiotherapy for, ^{99m}Tc GHA brain SPECT, 1011(ab)
recurrence
expert clinical judgment and imaging modalities, 1033(ab)
from post-radiation necrosis, ^{11}C choline PET, 1032(ab)
residual, progressive or recurrent, FDG PET detection, 1013(ab)
SPECT diagnosis, tumor cell activity in astrocytic tumor, 404(ab)
suspected, ^{18}F FET and FDG PET preoperative metabolic evaluation, 1010(ab)
Breast
application-specific emission and transmission tomography, 39(ab)
axillary uptake, during myocardial perfusion imaging, 177(ab)
normal tissue, FDG uptake, aging and breast density effects, 270(ab)
positron emission mammography, strategies for, 929(ab)
rotating multisegment slant-hole SPECT, lead shielding, 897(ab)
scintimammography, ^{99m}Tc MIBI SPECT, attenuation-free, 1578(ab)

Breast cancer
^{99m}Tc-labeled lipid concentration in tissue, 45N(8)
advanced, radionuclide therapy of bone metastases, 580(ab)
asymptomatic, after breast augmentation, ^{99m}Tc sestamibi scintimammography, 1161(ab)
body-outline imaging technique for localization, sentinel lymph nodes, 1181
^{11}C choline as a potential PET marker, athymic mice, 1458(ab)
chemotherapy response, monitoring with ^{18}F FLT and FDG, 1253(ab)
cilengitide targeting, 34N(10)
cystic, PET in, 36N(12)
CZT detector for scintimammography, phantom and patient studies, 1168(ab)
EGF-induced gene expression, antisense imaging of, 1493(ab)
EGFR-positive malignancies, ^{99m}Tc h-R3 monoclonal antibody study, 1254(ab)
estrogen receptor-positive
  ^{18}F FES PET in, 1157(ab)
  tissue surrounding, detection of, 1093(ab)
extra-axillary metastases, PET use in, 269(ab)
FDG PET, in therapy change, 1160(ab)
^{18}F FLT PET detection, 278(ab)
^{18}F fluoroemodin as potential imaging agent, 1092(ab)
high resolution scintimammography, 909, 916
imaging opioid receptors in, PET, 1131(ab)
internal mammary nodes
  lymphoscintigraphy and biopsy, 75(ab)
  radioguided sentinel node biopsy, 76(ab)
  local anesthesia, 77(ab)
locally advanced
  blood flow and glucose metabolism relations, 1100(ab)
  blood flow and metabolism in, response to therapy and, 500
  response to neoadjuvant chemotherapy, ^{99m}Tc sestamibi washout in, 745
local/regional evaluation, FDG PET, 44N(11)
luteinizing hormone-releasing hormone scintigraphy, with ^{111}In D-Trp6-LHRH, 1192(ab)
lymph node metastases in, ^{99m}Tc MIBI scintimammography comparison with CT, 1165(ab)
lymphoscintigraphy, dual-head gamma camera, 899(ab)
metastatic, ^{123}I imaging of, 428(ab)
MMP inhibitor radiotracers, PET tumor imaging agents, 316(ab)
multidrug resistance in, ^{99m}Tc sestamibi and furifosmin, 1119(ab)
multifocal/multicentric, sentinel node localization and, 71(ab)
NIS-expressing tumors, ^{188}Re therapy for, 433(ab)
non-sentinel node involvement, early systemic recurrence, 74(ab)
occult, missed by standard screening, scintimammography with SOV gamma camera, 1169(ab)
palpable lesions, ^{99m}Tc sestamibi compared with MDP and DMSA in, 882
PET mammography, pixelated NaI(Tl) arrays for, 37(ab)
preclinical radioimmunotherapy, mAb and a new residualizing ^{131}I, 556(ab)
previously treated, whole-body FDG PET and conventional imaging for, 325
primary early stage, ^{99m}Tc tetrofosmin SPECT scintimammography, 1162(ab)
radiolabeled guanine derivatives, PET imaging for DNA repair protein AGT, 1491(ab)
recurrent or metastatic, FDG PET comparison with other imaging modalities, 267(ab)
response to therapy, serial FDG PET, 34N(10)
revised staging in 2003, 36N(11)
with rising serum tumor markers, FDG PET in, 1158(ab)
scintimammography and mammography combination, over 50s, 272(ab)
sentinel lymph node in
  first lymph node radiodetected in, 73(ab)
  internal mammary nodes and diseased axillary nodes, 1174(ab)
  intradermal injection and intraoperative isosulfan dye in, 1175(ab)
  Oscar Lambret Center, 1173(ab)
sentinel lymph node mapping in, subareolar lymphoscintigraphy, 1176(ab)
sentinel node biopsy
  axillary detection in, tumor size effects, 1171(ab)
  gamma probe for intraoperative imaging, 924(ab)
  German multicenter study, 1170(ab)
  subareolar application of ^{99m}Tc nanocolloid, 1172(ab)
sentinode targeting in a rat model, ^{99m}Tc labeled liposomes, 1137(ab)
sestamibi scanning in, 125(le)
sigma receptor scintigraphy, with P-^{123}I MBA, 1647
sodium iodide symporter expressed in, ^{99m}Tc pertechnetate scintimammography, 431(ab)
staging and management, ^{18}F FDG PET effects, 268(ab)
^{99m}Tc anti-HER2/neu, tumor specific imaging agent, 487(ab)
^{99m}Tc D-glucaric acid, scintimammography with, 1164(ab)
^{99m}Tc DMSA uptake in, proliferation index (^{67}K), 1163(ab)
^{99m}Tc GLA high-resolution FastSPECT imaging, tumor targeting with, 1104(ab)
^{99m}Tc MIBI and DMSA uptake, calcitonin gene-related peptide and calcitonin effects on, 1167(ab)
^{99m}Tc MIBI scintimammography, ROC curve analysis, role of quantitative index in, 1166(ab)
^{99m}Tc MIBI SPECT, comparisons, 823(ab)
^{99m}Tc PNA-peptide for early detection, 448(ab)
^{99m}Tc sestamibi scintimammography, international prospective evaluation, 271(ab)
^{99m}Tc tetrofosmin scintigraphy in follow-up, 1159(ab)
tumor imaging in preclinical models, sigma receptor PET ligand, 1132(ab)
xenografts, localization of opioid receptors on, 1138(ab)
Bromine-76 BFU, as proliferation marker, rat comparison studies, 1688
Bromine-76 compounds, high specific activity, preparation of, 1501(ab)
Bronchiolitis, respiratory syncytial virus, β-agonist aerosol distribution in, infants, 487
Brown adipose tissue, visualization, ^{123}I MIBG or ^{125}I MIBG use in, 1234

C

C5a agonist, potentiation of radioimmunotherapy, 957
CADASIL, alterations in glucose metabolism with, FDG PET, 539(ab)
Cadmium zinc telluride (CZT), for scintimammography, phantom and patient studies, 1168(ab)
Calcitonin gene-related peptide, calcitonin and, effects on DMSA/MIBI uptake, breast cancer, 1167(ab)
Cancer. *see also* specific type or site
  ^{111}In DTPA, ^{67}Ga and ^{201}Tl, human tumors, 1091(ab)
  management, PET/CT imaging with FDG, 117(ab)
  pain, nuclear medicine response to, 31N(10)
  survival rates recalculated, 37N(12)
  targeted therapy with radiolabeled antibodies, 693
  U. S. death rates, decline in, 40N(7)
Captopril
  effects on renal cortical vascular resistance, heart failure patients, 770(ab)
  renal scintigraphy, renal artery stenosis with impaired renal function, 143(ab)
Carbon-11 acetate
  combined with FDG PET, oral cancer diagnosis, 1193(ab)
  discrete linear least squares method for diagnosis, nasopharyngeal cancer, 862(ab)
  FDG and, diagnosis of pulmonary tuberculosis, 461(ab)
  PET
    chronic ischemic dysfunction, dogs, 556
    dilated cardiomyopathy, 782(ab)
    hepatocellular carcinoma, 84(ab)
    kinetics in prostate cancer, 425(ab)
    lung cancer, 274(ab)
    primary and locally recurrent prostate cancer, 422(ab)
    prostate cancer, 181
    pulmonary nodules and mediastinal tumors, 275(ab)
Carbon-11 AMP, PET imaging of cancer, 1454(ab)
Carbon-11 annexin V, PET, imaging of apoptosis, 1457(ab)
Carbon-11 arachidonic acid, brain incorporation, effect of partial volume correction on, 969(ab)
Carbon-11 BATA, radioligand for norepinephrine transporters, 599(ab)
Carbon-11 BPA, stereoselective transport of, in melanoma, 317(ab)
Carbon-11 CGP12177, pre- and post-synaptic sympathetic dysfunction, CAD and left ventricular dysfunction, 513(ab)
Carbon-11 CGP 12388, inhaled PET, human airway, 1409(ab)
Carbon-11 choline
  FDG and, PET in thoracic cancer, 167
  PET
    factor analysis in brain tumor imaging, 1008(ab)
    recurrent high-grade brain tumor from post-radiation necrosis, 1032(ab)
  potential PET marker, breast cancer in athymic mice, 1458(ab)
  prostate cancer, determination of outcome of hormonal therapy, 421(ab)
Carbon-11 DASB
  ^{11}C MeN6562 comparison, as serotonin transporters under experimental conditions, 678
  PET serotonin transporter radioligand, dosimetry estimates for, 1438(ab)
Carbon-11 DWAY, PET, neuropsychiatric disorders, 292
Carbon-11 epinephrine, ^{11}C HED and, tandem studies, congestive heart failure, 512(ab)
Carbon-11 flumazenil
  PET
    distribution volume image of, cerebrovascular disease, 848(ab)
    noninvasive quantification of benzodiazepine receptor binding, 199(ab)
    viable cortical neurons, ischemic disease patients, 533(ab)
  rapid synthesis, microreactor placed in the HPLC loop, 1448(ab)
Carbon-11 FMAU
  pharmacokinetics and radiation dosimetry, 1075(ab)
  as proliferation marker, rat comparison studies, 1688
  tumor imaging, compared with FDG, 92(ab)
Carbon-11 glucose, FDG lumped constant, normal human brain, 1157
Carbon-11 GR103545, PET ligand, imaging Kappa opioid receptors, 602(ab)
Carbon-11 HED
  ^{11}C epinephrine and, tandem studies, congestive heart failure, 512(ab)
  myocardial presynaptic sympathetic innervations, CAD patients, 761(ab)
  pre- and post-synaptic sympathetic dysfunction, CAD and left ventricular dysfunction, 513(ab)
Carbon-11 iodomethane, polymer-supported reagents, 492(ab)
Carbon-11 MCG, PET, probe for NAALADase/PSMA, 493(ab)
Carbon-11 McN6562, ^{11}C DASB comparison, as serotonin transporters under experimental conditions, 678
Carbon-11 MET
  ^{18}F FDG and, PET in prostate cancer, 46
  FDG and, detecting metastatic thyroid cancer, 1306(ab)
  PET
    brain tumors, 1009(ab)
    rectal cancer patients, 279(ab)
    recurrent gynecologic cancer, 1142(ab)
    uptake in esophagus and stomach, 245(ab)
  PET, pancreatic function and, 40N(9)
  staging and restaging, head and neck cancer, 261(ab)
  use in hyperfunctioning parathyroid glands, 288(ab)
Carbon-11 mHED, PET, neuronal uptake and vesicular transport, 858(ab)

Carbon-11 NIDA-41020, radiosynthesis of, cerebral cannabinoid receptors, PET, 1443(ab)
Carbon-11 NPA, PET, dopamine agonist, 956(ab)
Carbon-11 OXP, potential brain NET marker, 1446(ab)
Carbon-11 PE21, dopamine transporter ligand, nonhuman primates, 951(ab)
Carbon-11 raclopride
binding, localized left-putamenal dopamine release, 954(ab)
B+-range–sensitive probe, radiopharmacology in small animals, 227
microPET and, comparative imaging with dopamine D2, 1570
Carbon-11 S12968, myocardial binding sites, PET study in dogs, 1227
Carbon-11 toluene, brain uptake, effects of vehicle, 158(ab)
Carbon-11 verapamil, PET, P-glycoprotein transport activity, 1120(ab)
Carbon-11 WAY, PET, neuropsychiatric disorders, 292
Carbon-11 WAY-100635, ^{11}C WAY-100635, imaging serotonin receptors, 1445(ab)
Carbon-11 ZbRET, PET imaging, serotonin transporters, 151(ab)
Carbon-11 ZIET, PET imaging, serotonin transporters, 151(ab)
Carbon-13 urea breath test, endoscopic, diagnosis of *Helicobacter pylori*, 1340(ab)
Carbon-14 acetate, cellular metabolism, prostate cancer cells, 1099(ab)
Carbon-14 IAP, FDG and, accumulation in sublingual gland, 1103(ab)
Carcinoembryonic antigen, anti-human radioimmunotherapeutics, transgenic mouse model for, 1368
Carcinoid tumor, ^{111}In pentetreotide in, 42N(5)
Cardiac adrenergic activity, ^{123}I MIBG SPECT assessment, in CAD, 1
Cardiac damage, induced, nuclear medicine assessment of, 42N(11)
Cardiac imaging, practice patterns, 31N(3)
Cardiac natriuretic peptides, tetrofosmin kinetics and, in chronic heart failure, 14(ab)
Cardiac PET, respiratory motion compensation, continuously rebinned gating for, 523(ab)
Cardiac phantoms, accuracy of SPECT imaging, acquisition orbits and, 1115
Cardiac resynchronization therapy, biventricular pacing, dilative cardiomyopathy and left bundle branch block, 187(ab)
Cardiac SPECT
myocardial fusion, 3D models of CAD, 12(ab)
^{99m}Tc MIBI, detection of hibernating myocardium, CAD, 342(ab)
Cardiac sympathetic nervous system
clinical determinants of sympathetic reinnervation, after heart transplant, 515(ab)
dual ^{123}I MIBG and ^{201}Tl kinetic study, myocardial infarction, rat, 717(ab)
natriuretic peptide effects on risk stratification, heart failure, 763(ab)
norepinephrine transporter binding agent for assessment, 1510(ab)
Cardiomyopathy
^{18}F 4-FM and ^{123}I MIBG, uptake, metabolism, and β-receptor binding, 366
dilated
^{11}C acetate PET, 782(ab)
^{18}F FDG histological findings, 762(ab)
^{125}I MIBG and carvedilol in, rats, 531, 536
^{201}Tl SPECT abnormalities documented at rest, 451
intraventricular dyssynchrony, blood-pool imaging, 809(ab)
left ventricular function in, gated blood-pool imaging, 807(ab)
prognostic value of right ventricular function, pediatric, 803(ab)
dilative
left bundle branch block and, cardiac resynchronization therapy, biventricular pacing, 187(ab)
left bundle branch block and, PET evaluation, 20(ab)
hypertrophic
cardiac sympathetic nerve activity in, ^{123}I MIBG evaluation, 15
exercise thallium findings in, 732(ab)
idiopathic dilated, gated myocardial SPECT in, 748(ab)
ischemic, myocardial blood flow and flow reserve in, PET, 781(ab)
Cardiotoxicity, adriamycin-induced, mitochondrial complex I activity reduced in, rat, 705(ab)
Carcinoid tumors, ^{18}F FFMMT as imaging agent, 1464(ab)
L-Carnitine, effects on acute myocardial infarction, fatty acid metabolism, 749(ab), 753(ab)
Carotid artery, internal, arterial blood supply from, anatomical map, 364(ab)
Carotid artery disease
cerebral metabolism after endarterectomy, acetazolamide stress brain perfusion SPECT, 537(ab)
endarterectomy, cerebral cortical perfusion changes after, 1038(ab)
Carvedilol, ^{125}I MIBG and, effects on cardiac function, in dilated cardiomyopathy, rats, 531, 536
Cassen Prize, Phelps, Michael, 11N(7)
Cell proliferation, dopamine role in, 36N(12)
Cellularity, marrow, dosimetric models of trabecular skeleton, 97
Centers for Medicare and Medicaid Services (CMS)
health market update, 30N(12)
HIPAA Transaction and Code Set Standards, 30N(12)
Central nervous system, ^{11}C SA4503 binding to sigma$_1$ receptors, aged monkey brain, 958(ab)
Cerebellum, benzodiazepine receptor binding in, essential tremor patients, 70(ab)
Cerebral blood flow (CBF)
blood volume and, changes after acetazolamide challenge, PET, 535(ab)
brain SPECT, during temporary balloon occlusion test and after carotid occlusion, 1616
changes
after unilateral endarterectomy, 1038(ab)
deep brain stimulation, essential tremor patients, PET, 992(ab)
during working memory, obsessive-compulsive disorder, PET, 1042(ab)
dopamine levels, heatstroke-induced ischemia, PET, 955(ab)
$GABA_A$ receptor in visual cortex, early onset blindness, 1027(ab)
$H_2{}^{15}O$ PET, before and after amphetamine, baboon, 1090
misery perfusion, changes after acetazolamide challenge, PET, 536(ab)
mood and cognition, in hypothyroidism, 1039(ab)
myocardial blood flow and, during mental stress, dual-PET study, 1006(ab)
noninvasive measurement, ^{99m}Tc HMPAO SPECT, 818(ab)
normal database, PET, 1004(ab)
during P_ACO_2 changes, aging effects, PET measurement, 534(ab)
quantitation, dynamic sinogram use in, 852(ab)
regional
with abnormal perfusion, subclinical hepatic encephalopathy, 545(ab)
during acetylcholinesterase inhibitors for Alzheimer's disease, 983
in acute depression, SPECT, 1050(ab)
amyotrophic lateral sclerosis, SPECT, 991(ab)
deep brain stimulation of subthalamic stimulation and, Parkinson's disease, 725
gender differences in verbal and nonverbal encoding tasks, 1021(ab)
SPECT in head injury, 476
Cerebral cortex, retention of ^{99m}Tc ECD, metabolic alterations in, rat, 166(ab)
Cerebral ischemia
hyper-acute stroke, oxygen metabolism, PET, 839(ab)
viable cortical neurons in, detection with ^{11}C FMZ PET, 533(ab)
Cerebral perfusion reserve
brain SPECT, during temporary balloon occlusion test and after carotid occlusion, 1616
delayed effects of acetazolamide and, triple injection of ECD, 577
Cerebral PET
cortical abnormalities, based on 3D asymmetry index, 825(ab)
essential tremor, rCBR changes due to deep brain stimulation, 992(ab)
glucose metabolism, diffuse *versus* focal brain injury, 1002(ab)
motion correction for, optical motion tracking system and listmode acquisition, 840(ab)
simian immunodeficiency virus, brain metabolism, 965(ab)
Cerebral SPECT
acetazolamide stress perfusion, after carotid endarterectomy, 537(ab)
amyotrophic lateral sclerosis, 991(ab)
anatomical standardization and reference to normal data, ROC-based comparison, 829(ab)
blood-brain barrier imaging, acute stroke, 1003(ab)
blood flow distribution, internal carotid artery, 364(ab)
cochlear implant, comparison of pre- and post-implant, 1023(ab)
crossed cerebellar diaschisis, children with refractory epilepsy, 1389(ab)
differential diagnosis, Alzheimer's disease and dementias, 988(ab)
distribution volume of ^{111}In IMP, regional differences, 962(ab)
dopamine D2 receptor occupancy, antipsychotic drugs, 1556(ab)
emergency room evaluation, amnesia after mild head trauma, 1001(ab)
estrogen replacement therapy effects, cortical density and, 1048(ab)
hypothyroidism, post-thyroidectomy patients, 1028(ab)
^{123}I IMP, compromised cerebral perfusion reserve measured by, 997(ab)
large normal rCBF database, age and gender effects, 235(ab)
mild cognitive impairment patients, evidence of Alzheimer's disease, 989(ab)
motion correction, data-driven, 908(ab)
nicotinic cholinergic receptors, in Alzheimer's disease, 229(ab)
operative indication and prediction of outcome, major subarachnoid hemorrhage, 1005(ab)
perfusion
cholinesterase inhibitor therapy in Alzheimer's disease, 236(ab)
during intellectual stress test, ADHD in children, 303(ab)
methylphenidate-induced changes in cerebral blood flow, ADHD in children, 302(ab)
preclinical prediction of Alzheimer's disease, 232(ab)
quantitative, use of striatal phantom, evaluation of scatter correction, 1555(ab)
reconstruction and correction algorithms, preclinical Alzheimer's disease, 880(ab)
SPM for diagnosis, Alzheimer's disease, 233(ab)
^{99m}Tc ECD
and ^{123}I IMP imaging, two independent activation tasks, 822(ab)
brain perfusion, cerebrovascular disease revascularization, 998(ab)
childhood autism, 1391(ab)
reactive attachment disorder, children, 1390(ab)
^{99m}Tc HMPAO balloon occlusion test, carotid occlusion, 1007(ab)
^{99m}Tc HSA, protein transudation, with cluster headache, 1036(ab)
^{99m}Tc sestamibi uptake, brain tumor proliferation and, 404(ab)
treatment-resistant depression, vagus nerve stimulation in, 1051(ab)
ultra-high resolution, quantification of dopamine transporters in mouse brain, 218(ab)
^{133}Xe, osteoarthritis pain with ROI and SPM methods, 1024(ab)
Cerebrospinal fluid (CSF), radioiodine injection, radiation dosimetry for, 314(ab)
Cerebrovascular disease
acetazolamide challenge and

NeuroPET, 538(ab)
PET, 535(ab)
CADASIL, alterations in glucose metabolism with, 539(ab)
carotid occlusion and stenosis, spatial disagreement of, 999(ab)
^{123}I IMP SPECT, compromised cerebral perfusion reserve measured by, 997(ab)
Cerebrovascular ischemic disease, delayed effects of acetazolamide and, triple injection of ECD, 577
Cerebrovascular reserve, oxygen extraction fraction and, spatial disagreements, in carotid occlusion, 999(ab)
Cervical cancer
advanced, PET in, 41N(7)
FDG PET, visual analysis of tumor characteristics, 100(ab)
FDG PET in, 30N(3)
lymphoscintigraphy, detection of sentinel nodes, 1184(ab)
metastatic/recurrent, FDG PET and MRI/CT discrepant findings, 99(ab)
squamous cell type uterine, FDG PET for prognosis prediction, 101(ab)
staging and restaging, combined PET/CT systems, 1250(ab)
CGP 12177, β-adrenergic receptor quantification, 215
Chelates
conjugation of DOTA to useful active esters, 1515(ab)
intrinsic, biodistribution of annexin V, 500(ab)
^{99m}Tc MAG3-like agents, renal radiopharmaceuticals, 1509(ab)
Chemotaxis, viability and, ^{99m}Tc exanetazime labeled leukocytes, 928
Chemotherapy
aerosolized, dose delivery in, ^{99m}Tc pentetate for estimation, 1208(ab)
intra-arterial, myocutaneous adverse side effects, bone and soft tissue tumors, 1452
neoadjuvant
response in locally advanced breast cancer, 745
response to, relation to blood flow and metabolism, breast cancer, 500
Non-Hodgkin's lymphoma, after radioimmunotherapy, 417(ab)
PET prediction of prognosis, aggressive lymphoma and Hodgkin's disease, 1018, 1028
prediction of response, ^{67}Ga citrate scintigraphy, lymphoma, 1071(ab)
response to, monitoring with FDG PET, non-small cell lung cancer, 1304
Chest pain
esophageal scintigraphy, myocardial perfusion imaging and, 740(ab)
^{123}I BMIPP SPECT, myocardial ischemia, 814(ab)
low-risk patients, rest and stress myocardial SPECT, 739(ab)
Chest Tumor Phantom, PET and SPECT, 25N(11), 31N(6)
Cholangiocarcinoma, nodular *versus* infiltrating subtypes, FDG PET in evaluation, 83(ab)
Cholecystitis, hepatic bile entry and transit pattern, gallbladder lumen, 901
Cholecystokinin, fatty meals and, for gallbladder ejection fraction, 1603
Cholecystokinin B, internalization of receptor agonists, 447(ab)
Cholelithiasis, CCK-8 infusion, during hepatobiliary imaging, 1604(ab)
Cholescintigraphy
fatty meal stimulated, gallbladder, 1345(ab)
hepatic bile entry and transit pattern, gallbladder lumen, 901
octreotide effects, gallbladder motor function in acromegaly, 474(ab)
Choline transporters, quantitation, PET, 393(ab)
Chromosomal aberrations
chronic low-level radiation exposure and, 34N(1)
leukocyte labeling with ^{99m}Tc HMPAO and, 203
workers in nuclear medicine centers in Iran, 1602(ab)
Chronic obstructive pulmonary disease (COPD), FDG PET, thoracic and abdominal muscles in, 1410(ab)
Cilengitide, targeting, breast cancer xenografts, 34N(10)
Cirrhosis, *see* Liver cirrhosis
with subclinical hepatic encephalopathy, regional cerebral blood flow in, 545(ab)
Cisplatin, effects on ^{89}Sr therapy, bone metastases from prostate cancer, 79, 87
Cluster analysis, replacement for arterial sampling, in kinetic modeling, 360(ab)
Cluster headache, protein transudation with, ^{99m}Tc HSA SPECT, 1036(ab)
CMRO2 calculation method, short bolus inhalation of ^{15}O water, 865(ab)
Cocaine
candidate medications, dopamine transporter occupancy, 948(ab)
chronic abuse, D2 receptors in the striatal substructures, PET, 387(ab)
Cochlear implant, comparison of pre- and post-implant function, SPECT, 1023(ab)
Cognitive decline, radiation-induced, 34N(12)
Cognitive disorders, amyloid β protein, in vivo labeling of, 1044, 1052
Cognitive performance, cerebral glucose uptake relations, frontotemporal dementia, 990(ab)
Coincidence imaging
^{18}F FDG dual-head gamma-camera, colorectal cancer, 603
^{62}Cu-labeled cardiac tracers, hybrid PET cameras, 42(ab)
detection camera, cascaded photons in ^{111}In imaging, 941(ab)
dual-head-hybrid PET system, measured transmission correction using, 1608(ab)
effective functional renal volume, small kidneys, 1416(ab)
fan-slat collimators, improved hybrid PET imaging, 32(ab)
FDG
chest malignancy assessment, 1217(ab)
dual-head gamma camera, malignant pleural mesothelioma, 1213(ab)
gamma camera, esophageal cancer, 1201(ab)
gamma camera, myocardial viability studies, 769(ab)
malignant pleural mesothelioma, 1144
^{18}F FDG, recurrence of testicular cancer, 1143(ab)
^{82}Rb and hybrid gamma camera, pig heart, 27(ab)
triple-head gamma camera, spatial resolution and image contrast of, 928(ab)
Colitis, leukotriene B4 antagonist for imaging, rabbit, 504(ab)
Collimation, collimators
enhanced sensitivity, SPECT, 881(ab)
high-resolution, ^{123}I IBZM SPECT, 857(ab)
rotating slant-hole, effects of camera positions in ectomography and, 898(ab)
single and double-edged, SPECT imaging of small volumes, 914(ab)
system parameters, development of ultra-high resolution SPECT for small animal imaging, 919(ab)
variable focal length fan-slat, improved hybrid PET imaging, 32(ab)
Colloid, liver and spleen uptake, SPECT in detection of liver cirrhosis, 312
Colon adenocarcinoma, anti-tag-72 antibody, phage displayed library technology, 1087(ab)
Colon cancer
antiangiogenic therapy, ^{131}I monoclonal antibody therapy and, 1081(ab)
new imaging reporter gene system, sodium iodide symporter gene, 1095(ab)
ovarian cancer and, treatment of tumor xenografts, 1082(ab)
Colony-stimulating factors, FDG PET and, 36N(12)
Colorectal cancer
endoscopic administration of ^{99m}Tc DTPA-*mannosyl*-dextran, lymph nodes, 475(ab)
FDG PET, PET-CT and, comparison, 78(ab)
GC-C-targeted, xenografts in immunodeficient mice, 392
hepatic metastases, FDG and gadolinium uptake, 1197(ab)
imaging or therapy, ^{111}In labeled *E. coli* ST_h analog for, 333(ab)
liver metastasis model, synergism and antiangiogenic therapy, 1079(ab)
metastatic
FOLFOX chemotherapy, FDG PET, 79(ab)
primary tumor resection, FDG PET, 80(ab)
modification of management, FDG PET and, 81(ab)
monoclonal antibody therapy, model of ^{131}I HuA33 pharmacodynamics, 861(ab)
occult recurrence, FDG PET in detection, 82(ab)
recurrent, FDG PET in, 492
recurrent or metastatic, ^{18}F FDG coincidence imaging, 603
before resection of hepatic metastases, FDG PET, 1196(ab)
therapy monitoring, ^{11}C MET PET, 279(ab)
Compound W, maternal, fetal thyroid function, 1332(ab)
Concanavalin A, lymphocyte activation, FDG uptake in model of inflammation, 658
Congenital heart disease, corrected dextro-transposition, great arteries, 1382(ab)
Congestive heart failure
^{11}C HED and ^{11}C epinephrine, tandem PET imaging, 512(ab)
cardiac sympathetic nerve activity, spironolactone improvement of, 1279
Consciousness, impairment of, ^{99m}Tc HMPAO SPECT use in, 1610(ab)
Continuous ambulatory peritoneal dialysis (CAPD), ^{99m}Tc DTPA excretion and, 1420(ab)
Contrast media
focal tracer uptake, potential artifact in, PET/CT scans, 1339
intravenous nonionic, effects on PET-CT systems, 46(ab)
oral
artifacts induced by, FDG PET-CT, 1241(ab)
coregistered PET-CT and, 41N(9)
CT, clinical PET/CT scanning using, 205(ab)
FDG PET-CT, 1240(ab)
preliminary clinical evaluation in PET-CT, 1242(ab)
Copper-62 PTSM, cardiac tracers, use with hybrid PET cameras, 42(ab)
Copper-64
experimental autoimmune anterior uveitis, 1346(ab)
intratumoral administration, therapeutic comparison in GW39 tumors, 1127(ab)
microPET, bone imaging, 494(ab)
Copper-64 ATSM, kinetics, Patlak analysis in animal tumor model, 871(ab)
Copper-64 DOTA CTTHWGFTLC, selective gelatinase inhibitor, tumor imaging, 1121(ab)
Copper-64 lipophilic complexes
synthesis, liver, 495(ab)
therapeutic, ultra-small cyclotron, 1499(ab)
Copper ATSM, PET, delineation of cardiac hypoxia, canine, 1557
Copper isotopes, uptake by tumor cells, nitrosipine effects, 1500(ab)
Copper radionuclides, radiolabeling with, new somatostatin analog for, 331(ab)
Coronarography, myocardial gated SPECT comparison, frequency of clandestine ischemia, 18(ab)
Coronary artery bypass graft (CABG)
pre-revascularization myocardial perfusion SPECT in, 354(ab)
septal wall motion after, myocardial gated SPECT, 791(ab)
wall thickening and motion, ^{99m}Tc MIBI SPECT, 589
Coronary artery disease (CAD)
angiogenesis in, myocardial exercise SPECT for evaluation, 19(ab)
apoptotic macrophages, noninvasive targeting with annexin V, 23(ab)
arbutamine stress perfusion imaging, dogs, 664
automated transient ischemic dilatation, 738(ab)
cardiac adrenergic innervation om, ^{123}I MIBG SPECT, 1
with dilated left ventricle, ^{99m}Tc tetrofosmin gated SPECT, 355(ab)
dobutamine atropine stress myocardial perfusion SPECT, tetrofosmin use in, 767

dobutamine stress perfusion imaging in, 1634
exercise supplementation to dipyridamole, myocardial scintigraphy, 725(ab)
gated SPECT, recognition of transient postischemic stunning, 346(ab)
gated SPECT and 2D echocardiography, comparison with left ventriculography, 344(ab)
heart failure due to, age and, myocardial gated SPECT, 768(ab)
left main or three vessel coronary disease, ^{82}Ru PET identification of, 728(ab)
matrix metalloproteinase expression, in atherosclerotic plaques, 4(ab)
multivessel
exercise ^{201}Tl gated SPECT for detection, 443
left ventricular ejection fraction for detection, 131
myocardial fusion, 3D models, 12(ab)
myocardial presynaptic sympathetic innervations, ^{11}C HED, 761(ab)
perfusion abnormalities, coronary risk factors and, 776(ab)
reduction in vasodilator function, myocardial infarction patients, 189(ab)
reduction or reversal by lipid lowering therapy, PET, 186(ab)
reverse mismatched BMIPP uptake higher than thallium, 741(ab)
stress SPECT and, 41N(4)
^{99m}Tc MIBI with nitrates, detection of hibernating myocardium, 342(ab)
^{99m}Tc sestamibi, coronary spastic angina, 764(ab)
therapeutic efficacy, assessment with myocardial perfusion imaging, 750(ab)
Coronary blood flow
endothelial dysfunction, rosiglitazone effects, PET measurement, 3(ab)
Higenamine in experimental and hemodynamic and tolerability study, 719(ab)
Coronary flow reserve, decreased, in diabetes, myocardial perfusion imaging, 507(ab)
Coronary vasoreactivity, nateglinide effects, in diabetes, 506(ab)
Cost effectiveness, PET evaluation, early dementia symptoms, 253
Craniosynostosis, ^{99m}Tc annexin V imaging, apoptosis, 1392(ab)
Cross-doses, intestinal wall activity and, dosimetry model for, 1657, 1665
Crosstalk compensation, model-based, dual isotope imaging, 193(ab)
CT
^{67}Ga scintigraphy and, bone lymphoma treatment, 1295
combined PET system, *see also* Multimodality imaging
4D NURBS-based cardiac-torso (NCAT) phantom, 43(ab)
with continuous bed movement, 38(ab)
count rate performance, 40(ab)
effects of nonionic intravenous contrast agents, 46(ab)
lesion size and volume, 47(ab)
mismatch in upper abdominal organs, 48(ab)
quantitative tracer uptake, 44(ab)
spatial registration of lung lesions, 49(ab)
combined SPECT system, small animal imaging, 35(ab)
FDG, thoracic aortic wall metabolic activity and calcification, 10(ab)
helical, ER patients with renal colic, effect of MAG_3F_0 diuretic renography, 145(ab)
patient dose, NCRP symposium, 40N(11)
versus PET, identification of melanoma metastases, 1187(ab)
regional pulmonary perfusion, acute pulmonary edema patients, 863
^{99m}Tc MIBI scintimammography comparison, lymph node metastases in breast cancer, 1165(ab)
CT angiography, spiral, after lung scintigraphy, diagnosis of pulmonary embolism, 585(ab)
Current Procedural Terminology (CPT) code, nuclear medicine therapy, 27N(7)
Cyclam, 2-nitroimidazole derivatives of, positive markers of tumor hypoxia, 837
Cyclic peptides, ^{18}F-labeled, solid phase synthesis, 1467(ab)
Cyclooxygenase (COX), ^{18}F-labeled inhibitors, radiosynthesis, 117
Cyclooxygenase (COX) 2, expression, focal cerebral ischemia, rat model, 967(ab)
Cyclophosphamide, treatment, uptake of ^{99m}Tc annexin V after, 258(ab)
Cyclosporine, aerosol, lung deposition of, transplant recipients, 1614(ab)
Cystic fibrosis
neutrophil imaging, lung, 584(ab)
pediatric patients, gastroesophageal reflux disease, gastric emptying studies in, 593(ab)
Cytomegalovirus (CMV), ^{18}F penciclovir as potential method for monitoring, 1348(ab)

D

Data acquisition, SPECT accuracy, effects of acquisition orbits on, 1115
Decision analysis, PET evaluation, early dementia symptoms, 253
Dementia, *see also* Alzheimer's disease
acetazolamide SPECT imaging, 538(ab)
AIDS, benzodiazepine receptors in, PET study, 234(ab)
algorithm for evaluation, FDG PET, 226(ab)
amyloid β protein, in vivo labeling of, 1044, 1052
early symptoms, evaluation by PET, 253
frontotemporal, cerebral glucose uptake, cognitive performance and, 990(ab)
with Lewy bodies, FDG PET and ^{123}I IMP SPECT comparison, 1035(ab)
prognostic evaluation, PET, 225(ab)
Department of Energy (DOE)
Center for nanoscale science research at Brookhaven, 45N(8)
Fast Flux Test Facility (FFTF) faces deactivation, 26N(2)
Femilab contract, 28N(2)
nuclear medicine concerns, 14N(3)
Office of Science, 38N(9)
Post-genomic research award, 38N(9)
radiation detectors, 37N(11)
supply of medical isotopes, 44N(8)
Depot clearance, lymphatic function, in lymphedema, 318
Depression
acute, regional cerebral blood flow in, 1050(ab)
anterior cingulotomy for, cerebral metabolic rates as predictors of response, FDG PET, 1053(ab)
dopamine transporter levels, ^{99m}Tc TRODAT-1 SPECT, 55(ab)
primarily untreated, serial FDG PET before and after, 1052(ab)
repeated transcranial magnetic stimulation for treatment, FDG PET, 1049(ab)
treatment-resistant, vagus nerve stimulation in, SPECT, 1051(ab)
Diabetes
assessment of insulin sensitivity, ^{125}I DIG, 1511(ab)
changes in coronary vasomotion in, PET myocardial blood flow measurements, 508(ab)
fluoroethoxyglyburide binding to beta cells, monitoring of cell transplantation, 321(ab)
insulin-dependent, myocardial fatty acid oxidation, PET, 510(ab)
left ventricular wall motion in, myocardial gated SPECT, 511(ab)
myocardial blood flow and vasoreactivity, effects of nateglinide on, 506(ab)
myocardial SPECT in, 30N(3)
osteopathy, MDP and gallium scintigraphy in, 1378(ab)
risk factor for coronary disease, myocardial PET with ^{82}Rb, 5(ab)
stress-induced myocardial ischemia in, stress testing and, 505(ab)
Diagnostic imaging, anticancer agents and, strong market outlook, 31N(3)
Diagnostic test comparisons, expert readers and polar-plot programs, compared with Perfit software, 181(ab)
DICOM, image display, PACS in nuclear medicine, 832(ab)
Digital phantoms, evaluation of image analysis tools, PET, 369(ab)
Dihydropyridine, myocardial binding sites, PET study in dogs, 1227
Dimercaptosuccinic acid (DMSA), use during febrile urinary tract infection, 1419(ab)
Diphosphonates, for heterotopic ossification, 346
Dipyridamole
exercise supplementation to, myocardial scintigraphy, 725(ab)
myocardial ischemia induced by, beta blockade effects, ^{99m}Tc MIBI imaging, 180(ab)
myocardial stunning assessed by, gated myocardial SPECT, 786(ab)
transient LV dysfunction induced by, ^{201}Tl gated myocardial SPECT, 737(ab)
Disseminated mycobacterium avium complex (DMAC)
in AIDS, FDG PET imaging of, 460(ab)
Dissolution test, radioiodide uptake, thyroid, 56
DNA, forensic laboratory, NYC, 35N(1)
DNA synthesis
metabolic studies in dogs, ^{18}F FBAU PET, 94(ab)
in tumor patients, ^{18}F FMAU PET, 93(ab)
Dobutamine, stress perfusion imaging, in CAD, 1634
Dobutamine stress, identification of myocardial viability, comparison with stress-rest perfusion SPECT and FDG PET, 337(ab)
Dopamine
cerebral level, heatstroke-induced ischemia, PET, 955(ab)
elevation, food and, PET, 39N(7)
physiological activation, localized left-putamenal release, 954(ab)
release, amphetamine-induced, schizotypal disorders, SPECT and ^{123}I IBZM studies, 51(ab)
role in obesity, 36N(12)
Dopamine D2 receptors
characterization of ^{11}C NPA PET tracer, 956(ab)
comparative imaging, ^{11}C raclopride and microPET, 1570
cue-induced activation of the orbitofrontal cortex, in FMRI and with alcohol craving, 1055(ab)
DAT and, standardized evaluation, 828(ab)
distribution volume ratio, rat brain, 219(ab)
dorsal striatum, food motivation in humans and, 388(ab)
^{18}F fallypride equilibrium dissociation constant, 953(ab)
^{18}F fallypride quantification of, D-amphetamine effects, baboons, 381(ab)
high-resolution collimator, ^{123}I IBZM SPECT, 857(ab)
imaging in mesolimbic and nigro-striatal dopamine systems, in tobacco smoking, 1054(ab)
kinetic analysis of ^{18}F DMFP, human dynamic PET, 970(ab)
in never-medicated ADHD, 56(ab)
quantitation of, thalamus, multiple injection protocol and PET, 203(ab)
striatal and extrastriatal, occupancy by atypical antipsychotic drugs, 50(ab)
striatal substructure, cocaine effects, PET, 387(ab)
ventral striatum/nucleus accumbens, craving associated with, 389(ab)
Dopamine receptors
binding of radiotracers, chronic dopamine depletion and, rat brain, 379(ab)
microPET imaging, rodent brain, 974(ab)
quantitative SPECT, FBP and OSEM comparison, scatter correction, 883(ab)
Dopamine transporters
3D imaging, voxel-based mapping, Parkinson's disease, 986(ab)
9-repeat allele of, protein availability and, 384(ab)
bolus-infusion technique for evaluation, PET or SPECT with altropane, 836(ab)
concentration, in Machado-Joseph disease gene carriers, 153
D2 receptors and
HIV effects, 1025(ab)
in never-medicated ADHD children, 56(ab)
standardized evaluation, 828(ab)
density
PET, Parkinson's disease, 952(ab)

schizophrenia assessed with ^{99m}Tc TRODAT-1 SPECT, 1057(ab)
depletion, behavioral abnormality and, unilateral parkinsonian rat model, 383(ab)
early-stage Parkinson's or essential tremor, ^{123}I IPT role in differentiation, 69(ab)
^{123}I altropane binding potential, test-retest reliability, 854(ab)
^{123}I altropane SPECT, test-retest variability, 1609(ab)
ligand ^{11}C PE21, kinetic analysis, nonhuman primates, 951(ab)
neuroimaging with ^{123}I βCIT, Parkinson's disease, 60(ab)
nicotine effects, in ADHD, ^{99m}Tc TRODAT-1 study, 1396(ab)
noninvasive imaging of gene transfer, SPECT, 434(ab)
occupancy, candidate cocaine medications, 948(ab)
Parkinson's treated with NIL-A, ^{123}I β-CIT SPECT assessment of, 68(ab)
PET imaging, activity of parkinsonian monkey, 949(ab)
quantification by ^{123}I PE21 SPECT and Logan's graphical method, Parkinson's disease, 221(ab)
quantification in mouse brain, ultra-high resolution SPECT, 218(ab)
striatal binding
parametric comparison, Parkinson's disease, 202(ab)
quantitation of iterative reconstruction, 200(ab)
Dose calculation software, 27N(10)
Dose calibrator, determination of settings, radionuclides exceeding potentiometer range, 1629(ab)
Dose limits, ^{131}I, treatment of thyroid cancer, 61
Dosimetry
3D, ^{131}I thyroid cancer therapy, 309(ab)
^{131}I tositumomab, patient release after, 354, 364
cellular, genetically modified tumor-specific T cells, 329(ab)
effective dose delivered, after injection of ^{11}C befloxatone, 1434(ab)
estimates, PET serotonin transporter radioligand ^{11}C DASB, 1438(ab)
^{18}F FPCT in human subjects, 1431(ab)
hematologic toxicity correlation, ^{131}I radioimmunotherapy using FLT3-L, 310(ab)
high-dose ^{166}Ho DOTMP, multiple myeloma, 1383
^{123}I BMIPP, distribution and safety, 517(ab)
^{111}In pentetreotide, gastropancreatic tumors, 124(ab)
maximum permissible dose of ^{131}I, using tracer and therapeutic doses, 1437(ab)
maximum tolerable dose, bone marrow, peptide-receptor radiotherapy, 325(ab)
MIRD dose estimate report, ^{18}F FDG, 210
murine-specific S-factors, 323(ab)
organ, operator dependent variation, 1432(ab)
posttherapeutic scan in, after ^{188}Re HEDP application, 1439(ab)
radiation
^{18}F FCH, 92
^{18}F FETNIM, in cancer studies, 1674
biodistribution and, nicotinic ligand ^{18}F Fluoro-A85380, 1425(ab)
calculating absorbed dose from radioactive patients, 1241
in cardiac SPECT, 40N(9)
CT-based organ volume estimation methods, MIRD absorbed dose, 817(ab)
^{111}In-labeled $\alpha_v\beta_3$ ligand, 327(ab)
intestinal wall activity and cross-doses, 1657, 1665
intracavitary injection of 8 radionuclides in 5 shell models, 324(ab)
^{131}I uptake, contamination as a route for, 1307(ab)
non-marrow-targeting ^{90}Y-antibody therapy, 1245
normal tissues adjacent to tumors containing ^{131}I or ^{90}Y, 328(ab)
patient-specific
liver, 311(ab)
peripheral blood stem cell transfusion using, 312(ab)
patient-specific, ^{111}In octreotide, neuroendocrine tumors, 313(ab)
PET-based, radiotracer for imaging prostate cancer, 315(ab)
pharmacokinetics and ^{11}C FMAU, 1075(ab)
radioiodine, intralumbar injection into CSF, 314(ab)
^{99m}Tc DTPA-mannosyl-dextran, 1469(ab)
tumor-adjacent tissue, 1110
vitronectin receptor antagonist DPCA80350, 1426(ab)
red marrow, patient-specific, theoretical considerations, 326(ab)
red marrow toxicity, ^{90}Y SMT487 therapy, 1267(ab)
reproducibility of calculations, radioimmunoimaging, 1603(ab)
skeletal, marrow cellularity in models of trabecular skeleton, 97
solid-state, International Proceedings published, 35N(12)
stability evaluation and, ^{11}C paclitaxel, 1455(ab)
therapeutic application of radionuclides, verification of a practical model, 1435(ab)
tumor, peptide-receptor radiotherapy, kidneys and tumors, 1271(ab)
DOTA-α-melanocyte-stimulating hormone, for metastatic melanoma imaging, 1699
Down syndrome, thyroid dysfunction, children, 1327(ab)
Drug abuse, comparative imaging with dopamine D2, ^{11}C raclopride and microPET, 1570
Dual-plane circular-orbit cone-beam SPECT, observer study, 1578

E

Early dumping syndrome, rapid gastric emptying and, 595(ab)
Echinococcosis, FDG PET, 462(ab)
Echocardiography
^{99m}Tc sestamibi and primary PTCA, acute myocardial infarction, 8
dobutamine, ^{201}Tl imaging and, left ventricular ejection fraction after revascularization, 795, 803
myocardial contrast, detection of viable myocardium, 779(ab)
Electrochemical fluorination, aromatic compounds, ^{18}F fluoride, 156(ab)
Emission-transmission imaging, simultaneous acquisition, CT-PET for whole-body studies, 36(ab)
Encephalomyopathy, SIV-infected monkey, ^{11}C PK-11195 PET, 976(ab)
Endometrial cancer
intraoperative localization, sentinel nodes, 1179(ab)
post-therapy surveillance, FDG PET, 426(ab)
recurrence, FDG PET detection of, 1144(ab)
sentinel node identification, ^{99m}Tc colloid and blue-dye, 1180(ab)
Endothelin receptors, targeting for molecular imaging, atherosclerosis, rabbits, 400
Energy restriction, during lactation, ^{99m}Tc O_4Na biodistribution and, 89
Enzyme inhibitors, COX-1 and COX-2, radiosynthesis and evaluation of, 117
Epidermal growth factor, primary tumor receptor imaging, ^{99m}Tc EC-C225, 1088(ab)
Epidermal growth factor receptor, imaging of breast neoplasm, ^{99m}Tc h-R3 monoclonal antibody, 1254(ab)
Epilepsy
abnormal cortical glucose metabolism, based on 3D asymmetry index, 825(ab)
acute and chronic vagus nerve stimulation, perfusion SPECT changes after, 733
brain SPECT, computer-aided intrapatient comparison, 715
cryptogenic focal, initial glucose metabolism and seizure outcome in, 983(ab)
frontal lobe, FDG PET in localization of, visual and SPM analysis, 1167
ictal-interictal subtraction brain SPECT, local normalization areas for, 1419
intractable extratemporal, lateralizing subcortical uptake and outcome, ictal SPECT, 540(ab)
intractable temporal lobe, ^{11}C FMZ PET in, 541(ab)
left temporal lobe, altered brain activity, PET, 980(ab)
refractory
crossed cerebellar diaschisis in children, 1389(ab)
vagus nerve stimulation, dynamic $C^{15}O_2$ PET, 544(ab)
refractory partial, ictal SPECT *versus* FDG PET in evaluation of, 1031(ab)
temporal lobe
detection of focus with SPECT and PET, 1040(ab)
FDG PET, abnormalities between medial and lateral, 982(ab)
FDG PET and magnetoencephalography in, 981(ab)
PET and SISCOM correlation, 991
quantified metabolic abnormalities and surgical outcome, FDG PET, 542(ab)
Esophageal cancer
detection and prediction of therapy response, ^{201}Tl SPECT, 1200(ab)
initial staging, comparison of PET, CT and EUS, 239(ab)
preoperative chemotherapy, FDG PET, 242(ab)
recurrence, FDG PET comparison with CT, 1202(ab)
squamous and adenocarcinoma differences, FDG PET, 1199(ab)
staging, FDG PET, 240(ab)
staging by coincidence imaging, 1201(ab)
Esophageal dysfunction, investigated with scintigraphy, myocardial perfusion imaging and, 740(ab)
Esophageal reflux, scintigraphy, clinical role, 589(ab)
Esophageal scintigraphy, transit and reflux, 1554(ab)
Esophageal transit, corrosive and esophageal cicatrization, 1344(ab)
Esophagogastric cancer, lymphatic drainage from foci of, ^{99m}Tc tin colloid, 241(ab)
Esophagus, complications in systemic sclerosis, assessment of severity, 1343(ab)
Estrogen, cardioprotective effects, ^{11}C L159 PET, 144(ab)
Estrogen receptors
^{18}F FPPT radiosynthesis, 1461(ab)
novel subtype selective ligands, CoMFA and docking study, 1516(ab)
tissue positive for, surrounding histological breast cancer, 1093(ab)
European pharmacopeia, procedures for FDG injection, quality assurance, 1495

F

False discovery rate (FDR), extent of glucose metabolism reductions, elderly depression of early Alzheimer's disease, 838(ab)
False-positive, ^{131}I whole-body scans, posttraumatic superficial scabs, 207
Fatty acid metabolic disorder, BMIPP dynamic SPECT, myocardial damage, 1286
Fatty acid metabolism, vasospastic angina, SPECT images of, 1476
Fatty acids
iodinated, experimental low-flow myocardial ischemia, 421
metabolism, body distribution of orally administered lipids, 1336(ab)
myocardial imaging
adriamycin-induced cardiotoxicity, 705(ab)
angiotensin II type-I receptor blockade, 742(ab)
volume-overloaded rabbit hearts, 715(ab)
myocardial metabolism, 17-^{11}C-hepatodecanoic acid for measurement of, 1707
reverse mismatch, BMIPP uptake higher than thallium, 741(ab)
Fatty meal, intravenous CCK comparison, for gallbladder ejection fraction, 1603
Femoral neck, asymptomatic abnormal uptake, on bone scintigraphy, 484
Fever of unknown origin (FUO), ^{111}In granulocyte scintigraphy in, 140
Filtered backprojection, iterative reconstruction as alternative to, striatal DAT binding, 200(ab)
Filtering
microbiological burden measurement, FDG, 1523(ab)
nonlinear, post-reconstruction smoothing of, PET, 875(ab)
vector Weiner filter, restoration of multicollimator/multihead SPECT data, 895(ab)
FK960
cerebral blood flow and glucose metabolism with, aged monkey brain, 957(ab)

pharmacokinetic study, PET, conscious monkey, 959(ab)
Fluorine-18
catheter-based detector, atheromatous plaques, 701(ab)
COX-1 and COX-2 enzyme inhibitors, radiosynthesis and evaluation of, 117
cyclic peptides labeled with, solid phase synthesis, 1467(ab)
fluorination of peptides, direct single step, 497(ab)
PET, bone metabolism, 134(ab)
tumor imaging agents, uptake profiles, 149(ab)
Fluorine-18 4-FM, uptake, normotensive and hypertensive rats, 366
Fluorine-18 A-85380, PET, tracer synthesis, imaging of nicotinic acetylcholine receptors, Parkinson's, 608(ab)
Fluorine-18 altanserin, cluster analysis, as a replacement for arterial sampling, in kinetic modeling, 360(ab)
Fluorine-18 difluoroestradiols, as estrogen receptor binders, 41N(9)
Fluorine-18 DMFP
kinetic analysis of D2 receptors, human dynamic PET, 970(ab)
PET, schizophrenic patients treated with amisulpride, 1058(ab)
Fluorine-18 DOPA, PET, physiological characteristics-based segmentation technique, 847(ab)
Fluorine-18 fallypride
D-amphetamine effects on binding of, striatal and extrastriatal regions, baboon, 381(ab)
displacement, thalamus, nicotine- and amphetamine-induced dopamine and, 382(ab)
electrophilic or nucleophilic substitution, custom manufactured fluorination module, 1522(ab)
equilibrium dissociation constant, quantification of, 953(ab)
Fluorine-18 FAZA
hypoxia tracer, cell culture studies and experimental tumors, 1466(ab)
imaging tumor hypoxia, improved biokinetics in, 1123(ab)
synthesis, tracer for hypoxia, 1463(ab)
Fluorine-18 FBAU, PET, DNA synthesis, metabolic studies in dogs, 94(ab)
Fluorine-18 FCH, pharmacokinetics and radiation dosimetry of, 92
Fluorine-18 FCWAY, serotonin ligand, human functional image creation, 198(ab)
Fluorine-18 FDG
1-^{11}C glucose comparison, quantifying myocardial glucose use with PET, 1530, 1542
^{11}C choline and, PET in thoracic cancer, 167
^{11}C methionine and, PET in prostate cancer, 46
^{123}I IPPA and, myocardial ischemia, 421
after chemotherapy, stem cell transplant in lymphoma, 282(ab)
anthracycline-based chemotherapy, stem cell transplant in lymphoma, 283(ab)
bioburden studies, 1523(ab)
bone scans and, evaluation of bone metastases, 1151(ab)
^{11}C acetate and, diagnosis of pulmonary tuberculosis, 461(ab)
cerebral metabolic deficits, Alzheimer's disease, 231(ab)
cerebral metabolic reactivity, Alzheimer's disease, 230(ab)
^{11}C FMAU comparison, tumor imaging, 92(ab)
^{14}C IAP and, accumulation in sublingual gland, 1103(ab)
^{11}C MET and, detection of thyroid cancer, 1306(ab)
coincidence, recurrent or metastatic colorectal cancer, 603
coincidence detection emission tomography, recurrent ovarian cancer, 105(ab)
coincidence detection imaging, recurrence of testicular cancer, 1143(ab)
coincidence imaging, malignant pleural mesothelioma, 1144
combined with ^{11}C acetate, oral cancer diagnosis, 1193(ab)
comparison with ^{99m}Tc EC-DG, tumor targeting, 1102(ab)
comparison with conventional imaging, recurrence of malignant primary bone tumors, 127(ab)
coregistered PET-CT
oral contrast agent-induced artifact, 1241(ab)
oral contrast media in, 1240(ab)
dilated cardiomyopathy, histological findings, 762(ab)
dominant negative HIF-1α effects, pancreatic cancer cells, 88(ab)
dual time point PET, evaluation of pulmonary nodules, 871
versus FCH, PET, in prostate cancer, 46N(8)
^{67}Ga citrate blinded comparison, Hodgkin's disease patients, 109(ab), 110(ab)
gamma PET, differentiated thyroid cancer, 1321(ab)
glucose metabolism and cell proliferation, implanted murine tumors, 89(ab)
heat sterilized, nuclear interface dispenser in production of, 161(ab)
high-energy gamma probe, intraoperative detection of PET tracers, 1136(ab)
^{124}I and, PET, localization of recurrent thyroid cancer, 1286(ab)
increased uptake
hypothyroidism, 450(ab)
symmetrical skeletal muscle, 137(ab)
inflamed joints, rheumatoid arthritis patients, 138(ab)
inflammatory cell infiltration, acute myocardial infarction, 780(ab)
initial glucose metabolism and seizure outcome, epilepsy, 983(ab)
injection, quality assurance procedures, 1495
in-line PET-CT system, improvement in diagnostic accuracy, 1235(ab)
intravascular beta probe and, atherosclerotic lesions, 9(ab)
kinetic data and VEGF expression, sarcoma, 91(ab)
metabolic fate of, SSCVII squamous cell carcinoma or C3H mammary carcinoma, 940
MIRD dose estimate report, 210
muscle uptake artifact, evaluation with PET/CT, 113(ab)
myocardial viability studies, gamma camera coincidence imaging, 769(ab)
noninvasive characterization, atherosclerotic plaques, 24(ab)
oral cancer, 1148(ab)
organ preserving primary radiochemotherapy, cancer of hypopharynx/larynx, 260(ab)
PET
abdominal and pelvic tumors, beginner PET oncologist, 1198(ab)
abnormal patterns of spine as benign or metastatic, 1247(ab)
accumulation of amino acid tracers, inflammatory tissue, 87(ab)
acquisition protocols and reconstruction methods, gastric cancer, 1251(ab)
activity in testicles, 856(ab)
addiction to computer games, adolescents, 1393(ab)
advanced epithelial ovarian cancer, 1141(ab)
after fractures and surgical intervention, 136(ab)
before and after primarily untreated depression, 1052(ab)
after radioimmunotherapy, recurrent non-Hodgkin's lymphoma, 281(ab)
alterations in glucose metabolism with CADASIL, 539(ab)
alternative to WBC imaging in orthopedic infections, 458(ab)
assessing response in chemotherapy for osteosarcoma, 1154(ab)
atherosclerotic plaque inflammation, 45N(8)
attenuation correction in, metastatic thyroid cancer, 1314(ab)
benign entities mimicking malignancy, 1623(ab)
benign or malignant pleural disease, 583(ab)
biodistribution in brain of fasting and non-fasting mice, 868(ab)
blood flow and metabolism, locally advanced breast cancer, 500
blood flow kinetic analysis, breast cancer, 1100(ab)
bone and soft-tissue oncologic imaging, 1225(ab)
bowel uptake, oral spasmolytic premedication effects, 833(ab)
brain function and blood flow changes in back pain, 1376(ab)
brain imaging at Yoga practice, 1017(ab)
breast cancer with rising serum tumor markers, 1158(ab)
bronchioloalveolar carcinoma, 1214(ab)
camera-based, papillary thyroid cancer, 1316(ab)
cancer screening with, 1245(ab)
cerebral cortex, Alzheimer's disease, 985(ab)
cerebral lesions incidentally detected, 1016(ab)
cerebral metabolic rates as predictors of response to anterior cingulotomy for depression, 1053(ab)
childhood lymphoma, 130(ab), 131(ab)
chronic ischemic dysfunction, dogs, 556
chronic vertebral infections, 481(ab)
coincidence detectors, chest malignancy assessment, 1217(ab)
comparison with ^{99m}Tc MIBI SPECT and ^{131}I scintigraphy, thyroid cancer, 1312(ab)
comparison with CT, esophageal cancer recurrence, 1202(ab)
comparison with FLT, differentiation between tumor and infection, rats, 1074(ab)
comparison with other modalities, breast cancer, 267(ab)
CT and pathological correlation, lung cancer, 1216(ab)
CT comparison, extrahepatic bile duct cancer, 1195(ab)
CT fusing and, radiation oncology, 1563(ab)
cystic pancreatic tumors and intraductal papillary mucinous tumor, 1204(ab)
defining strategy for mediastinoscopy, 1222(ab)
deoxyglucose uptake, human neutrophil granulocytes, 652
detecting extrahepatic disease, colorectal cancer patients, 1196(ab)
detection of focus in temporal lobe epilepsy, 1040(ab)
detection of lymphomatous marrow infiltration using, 1067(ab)
detection of marrow disease in Hodgkin's disease, 1069(ab)
detection of residual disease after chemotherapy in NSCLC, 1575(ab)
differences in uptake, respiratory motion artifacts and, 210(ab)
differentiation of bone lesions, 510
discrepant findings, cervical cancer, 99(ab)
disseminated mycobacterium avium complex in AIDS, 460(ab)
dosage of, body weight effects, 1565(ab)
dual-phase, retention index and, pancreatic cancer, 1203(ab)
dual *versus* single-time point, pulmonary nodules, 564(ab)
dynamic gadolinium uptake and, colorectal liver metastases, 1197(ab)
evaluation of cholangiocarcinoma, 83(ab)
evaluation of primary gallbladder cancer, 473(ab)
extrapulmonary tuberculosis, 1350(ab)
false-positive and false-negative findings, lung cancer, 413(ab)
fractal dimension based on box counting, 850(ab)
glucose metabolic changes, traumatic brain injury, 224(ab)
GSO-based whole body scanner, 1194(ab)
hexokinase-II and glucose transporter-1, pancreatic cancer, 173
high-dose chemotherapy and stem cell transplant, in lymphoma, 1062(ab)
histopathologic subtypes and marrow infiltration in Hodgkin's lymphoma, 1068(ab)
hybrid camera, response to cancer therapies, 1244(ab)
hypothyroidism secondary to Hashimoto's disease, brain metabolism, 1030(ab)
versus ictal SPECT, refractory partial epilepsy, 1031(ab)

increased uptake at tip of total hip prosthesis, 1374(ab)
for induction chemotherapy in non-Hodgkin's lymphoma, 1060(ab)
injected dose based on body size, higher quality scans and, 1577(ab)
input function estimate without blood samples, 361(ab)
interleaved septa-in/septa-out acquisition protocol, 206(ab)
intraperitoneal metastatic tumor, ovarian cancer, 103(ab)
kinetic analysis, cancer, 1097(ab)
lesion conspicuity in cancer diagnosis, 1233(ab)
leukocytes labeled with, biodistribution and dosimetry studies, 1430(ab)
localization of frontal lobe epilepsy, 1167
long-lasting non-specific uptake in hip arthroplasty, 140(ab)
LS174T carcinoma and *E. coli* infection, rat, 1576(ab)
lung, respiratory motion effects, 208(ab)
lung cancer, 3D radiotherapy for, 552(ab)
lung cancer, extra-thoracic metastases in, 551(ab)
lymph node metastases in medullary thyroid cancer, 66
magnetically targeted therapy, quantitative measurement, 1227(ab)
malignant and benign bone lesions, 1153(ab)
malignant gliomas, delayed intervals, 1012(ab)
malignant pleural mesothelioma, 1213(ab)
management of lung cancer and, 752
metabolic fate of, mammary or squamous cell carcinoma, 1101(ab)
metabolic imaging in lung cancer, significance of negative scan, 412(ab)
metastasis or recurrence of gastric cancer, 244(ab)
metastatic colorectal cancer, FOLFOX chemotherapy, 79(ab)
modification of management in colorectal cancer, 81(ab)
monitoring therapy and predicting treatment response in lymphoma, 1063(ab)
MRI-based partial volume correction, 358(ab)
myocardial uptake, respiratory motion effects, 785(ab)
neoadjuvant chemotherapy in stage III non small cell lung cancer, 1248(ab)
neoadjuvant chemotherapy with gastric cancer, 243(ab)
non small cell lung cancer, 1212(ab)
non-small cell lung cancer, response to chemotherapy, 1304
normal bone marrow uptake, aging and, 1066(ab)
occult head and neck cancer, 1146(ab)
occult recurrence, colorectal cancer, 82(ab)
orofacial and maxillomandibular tumors, 1238(ab)
outcomes assessment, lung cancer, 1219(ab)
paraneoplastic syndrome, central and peripheral nervous system, 1037(ab)
paraneoplastic syndrome and autoantibodies, detection of carcinoma in, 1014(ab)
paraneoplastic syndrome and underlying malignancy, 1015(ab)
pathology and survival in gliomas, 400(ab)
perfusion/metabolism match/mismatch, 525(ab)
PET-CT comparison, colorectal cancer, 78(ab)
P-glycoprotein correlation, lung cancer, 1215(ab)
post-probability of malignancy in solitary pulmonary nodules, 1223(ab)
post-therapy surveillance of endometrial cancer, 426(ab)
prediction of malignancy grade, non-Hodgkin's lymphoma, 286(ab)
preoperative chemotherapy in esophageal cancer, 242(ab)
preoperative staging of squamous cell carcinoma, neck, 574(ab)
previously treated breast cancer, 325
primary auditory regions in deafness, 546(ab)
primary tumor resection, colorectal cancer, 80(ab)
principal component analysis and similarity mapping, 851(ab)
pulmonary tuberculoma, 1406(ab)
quantification of glucose metabolism, 964(ab)
recurrence of malignant lymphoma, 1064(ab)
recurrent colorectal cancer, 492
recurrent head and neck cancer, 262(ab)
recurrent in endometrial cancer, 1144(ab)
redifferentiation therapy of radioiodine negative thyroid cancer, 1295(ab)
reduction in glucose phosphorylation, traumatic brain injury, 1000(ab)
residual, progressive or recurrent brain tumor detection, 1013(ab)
rheumatoid arthritis treated by infliximab infusions, 139(ab)
sarcoma patients, 1155(ab)
selective attention and anosognosia in mild Alzheimer's disease, 1034(ab)
solitary thoracic lesions, delayed imaging for, 563(ab)
specificity of, in painful joint prostheses, 457(ab)
squamous and adenocarcinoma differences, esophagus, 1199(ab)
squamous cell cancer, head and neck, after chemotherapy, 264(ab)
stabilizing of body temperature of small animals, 1574(ab)
staging and management, breast cancer, 268(ab)
staging for plasmacytoma, 1059(ab)
staging of advanced head and neck cancer, 1147(ab)
staging of bladder cancer, 423(ab)
staging of esophageal cancer, 240(ab)
staging of malignant lymphoma, 1061(ab)
standardized uptake values in oncology, 1224(ab)
suspected infections in diverse settings, 456(ab)
SUV in solitary pulmonary nodules, 566(ab)
tabulated summary of literature, 441(le)
^{99m}Tc ciprofloxacin comparison, orthopedic infections, 477(ab)
testicular cancer, treatment response, 424(ab)
thoracic and abdominal muscles, COPD patients, 1410(ab)
thoracic aortic wall metabolic activity and calcification, 10(ab)
thyroid cancer imaging, 294(ab)
thyroid hormone replacement therapy effects on brain metabolism, 1029(ab)
^{201}Tl and ^{131}I combination in detection of thyroid cancer, 1315(ab)
tongue acupuncture treatment in autism, 304(ab)
treatment response of lung cancer, after stereotactic radiotherapy, 1218(ab)
tumor recurrence, in ovarian cancer, 1140(ab)
uptake, primary osteosarcoma, 1012
uptake in bone marrow and spleen, 1070(ab)
uptake in different histological subtypes of lymphoma, 1065(ab)
uptake in model of inflammation, 658
uptake in soft tissue surrounding shoulder joint, 1377(ab)
uptake in stomach, serum glucose level effects, 1339(ab)
uptake patterns in sarcoidosis, 1398(ab)
uptake relations, lung cancer, 1246(ab)
value in breast cancer, 1160(ab)
viability of echinococcus multilocularis, 462(ab)
visual analysis of tumor characteristics, cervical cancer, 100(ab)
volumetric analysis of glioblastoma multiforme, 1667
voxel-based analysis, in amblyopia, 1018(ab)
voxel-classification method for, 359(ab)
whole-body, staging and diagnostic accuracy, 1229(ab)
whole-body oncologic, non-coronary cardiovascular findings, 773(ab)
whole-body scan, staging of nasopharyngeal cancer, 263(ab)

PET/CT
functional and structural evaluation of cancer patients, 1129
hybrid imaging, recurrent lung cancer, 114(ab)
metallic object artifacts, 1239(ab)
transmission scanning for attenuation correction, 1137
prognosis prediction, squamous cell type uterine cervical cancer, 101(ab)
prognostic significance, primary osteosarcoma, 128(ab)
respiratory gating PET, lung cancer, 876
solitary pulmonary nodules, changes of SUV in, 561(ab)
spatially normalized PET and SPECT, direct comparison, Alzheimer's disease, 21
SPECT
myocardial viability, 820(ab)
recent myocardial infarction, 17(ab)
standard uptake values, patient weight and residual dosage effects, 1622(ab)
surgery guided by, intraoperative probe with background rejection capability, 217(ab)
^{99m}Tc sestamibi comparison, lung lesions, 410(ab)
treatment of colorectal liver metastases, evaluation by ^{90}Y TheraSpheres, 1276(ab)
uptake
breast density and age relations in normal breasts, 270(ab)
liver, dynamic PET, 439(le)
surgically resected non-small cell lung cancer, 39
target to background ratio in assessment of, lung cancer, 370(ab)
thoracic aorta, risk factors for CAD, 784(ab)
vascular targeting therapy of tumor with, 440(ab)
versus ^{99m}Tc annexin V, identification of plaques in atherosclerosis, 2(ab)
whole-body, evaluation of bone metastases, 1152(ab)
whole-body PET
identification of high-risk myeloma, 1457
suspected metastatic brain tumors, 1432
Fluorine-18 FDHT, PET radiopharmaceutical, imaging prostate cancer, 315(ab)
Fluorine-18 FDOPA
^{11}C methionine and, in brain tumor imaging, 405(ab)
PET, comparison with ^{99m}Tc TRODAT-1 SPECT, in Parkinson's disease, 994(ab)
production, assessment with commercially available synthesis unit, 1519(ab)
synthesis improvement, Parkinson's disease, 1520(ab)
Fluorine-18 FECh, PET, development for cancer imaging, 187, 201
Fluorine-18 FECys, uptake, tumor cells, lymphocytes, macrophages, and xenotransplanted tumors, 318(ab)
Fluorine-18 FES, PET, estrogen receptor-positive breast cancer, 1157(ab)
Fluorine-18 FET
amino acid transport, tumor and inflammatory cells, 86(ab)
FDG PET and, preoperative metabolic evaluation of brain tumors, 1010(ab)
metastatic liver lesions, PET/CT, 878(ab)
PET, recurrence of brain tumors, 403(ab)
tumor imaging, direct radiofluorination, 1521(ab)
Fluorine-18 FETNIM, radiation dosimetry, cancer studies, 1674
Fluorine-18 FFAU, synthesis of high specific activity, PET gene imaging agent, 320(ab)
Fluorine-18 FFMMT, synthesis, carcinoid tumor imaging agent, 1464(ab)
Fluorine-18 FHBG
comparison of probes, imaging HSV1-*tk*, 1072
monitoring of gene therapy, 155(ab)
PET, imaging of gene expression, 157(ab)
Fluorine-18 FHPG
membrane transport and endogenous thymidine effects, HSVTK expressing cells, 1107(ab)
PET, imaging HSV-1tk gene expression, 246(ab)
robotic synthesis, 160(ab)
Fluorine-18 FLT
drug-induced modulation of tumor proliferation, PET, 97(ab)
glucose metabolism and cell proliferation, implanted murine tumors, 89(ab)
high yield synthesis, using a nolsylate precursor, 319(ab)
identification of p53 integrity, tumor cells, 254(ab)
monitoring of chemotherapy response, breast cancer, 1253(ab)

multitracer PET, identification of target tissue for gene therapy in glioblastoma, 90(ab)
new intramolecular protected precursor for, 1524(ab)
PET
comparison with FDG, differentiation between tumor and infection, rats, 1074(ab)
mammary, laryngeal and soft tissue tumors, 278(ab)
primary and metastatic brain tumors, 401(ab)
proliferative activity of non-small cell lung cancer, 277(ab)
PET tracer, murine lymphoma model, 96(ab)
as proliferation marker, rat comparison studies, 1688
prostate cancer detection, microPET, 98(ab)
uptake, thymidine kinase-1 activity, A549 cancer cells, 1210
validation studies, A549 cells, 95(ab)
Fluorine-18 fluoride
electrochemical radiofluorination of aromatic compounds, 156(ab)
PET
bone metabolism, 135(ab)
diagnosis of bone metastases, 1150(ab)
Fluorine-18 fluoroemodin, potential imaging agent, breast and lung cancer, 1092(ab)
Fluorine-18 fluoroestrogens, synthesis, estrogen receptor density in breast cancer, 1465(ab)
Fluorine-18 fluoro-L-dopa, striatal uptake, Parkinson's disease, 201(ab)
Fluorine-18 FMAU, PET, DNA synthesis, in tumor patients, 93(ab)
Fluorine-18 FMISO
hepatic uptake, flow-weighted total input functions, 30(ab)
hypoxia tracer, cell culture studies and experimental tumors, 1466(ab)
PET, hypoxia imaging, 367(ab)
Fluorine-18 FMT, conversion of fluorobenzophenone amino acid to, 159(ab)
Fluorine-18 FP
PET, pulmonary fibrosis, rabbit model, 413
radiosynthesis of, lung deposition studies in asthmatics, 496(ab)
Fluorine-18 FPCT
dosimetry, human subjects, 1431(ab)
striatal uptake, parametric comparison, Parkinson's disease, 202(ab)
Fluorine-18 FPPT, radiosynthesis, ligand selective for estrogen receptors, 1461(ab)
Fluorine-18 FPS, sigma receptor PET ligand, tumor imaging in preclinical models, 1132(ab)
Fluorine-18 FPT, PET, tumor imaging, 1456(ab)
Fluorine-18 FP-TZTP, regional brain uptake, functional M1 receptors and, 399(ab)
Fluorine-18 FRP170, imaging of ischemic but viable myocardium, 109
Fluorine-18 F-Tyr, PET, whole-body tumor imaging, 280(ab)
Fluorine-18 NMB, microPET I imaging, rodent brain, 974(ab)
Fluorine-18 RGD-peptides, noninvasive determination, alpha(v)beta3 expression, 322(ab)
Fluorine-18 sodium fluoride, PET, SPECT and, initial staging of lung cancer, 1220(ab)
Fluorine-18 ThT, for amyloid assessment, Alzheimer's disease, 605(ab)
Fluorobenzophenone amino acid, rapid conversion to FMT, 159(ab)
Fluorodeoxyglucose. *see* Fluorine-18(ab) FDG
PET, suspected metastatic brain tumors, 1432
Fluorodeoxyglucose (FDG). *see also* Fluorine-18 FDG
as biologic prognostic factor, in surgically resected non-small cell lung cancer, 39
lumped constant, normal human brain, 1157
PET, lymph node metastasis in medullary thyroid cancer, 66
PET incidentaloma, 44N(6)
Fluoroethoxyglyburide, binding to beta cells, diabetes, 321(ab)
Folate, ^{99m}Tc EC20 derived from, for cancer imaging, 1477(ab)
Food and Drug Administration (FDA)
pharmaceutical review, 36N(11)
procedures for FDG injection, quality assurance, 1495
Fractal dimension, dual character and extent, application in pulmonary diseases, 830(ab)
Functional reserve, hepatic, in asialoglycoprotein receptor scintigraphy, 1611
Fusion imaging, audio conference, 25N(11)

G

GABA-A receptors, cortical function, acutely detoxified alcohol-dependent patients, 392(ab)
GABA-T, ^{11}C GVC as suicide inhibitor of, treatment of substance abuse, 398(ab)
β-Galactosidase, monitoring of gene expression, 1115(ab)
Gallbladder
cholescintigraphy, fatty meal stimulated, 1345(ab)
ejection fraction
association with gastroesophageal reflux, 590(ab)
fatty meal and intravenous CCK-8 for, 1603
motor function, in acromegaly, octreotide effects, 474(ab)
primary cancer, FDG PET evaluation, 473(ab)
Gallbladder lumen, transit pattern within, hepatic bile entry into and, 901
Gallium, repeated scans, lymphoma, 1072(ab)
Gallium-67
scintigraphy
CT and, bone lymphoma treatment, 1295
infection after colorectal surgery, 48N(8)
skeletal imaging, evaluation of diabetic osteopathy, 1378(ab)
SPECT, triple energy window compensation methods, scatter correction, 194(ab)
Gallium-67 citrate
blinded comparison with FDG, Hodgkin disease, 109(ab), 110(ab)
in Graves' ophthalmopathy, 1299(ab)
SPECT, attenuation correction effects on lesion detection, 368(ab)
tumor uptake, enhancement by photodegraded nifedipine, 1134(ab)
Gallium-67 DOTATOC, metabolic regulation by, somatostatin receptor binding sites, 1488(ab)
Gallium-68 DOTATOC, PET, small metastases of neuroendocrine tumors, 1252(ab)
Gamma camera
16 x 20 CM^2 CZT, for scintimammography, 943(ab)
calibrating with optical images, for motion detection, SPECT, 909(ab)
CZT intraoperative, sentinel node imaging, 945(ab)
dual-head, ^{201}Tl myocardial SPECT, artifacts in, 285
high resolution, breast neoplasm, 909, 916
hybrid PET, variable focal length fan-slat collimators, 32(ab)
intraoperative sentinel node imaging, sterile-field imaging, 569(ab)
intraoperative use of a small field of view, sentinel node biopsy, 923(ab)
mobile, use in pediatrics, 1613(ab)
PMT equalization, using all spectral data, 932(ab)
scintimammography, mounted on upright mammography gantry, 273(ab)
small field of view, CdZnTe-based nuclear medical imager, 935(ab)
triple-head, compared with dedicated PET, 48N(8)
Gamma globulin, reticuloendothelial system blocking regimens, cancer therapy, 1260(ab)
Gamma probe
hand-held, systemic leakage during isolated limb perfusion, 1243(ab)
intraoperative, procedure guideline, sentinel node localization in melanoma, 1414
Gastric cancer
alpha-emitting radionuclides, selective killing of cells, 1086(ab)
endoscopic administration of ^{99m}Tc DTPA-*mannosyl*-dextran, lymph nodes, 475(ab)
FDG PET, acquisition protocols and reconstruction methods, 1251(ab)
metastasis or recurrence, FDG PET in, 244(ab)
neoadjuvant chemotherapy with, FDG PET, 243(ab)
sentinel node biopsy, minimally invasive approaches for, 1185(ab)
skeletal metastases from, bone scintigraphy for, 1205(ab)
Gastric emptying
assessment, in morbid obesity, 1338(ab)
evaluation in pediatric patients with cystic fibrosis, for gastroesophageal reflux disease, 593(ab)
evaluation of effect of laparoscopic fundoplication, for gastroesophageal reflux disease, 591(ab)
evaluation of gastroparesis, predicting response to metoclopramide, 594(ab)
liquid, concentration of inhaled isoflurane, pigs, 968
rapid, early dumping syndrome and, 595(ab)
Gastrin/cholecystokinin peptides, diagnosis and therapy, medullary thyroid cancer, 289(ab)
Gastrin-releasing peptide receptor, scintigraphy, radionuclide therapy and, 1650
Gastroenteropancreatic tumors
abdominal imaging of, prescintigraphic morphin application and, 472(ab)
liver metastases from, somatostatin receptor imaging, 1206(ab)
Gastroesophageal reflux (GER)
abnormal gallbladder ejection fraction and, 590(ab)
asthma and respiratory infection relations, children, 306(ab)
corrosive and esophageal cicatrization, 1344(ab)
gastric emptying studies, effect of laparoscopic fundoplication, 591(ab)
scintigraphy
clinical role, 589(ab)
esophageal transit and, 1554(ab)
Gastrointestinal bleeding, anatomical mapping of, ^{99m}Tc-labeled red blood cells, 1334(ab)
Gastropancreatic tumors, ^{111}In pentetreotide dose estimation, high-dose radiotherapy, 124(ab)
Gastroparesis, gastric emptying studies for, predicting response to metoclopramide, 594(ab)
Gelatinases, peptides to quantify activity, 1489(ab)
Gender differences
aging and, effects on large normal SPECT rCBF database, 235(ab)
regional cerebral blood flow, verbal and nonverbal encoding tasks, 1021(ab)
Gene expression
cardiac reporter gene, PET and optical imaging, 1(ab)
D2 knockout and wild type mice, comparative imaging with ^{11}C raclopride and microPET, 972(ab)
dopamine transporter, protein availability and, 384(ab)
^{18}F FFHBG PET imaging of, 157(ab)
HIF-1α, hypoxia-induced signaling, PET, 250(ab)
high-resolution imaging, PET, 246(ab)
HSV1-sr39tk, optical and PET imaging, 248(ab)
HSV1-sr39tk reporter gene
^{18}F FHBG microPET imaging, 7(ab)
two-step transcriptional amplification for enhancement, 247(ab)
HSV1-tk, FIAU and FHBG comparison, 148(ab)
HSV-tk reporter gene, ^{18}F FHBG for PET assessment of, 1109(ab)
imaging, in breast cancer, 448(ab)
kinetic PET data and VEGF, sarcoma, 91(ab)
molecular imaging of, 34N(12)
monitoring, β-galactosidase, 1115(ab)
mu-opiate receptor availability and genotype, alcohol craving and, 391(ab)
noninvasive imaging of gene transfer, SPECT, 434(ab)
novel non-immunogenic reporter gene, thymidine kinase type 2, 252(ab)
signal transduction, NFκB, 1110(ab)
somatostatin receptor labeling of T cells, hCAR transgenic mouse, 1078(ab)
thyroid cancer, all-trans retinoic acid effects, 484(ab)
Gene therapy
comparative imaging with dopamine D2, ^{11}C raclopride and microPET, 1570
^{18}F FHBG and FIAU as gene probes in, HSV1-tk, 1108(ab)
HSV1-tk, ^{18}F FHBG monitoring, 155(ab)
^{131}I MIBG, modulation of transport, hepatoma, rat, 1139(ab)
neuroblastoma cells overexpressing the TRK-A gene, nerve growth factor stimulation and, 1116(ab)

radiolabeled IVDU as monitoring agents, HSV1-Tk gene transduced hepatocellular carcinoma, 1105(ab)
sodium iodide symporter, role in thyroid cancer, 1188
TAT mediated reporter protein transduction, imaging in living subjects, 1106(ab)
enetics, uptake of ^{99m}Tc TRODAT-1 and, Parkinson's disease, 67(ab)
ene transfer
genetically modified tumor-specific T cells, dosimetry for, 329(ab)
somatostatin receptor type 2 chimeric, noninvasive monitoring, 406
estalt interpretation, ventilation-perfusion lung scintigraphy, 1317
lioblastoma, gene therapy, identification of target tissue by PET, 90(ab)
lioblastoma multiforme, volumetric analysis, FDG PET, 1667
lioma
delineation in, FET PET compared with MRI, 402(ab)
FDG PET prediction of pathology and survival in, 400(ab)
intracerebral, gene transfer/radioiodine treatment, 1094(ab)
malignant, ^{111}In DTPA-D-Glu1-minigastrin in viability of, 406(ab)
malignant, FDG PET at delayed intervals, 1012(ab)
lioma cells, F98, ^{18}F-labeled amino acid transport mechanisms, 1459(ab)
lomerular filtration rate, Bayesian regression model for, 762
lucagon-like peptide-1, incretin hormone, detection of insulinomas, 1191(ab)
lucosamine, pathway imaging, ^{99m}Tc EC-deoxyglucose comparison with FDG, 1478(ab)
lucose metabolic rates
cerebral
noninvasive PET without blood sampling, 966(ab)
treatment of depression, 1049(ab)
malignant and nonmalignant cells, 963(ab)
lucose metabolism
cerebral, serotonin effects on PET, 42N(9)
FDG and 1-^{11}C comparison, PET, myocardium, 1530, 1542
FDG lumped constant, normal human brain, 1157
uptake of FDG and ^{99m}Tc MDP and, primary osteosarcoma, 1012
lucose transporter, dual-phase FDG PET and hexokinase II relations, pancreatic cancer, 173
lutamate receptors
drug targeting, PET, 609(ab)
metabotropic, new targets for neuroimaging, 397(ab)
ranulocytes
autologous, ^{99m}Tc HMPAO-labeled, infection imaging, 918, 925
radiolabeled, infection imaging, 1354(ab)
raphical analysis, FDOPA PET, Parkinson's disease, 1324
rave's disease. *see* Hyperthyroidism
raves' ophthalmopathy, ^{67}Ga citrate imaging, 1299(ab)
uanylyl cyclase C, targeted colon cancer imaging, 392
ynecologic cancer, postoperative state, ^{11}C MET PET, 1142(ab)
ynecologic oncology, endometrial surveillance, FDG PET post-therapy surveillance, 426(ab)

H

Halogen radionuclides, radiolabeling with, new somatostatin analog for, 331(ab)
Head and neck cancer
advanced, FDG PET in staging, 1147(ab)
^{11}C MET for staging and restaging, 261(ab)
^{18}F FMISO PET hypoxia imaging, primary tumor *versus* lymph node metastases, 266(ab)
occult, MRI coregistration with PET for detection of, 1146(ab)
oral, FDG PET in, 1148(ab)
radiation-induced xerostomia, pilocarpine for prevention, 1288(ab)
radiochemotherapy, intraoperative gamma probe-guided sentinel node detection after, 573(ab)
radioimmunotherapy, ^{186}Re bivatuzumab, 575(ab)
radiolocalization, sentinel node imaging in, 568(ab)
radiotherapy planning, PET/CT registration for, 1230(ab)
recurrent, detection with PET, 262(ab)
sentinel lymph node in, fine-needle aspiration cytology, 1585
sentinel node imaging, 571(ab)
squamous cell
FDG PET after chemotherapy, 264(ab)
^{123}I IMT SPECT, 1145(ab)
metastatic lymph node detection, TYR and FDG PET, 265(ab)
sentinel node biopsy and FDG in preoperative staging, 574(ab)
sentinel node biopsy for staging of, 1178(ab)
treatment response, prediction with PET, 41N(4)
Head injury
diffuse *versus* focal, glucose metabolism in, PET, 1002(ab)
heterotopic ossification, 346
mild, amnesia after, emergency room SPECT evaluation, 1001(ab)
SPECT, interpreted with statistical parametric mapping, 476
Health and Human Services (HSS)
Council on Preparedness, 31N(10)
Transaction and Code Set Standards, 30N(12)
Health Insurance Portability and Accountability ACT (HIPAA), 26N(2), 30N(10)
Heart
dihydropyridine binding sites, PET study in dogs, 1227
function, comparison of gated PET and MRI, 806
new perfusion imaging agents, ^{99m}Tc heterocomplexes, 499(ab)
opioid receptors, PET assessment of, 8(ab)
phantom study, myocardial perfusion SPECT images, motion artifacts on, 173(ab)
small, application of left ventricular ejection fraction without edge detection, 786
Heart disease, ischemic, BMIPP dynamic SPECT with Rutland method, 1286
Heart failure
^{125}I MIBG and carvedilol effects, dilated cardiomyopathy, rats, 531, 536
chronic
β-Blocker therapy in, ^{123}I MIBG, 752(ab)
exercise in, antiarrhythmic agents and left ventricular function, 755(ab)
exercise training in, 773
chronic tetrofosmin scintigraphy, 14(ab)
fatty acid imaging, ACE inhibitor blockade effects, 742(ab)
natriuretic peptide effects on risk stratification, sympathetic nerve innervation, 763(ab)
Heart model, cylindrical, estimation of end-diastolic pressure, SPECT, 170(ab)
Heat sterilization, ^{18}F FDG, nuclear interface dispenser in production of, 161(ab)
Helicobacter pylori, endoscopic ^{13}C urea breath test for diagnosis, 100 mg and 50 mg, 1340(ab)
Hemi-Parkinson's disease, preclinical diagnosis, ^{99m}Tc TRODAT-1 SPECT, 58(ab)
Hemodialysis, long-term, end-stage renal disease, bone scan, 1375(ab)
Hemoglobinopathies, sickle, bone and bone marrow infarction in infants and children, 896
Henoch Schönlein purpura, ^{99m}Tc pertechnetate abdominal scan, children, 1397(ab)
Hepatectomy
liver scintigraphy, fibrosis and regeneration after, ^{99m}Tc GSA, 1341(ab)
partial, intrahepatic tumor growth after partial hepatectomy, ^{111}In DTPA^0-octreotide effects, 1681
Hepatobiliary imaging, CCK-8 infusion during, diagnosed cholelithiasis, 1604(ab)
Hepatobiliary imaging, gallbladder ejection fraction, fatty meal and intravenous CCK-8 for, 1603
Hepatocellular carcinoma, ^{11}C acetate PET, 84(ab), 841(ab)
Hepatocytes, dynamic function, asialoglycoprotein receptor scintigraphy, 1611
Hepatodecanoic acid, 17-^{11}C-, myocardial fatty acid metabolism, 1707
Hepatoma cells, uptake of ^{99m}Tc annexin V, after single-dose chemotherapy, experimental tumor model, 258(ab)
Hepatopulmonary shunt fraction, evaluation of, prior to treatment of hepatic malignancy, 1275(ab)
Herceptin
antibody labeling, MCF-7 and SKBR-3 cell lines, 1494(ab)
anti-HER2 humanized antibody, radioimmunotherapy in breast cancer, 554(ab)
Herniation pit, asymptomatic femoral neck uptake, on bone scintigraphy, 484
Herpes simplex virus thymidine kinase
combined gene-radionuclear therapy with ^{125}I IVDU, 1114(ab)
FDG uptake in, membrane transport and endogenous thymidine effects, 1107(ab)
^{18}F FFHBG PET imaging, 157(ab)
^{18}F FHBG and FIAU as gene probes, in gene therapy, 1108(ab)
gene expression, comparison of FHBG and FIAU for, 1113(ab)
gene transduced hepatocellular carcinoma, radiolabeled IVDU as monitoring agents, 1105(ab)
Heterotopic ossification, bone, 346
Hexokinase, FDG PET and, pancreatic cancer, 173
Higenamine, pharmacological stress agent, in experimental and hemodynamic and tolerability study, 719(ab)
High resolution research tomograph (HRRT), PET scanner, single LSO crystal, small animal imaging, 926(ab), 927(ab)
Hippocampus
^{18}F MPPF pharmacokinetics, microPET I imaging, 973(ab)
muscarinic receptors, estrogen upregulation of, 979(ab)
History corner, 18N(12), 25N(3), 25N(7), 30N(1)
HIV, effects in brain dopamine transporters, D2 receptors and, 1025(ab)
Hodgkin's disease
chemotherapy in, PET prediction of prognosis, 1018, 1028
^{67}Ga citrate and ^{18}F FDG blinded comparison, 109(ab), 110(ab)
histopathologic subtypes and marrow infiltration in, FDG PET imaging, 1068(ab)
marrow disease in, FDG PET for detection, 1069(ab)
Holmium-166 DOTA, agent for intravascular radiation therapy, 1129(ab)
Holmium-166 DOTMP, high-dose, myeloablative treatment of multiple myeloma, 1383
Holmium-166 DTPA, dosimetry, large balloon angio catheter, 1428(ab)
Holmium-166 ferric hydroxide, radiation synovectomy with, 1489
Hormonal therapy, prostate cancer, determination of outcome with ^{11}C choline, 421(ab)
Hospital Outpatient Prospective Payment System (HOPPS), 24N(12)
HSV1-sr39tk reporter gene
adenoviral mediated, microPET and ^{18}F FHBG, 7(ab)
enhancement of, two-step transcriptional amplification for, 247(ab)
renilla luciferase fusion, optical and PET imaging, 248(ab)
HSV1-*tk*
comparison of probes for imaging, 1072
imaging gene expression, ^{18}F FHPG PET, 246(ab)
Human IgG anti-mouse antibody (HAMA), radioimmunotherapy, B-cell malignancies, 1256(ab)
Huntington's disease
neural degeneration, high-resolution PET, comparison to MRI/MRS, 220(ab)
targeted antisense radiopharmaceuticals, imaging gene expression in the brain, 948

Hurthle cell carcinoma
thyroid, FDG PET, 294(ab)
thyroid, somatostatin analog imaging, 1309(ab)
Hydrazinonicotinamide (HYNIC)
annexin V derived from, optimization of, 1532(ab)
biodistribution and dosimetry, first human evaluation, 255(ab)
Hydronephrosis
normal residual activity, renogram in evaluation of, 33
urinary obstruction in, ^{99m}Tc MAG3 renography in diagnosis, 1421(ab)
Hydroxyephedrine, cardiac, exercise training in chronic heart failure and, 773
5-Hydroxytryptamine-1A. *see* Serotonin-1A
Hyperparathyroidism
double-phase ^{99m}Tc mibi SPECT in, 452(ab)
preoperative localization, ^{99m}Tc sestamibi scintigraphy, 1313(ab)
presurgical localization, two combined methods, 1281(ab)
sensitivity of parathyroid scintigraphy, major discrepancies between studies, 1296(ab)
surgery for, nuclear medicine in, 47N(8)
^{99m}Tc MIBI radioguided surgery in, 1279(ab)
Hypertension
exercise renography in, ^{99m}Tc DTPA, in young hypertensives with negative captopril renograms, 1423(ab)
renovascular, captopril renography evaluation of, interobserver agreement in, 330
Hyperthyroidism
^{131}I therapy procedure guidelines for, 856
after ^{131}I therapy, prednisolone effects on TRAB and TPOAB, 1290(ab)
athyreotic patients, differentiated thyroid cancer, 1300(ab)
gestational, treated with antithyroid medication, 1332(ab)
HCV-positive patients, treated with αinterferon, 1326(ab)
iopanoic acid use in, before ^{131}I therapy, 454(ab)
^{131}I therapy, 24-hour radioiodine uptake in, 469(ab)
management, ^{131}I *versus* ^{131}I plus antithyroid drug, 451(ab)
Plummer's disease, sclerotherapy in, 1317(ab)
radioiodine therapy
effects of antithyroid drugs, 1293(ab)
thyroid maximum uptake, effective half-life and, 1328(ab)
radioiodine therapy in, radioresistant/sensitive follicular types, 1298(ab)
Hypometabolism, voxel-based analysis, FDG PET, children, 1018(ab)
Hypopharynx cancer, organ preserving primary radiochemotherapy, FDG imaging after, 260(ab)
Hypothyroidism
brain perfusion SPECT, post-thyroidectomy patients, 1028(ab)
cerebral blood flow, mood and cognition in, 1039(ab)
consequent, iodine deficiency and, neonatal hyperbilirubinemia, 1305(ab)
increased uptake of FDG in, PET, 450(ab)
secondary to Hashimoto's disease, regional brain metabolism in, 1030(ab)
subclinical, impaired coronary vasoreactivity in, 183(ab)
thyroid hormone replacement therapy effects, regional brain metabolism, 1029(ab)
Hypoxia
delineation in myocardium, PET and Cu ATSM, canine, 1557
^{18}F FAZA and ^{18}F FMISO as tracers, 1466(ab)
^{18}F FAZA as new tracer for, 1463(ab)
myocardial, targeted marker of angiogenesis, ischemic rat model, 26(ab)
^{99m}Tc complexes, tumor imaging, 1476(ab)
^{99m}Tc-labeled nitroimidazole analogs for, 1475(ab)
^{99m}Tc MNZ-CAA as specific agent for, tumor imaging, 1474(ab)
tolerance of, 3-nitropropionic acid pretreatment effects, rat brain slices, 968(ab)
tumor
^{18}F FAZA imaging, 1123(ab)
MicroPET I imaging, 1122(ab)

I

Ibritumomab tiuxetan in, in NHL, 32N(10)
Ichise noninvasive plot (INP), improved, serotonin transporters, PET/SPECT imaging, 842(ab)
Image analysis
computation of the channelized hotelling observer, 846(ab)
digital phantom, performance analysis of tools in PET, 369(ab)
dual character, extent of fractal behavior in, pulmonary diseases, 830(ab)
histogram, optimization of markers, 527(ab)
hypoxia imaging, ^{18}F FMISO PET, 367(ab)
PET oncology, noninvasive extraction of blood time activity, 366(ab)
phantom proficiency test, Dept. of Veterans Affairs, 816(ab)
pinhole imaging, utility for foot and ankle, 1601(ab)
quantitative
dynamic phantom for simulation of heart movement, 938(ab)
magnetically targeted therapy, FDG PET, 1227(ab)
varying acquisition and reconstruction parameters, pinhole SPECT, 870(ab)
Image comparison, computer-aided intrapatient, brain SPECT, 715
Image coregistration
combined PET/CT systems, accuracy in abdominal imaging, 890(ab)
CT/PET fusion algorithm, whole-body, staging and diagnostic accuracy, 1229(ab)
FDG PET-CT, oral contrast media in, 1240(ab)
FDG PET images, gamma camera with X-ray transmission, 877(ab)
intraoperative gamma probe-guided sentinel node, after radiochemotherapy, head and neck cancer, 573(ab)
PET/CT
4D NURBS-based cardiac-torso (NCAT) phantom, 43(ab)
cancer, 117(ab)
cancer patients with risking tumor markers, 1232(ab)
symmetrical skeletal muscle uptake, 137(ab)
treatment planning for radiation therapy, 119(ab)
pulmonary lesions, non-small cell lung cancer, integrated PET/CT system, 1469
respiration level effects, measured FDG concentration in normal tissues, 887(ab)
ROI analysis, 363(ab)
sentinel node imaging, head and neck cancer, 571(ab)
SPECT/CT
^{111}In ProstaScint, 195(ab)
hybrid imaging, neuroendocrine tumors, 290(ab)
Image enhancement, improving quality, low count density, 894(ab)
Image fusion
combined PET/CT systems, optimized CT scanning protocols and effects on PET quality, 1236(ab)
combined transmission and emission tomography, bone scintigraphy with, 1366(ab)
coregistration impact, management of pediatric diseases, 305(ab)
hand-held nuclear medicine imaging probe, 922(ab)
nuclear technique, location of anatomical abnormality, 1564(ab)
PET/CT
cancer, 117(ab)
display, optimizing visual interpretation of, 1571(ab)
equivocal PET lesions in oncology, 115(ab)
phantom measurements, validation of tool, 1605(ab)
pulmonary lesions, non-small cell lung cancer, integrated PET/CT system, 1469
Image management, display on WWW, 1566(ab)
Image normalization, computer-aided intrapatient comparison, brain SPECT, 715
Image processing
motion correction, accuracy evaluation with optical motion tracking system, 855(ab)
whole-body image database, technical development an initial application, 872(ab)
Image reconstruction
computation of the channelized hotelling observer, 846(ab)
crosstalk compensation, in dual-isotope myocardial SPECT, 520(ab)
fan-beam and variable-focal-length fan-beam SPECT, nonuniform attenuation, 1607(ab)
FDG PET images, gamma camera with X-ray transmission, 877(ab)
filtered back projection *versus,* parametric mapping of PET activation studies, 892(ab)
filtering effects and, dynamic SPECT kinetic paramete bias and reliability, 831(ab)
improvement through modeling, pinhole SPECT, 378(ab)
iterative, for emission and attenuation images, PET, 876(ab)
for MADPET, high resolution dual-layer positron tomograph, 374(ab)
motion correction, using event-based rebinning metho 530(ab)
multi-slice rebinning algorithm, orthogonal projection in 3D PET, 879(ab)
noniterative quantitative method, myocardial SPECT, 377(ab)
optimizing data-driven motion correction, brain SPEC 908(ab)
PET, cancer patients, 567(ab)
SPECT and PET, sinogram restoration filters for, 874(ab)
SPECT data, direct matrix inversion for, 376(ab)
statistically-regulated expectation-maximization, PET, 372(ab)
vector Weiner filter, restoration of multicollimator/multihead SPECT data, 895(ab)
Image registration
^{131}I with Monte Carlo simulation, 3D dose calculation SPECT, 1101
combined PET/CT systems, surface-rendering 3D images, 531(ab)
to correct emission-transmission scan mismatch, 362(ab)
CT/PET
mismatch in abdominal organs, 48(ab)
mutual information warping, 1184
Klinefelter syndrome, men, inverse hemispheric dominance in, 1026(ab)
MR and SPECT brain images, maximization of mutual information and, 160
partial volume effect, PET striatal imaging, 1715
PET/MR, soft-tissue masses, 29(ab)
planar activity quantification, CT, 972
speed, accuracy and capture range comparison, multimodality imaging, 819(ab)
Image segmentation
statistical, estimation of ^{90}Y TheraSphere treatment effectiveness 371(ab)
tumor quantitation and volume estimation, oncology PET, 837(ab)
Immunohistochemistry, GLUT-1 and hexokinase expression, in lung cancer, 1221(ab)
Immunoscintigraphy
breast cancer, HER2/neu expressing, trastuzumab therapy, 1189(ab)
cystic fibrosis, neutrophil imaging of the lung, 584(ab)
Immunotherapy, cellular, monitoring with radiolabeled RGD peptides, 439(ab)
Indium-111
coincidence detection of cascaded photons, use of gamma camera without collimators, 941(ab)
GLP-1 labeled with, diagnosis of insulinomas, 332(ab)
granulocyte scintigraphy, fever of unknown origin, 140
labeled ligand for asialoglycoprotein receptors, MRI contrast agent, 503(ab)
myocarditis and, 40N(11)
physical-chemical status of, one-detector gamma-gamma perturbed angular correlation technique, 165(ab)
ProstaScint WPECT, fusion with anatomical CT images, 195(ab)

Indium-111 antimyosin, opoptotic and oncotic myocardial necrosis, 25(ab)
Indium-111 capromab pendetide, prediction of response after postprostatectomy PSA relapse, radiotherapy, 1188(ab)
Indium-111 DOTA folate, targeting of tumor-associated folate receptor, 1481(ab)
Indium-111 DTPA, ^{67}Ga and ^{201}Tl, imaging of human tumors, 1091(ab)
Indium-111 DTPA, PET, neuroendocrine tumors, 1391
Indium-111 DTPA^0-octreotide, inhibitory effects of, intrahepatic tumor growth after partial hepatectomy, 1681
Indium-111 DTPA-D-GLU1-minigastrin
CCK-B receptor scintigraphy, 447(ab)
determination of viability, malignant brain tumors, 406(ab)
Indium-111 DTPA-D-Phe^1 octreotide, therapy and efficacy, metastatic neuroendocrine tumors, 1269(ab)
Indium-111 DTPA-GLu^1-minigastrin, comparison to FDG PET and CT, thyroid cancer, 467(ab)
Indium-111 DTPA or DOTA bombesin, receptor-targeted scintigraphy, radionuclide therapy and, 1650
Indium-111 G4-Av, radiolabeling of, intraperitoneally disseminated tumors, 1090(ab)
Indium-111 HER2, uptake studies, MCF-7 and SKBR-3 cell lines, 1494(ab)
Indium-111-labeled TFO, targeting human N-myc, overexpression of target gene, 1492(ab)
Indium-111 leukocytes, utility in febrile postpartum patient, 1359(ab)
Indium-111 N-myc-AS, auger electrons internalized as, neuroblastoma cells, 253(ab)
Indium-111 octreotide
imaging, neuroendocrine tumors, 1149(ab)
noninvasive monitoring, somatostatin receptor type 2 chimeric gene transfer, 406
patient-specific dosimetry, neuroendocrine tumors, 313(ab)
prediction of biodistribution, therapeutic ^{90}Y lanreotide, 1268(ab)
therapy, long-term efficacy, 125(ab)
Indium-111 pegylated annexin V, uptake, apoptosis and, MDA-MB468 tumors, 150(ab)
Indium-111 pentetreotide
carcinoid tumor, 42N(5)
dose estimation, radiotherapy in gastropancreatic tumors, 124(ab)
scintigraphy, compared with ^{99m}Tc P829, neuroendocrine tumors, 889
Indium-111 radiogastrin, receptor-targeted therapy, medullary thyroid cancer, 126(ab)
Indium-111 trastuzumab, therapy, HER2/neu expressing breast cancer, 1189(ab)
Indium-111 Zevalin, biodistribution assessment, nuclear medicine expert panel, 1258(ab)
Indium-123 IMP, distribution volume of, regional differences, cerebral perfusion SPECT, 962(ab)
Indomethacin, for heterotopic ossification, 346
IndyPET II. *see* PET
Infection imaging
^{67}Ga scintigraphy, after colorectal surgery, 48N(8)
^{99m}Tc HMPAO, radiolabeled leukocytes, 918, 925
acute pyelonephritis and prediction of scarring, color and power Doppler sonography or DMSA scintigraphy, 27
bacterial and *Candida albicans,* antimicrobial peptides for, 1125(le)
combined labeled leukocyte/marrow, antibiotic therapy effects, joint infection, 297(ab)
^{11}C PK-11195 PET, encephalitis, SIV-infected monkey, 976(ab)
FDG and ^{11}C acetate, diagnosis of pulmonary tuberculosis, 461(ab)
FDG PET
alternative to WBC imaging in orthopedic infections, 458(ab)
chronic vertebral infections, 481(ab)
osteomyelitis distinguished from soft-tissue infection, 1355(ab)
specificity of, in painful joint prostheses, 457(ab)
suspected infections in diverse settings, 456(ab)
viability of echinococcus multilocularis, 462(ab)
febrile postpartum patient, utility of ^{111}In leukocytes, 1359(ab)
^{18}F FMISO PET, patients with tuberculosis therapy, 459(ab)
^{125}I spermine analog as potential tracer for, 1512(ab)
meta-analysis of sulesomab, 295(ab)
musculoskeletal, ^{99m}Tc ciprofloxacin and HMPAO leukocyte, 300(ab)
novel leukotriene B4 antagonist for, 504(ab)
osteomyelitis, ^{99m}Tc ciprofloxacin findings, 301(ab)
radiolabeled granulocyte stimulation, 1354(ab)
real-time, single-molecule, 34N(1)
S. aureus prosthetic joint infection, ^{99m}Tc ciprofloxacin evaluation of, 239
^{99m}Tc ciprofloxacin SPECT and FDG PET comparison, orthopedic infections, 477(ab)
^{99m}Tc Depreotide, 296(ab)
^{99m}Tc HMPAO autologous *versus* heterologous leukocytes for, 1351(ab)
^{99m}Tc HMPAO leukocytes, bone and joint infection, 1352(ab)
^{99m}Tc INH, detection of tubercular lesions, 1349(ab)
^{99m}Tc leukokinin residue, 1347(ab)
Inflammation imaging
amino acid transporter subtypes, tumor and inflammatory cells, RT-PCR, 85(ab)
^{11}C PK-11195 PET, encephalitis, SIV-infected monkey, 976(ab)
FDG PET
alternative to WBC imaging in orthopedic infections, 458(ab)
kinetic analysis, cancer, 1097(ab)
rheumatoid arthritis treated by infliximab infusions, 139(ab)
suspected infections in diverse settings, 456(ab)
FDG uptake, concanavalin A-mediated lymphocyte activation, 658
FDG uptake in soft tissue surrounding shoulder joint, 1377(ab)
meta-analysis of sulesomab, 295(ab)
novel leukotriene B4 antagonist for, 504(ab)
pulmonary tuberculoma, FDG PET multiple findings, 1406(ab)
sarcoidosis, FDG uptake patterns in, 1398(ab)
sterile model, ^{99m}Tc annexin V, 1357(ab)
SUV or lung cancer, FDG and choline use in, 276(ab)
^{99m}Tc anti-intercellular adhesion molecule-1, lung, 1506(ab)
^{99m}Tc Depreotide, 296(ab)
^{99m}Tc HIG, in adhesive capsulitis, 482(ab)
Inhalation, cigar smoke particles, lung, ventilation scan with ^{99m}Tc sulfur colloid particles, 1591
Inhalation therapy, β-agonist aerosol distribution, respiratory syncytial virus bronchiolitis, infants, 487
In Memoriam
Becker, Wolfgang, 15N(7)
Cuaron, Alfredo, 40N(5)
Farrer, Paul, 29N(9)
Groch, Mark W., 25N(9)
Sastry, Kandula S. R., 33N(1)
Instrumentation
3D PET, GSA as a scintillator for, 41(ab)
animal PET
compact detectors based on pixellated NaI(Tl) crystal arrays, 213(ab)
performance measurements, 212(ab)
A-SPECT, small animal imaging, 35(ab)
CdZnTe-based nuclear medical imager, 935(ab)
combined PET/CT scanner, continuous bed movement, 38(ab)
combined PET/CT systems, single CdZnTe detector, 215(ab)
dose calibrator settings, radionuclides exceeding potentiometer range, 1629(ab)
gamma-ray optics, design for small animal imaging, 944(ab)
high-resolution detector modules, based on high-granularity NaI(Tl) arrays, SPECT small animal imaging, 942(ab)
IndyPET II, initial imaging experience, 214(ab)
intraoperative gamma probes, dead-time effects, 1606(ab)
multicontrast single-chamber hot spheres phantom, PET and SPECT, 940(ab)
nuclear cameras, preventing hyper pileup-prevention method, 931(ab)
PET, five minute routine whole body studies, 36(ab)
pinhole SPECT sampling, spiral orbits in, 34(ab)
positron intra-operative probe, background rejection capability, 217(ab)
septa configurations, PET, count rate performances for, 33(ab)
small solid state digital gamma camera, use in pediatrics, 1613(ab)
system parameters, development of ultra-high resolution SPECT for small animal imaging, 919(ab)
two-dimensional decoding map in PET cameras, photomultiplier gain drift due to radiation exposure effects, 930(ab)
Insulinomas, diagnosis, ^{111}In labeled GLP-1 use in, 332(ab)
Insulin resistance, endothelial dysfunction in, endothelial dysfunction and, 509(ab)
Insulin-resistance syndrome, ^{125}I DIG, new tracer of glucose transport, 1511(ab)
Interferon-α, therapy, HCV, hyperthyroidism in course of, 1326(ab)
Interleukin-2 receptors, ^{99m}Tc Dac binding specificity on, 1472(ab)
Interleukin-8, imaging potential of, labeling method effects, 1128(le)
Interobserver agreement, captopril renography, assessment of renal vascular disease, 330
Intestine, wall activity and cross-doses, dosimetry model for, 1657, 1665
Intralesional therapy, intracavitary radionuclide injection, dosimetry for, 324(ab)
Intrathecal cancer therapy, treatment of neoplastic meningitis, 1125(ab)
Iodination, annexin V, imaging of apoptosis, 671
Iodine-123
^{131}I comparison, whole-body imaging of thyroid cancer, 632
breast imaging with, 428(ab)
diagnostic scanning, recurrence of thyroid cancer, 1285(ab)
diagnostic scanning of remnant, after surgery for thyroid cancer, 468(ab)
dual isotope imaging, model-based crosstalk compensation in, 193(ab)
interruption of breast-feeding after, 1624(ab)
low-dose scans, evaluation of well-differentiated thyroid cancer, 464(ab)
scan and uptake, work-up of abnormal TSH levels, 1330(ab)
scintigraphy, 5 and 24 hours, comparison in thyroid cancer, 72, 77
stilbenes labeled with, abeta-plaque imaging, Alzheimer's disease, 1442(ab)
whole-body scan, thyroid cancer, 466(ab)
Iodine-123 3-IMT, increased tumor uptake, preloading with amino acids, 1201, 1207
Iodine-123 5-IA, imaging nicotinic acetylcholine receptors, brain metabolite composition, 163(ab)
Iodine-123 5-I-A-85380, SPECT, quantification of nicotinic acetylcholine receptors, 395(ab)
Iodine-123 altropane
binding potential, test-retest reliability, 854(ab)
SPECT, test-retest variability, 1609(ab)
Iodine-123 βCIT
neurofocus SPECT device, small animal imaging, 936(ab)
routine preparation of, improved procedure, 168(ab)
SPECT
Parkinson's disease, pramipexole *versus* L-dopa, 60(ab)
Parkinson's disease treated with neuroimmunophilin ligand NIL-A, 68(ab)
serotonin transporters in OCD patients, 1044(ab), 1045(ab)

Iodine-123 BMIPP
cardiac fatty acid metabolism, ischemic preconditioning, 743(ab)
dosimetry, distribution and safety, 517(ab)
dynamic myocardial SPECT, Rutland method, 1286
normal imaging, angina patient without prior infarction, 518(ab)
SPECT
ischemic preconditioning, 743(ab)
vasospastic angina, 1476
Iodine-123 FP-CIT, SPECT
diagnosis of Parkinson's disease, 65(ab)
differential diagnosis of Parkinson's disease, 62(ab)
Iodine-123 IBZM
^{99m}Tc TRODAT-1 SPECT and, Parkinson's disease, 59(ab)
SPECT, differential diagnosis of Parkinson's disease, 62(ab)
Iodine-123 IMP, SPECT, misery perfusion and, 42N(11)
Iodine-123 IMPY, as abeta-plaque imaging agent, Alzheimer's disease, 603(ab)
Iodine-123 IMT, SPECT, squamous cell head and neck tumor, 1145(ab)
Iodine-123 IMZ
brain SPECT, age-related changes, 237(ab)
distribution, focal cerebral ischemia, comparison with Cox-2 expression, 967(ab)
Iodine-123 IPPA, FDG and, myocardial ischemia, 421
Iodine-123 IPT
differentiation, early-stage Parkinson's or essential tremor, 69(ab)
dual isotope SPECT, clinical feasibility, Parkinson's disease, 827(ab)
Iodine-123 lipiodol, orally administered lipids, body distribution of, 1336(ab)
Iodine-123 MIBG
β-Blocker therapy, chronic heart failure patients, 752(ab)
cardiac adrenergic innervation, in CAD, 1
cardiac sympathetic nerve activity, in hypertrophic cardiomyopathy, 15
SPECT, vasospastic angina, 1476
uptake, normotensive and hypertensive rats, 366
visualization of brown adipose tissue, 1234
Iodine-123 subtraction, parathyroid imaging with, in an endemic goiter area, 1175
Iodine-123 TSH, assessment of thyroid cancer, 463(ab)
Iodine-124, production, PET/CT, thyroid cancer, 162(ab)
Iodine-124 annexin V, detection of cell death, 256(ab)
Iodine-124 FIAU, comparison of probes, imaging HSV1-*tk*, 1072
Iodine-124 IUdR, intratumoral injection, PET imaging after, malignant gliomas, 1444
Iodine-125, interruption of breast-feeding after, 1624(ab)
Iodine-125 BMIPP
time course of fatty acid metabolism, ischemia/reperfusion, rat heart, 716(ab)
uptake, myocardial fatty acid, adriamycin-induced cardiotoxicity, 705(ab)
Iodine-125 ITAU, potential iodinated proliferation marker, 1218
Iodine-125 ITdU, potential iodinated proliferation marker, 1218
Iodine-125 IUdR
bystander effect produced by, tumor cells, 1117(ab)
methotrexate and, treatment of neoplastic meningitis, 1125(ab)
Iodine-125 IVDU, combined gene-radionuclear therapy with, 1114(ab)
Iodine-125 MIBG
autoradiography and, endomyocardial laser channels, 551
carvedilol and, effects on cardiac function, in dilated cardiomyopathy, rats, 531, 536
uptake, effects of commonly prescribed drugs, 1387(ab)
visualization of brown adipose tissue, 1234
Iodine-125 RC-160, somatostatin receptor internalization, NCI-H446 cells, 443(ab)
Iodine-125 SA, radioimmunoassay, macrophage inhibitory factor, prediction of septic shock, 1356(ab)
Iodine-125 spermine analog, potential tracer for infection/inflammation imaging, 1512(ab)
Iodine-131
^{123}I comparison, whole-body imaging of thyroid cancer, 632
ablation, thyroid remnants, diagnostic dose effects, 1289(ab)
adenoviral protein scaffolds, molecular imaging, 1513(ab)
diagnostic scanning of remnant, after surgery for thyroid cancer, 468(ab)
for focal activity, ultra-high and high-energy collimation, 882(ab)
formulation effects, thyroid uptake, 56
high-dose ablation therapy, differentiated thyroid cancer, 1427(ab)
irradiation, cultured thyroid epithelial cells, 828, 835
negative scan, thyroid cancer, 1318(ab)
outpatient therapy, external and internal dose, 575(le)
patient-specific dosimetry, thyroid cancer therapy, 309(ab)
plus antithyroid drug, management of Graves disease, 451(ab)
sodium therapy, prostate adenocarcinoma, rat, 1096(ab)
SPECT, 3D dose calculation, Monte Carlo simulation, 1101
therapy
diagnostic whole body scanning with 185 MBq and, thyroid cancer, 1311(ab)
factors influencing outcome, thyroid cancer, 291(ab)
Grave's disease, 469(ab)
procedures in thyroid disease, 856
radiation dosimetry, contamination as a route for, 1307(ab)
thyroid cancer, ^{123}I scintigraphy after, 72, 77
thyroid cancer, long-term survival, 1297(ab)
thyroid remnant ablation, 1320(ab)
thyroid cancer treated with, hospital discharge, 61
treatment
Grave's disease, prednisolone effects on TRAB and TPOAB, 1290(ab)
maximum permissible dose, 1437(ab)
in tumors, radiation dose distributions in normal tissue adjacent to, 1110
whole-body scanning, false-positive findings in, 207
Iodine-131 HuA33, pharmacodynamics, colorectal cancer, 861(ab)
Iodine-131 MIBG
modulation of transport, hepatoma, rat, 1139(ab)
uptake, neuroblastoma cells overexpressing the TRK-A gene, 1116(ab)
Iodine-131 sodium therapy
for differentiated thyroid cancer, 1303(ab)
whole-body scan, differentiated thyroid cancer, 1287(ab)
Iodine-133, planar activity quantification, CT, 972
Iodobenzamides, use in signa receptor scintigraphy, suspected breast cancer, 1647
Iopanoic acid, before ^{131}I therapy, in hyperthyroidism, 454(ab)
Irreversible tracers, MAO A, parametric PET images, strategy for formation, 197(ab)
Ischemia-reperfusion, acute MI in hearts with, using high-resolution stationary SPECT, 933
Ischemic heart disease, preoperative PET in, 41N(7)
Isoflurane, inhaled, effects on liquid gastric emptying, pigs, 968
Isoprostanes, dose-dependent oxidation injury, radioiodine therapy induced, 1254
Isotretinoin, redifferentiation with, metastatic thyroid cancer, 465(ab)
Iterative reconstruction
analytic algorithms, SPECT, 1343
PET whole-body images, reducing loss of image quality, 1054
striatal DAT binding, quantitation of, 200(ab)

J

Joint, prosthetic, *S. aureus* infection, ^{99m}Tc ciprofloxacin evaluation of, 239
Journal of Nuclear Medicine
Annual Newsline Review
letters, 35N(5)
state of nuclear medicine, 11N(1)
impact in top 5% of all scientific journals, 40N(8)
new online feature, 32N(12)
Newsline to publish submitted notices of clinical trials, 26N(6)
outstanding articles for 2001, 35N(7)

K

Kaposi sarcoma, different variants, ^{99m}Tc tetrofosmin scans in, 1156(ab)
Kappa opioid receptors, PET ligand for imaging, ^{11}G GR103545, 602(ab)
Kawasaki disease
coronary artery stenosis in, myocardial SPECT, 736(ab)
coronary evaluation after, ^{15}O water PET, 47N(8)
coronary flow insufficiency in, hyperemic stress SPECT, 733(ab)
myocardial flow reserve, endothelial function and, PET, 1381(ab)
Kidney
acute pyelonephritis and prediction of scarring, color and power Doppler sonography or DMSA scintigraphy, 27
drainage, renography in normalized residual activity, 33
function
bone marrow transplantation effects, 1417(ab)
correlation of MAG3 and creatinine clearances, 1414(ab)
effects on renal output efficiency, 851
optimizing renal counting method for ^{99m}Tc MAG3 clearance, 1418(ab)
plasma clearance, Bayesian regression model for, 762
preliminary evaluation of ^{99m}Tc MAEC, 1422(ab)
unilateral multicystic kidney, follow-up renal function, children, 1385(ab)
MAb uptake, negatively charged substituent-bearing acylation agent for, 1470(ab)
parenchymal scintigraphy, renal damage in acute pyelonephritis, children, 1384(ab)
protection, during radiopeptide therapy, mice, 1076(ab)
split renal function measurement, different correction factors, 142(ab)
transplantation, *see* Transplantation
volume imaging, hybrid gamma camera and ^{52}R, 1416(ab)
Kinetic modeling, cluster analysis in, as a replacement for arterial sampling, 360(ab)
Klinefelter syndrome, inverse hemispheric dominance in, men, brain SPECT, 1026(ab)
Knee replacement, ^{99m}Tc HMDP bone imaging of, 1363(ab)
Kyoto Award, 2002, Hood, Leroy E., 44N(8)

L

Lactation, malnutrition during, ^{99m}Tc O_2Na biodistribution and, 89
Laryngeal carcinoma
^{18}F FLT PET detection, 278(ab)
organ preserving primary radiochemotherapy, FDG imaging after, 260(ab)
Lasers, endomyocardial channels, effects on regional innervation, ^{125}I MIBG, 551
Left bundle branch block
baseline septal perfusion disparity in, 727(ab)
dilative cardiomyopathy and
cardiac resynchronization therapy, biventricular pacing, 187(ab)
PET evaluation, 20(ab)
scan findings on, myocardial SPECT, 729(ab)
Left ventricular blood volume, quantitative evaluation, single dose of $^{13}NH_3$ and gated PET, 999
Left ventricular dysfunction, ^{201}Tl exercise-redistribution SPECT, reverse redistribution on, 621, 628
Left ventricular ejection fraction
2D planar *versus* 3D SPECT blood-pool imaging, 1626(ab)
^{99m}Tc sestamibi, echocardiography and PTCA, after myocardial infarction, 8

^{201}Tl gated myocardial perfusion imaging, in CAD, 131
after revascularization, dobutamine echocardiography and ^{201}Tl imaging, 795, 803
automatic evaluation by ECG-gated blood pool SPECT, 349(ab)
automatic method for computing, gated perfusion SPECT, 521(ab)
gated blood pool SPECT, *versus* myocardial perfusion SPECT, 347(ab)
gated SPECT, maximum counts at end-diastole and end-systole, 169(ab)
gated SPECT with MUGA, 790(ab)
matrix size or filtering effects, gated SPECT, 800(ab)
myocardial blood flow and, single dose of $^{13}NH_3$, 771(ab)
quantitative evaluation, single dose of $^{13}NH_3$ and gated PET, 999
quantitative gated PET for, small animals, 709(ab)
time intervals used to calculate, radionuclide ventriculography studies, 805(ab)
validation, left ventricular volume validation and, 796(ab)
volume and, myocardial gated SPECT, 792(ab)
without edge detection, application to small hearts, 786
Left ventricular enlargement, myocardial perfusion SPECT results, prognostic role, 356(ab)
Left ventricular function
accuracy and reproducibility, gated SPECT different smooth filters, 826(ab)
after stress, myocardial gated SPECT, 787(ab)
age and, in coronary artery disease, 768(ab)
antiarrhythmia agents and, chronic heart failure patients under exercise, 755(ab)
automatic software for processing, gated blood-pool imaging, 802(ab)
CAD patients, blood-pool SPECT, 805(ab)
continuous monitoring at exertion, athletes, 799(ab)
defect comparison, stress quantitative gated SPECT MPI, 795(ab)
ECTools and QGS for evaluation, gated myocardial tomography, 808(ab)
exercise ^{201}Tl gated SPECT, detection of CAD, 443
Fourier phase and amplitude analysis, gated blood-pool imaging, 810(ab)
gated ^{99m}Tc MIBI and FDG measurement of, comparison, 789(ab)
gated SPECT, scintillation crystal and semiconductor detectors camera system, 821(ab)
gated SPECT and 2D echocardiography, ischemic heart disease patients, 344(ab)
global, ^{201}Tl gated myocardial SPECT, 765(ab)
heart failure and, day-to-day variability in myocardial gated SPECT, 731(ab)
improved perfusion, sublingual nitroglycerin, myocardial SPECT, 766(ab)
ischemic cardiomyopathy and, PET, 21(ab)
^{13}N ammonia PET, CAD patients, 774(ab)
post-stress, rest and stress ECG-gated ^{13}N ammonia PET, 775(ab)
post-stress myocardial stunning, dual-isotope gated myocardial SPECT, 778(ab)
^{201}Tl gated SPECT, window time for, 788(ab)
volume validation, 796(ab)
Left ventricular hypertrophy, ischemia in, adenosine in prediction of, 724(ab)
Left ventricular mass, women without perfusion defects, echocardiography comparison with myocardial SPECT, 735(ab)
Left ventricular remodeling, myocardial oxidative metabolism and, after myocardial infarction, 780
Lesion detectability, comparison of PET imaging platforms, localization ROC analysis, 1545, 1555
Leukemia
chronic lymphocytic
apoptosis induction in, 1262(ab)
FDG PET in identifying Richters transformation in, 108(ab)
^{123}I tositumomab radioimmunotherapy, 1255(ab)
high-dose ^{131}I radioimmunotherapy, radioiodination for, 1526(ab)
pediatric, ^{188}Re anti-CD66-mab radiotherapy, 133(ab)
Leukocyte labeling, ^{99m}Tc HMPAO, chromosomal aberrations in lymphocytes and, 203
Leukocytes, radiolabeled
^{99m}Tc exanetazime, viability and chemotaxis, 928
infection imaging, 918, 925
Limbic system
mesolimbic dopaminergic, role in Parkinson's disease, 993(ab)
serotonin transporters in, alcoholism effects, 390(ab)
Liver
^{18}F FDG uptake, dynamic PET, 439(le)
^{99m}Tc mebrofenin evaluation, rat model of Wilson's disease, 246
biliary bicarbonate excretion after transplant, HCO_3 PET, 476(ab)
carcinoid metastasis, radioimmunotherapy with ^{131}I chTNT, 578(ab)
^{64}Cu lipophilic complexes, synthesis, biodistribution and microPET, 495(ab)
dynamic SPECT
attenuation correction using X-ray CT and, 471(ab)
spectral analysis, 470(ab)
^{18}F FMSO PET, flow-weighted total input functions, 30(ab)
malignancy, measurement of hepatopulmonary shunt fraction prior to treatment, 1275(ab)
metastases, intrahepatic tumor growth after partial hepatectomy, ^{111}In DTPA^0-octreotide effects, 1681
metastatic lesions, ^{18}F FET PET/CT, 878(ab)
patient preparation effects of ^{99m}Tc teboroxime, 815(ab)
reduced interference, improved lesion contrast and, parametric images, 522(ab)
subclinical encephalopathy, regional cerebral blood flow with abnormal perfusion in, 545(ab)
transplant, *see* Transplantation
unresectable malignancies, TheraSphere treatment, 1274(ab)
Liver cancer
intrahepatic artery ^{188}Re lipiodol therapy, treatment planning protocol, 1429(ab)
lung shunting in
planar and SPECT imaging for, 1611(ab)
variability of ^{99m}Tc MAA measurements, 1612(ab)
metastatic, intraarterial administration of ^{99m}Tc MIBI, 1337(ab)
^{188}Re HDD-lipiodol therapy, 153(ab)
therapy, ^{188}Re HDD kit for, 1527(ab)
^{90}Y microsphere hepatopulmonary shunt estimation procedures, 1553(ab)
^{90}Y TheraSphere treatment effectiveness, estimation by statistical segmentation, 371(ab)
Liver cirrhosis, uptake of colloid, SPECT, 312
Loevinger-Berman Award, 2002, Strand, Sven-Erik, 20N(10)
Losartan, renal scintigraphy, renal artery stenosis with impaired renal function, 143(ab)
Low density lipoprotein, modified binding, monocytes and endothelial cells, 706(ab)
Lumped constant, FDG, normal human brain, 1157
Lung
aerosol cyclosporine clearance, transplant recipients, 1614(ab)
artificial embolism, ventilation/perfusion SPECT for, 640, 648
baseline scintigraphy, positive helicoidal CT or venous sonography, 1408(ab)
COPD patients, FDG PET of thoracic and abdominal muscles in, 1410(ab)
deposition of cigar smoke particles in, ventilation scan with ^{99m}Tc-labeled sulfur colloid particles, 1591
dual isotope ^{81M}Kr/^{99m}Tc, practical considerations for, 1411(ab)
emphysema, α^1-antitrypsin-related, 1503(ab)
imaging techniques, PET and radioactive microsphere comparison, 1063
inhaled ^{11}C CGP 12388 PET, 1409(ab)
neutrophil imaging, cystic fibrosis, 584(ab)
nonmalignant neoplasms, infections and, detection with ^{99m}Tc depreotide, 1210(ab)
perfusion irregularity, primary pulmonary hypertension, 1402(ab)
scintigraphy, survival in diagnosis of pulmonary embolism, 588(ab)
shunting
in hepatic cancer, planar and SPECT imaging for, 1611(ab)
variability of ^{99m}Tc MAA measurements, 1612(ab)
spatial registration of lesions, PET and CT, 49(ab)
ventilation-perfusion coregistration, comparison with planar imaging, 1561(ab)
ventilation-perfusion scans, distribution in pulmonary embolism, 1596
Lung cancer
3D radiotherapy for, FDG PET imaging, 552(ab)
asymptomatic, bone scintigraphy use in, 1207(ab)
bronchioloalveolar
^{201}Tl SPECT detection, 1211(ab)
FDG PET detection, 1214(ab)
^{11}C PET imaging, 274(ab)
extra-thoracic metastases, detection with FDG PET, 551(ab)
false-positive and false-negative findings, FDG PET, 413(ab)
FDG PET
diagnosis and staging, CT and pathological correlation, 1216(ab)
significance of negative scan, 412(ab)
treatment planning, radiation therapy, 553(ab)
FDG uptake, GLUT-1 and hexokinase expression in, 1221(ab)
FDG uptake relations, abnormalities in tumor suppressor genes, 1246(ab)
^{18}F FDG comparison and ^{99m}Tc sestamibi comparison, 410(ab)
^{18}F FDG uptake, target to background ratio in assessment of, 370(ab)
^{18}F fluoroemodin as potential imaging agent, 1092(ab)
initial staging, bone scintigraphy with SPECT and FDG PET, 1220(ab)
lesion volume, combined PET/CT systems, 1234(ab)
malignant nodules, ^{99m}Tc depreotide, 1209(ab)
multidrug resistance, P-glycoprotein correlation with FDG PET, 1215(ab)
non-small cell
^{18}F FLT PET in proliferative activity of, 277(ab)
^{99m}Tc MIBI comparison with tetraphenylphosphonium, 234
FDG PET in staging of, 46N(11)
FDG PET management of, 1212(ab)
image coregistration of pulmonary lesions, PET/CT system, 1469
mediastinal staging, FDG PET, 550(ab)
residual disease after, FDG PET in detection of, 1575(ab)
response to chemotherapy, FDG PET, 1304
stage III, neoadjuvant chemotherapy, FDG PET, 1248(ab)
surgically resection, ^{18}F FDG uptake in, 39
peripheral solitary nodules, gamma-probe guided video assisted thoracoscopic surgery, 411(ab)
preoperative staging
combined PET/CT systems, 547(ab)
FDG PET and CT in, 549(ab)
pulmonary nodules, dual *versus* single-time point FDG PET, 564(ab)
quantifying PET images, effects of respiratory gating on, 876
recurrence, PET/CT with ^{18}F FDG in, 114(ab)
recurrent and posttherapeutic changes, FDG PET outcomes assessment, 1219(ab)
respiratory-gated set of images for SPECT, pulmonary nodules, 915(ab)
small cell
peptide-receptor radiotherapy in, 445(ab)
somatostatin receptor imaging, PET, 409(ab)
solitary pulmonary nodules
changes of SUV in FDG PET, 561(ab)
USV in FDG PET, 566(ab)
solitary thoracic lesions, delayed FDG PET imaging for, 563(ab)
staging, FDG PET and, 752
staging and restaging, FDG PET and PET/CT imaging comparison, 548(ab)
SUV, FDG and choline use in, 276(ab)

^{99m}Tc Depreotide
mapping of lymphatic drainage, 407(ab)
qualitative analysis, 408(ab)
treatment response to stereotactic radiotherapy, FDG PET evaluation of, 1218(ab)
tumor necrosis therapy in, ^{131}I labeled chimeric TNT antibody, 1265(ab)
Lung disease, interstitial
^{99m}Tc DTPA aerosol and ^{67}Ga comparison, 1404(ab)
nuclear medicine tests in, 1400(ab)
Lung perfusion, quantitative analysis of, primary pulmonary hypertension patients, 757
Lung volume, transmission map, comparison, 885(ab)
Luteinizing hormone-releasing hormone, scintigraphy, with ^{111}In D-Trp6-LHRH, breast cancer visualization, 1192(ab)
Lutetium, DOTATOC and DOTATATE labeled with, biodistribution in neuroendocrine tumors, 442(ab)
Lutetium-177
^{90}Y combination, for radionuclide therapy, 446(ab)
octreotate therapy, tumor response and side effects, 444(ab)
Lutetium-177 DOTA-huJ591, dose escalation study, prostate cancer, 577(ab)
Lutetium DOTA-Tyr3 octreotate
DTPA with, reduction in skeletal uptake, 167(ab)
therapy, somatostatin receptor-positive tumors, 123(ab)
Lymphatic function, quantification of, in lymphedema, 318
Lymphedema
lymphatic studies, animal model for, 720(ab)
quantitative measurement of lymphatic function, 318
Lymph node metastasis, in medullary thyroid cancer, FDG PET detection, 66
Lymph nodes, non-sentinel, risk of recurrence of breast cancer and, 74(ab)
Lymphocytes
chromosomal aberrations in, leukocyte labeling with ^{99m}Tc HMPAO and, 203
concanavalin A-mediated activation, FDG uptake in model of inflammation, 658
Lymphoma
aggressive
chemotherapy in, PET prediction of prognosis, 1018, 1028
outcome prediction by FDG PET, 284(ab)
in AIDS patients, brain SPECT in, 31N(3)
autologous stem cell transplant in, FDG PET after chemotherapy, 282(ab)
bone, ^{67}Ga scintigraphy and CT after treatment, 1295
childhood, ^{18}F FDG PET imaging, 130(ab), 131(ab)
cytotoxicity with radiolabeled antibodies, 560(ab)
detection, FDG PET sensitivity for, WHO/REAL classification, 285(ab)
different histological subtypes, uptake of FDG PET, 1065(ab)
EBV, cytotoxic T cells targeting, dynamic imaging, 1111(ab)
FDG PET, tumor characteristics obtained by, for 3D radiation therapy, 107(ab)
^{67}Ga citrate scintigraphy, prediction of chemotherapy response, 1071(ab)
high-dose ^{131}I radioimmunotherapy, radioiodination for, 1526(ab)
malignant
FDG PET or ^{67}Ga SPECT for staging of, 1061(ab)
recurrence, camera-based FDG PET in, 1064(ab)
monitoring therapy and predicting treatment response in, FDG PET, 1063(ab)
murine model, ^{18}F FLT PET tracer, 96(ab)
non-Hodgkin's. *see* non-Hodgkin's lymphoma
PET/CT multimodality imaging, 106(ab)
repeated gallium scans for, 1072(ab)
reproducibility of dosimetric calculations, radioimmunoimaging, 1603(ab)
Lymphoscintigraphy
axillary sentinel lymph node status, nodular drainage patterns and tumor location, breast cancer, 1177(ab)
biopsy and, internal mammary nodes, breast cancer, 75(ab)
blood-pool scintigraphy and, congenital venous and lymphovenous malformations, 1369(ab)
breast, intradermal injection and intraoperative isosulfan dye in, 1175(ab)
breast cancer, subareolar application of ^{99m}Tc nanocolloid, 1172(ab)
combined SPECT/CT, sentinel node located by, 572(ab)
detection of sentinel nodes, cervical cancer, 1184(ab)
lymphatic studies, animal model for, 720(ab)
primary lymphedema, children, 1388(ab)
procedure guideline, sentinel node localization in melanoma, 1414
radioguided biopsy, malignant cutaneous melanoma, 811
sentinel node mapping, breast cancer, dual-head gamma camera, 899(ab)
for skin melanoma, 570(ab)
subareolar, sentinel lymph node mapping in breast cancer, 1176(ab)

M

Machado-Joseph disease, gene carriers, DAT concentrations in, 153
Magnetic resonance microscopy, marrow cellularity, in models of trabecular skeleton, 97
Magnetoencephalography, FDG PET and, temporal lobe epilepsy, 981(ab)
Malignant cutaneous melanoma, radioguided sentinel lymph node biopsy in, 811
Malpractice, bill passes House, 40N(11)
Mammary carcinoma
C3H, metabolic fate of FDG, 940
FDG imaging, metabolic fate, 1101(ab)
Mammary nodes, internal
lymphoscintigraphy and biopsy, breast cancer, 75(ab)
sentinel node biopsy, breast cancer, 76(ab)
Mammography, ^{99m}Tc sestamibi scintimammography combination, cancers in over 50s, 272(ab)
Mammography, positron emission
full breast, strategies for, 929(ab)
MLEM application to, 373(ab)
pixelated NaI(Tl) arrays for, 37(ab)
Mammotomography, application-specific emission and transmission tomography, 39(ab)
MAPLE reactors, new ruling, 11N(3)
Marijuana, cerebral cannabinoid receptors, ^{11}C NIDA-41020 PET evaluation, 1443(ab)
Matrix metalloproteinase-2 inhibitor, ^{18}F-labeled, PET cancer imaging, 1462(ab)
Matrix metalloproteinase inhibitor radiotracers, PET, breast cancer imaging, 316(ab)
Matrix metalloproteinases, peptide to quantify activity, 1489(ab)
Maxillomandibular tumors, GSO PET system, 3D presurgical planning, 1238(ab)
Maximum likelihood expectation maximization (MLEM), iterative reconstruction, PET, 373(ab)
Mean transit time, in asialoglycoprotein receptor scintigraphy, hepatocyte function, 1611
Mediastinitis, acute postoperative, ^{99m}Tc liposomes in, 42N(9)
Mediastinoscopy, strategy for, FDG PET use in, 1222(ab)
Medical Internal Radiation Dose (MIRD) method, mass correction of beta dose, 817(ab)
Melanocortin type 1 receptor, imaging of metastatic melanoma, 1699
Melanoma
^{11}C BPA, stereoselective transport of, 317(ab)
cutaneous malignant
sentinel lymph node in, 1183(ab)
sentinel node imaging, 570(ab)
detection of micrometastases, sentinel node, radioguided surgery, 1182(ab)
intermediate thickness, sentinel node location in, lymphoscintigraphy and intraoperative gamma probe, 1414
malignant cutaneous, radioguided sentinel lymph node biopsy in, 811
metastases, PET *versus* CT for identification of, 1187(ab)
metastatic, novel DOTA-α-melanocyte-stimulating hormone analog for diagnosis, 1699
PET and sentinel node detection, 34N(10)
tumor to kidney uptake ratio, ^{11}Re alpha-MSH peptide analogs, 152(ab)
Mesothelioma
malignant pleural, assessment with FDG dual-head gamma camera coincidence imaging, 1144
malignant pleural, FDG dual-head gamma camera coincidence imaging, 1213(ab)
Metaiodobenzylguanidine (MIBG)
acute myocardial infarction, early revascularization and, 514(ab)
novel positron emitting analog of, 1460(ab)
synthesis and specific uptake, pheochromocytoma cells, 1479(ab)
Metalloproteinase (MMP), matrix, in experimental atherosclerotic plaques, 4(ab)
Methotrexate, ^{125}I IUdR, treatment of neoplastic meningitis, 1125(ab)
Methylene blue, effects on viability and chemotaxis, ^{99m}Tc exanetazime labeled leukocytes, 928
α-Methyl-L-tryptophan, PET, changes in blood oxygen after brain serotonin synthesis, 947(ab)
Methylphenidate
behavioral responses to, expectation effects, 386(ab)
discontinuation, effects on cerebral blood flow, boys with ADHD, 1624, 1630
Microdialysis, ^{201}Tl and ^{99m}Tc retention, heart model of low-flow ischemia and stunning, 566
Micrometastatic cancer, targeted alpha therapy for, 1277(ab)
MicroPET
^{11}C raclopride and, comparative imaging with dopamine D2, 1570
^{11}C flumazenil, rapid synthesis in a microreactor placed in the HPLC loop, 1448(ab)
^{11}C raclopride
comparative imaging of D2 knockout and wild type mice, 972(ab)
distribution volume ratio in rat brain, 219(ab)
^{64}Cu, bone imaging, 494(ab)
^{64}Cu lipophilic complexes, liver, 495(ab)
FDG and FLT, glucose metabolism and cell proliferation, implanted murine tumors, 89(ab)
^{18}F FHBG, imaging adenoviral mediated HSV1-sr39tk reporter gene, 7(ab)
^{18}F FLT, prostate cancer detection, 98(ab)
$^{13}NH_3$, quantitative measurement of myocardial blood flow, mice, 718(ab)
optical CCD imaging and, cardiac gene, 1(ab)
MicroPET I
experimental autoimmune anterior uveitis, 1346(ab)
^{18}F MPPF pharmacokinetics, hippocampus, rat, 973(ab)
imaging of neuroreceptor binding, rodent brain, 974(ab)
selective gelatinase inhibitor, tumor imaging, 1121(ab)
tumor hypoxia, 1122(ab)
^{86}Y HER, ovarian cancer model, 555(ab)
Microprobe, beta
alternative to PET scanning of small animals, 921(ab)
measurement of blood radioactivity, PET scanning of small animals, 211(ab)
Molecular imaging
amino acid transporter subtypes, tumor and inflammatory cells, RT-PCR, 85(ab)
gene expression, 34N(12)
imaging technology conference, 27N(5)
nuclear medicine and, 13N(2)
targeting of endothelin receptors, atherosclerosis, 400
Molecular nuclear medicine
adenoviral protein scaffolds for, 1513(ab)
HSV1-tk reporter gene expression, FHBG and FIAU for, 1113(ab)
TAT mediated reporter protein transduction, imaging in living subjects, 1106(ab)
Monoamine oxidase B, PET imaging, in peripheral organs, 1331
Monoamine oxidase (MAO), PET study, effective dose delivered after injection of ^{11}C befloxatone, 1434(ab)
Monoamine oxidase (MAO) inhibitors
downregulation of striatal aromatic acid decarboxylase, monkey, 385(ab)

parametric PET images, strategy for formation, 197(ab)
peripheral organs, PET imaging, 961(ab)
Monoclonal antibodies (MAb)
anti-CD20, ^{90}Y-labeled, radioimmunotherapy of non-Hodgkin's lymphoma, 267
B-cell non-Hodgkin's lymphoma, radioimmunotherapy of, 1507
radiohalogenation of, negatively charged substituent-bearing acylation agent for, 1470(ab)
SZ51, radioimaging of experimental pulmonary embolism, 1399(ab)
therapy, model of ^{131}I HuA33 pharmacodynamics, colorectal cancer, 861(ab)
Monte Carlo simulation
acceleration using delta scattering, SPECT, 191(ab)
down-scatter correction, ^{99m}Tc/^{201}Tl dual-isotope SPECT, 192(ab)
gamma-ray optics, design for small animal imaging, 944(ab)
image reconstruction, for MADPET, 374(ab)
rotating multisegment slant-hole SPECT, breast, with lead shielding, 897(ab)
scatter correction and penetration, pinhole SPECT, 896(ab)
standardization and validation, SPECT and PET, 849(ab)
tracer-kinetic PET and SPECT studies, dynamic hybrid phantoms, 528(ab)
Morpholino, DNA analog, ^{99m}Tc-labeled, tumor pretargeting with, 384
Motion correction
PET, event-based rebinning method, 530(ab)
respiratory, cardiac PET, 523(ab)
SPECT
calibrating optical images and gamma camera images, 909(ab)
head movement in CBF-SPECT, annular gamma camera, 911(ab)
using stereo optical cameras, 910(ab)
Motor cortex, methylphenidate discontinuation effects, prepubescent boys with ADHD, 1624, 1630
Movement correction, heart, quantitative image analysis, 938(ab)
Movement disorders, parkinsonian syndrome with, with ^{123}I altropane SPECT, 61(ab), 64(ab)
MR, neuroreceptor images, coregistration of, 853(ab)
MRI
Alzheimer's disease, morphologic and functional changes, 304
anti-angiogenic therapy, relations to dynamic PET, 441(ab)
comparison to high-resolution PET, neural degeneration in Huntington's disease, 220(ab)
comparison with bone scan, spinal fractures in children, 483(ab)
contrast-enhanced, PET comparison, myocardial flow reserve, 28(ab)
gated ^{99m}Tc MIBI and FDG, measurement of left ventricular function, 789(ab)
gated PET comparison, measurement of cardiac function, 806
induced hypothyroidism, effects on thyroid tumor metabolism and proliferation, 1322(ab)
late enhancement, comparison with FDG PET, myocardial viability, 340(ab)
porphyrin-based agent for detection, sentinal lymph node, 1135(ab)
SPECT and, mutual-information registration, 160
MR spectroscopy, in thyroid cancer, 46N(8)
Mucoepidermoid carcinoma, somatostatin receptors in, MEC-1 and MC3 cells, 1077(ab)
Multicenter study, PET scanners, calibration of, 635
Multidrug resistance
breast cancer, modulation with toremifene, ^{99m}Tc sestamibi assessment of, 519, 526
neoadjuvant chemotherapy, locally advanced breast cancer, 745
Multimodality imaging
A-SPECT, small animals, 35(ab)
automatic rigid registration algorithms, speed, accuracy and capture range comparison, 819(ab)
clinical management of pediatric diseases with, 305(ab)
combined PET/CT systems
accuracy in abdominal imaging, 890(ab)
cancer patients with risking tumor markers, 1232(ab)
comparison of ^{68}Ge and CT transmission maps of thorax, 885(ab)
count rate performance, 40(ab)
CT-based attenuation correction, 375(ab)
effects of respiratory motion, 209(ab)
equivocal PET lesions in oncology, 115(ab)
external beam radiation treatment planning, 118(ab)
FDG, metallic object artifacts on, 1239(ab)
FDG PET comparison, staging of lung cancer, 548(ab), 549(ab)
with ^{18}F FDG in recurrent lung cancer, 114(ab)
improvement in diagnostic accuracy, 1235(ab)
inaccurate localization of lesions, 116(ab)
incidental findings on non-contrast CT portion, 1237(ab)
intuitive registration, 531(ab)
^{124}I production, thyroid cancer, 162(ab)
lesion size and volume, 47(ab)
lung lesion volume, 1234(ab)
metabolic activity of prostate cancer, 427(ab)
neuroshield with, 937(ab)
optimized CT scanning protocols and effects on PET quality, 1236(ab)
optimizing visual interpretation of, 1571(ab)
oral contrast in, 1240(ab), 1241(ab), 1242(ab)
oral CT contrast agents in, 205(ab)
preoperative staging of lung cancer, 547(ab)
quality control, 1569(ab)
radiographic contrast effects on attenuation correction, 888(ab)
radiotherapy planning for head and neck cancer, 1230(ab)
radiotherapy treatment planning, lung, 119(ab)
respiration level effects, 887(ab)
respiratory motion artifacts on, 1228(ab)
restaging patients with cervical carcinoma, 1250(ab)
restaging patients with ovarian carcinoma, 1249(ab)
single CdZnTe detector, 215(ab)
small animal imaging for clinical oncology, 893(ab)
staging in differentiated thyroid cancer, 1133(ab)
using software-based algorithms, 1231(ab)
whole-body FDG, lymphoma, 106(ab)
combined transmission and emission tomography, bone scintigraphy with, 1366(ab)
FDG 3D-CT/PET, lesion conspicuity in cancer diagnosis, 1233(ab)
gated SPECT and 2D echocardiography, comparison with left ventriculography, 344(ab)
hybrid SPECT/CT system, attenuation correction in, 171(ab)
^{131}I SPECT and CT, fusion images in thyroid cancer, 1291(ab)
PET and optical imaging, HSV1-sr39tk renilla luciferase fusion, 248(ab)
PET/CT
contrast-enhanced, potential artifact in, 1339
functional and structural evaluation of cancer patients, 1129
SPECT and MR, CT image fusion, accuracy of, brain phantom, 867(ab)
SPECT/CT, sentinel node located by, 572(ab)
viability tests, sequential strategy using, 795, 803
Muscarinic acetylcholine receptors, ^{18}F FP-TZTP binding to, regional brain uptake, 399(ab)
Muscarinic receptors, estrogen upregulation of, hippocampus and thalamus, rat, 979(ab)
Mutual information
CT/PET, 1184
MRI and SPECT, image registration, 160
Myeloablation, high-dose ^{166}Ho DOTMP, multiple myeloma, 1383
Myeloma
multiple
high-dose ^{166}Ho DOTMP myeloablative treatment, 1383
high-risk
^{99m}Tc tetrofosmin scintigraphy, 112(ab)
whole body scanning with FDG PET, 111(ab)
identification with whole-body FDG PET, 1457
osteosclerotic, ^{89}Sr in, 32N(10)
Myelotoxicity, prediction of, non-marrow-targeting ^{90}Y-antibody therapy, 1245
Myocardial blood flow
absolute quantification, $H_2{}^{15}O$ and 3D PET, 1031, 1041
during adenosine triphosphate infusion, dipyridamole administration and, 179(ab)
automatic determination, factor analysis for, PET, 188(ab)
cerebral blood flow and, during mental stress, dual-PET study, 1006(ab)
ejection fraction and, single dose of $^{13}NH_3$ and gated PET, 999
endothelial dysfunction, rosiglitazone effects, PET measurement, 3(ab)
exercise training effects, chronic heart failure, 773
flow reserve and
in ischemic cardiomyopathy, PET, 781(ab)
measured by ^{15}O water PET, 772(ab)
left ventricular ejection fraction and, single dose of $^{13}NH_3$, 771(ab)
nateglinide effects, in diabetes, 506(ab)
PET measurements, changes in coronary vasomotion, diabetes, 508(ab)
quantitative measurement, $^{13}NH_3$ microPET in, mice, 718(ab)
Myocardial contractile reserve, perfusion defect severity and, ^{99m}Tc sestamibi SPECT, dogs, 540
Myocardial flow reserve
contrast-enhanced MRI and PET comparison, 28(ab)
dietary supplementation with folic acid effects, in CAD patients, 184(ab)
simvastatin and pravastatin, in hypercholesterolemics, 751(ab)
subclinical hypothyroidism, impaired coronary vasoreactivity in, 183(ab)
Myocardial fusion, 3D models of CAD, SPECT, 12(ab)
Myocardial infarction
acute
^{99m}Tc sestamibi, echocardiography, and primary PTCA, 8
after reperfusion, delayed ^{99m}Tc sestamibi and ^{123}I BMIPP images in, 1557(ab)
angina preceding, infarct size relations, 16(ab)
antimyosin and glucaric acid imaging, 25(ab)
cardioprotective effect of nicorandil, 753(ab)
early revascularization and, MIBG scintigraphy, 514(ab)
imaging after onset, abnormal radiotracer uptake and, 15(ab)
^{111}In antimyosin-antibody and ^{99m}Tc annexin V comparison, 703(ab)
perfusion, glucose metabolism, and wall motion in, 17(ab)
simultaneous dual isotope ^{201}Tl/^{99m}Tc annexin SPECT, 11(ab)
cardioprotective effects of nicorandil, ^{99m}Tc tetrofosmin and ^{123}I BMIPP imaging, 747(ab)
dual ^{123}I MIBG and ^{201}Tl kinetic study, cardiac sympathetic nerve function, 717(ab)
inflammatory cell infiltration, FDG PET, 780(ab)
intramyocardial revascularization therapy, FDG PET of LV function in, rats, 704(ab)
with ischemia-reperfusion, using high-resolution stationary SPECT, 933
left ventricular remodeling, oxidative metabolism and, 780
low-dose dobutamine gated SPECT ^{201}Tl, contractile reserve assessment, 338(ab)
measurement, pinhole SPECT, 174(ab)
myocardial contractile reserve, resting perfusion scintigraphy and, dogs, 540
^{99m}Tc labeling of mesenchymal stem cells, imaging of body distribution, 712(ab)
Myocardial ischemia
automated transient ischemic dilatation, unreliable index of, 738(ab)
clandestine, frequency of, 18(ab)
Cu ATSM PET, canine, 1557
diabetes and, myocardial PET with ^{82}Rb, 5(ab)
dipyridamole-induced, beta blockade effect, ^{99m}Tc sestamibi, 180(ab)
exercise thallium findings in, 732(ab)

experimental low-flow, ^{123}I IPPA retention and FDG accumulation, 421
fractional flow reserve, myocardial perfusion SPECT and, assessment of coronary artery stenosis, 734(ab)
^{123}I BMIPP SPECT, acute chest pain patients, 814(ab)
ischemia-reperfusion injury and, FASTSPECT in detection, rats, 175(ab)
low-flow, stunning and, ^{201}Tl and ^{99m}Tc retention in heart model, 566
measurement, stress imaging, quality of life and, 754(ab)
perfusion impairment in, time course of recovery after revascularization, 343(ab)
reperfusion and, apoptotic process in, ^{99m}Tc annexin V assessment of, 708(ab)
stress-induced, in diabetes, 505(ab)
time course of fatty acid metabolism, ischemia/reperfusion, rat heart, 716(ab)
^{201}Tl myocardial SPECT, SyndromeX patients, 812(ab)
^{201}Tl SPECT lung/heart index, SyndromeX patients, 793(ab)
Myocardial perfusion imaging
^{201}Tl gated, left ventricular ejection fraction and multivessel CAD, 131
acute MI, perfusion, glucose metabolism, and wall motion in, 17(ab)
adenosine triphosphate in
isometric handgrip exercise effects, caffeine intake and, 722(ab)
safety profile, 721(ab)
SPECT, 723(ab)
arbutamine stress, critical coronary artery stenoses, dogs, 664
BMIPP imaging, angina without prior myocardial infarction, 518(ab)
breast and/or axillary uptake during, 177(ab)
changes in lesion size, 519(ab)
characteristic of motion artifacts, cardiac phantom study, 173(ab)
coronary artery vasodilator function, smokers and healthy adults, 185(ab)
^{62}Cu-labeled cardiac tracers, hybrid PET cameras, 42(ab)
decreased coronary flow reserve, diabetes, 507(ab)
defect comparison, stress quantitative gated SPECT MPI, 795(ab)
dobutamine stress, in CAD, 1634
esophageal scintigraphy and, investigation of esophageal dysfunction, 740(ab)
evaluation, improved phantom population for, 31(ab)
exercise ECG and, patients with single vessel disease after PTCA, 744(ab)
fractional flow reserve comparison, assessment of coronary artery stenosis, 734(ab)
gated, exercise ^{201}Tl, multivessel coronary artery disease, 443
gated blood pool SPECT, left ventricular ejection fraction, 347(ab)
integrated report generation for, comparison to report dictation, 182(ab)
left bundle branch block, baseline septal perfusion disparity in, 727(ab)
left ventricular mass, women without perfusion defects, echocardiography comparison, 735(ab)
^{13}N ammonia, relation to coronary risk factors, 776(ab)
practice patterns, 26N(2)
prognostic implications, atrial fibrillation, 351(ab)
prognostic value, patients with permanent pacemaker, 353(ab)
^{82}Rb and hybrid gamma camera, pig heart, 27(ab)
rest and stress, one- and three-hour delays, comparison of activity, 1621(ab)
rest-stress, arm positioning effects, 1560(ab)
^{82}Ru, left main or three vessel coronary disease, 728(ab)
SPECT
attenuation correction in, joint position statement, 273
diabetic patients, 30N(3)
^{99m}Tc, ROC evaluation of attenuation, scatter and resolution compensation, 6(ab)
^{99m}Tc sestamibi, strategies to minimize abdominal activity, 813(ab)
therapeutic efficacy, CAD patients, 750(ab)
^{201}Tl, extracardiac disease detected by, 730(ab)
Myocardial PET
^{82}Rb, 2D and high dose and low dose 3D gated, 777(ab)
with ^{82}Rb, diabetes effects on coronary disease, 5(ab)
contrast-enhanced MRI, comparison, myocardial flow reserve, 28(ab)
Myocardial SPECT
^{201}Tl, dual-head gamma camera, artifacts caused by, 285
adenosine triphosphate in, 723(ab)
age and, heart failure due to CAD, 768(ab)
attenuation correction, hybrid SPECT/CT system, 171(ab)
attenuation correction for, 939(ab)
attenuation correction in, joint position statement, 273
attenuation maps statistics in, 904(ab)
coronary artery disease, nonuniform attenuation correction and scatter correction effects, 176(ab)
decreased coronary flow reserve, diabetes, 507(ab)
detection of CAD, U. S. and European markets, 726(ab)
diabetic patients, 30N(3)
diaphragmatic respiratory motion effects, with and without attenuation correction, 1259
dobutamine atropine stress, in CAD patients, 767
dual-isotope, crosstalk compensation in, 520(ab)
dual-isotope gated, post-stress myocardial stunning, 778(ab)
exercise, angiogenesis in CAD patients, 19(ab)
gated
Batista-operation using, myocardial remodeling, 794(ab)
coronary artery stenosis in Kawasaki disease, 736(ab)
day-to-day variability of, CAD and heart failure patients, 731(ab)
dilated left ventricle by stress and rest ^{99m}Tc tetrofosmin, 355(ab)
dipyridamole-induced transient LV dysfunction, 737(ab)
ECTools and QGS for evaluation of left ventricular function, 808(ab)
frequency of clandestine ischemia, 18(ab)
ischemic myocardial dysfunction, time course of recovery, 343(ab)
left and right ventricular ejection fraction, 349(ab)
left sided bundle of Kent, 797(ab)
left ventricular dysfunction, window time for, 788(ab)
left ventricular ejection fraction, 790(ab)
left ventricular function after stress, 787(ab)
left ventricular volumes and ejection fraction, 792(ab)
left ventricular wall motion in diabetic heart, 511(ab)
matrix size or filtering effects, 800(ab)
post-dipyridamole stunning assessed by, 786(ab)
recognition of transient postischemic stunning, in CAD, 346(ab)
septal wall motion after CABG, 791(ab)
transient myocardial stunning in, 345(ab)
ungated *versus* end-diastolic imaging in, 798(ab)
^{123}I BMIPP, acute chest pain patients, 814(ab)
idiopathic dilated cardiomyopathy, 748(ab)
^{123}I MIBG, idiopathic ventricular fibrillations, 760(ab)
intravenous nicorandil, cardioprotective effects of, 746(ab)
ischemic mitral regurgitation, myocardial viability relations, 756(ab)
left bundle branch block, scan findings on, 729(ab)
left ventricular ejection fraction, automatic method for computing, 521(ab)
left ventricular function, scintillation crystal and semiconductor detectors camera system, 821(ab)
new fully automatic algorithm for blood-pool, 348(ab)
noniterative quantitative method, reconstruction, 377(ab)
optimum compensation method, filter cutoff frequency and, 432
Perfit software, comparison with expert readers and polar-plot program, 181(ab)
pre-revascularization, CABG patients, 354(ab)
prognostic implications, atrial fibrillation, 351(ab)
prognostic role
left ventricular enlargement, 356(ab)
with resting ST segment depression, 357(ab)
radiation dose in, 40N(9)
rest and stress, low-risk chest pain patients, 739(ab)
rest/stress, arm positioning effects, 1560(ab)
revascularization, prediction of functional recovery after, 759(ab)
Rutland method, ischemic myocardium and damaged myocardium, 1286
^{99m}Tc and ^{201}Tl, sublingual nitroglycerin, left ventricular ejection fraction, 766(ab)
^{99m}Tc MIBI, after coronary angioplasty, 745(ab)
^{99m}Tc Myoview, aging effects on prognostic value, 352(ab)
^{99m}Tc Noet and sestamibi, defects in same patient, 13(ab)
^{201}Tl, extent of myocardial ischemia, 812(ab)
^{201}Tl gated, global left ventricular function, 765(ab)
triple-head 360 degree *versus* dual-head 180 degree, ROC, 190(ab)
unnecessary rest imaging, 178(ab)
Myocardial viability
^{201}Tl exercise-redistribution SPECT, reverse redistribution on, 621, 628
contractile reserve, resting perfusion scintigraphy and, dogs, 540
dobutamine echocardiography, ^{201}Tl imaging and, after revascularization, 795, 803
dynamic cardiac FDG SPECT for, 820(ab)
ECG, dobutamine ECG and ^{99m}Tc sestamibi SPECT detection, 779(ab)
FDG studies, optimal imaging time using coincidence imaging, 769(ab)
infarction and reperfusion injury, FASTSPECT in detection, rats, 175(ab)
intravenous nicorandil, cardioprotective effects of, 746(ab)
ischemia and, imaging with ^{18}F FRP170, 109
ischemic cardiomyopathy, flow defect sizes in, left ventricular ejection fraction and, 21(ab)
ischemic mitral regurgitation and, gated SPECT, 756(ab)
late enhancement MRI, comparison with FDG PET, 340(ab)
low-dose dobutamine addition, routine dual isotope gated SPECT, 339(ab)
low-dose dobutamine gated SPECT ^{201}Tl, contractile reserve assessment, 338(ab)
low-dose dobutamine stress gated ^{99m}Tc tetrofosmin SPECT, 337(ab)
nitrate augmented ^{99m}Tc MIBI, nitrate augmented MIBI bolus injection and, 757(ab)
reverse redistribution on stress-redistribution, ^{201}Tl SPECT, 341(ab)
SPECT determination, ^{201}Tl/^{99m}Tc BRU 59–21, 758(ab)
time course of recovery after revascularization, ischemic dysfunction, 343(ab)
Myocardial wall stress, ^{201}Tl SPECT abnormalities, in dilated cardiomyopathy, 451
Myocarditis
^{111}In and, 40N(11)
experimental, imaging of apoptosis with ^{99m}Tc annexin V, 713(ab)
viral, pediatric, myocardial SPECT in, 767(ab)
Myocardium
doxorubicin-induced damage, BMIPP dynamic SPECT with Rutland method, 1286
fatty acid metabolism
17-^{11}C-hepatodecanoic acid for measurement of, 1707
volume-overloaded rabbit hearts, 715(ab)
hibernation, chronic ischemic dysfunction, dogs, 556
ischemic, imaging with ^{18}F FRP170, 109
metabolism, insulin-dependent diabetes, PET, 510(ab)
nitrate hibernating, ^{99m}Tc MIBI for detection, CAD, 342(ab)
oxidative metabolism, left ventricular remodeling after myocardial infarction, 780

protein synthesis, measurement, 711(ab)
quantifying glucose use, PET, FDG and 1-^{11}C glucose comparison, 1530, 1542
reinnervation, after transplant, 516(ab)
remodeling, Batista-operation using, myocardial gated SPECT, 794(ab)
stunned, L-carnitine administration effects on fatty acid metabolism, 749(ab)
stunning, myocardial contractile reserve in, dogs, 540
Myocutaneous inflammatory change, after intra-arterial chemotherapy, bone and soft tissue tumors, 1452

N

Nanocomposite devices, dendrimer, radiopharmaceutical development, 490(ab)
Nasopharyngeal cancer
discrete linear least squares method for diagnosis, 862(ab)
staging, whole-body PET impact on, 263(ab)
Nateglinide, antidiabetic agent, effects on myocardial blood flow and vasoreactivity, in diabetes, 506(ab)
National Academy of Sciences Institute of Medicine, racial, ethnic treatment gap, 40N(5)
National Cancer Institute, von Eschenbach named director, 35N(1)
National Council on Radiation Protection and Measurements (NCRP), symposium on CT patient dose, 40N(11)
National Institutes of Health (NIH)
Biomedical Imaging and Bioengineering
first research RFAs announced, 37N(4)
new director, Pettigrew, Roderic, 20N(7), 36N(11)
new member of, 22N(1)
news from, 30N(3)
new staff members and organizational changes, 30N(10)
Institute of general Medical Sciences (NIGMS), complex systems research, 30N(10)
new director, Zerhouni, Elias A., 40N(7)
supermagnets get funding boost, 45N(8)
Zerhouni, Elias A., new director, 38N(4)
Neural stem cells, monitoring using sodium iodide symporter gene, 971(ab)
Neuroactivation probe, clinical activation with SPECT, spatial working memory task, 1426
Neuroblastoma, metabolic characterization, 132(ab)
Neuroendocrine tumors
^{90}Y DOTATOC for, 610
acute red marrow toxicity, during ^{90}Y SMT487 therapy, 1267(ab)
detection, ^{99m}Tc P829 compared with ^{111}In pentetreotide, 889
DOTATOC and DOTATATE, yttrium and lutetium labeled, 442(ab)
^{111}In octreotide therapy, patient-specific dosimetry, 313(ab)
^{111}In pentetreotide, SPECT/CT hybrid imaging, 290(ab)
insulinomas, incretin hormone GLP-1 for detection, 1191(ab)
metastatic, ^{111}In DTPA-D-Phe^1 octreotide therapy in, 1269(ab)
non-secreting and secreting, ^{111}In octreotide imaging, 1149(ab)
PET, ^{111}In DTPA, 1391
response, ^{90}Y DOTATOC constant injected dose, 1266(ab)
small metastases from, ^{68}Ga DOTATOC PET, 1252(ab)
somatostatin receptor-positive
^{177}Lu DOTA-Tyr3 octreotate therapy, 123(ab)
^{90}Y and ^{111}In comparison, 121(ab)
^{90}Y lanreotide therapy, 122(ab)
^{90}Y SMT487 therapy in, 120(ab)
^{90}Y lanreotide given intra-arterially, 1270(ab)
Neuroimage database, 44N(5)
Neuroimaging
with ^{123}I altropane SPECT, Parkinsonian syndrome with movement disorders, 61(ab), 64(ab)
with ^{123}I βCIT, dopamine transporters in Parkinson's disease, 60(ab)
Parkinson's disease, treated with neuroimmunophilin ligand NIL-A, ^{123}Iβ-CIT SPECT, 68(ab)
Parkinson's plus syndromes, altropane SPECT binding ratios in, 64(ab)
Neuroimmunophilin ligand NIL-A, Parkinson's treated with, ^{123}I β-CIT SPECT assessment of, 68(ab)
Neuroleptic treatment
altered expression induced by, D2 receptors, PET, 380(ab)
mechanism of extrapyramidal side effects, antipsychotic drug treatment effects, 950(ab)
schizophrenic patients, receptor imaging, 1056(ab)
NeuroSPECT, acetazolamide challenge, dementia study, 538(ab)
Neurotensin(8–13), pseudopeptide, radiolabeled with ^{99m}Tc, preclinical evaluation, 374
Neurotransmitters, quantification of activity, PET, 393(ab)
Neutrophils, respiratory burst and, interpretation of ^{18}F FDG PET images, 652
NFκB signal transduction, imaging, using reporter gene approach, 1110(ab)
Nicotinic acetylcholine receptors
5IA-SPECT studies, 975(ab)
6-OHDA model of Parkinson's disease, brain PET, 608(ab)
α4β2 subtype, PET, 1433(ab)
development of allosteric potentiating ligands, in Alzheimer's disease, 394(ab)
^{123}I 5-IA imaging brain metabolite composition, baboon, 163(ab)
inhibition of cytochrome P-450 effects, brain PET and SPECT, 607(ab)
quantification of, using ^{123}I 5-I-A-85380 SPECT, 395(ab)
tracer for, acetylcholine level effects on binding of, 978(ab)
Nicotinic receptors, evaluation by SPECT, Alzheimer's disease, 229(ab)
Nifedipine, photodegraded, enhancement of tumor uptake of ^{67}Ga citrate, 1134(ab)
Nitrogen-13 ammonia, PET
chronic ischemic dysfunction, dogs, 556
factor analysis for determination of myocardial blood flow, 188(ab)
noninvasive quantitation, 524(ab)
relation to coronary risk factors, 776(ab)
2-Nitroimidazole
^{18}F-labeled, imaging of ischemic but viable myocardium, 109
derivatives of cyclam, positive markers of tumor hypoxia, 837
Nitroimidazole, marker of myocardial angiogenesis, ischemic rat model, 26(ab)
3-Nitropropionic acid, pretreatment, hypoxic tolerance and, rat brain slices, 968(ab)
N-methyl-D-aspartate receptor, CNS5161 for PET imaging of, 1447(ab)
Noise equivalent count rate, 2D and 3D whole-body PET, 1268
Non-Hodgkin's lymphoma (NHL)
^{131}I tositumomab therapy, patient release after, 354, 364
anthracycline-based chemotherapy, FDG PET prediction of 1-year survival, 283(ab)
B-cell, radioimmunotherapy of, 1507
B-lineage, treatment with ^{213}Bi-labeled anti-CD20-CHX-A-DTPA antibody conjugate, 418(ab)
^{18}F FLT PET tracer, SCID mouse model, 96(ab)
high-dose chemotherapy and stem cell transplant, FDG PET predicts outcome, 1062(ab)
^{131}I Bexxar and cytotoxic chemotherapy in, 417(ab)
ibritumomab tiuxetan in, 32N(10)
^{131}I-labeled chimeric 81C6 anti-tenascin monoclonal antibody, radioimmunotherapy with, 1259(ab)
induction chemotherapy, FDG PET for tailoring of, 1060(ab)
mantle cell, radioimmunotherapy, 414(ab)
prediction of malignancy grade, FDG PET, 286(ab)
pretarget radioimmunotherapy, anti-CD20 fusion protein, 419(ab)
radioimmunotherapy, ^{90}Y-labeled anti-CD20 monoclonal antibody, 267
radioimmunotherapy and, 11N(4)
recurrent, after radioimmunotherapy, FDG PET use in, 281(ab)
reinfusion of cold antibody, radioimmunotherapy, 416(ab)
relapsed or refractory
^{123}I tositumomab radioimmunotherapy in, 1257(ab)
^{131}I anti-CD20 radioimmunotherapy, 415(ab)
sensitivity of FDG PET for, WHO/REAL classification, 285(ab)
stem cell transplant outcomes, FDG PET prediction, 39N(9)
two promising therapies, 26N(2)
Zevalin for, infusion symptoms, 1579(ab)
Norepinephrine transporters
^{11}C OXP as a selective marker for, brain, 1446(ab)
PET radioligand for, 599(ab)
radioiodinated, assessment of cardiac sympathetic nervous dysfunction, 1510(ab)
Normalized residual activity, renogram use in, 33
Nuclear cardiology, practice in the UK, 40N(5)
Nuclear medicine
chemistry and, 20N(1)
development of radioactive dendrimer nanocomposites, 490(ab)
diagnosis and treatment of ovarian cancer, 42N(5)
Henry N. Wagner, Jr., MD Professorship, 11N(5)
military perspective on, 24N(1)
molecular medicine, molecular imaging and, 13N(2)
PET and, 11N(2)
phantom measurements, validation of image fusion tool, 1605(ab)
pharmaceutical market in, 38N(9)
practice in focus, Our Lady of the Lake Regional Medical Center, 11N(10)
public affairs update, 24N(12)
response to cancer pain, 31N(10)
sodium iodide symporter role in, 1188
studies, semi-automated example case file system for, 1572(ab)
telenuclear medicine procedure guideline, 1410
therapeutic, CPT code recommendations, 27N(7)
training, integrated teaching laboratory for, 1630(ab)
UK and Europe, 41N(4)
Nuclear pharmacy, heat sterilized ^{18}F FDG, nuclear interface dispenser in production of, 161(ab)
Nuclear Regulatory Commission (NRC)
nominations for ACMUI, 34N(1)
nuclear medicine concerns, 14N(3)
Part 35, SNM publishes specific guidance on, 26N(12)
Regulatory Guide 8.39, online errors, 284(le)
web site, 28N(2)
Nucleoside kinases, as proliferation-imaging agent, SPECT, 1218

O

Obesity
adjustable laparoscopic gastric banding for, radiography *versus* ^{99m}Tc pertechnetate, 592(ab)
dopamine role in, 36N(12)
morbid, assessment of gastric emptying in, 1338(ab)
ventilation-perfusion scan results in, 1407(ab)
Observer study, optimum compensation method, filter cutoff frequency and, myocardial SPECT, 432
Obsessive-compulsive disorder (OCD)
cerebral blood flow, change during working memory, PET, 1042(ab)
^{123}I βCIIT SPECT, imaging of serotonin transporters, 1044(ab), 1045(ab)
serotonin receptor binding in, right caudate nucleus, PET, 1046(ab)
serotonin receptors in, measurement with ^{11}C (+)McN-5652, 54(ab)
Octreotate, hydrophilic and lipophilic derivatives of, tumor targeting, 1528(ab)
Octreotide
effects on gallbladder motor function, in acromegaly, 474(ab)
peptide receptor radionuclide therapy, tumor response to, 617
radiolabeled somatostatin analog, neuroendocrine tumor response to, 610

Octreotide analogs, glycated, labeled with radioiodine and ^{211}At via a tin precursor, 330(ab)
Oligodeoxynucleotides
inhibition of cell cycle progression, induction of apoptosis and, carcinoma cell line, 257(ab)
^{99m}Tc tricarbonyl, specific binding in, 1505(ab)
Oncology
^{18}F FCH pharmacokinetics and radiation dosimetry, 92
improved detection rate, PET tumor tracers, 562(ab)
Interventional oncology conference, 44N(8)
Opiate receptors, effects in alcohol dependence, 391(ab)
Opioid receptors
imaging with PET, breast cancer, 1131(ab)
localization of, breast cancer, SCID mice, 1138
myocardial, PET assessment of, 8(ab)
Optimum compensation method, filter cutoff frequency and, myocardial SPECT, 432
Oral cancer, FDG combined with ^{11}C acetate in diagnosis of, 1193(ab)
Organ volume, exact estimation of, nuclear imaging procedures, 1568(ab)
Orofacial tumors, GSO PET system, 3D presurgical planning, 1238(ab)
Osteomyelitis
3-phase bone scan *versus* FDG, painful joint prosthesis, 1380(ab)
acute hematogenous, skeletal scintigraphy-based diagnosis, children, 1310
distinguished from soft-tissue infection, FDG PET, 1355(ab)
mandible, three-phase bone scanning with ^{99m}Tc HMDP, 1365(ab)
^{99m}Tc ciprofloxacin findings, 301(ab)
^{99m}Tc MDP or HMPAO labeled leukocyte scans, 1358(ab)
Osteonecrosis
bone grafting for, serial pinhole bone scintigraphy, 1367(ab)
femoral head, after renal transplant, bone SPECT detection of, 1006
Osteopenia, three sites in, 1627(ab)
Osteoporosis
FDG PET in, 42N(11)
three sites in, 1627(ab)
Osteosarcoma
chemotherapy, FDG PET in assessment of response, 1154(ab)
malignant primary tumors, FDG comparison with conventional imaging, 127(ab)
primary, FDG prognostic significance, 128(ab)
primary, uptake of FDG and ^{99m}Tc MDP in, 1012
prognosis, ^{99m}Tc sestamibi tumor uptake, 129(ab)
Outcomes assessment, lateralizing subcortical uptake and outcome, extratemporal epilepsy and, 540(ab)
Ovarian cancer
advanced epithelial, FDG PET role in, 1141(ab)
intraperitoneal metastatic tumor, FDG PET, 103(ab)
intraperitoneal radioimmunotherapy, 1580(ab)
nuclear medicine advances in diagnosis and treatment, 42N(5)
recurrence
FDG on coincidence detection emission tomography, 105(ab)
FDG PET, 102(ab)
restaging, combined PET/CT systems, 1249(ab)
surgicopathologic findings, correlation with FDG PET, 104(ab)
tumor recurrence, FDG PET detection of, 1140(ab)
Oxgen-15 water, PET, myocardial blood flow and flow reserve measured by, 772(ab)
Oxidation disorders, fatty acid, myocardial, 17-^{11}C-hepatodecanoic acid for measurement of, 1707
Oxidation injury, radioiodine injury-induced, isoprostane 8-Epi-PGF$_{2\alpha}$, 1254
Oxidative metabolism
cerebral
bedside measurement, *versus* PET, 222(ab)
rapid clinical imaging of rCMRO2, rCBF and rOEF, PET, 223(ab)
malignant and nonmalignant cells, 963(ab)
Oxygen-15 inhalation, method for measurement, cerebral oxygen metabolism, 866(ab)
Oxygen-15 water
PET
after Kawasaki disease, 47N(8)
blood flow and metabolism, locally advanced breast cancer, 500
CAD, reduction in vasodilator function, myocardial infarction patients, 189(ab)
misery perfusion detected by, 536(ab)
perfusion changes induced by pain, 1019(ab)
semantic processing and cognitive demand interaction, 1022(ab)
semantic processing, interaction of cognitive demand, 1022(ab)
short bolus inhalation of, two CMRO2 quantitation methods with, 865(ab)
Oxygen extraction fraction, cerebral, normal database, PET, 1004(ab)
Oxygen metabolism, cerebral
dynamic sinogram use in, 852(ab)
normal database, PET, 1004(ab)
^{15}O-labeled gas inhalation method for measurement, 866(ab)
oxygen fraction relations, intensity-filtered VOI method, 995(ab)

P

p53, functional integrity, tumor cells, identification by tumor tracer FLT, 254(ab)
Pacemaker, permanent, nuclear scan abnormalities in patients, 353(ab)
Paclitaxel
^{11}C-labeled, dosimetry and stability evaluation of, 1455(ab)
fluorinated and tritiated, comparison of biodistribution, 1118(ab)
Pain
central processing, statistical autoradiographic mapping of, 860(ab)
perfusion changes induced by, apallic patients, PET, 1019(ab)
Pancreatic β-cells, fluoroethoxyglyburide binding with, diabetes, 321(ab)
Pancreatic cancer
cystic tumors and intraductal papillary mucinous tumor, FDG PET, 1204(ab)
dominant negative HIF-1α effects, FDG uptake, 88(ab)
dual-phase ^{18}F FDG PET, hexokinase-II and, 173
FDG PET, dual-phase, retention index and, 1203(ab)
imaging and therapy, pretargeting, bispecific antibody method for, 1484(ab)
Parametric imaging
algorithm for construction of, FDG PET, 869(ab)
alternative in kinetic modeling, Volterra integral equation approach, 529(ab)
cardiac β-adrenergic receptor density, 215
FDOPA PET, physiological characteristics-based segmentation technique, 847(ab)
fractal dimension based on box counting, FDG PET, 850(ab)
Patlak tumor images revisited, 365(ab)
PET and $H_2{}^{15}O$, renal blood flow, 470
principal component analysis and similarity mapping, FDG PET, 851(ab)
statistical mapping, SPECT, head injury, 476
statistical mapping
analysis of brain SPECT data, 458
localization of frontal lobe epilepsy, FDG PET, 1167
methylphenidate discontinuation, effects on cerebral blood flow, boys with ADHD, 1624, 1630
pre- and post-amphetamine ^{15}O water PET data, 844(ab)
statistical, SPECT and MRI in Alzheimer's disease, 304
use of direct algorithm, 859(ab)
voxel-classification method for, quantitative PET brain studies, 359(ab)
Paraneoplastic syndrome
autoantibodies and, detection of carcinoma with FDG PET in, 1014(ab)
central and peripheral nervous system, FDG PET in, 1037(ab)
underlying malignancy and, detection of carcinoma with FDG PET in, 1015(ab)
Parathyroid adenoma
ectopic, SPECT, 1310(ab)
hyperplasia or, ^{99m}Tc MIBI SPECT *versus* double-phas planar, 449(ab)
intrathymic/anterior mediastinal, pinhole sestamibi imaging, 1324(ab)
Parathyroidectomy, radioguided probe in, ^{99m}Tc sestamibi SPECT, 453(ab)
Parathyroid gland
^{99m}Tc sestamibi/^{123}I subtraction imaging, in an endemi goiter area, 1175
abnormal, double-phase ^{99m}Tc mibi SPECT in, 452(ab)
hyperfunctioning
^{11}C MET use in, 288(ab)
presurgical localization, two combined methods, 1281(ab)
retroesophageal lesion, preoperative ^{99m}Tc sestamibi imaging, 1282(ab)
scintigraphy *versus* ultrasound, directing targeted surgery, 1329(ab)
sensitivity of scintigraphy, major discrepancies betwee studies, 1296(ab)
SPECT *versus* planar scintigraphy, hyperparathyroidism, 1313(ab)
Parkinson's disease
activity, PET imaging of dopamine transporters, 949(ab)
Alzheimer's disease and, PET comparison, 227(ab)
deep brain stimulation of subthalamic nucleus in, rCBF changes and, 725
differential diagnosis, combined ^{123}I FP-CIT and IBZM SPECT, 62(ab)
dopaminergic system in, ^{99m}Tc TRODAT-1 and ^{123}I IBZM SPECT, 59(ab)
dopamine transporter density, PET, 952(ab)
dopamine transporter depletion, correlation with behavioral abnormality, rat model, 383(ab)
dopamine transporter imaging agent, new kit for ^{99m}Tc TRODAT-1, 1530(ab)
dopamine transporters, quantification by ^{123}I PE21 SPECT and Logan's graphical method, 221(ab)
essential tremor and
cerebellar benzodiazepine binding in, 70(ab)
^{123}I IPT role in differentiation, 69(ab)
^{18}F FDOPA synthesis improvement, PET, 1520(ab)
idiopathic, aging and, ^{99m}Tc TRODAT-1 SPECT, 57(ab)
^{123}I FP-CIT SPECT in diagnosis, 65(ab)
^{123}I IPT/^{99m}Tc HMPAO dual isotope SPECT, clinical feasibility, 827(ab)
MAO inhibitors, downregulation of striatal aromatic acid decarboxylase, 385(ab)
mesolimbic dopaminergic system role in, 993(ab)
movement disorders and, altropane SPECT, 64(ab)
movement disorders with, ^{123}I altropane SPECT, 61(ab), 64(ab)
progression, pramipexole *versus* L-dopa, SPECT, 60(ab)
striatal FDOPA uptake in, ratio and graphical methods in, 1324
striatal uptake of ^{18}F fluoro-L-dopa, 201(ab)
subtypes of multiple atrophy, ^{99m}Tc TRODAT-1 SPECT, 63(ab)
^{99m}Tc TRODAT-1 SPECT, comparison with ^{18}F FDOPA PET, 994(ab)
uptake of ^{99m}Tc TRODAT-1, effects of genetic polymorphisms, 67(ab)
voxel-based mapping, 3D pattern of dopamine transporters, 986(ab)
Partial-volume effect
age-related decline in cerebral glucose metabolism and, 238(ab)
correction, brain incorporation of ^{11}C arachidonic acid, PET, 969(ab)
MRI-based correction, evaluation for PET, 358(ab)
PET, striatal imaging, correction for, 1715
Particle accelerator, pocket, 28N(2)
Patellofemoral pain, ^{99m}Tc MDP SPECT in, 480(ab)
Patient release, after ^{131}I tositumomab radioimmunotherapy, 354, 364

Patient Safety Improvement Act, 36N(11)
Patlak analysis
^{64}Cu ATSM kinetics, animal tumor model, 871(ab)
PET quantification, SUV *versus* actual measurement, rectal cancer, 873(ab)
simplified, tumor therapy, 565(ab)
Pediatric patients
acute appendicitis, ^{99m}Tc HMPAO and, 48N(11)
acute hematogenous osteomyelitis, skeletal scintigraphy diagnosis, 1310
ADHD
intellectual stress test, brain SPECT during, 303(ab)
methylphenidate-induced changes in cerebral blood flow, 302(ab)
SPECT before and after methylphenidate, 1394(ab)
autism, ^{99m}Tc ECD cerebral SPECT, 1391(ab)
bone and bone marrow infarction, sickle hemoglobinopathies, 896
brain, FDG and MET PET, 42N(11)
clinical management, multimodality image coregistration impact on, 305(ab)
CNS malignancies, evaluation with ^{99m}Tc MIBI SPECT, 1438
cystic fibrosis, for gastroesophageal reflux disease, gastric emptying studies in, 593(ab)
dilated cardiomyopathy, prognostic value of right ventricular function, 803(ab)
Down syndrome, thyroid dysfunction in, 1327(ab)
epilepsy, abnormal cortical glucose metabolism, based on 3D asymmetry index, 825(ab)
GER, asthma and respiratory infection relations, 306(ab)
hemophilia, ^{32}P phosphorous colloid radiosynoviorthesis in, 308(ab)
Henoch Schönlein purpura, ^{99m}Tc pertechnetate abdominal scan, 1397(ab)
infants, β-agonist aerosol distribution, respiratory syncytial virus bronchiolitis, 487
leukemia, ^{188}Re anti-CD66-mab radiotherapy, 133(ab)
liver trauma, ^{99m}Tc TBIDA and, 44N(11)
lymphoma, FDG PET imaging in, 130(ab), 131(ab)
never-medicated ADHD, brain dopamine transporters and D2 receptors, 56(ab)
on-line bone atlas debuts, 32N(12)
pelvic ureteric junction obstruction, F+0 diuretic renography, 147(ab)
prepubescent boys, methylphenidate discontinuation effects, ADHD, 1624, 1630
primary auditory regions, FDG PET study, 546(ab)
primary lymphedema, lymphoscintigraphy of, 1388(ab)
reactive attachment disorder, ^{99m}Tc ECD cerebral perfusion SPECT, 1390(ab)
refractory epilepsy, crossed cerebellar diaschisis in, 1389(ab)
renal damage in acute pyelonephritis, renal scintigraphy abnormalities, 1384(ab)
renal function, with unilateral multicystic kidney, renography in, 1385(ab)
small solid state digital mobile camera, 1613(ab)
^{99m}Tc MAG3, normal extraction fraction values, 1383(ab)
traumatic injury, bone scan in spine fractures, 483(ab)
viral myocarditis, myocardial SPECT, 767(ab)
PEGylation, molecular size of peptide effects, pharmacokinetics and tumor targeting, lymphoma, 334(ab)
Pelvic ureteric junction obstruction, F+0 diuretic renography, children, 147(ab)
Peptide receptor imaging
alpha(v)beta3 expression
melanoma cells, 436(ab)
monitoring of cellular immunotherapy, 439(ab)
noninvasive determination, 322(ab)
short chain bitistatin analog, thrombosis imaging, 502(ab)
tumor-specific agents, anti-HER2/neu peptide, 487(ab)
Peptide receptors, radionuclide therapy, new advances, 617
Peptides, simple labeling method, ^{18}F fluorination methods, 497(ab)
Percutaneous transluminal coronary angioplasty (PTCA)
^{99m}Tc sestamibi and echocardiography, in acute myocardial infarction, 8
with stenting, stress ECG compared to stress MPI, 744(ab)
^{99m}Tc MIBI SPECT after, 745(ab)
Performance measurements, PET, NEMA NU 202001 standard, 1398
Peripheral organs, monoamine oxidase B in, PET imaging, 1331
Peroxisome proliferator-activated receptor, expression, myocardial fatty acid imaging and, rabbit hearts, 715(ab)
PET
2D and 3D comparison, interleaved septa-in/septa-out acquisition protocol, 206(ab)
2D and 3D whole-body, noise equivalent count rates for, 1268
3D
GSA as a scintillator for, 41(ab)
orthogonal projection in, 879(ab)
partial-volume effect, correction for, 1715
single scatter simulation algorithm for, 207(ab)
2001: A wonderful year of growth, 13N(1)
ACE inhibitor, renal blood flow, heart failure patients, 770(ab)
activation study
CBF and MBF during mental stress, 1006(ab)
parametric mapping of, 892(ab)
advanced cervical cancer, 41N(7)
age differences and cognition, 40N(9)
alpha(v)beta3 expression, radiolabeled cyclic RGD peptides and, melanoma cells, 436(ab)
altropane, bolus-infusion technique for evaluation of dopamine transporters, 836(ab)
in Alzheimer's diagnosis, UCLA, 20N(2)
anti-angiogenic therapy, relations to dynamic MR, 441(ab)
antisense probe, biological activity of oligonucleotides, 1452(ab)
arterial-venous difference, assessment of cerebral oxygen consumption, 222(ab)
attenuation correction, radiographic contrast effects, hybrid PET/CT device, 888(ab)
attenuation correction effects, tumor-to-background activity ratios, 834(ab)
auditory system imaging and, 46N(11)
automated dispensing unit for radiopharmaceuticals, 1518(ab)
bladder and brain, 36N(12)
brain
hunger and, 47N(8)
neural correlates of fear conditioning, 53(ab)
B+-range–sensitive probe, radiopharmacology in small animals, 227
breast cancer cells, gene therapy imaging, 1112(ab)
$C^{15}O_2$, vagus nerve stimulation in refractory epilepsy, 544(ab)
^{11}C acetate
dilated cardiomyopathy, 782(ab)
imaging of prostate cancer, 181
kinetic modeling, hepatocellular carcinoma, 841(ab)
kinetics in prostate cancer, 425(ab)
CAD, dietary supplementation with folic acid effects, 184(ab)
camera-based, functional and structural evaluation of cancer patients, 1129
^{11}C AMP as new radioligand, cancer imaging, 1454(ab)
cardiac opioid receptors assessed by, 8(ab)
^{11}C BPA, stereoselective transport of, in melanoma, 317(ab)
^{11}C choline and ^{18}F FDG, in thoracic cancer, 167
^{11}C EADAM, radiolabeling and characterization of, PET, 597(ab)
cell proliferation and, 36N(12)
cerebral blood flow
oxygen extraction fraction relations, 995(ab)
during P_ACO_2 changes, aging effects, 534(ab)
cerebral ischemia, without blood sampling, 839(ab)
^{11}C flumazenil
distribution volume image of, cerebrovascular disease, 848(ab)
metabolites in blood, 863(ab)
^{11}C FMAU and FDG comparison, tumor imaging, 92(ab)
^{11}C FMZ PET, intractable temporal lobe epilepsy, 541(ab)
^{11}C HED, clinical determinants of sympathetic reinnervation, 515(ab)
^{11}C L159, cardioprotective effects of estrogen, 144(ab)
^{11}C MADAM labeled in two different positions, for serotonin transporters, monkey brain, 596(ab)
^{11}C methionine, pancreatic function and, 40N(9)
^{11}C MET uptake, esophagus and stomach, 245(ab)
^{11}C mHED, neuronal uptake and vesicular transport, 858(ab)
CNS5161, for NMDA receptor imaging, 1447(ab)
combined CT system
4D NURBS-based cardiac-torso (NCAT) phantom, 43(ab)
with continuous bed movement, 38(ab)
contrast-enhanced, potential artifact in, 1339
count rate performance, 40(ab)
effects of nonionic intravenous contrast agents, 46(ab)
FDG PET comparison, colorectal cancer, 78(ab)
functional and structural evaluation of cancer patients, 1129
germanium and CT transmission attenuation-correction images, 1137
image coregistration of pulmonary lesions, non-small cell lung cancer, 1469
lesion size and volume, 47(ab)
mismatch in upper abdominal organs, 48(ab)
mutual information warping, 1184
oral contrast media in, 41N(9)
quantitative tracer uptake, 44(ab)
spatial registration of lung lesions, 49(ab)
thoracic cancer, 42N(9)
comparison of imaging platforms, lesion detectability, 1545, 1555
comparison studies of proliferation markers, rat, 1688
comparison with radioactive microspheres, assessment of pulmonary blood flow, 1063
confirmations of value, 42N(6)
continuous blood sampling system, GSO detector assembly for, 933(ab)
coronary blood flow in insulin-resistant patients, rosiglitazone effects on endothelial function, 3(ab)
^{11}C PET, L-enantiomer of methylphenidate, ADHD, 1043(ab)
^{11}C PK11195, benzodiazepine receptors in AIDS dementia, 234(ab)
Crohn's disease, 33N(10)
^{11}C SA4503, sigma$_1$ receptors in Alzheimer's disease, 987(ab)
versus CT, identification of melanoma metastases, 1187(ab)
Cu ATSM, delineation of cardiac hypoxia, canine, 1557
^{11}C WAY and ^{11}C DWAY brain imaging, neuropsychiatric disorders, 292
^{11}C YP186, for serotonin transporters, 598(ab)
in cystic breast cancer, 36N(12)
^{11}C ZbRET and ZIET, serotonin transporters, 151(ab)
D2 receptors
in the dorsal striatum, food motivation in humans and, 388(ab)
in striatal substructures, cocaine effects, 387(ab)
in the ventral striatum/nucleus accumbens, craving associated with, 389(ab)
decision-making in mania and, 28N(2)
dedicated system, triple-head gamma camera compared with, 48N(8)
detection of extra-axillary metastases, outer breast quadrants, 269(ab)
dopamine elevation, food and, 39N(7)
DOTATOC, small cell lung cancer, 409(ab)
dual time point, FDG, evaluation of pulmonary nodules, 871
dynamic, ^{18}F FDG uptake, liver, 439(le)
early and late Alzheimer's onset, 41N(9)
EBV lymphoma, cytotoxic T cells targeting, 1111(ab)
emission data only, iterative reconstruction for, 876(ab)

emission images, respiratory motion artifacts on, 1228(ab)
endothelial dysfunction, subclinical atherosclerosis, 509(ab)
estimating reversible neuroreceptor parameters, linear methods to reduce bias, 843(ab)
FDG
abnormalities between medial and lateral temporal lobe epilepsy, 982(ab)
activity in testicles, 856(ab)
after fractures and surgical intervention, 136(ab)
after radioimmunotherapy, recurrent non-Hodgkin's lymphoma, 281(ab)
algorithm for construction of parametric images in, 869(ab)
algorithm for evaluation of dementia, 226(ab)
application of anisotropic smoothing, brain trauma, 891(ab)
atherosclerotic plaque inflammation, 45N(8)
benign or malignant pleural disease, 583(ab)
biodistribution in brain of fasting and non-fasting mice, 868(ab)
blood flow and metabolism, locally advanced breast cancer, 500
bone and soft-tissue oncologic imaging, 1225(ab)
bone metastases from renal cell carcinomas, 44N(11)
bowel uptake, oral spasmolytic premedication effects, 833(ab)
cancer screening with, 1245(ab)
cerebral cortex, Alzheimer's disease, 985(ab)
cervical cancer, 30N(3)
childhood lymphoma, 130(ab), 131(ab)
colony-stimulating factors and, 36N(12)
correlation with surgicopathologic findings, ovarian cancer, 104(ab)
cost-effectiveness, 35N(1)
CT and, whole-body scan, lymphoma, 106(ab)
CT comparison, extrahepatic bile duct cancer, 1195(ab)
delayed imaging, solitary thoracic lesions, 563(ab)
deoxyglucose uptake, human neutrophil granulocytes, 652
differentiation of bone lesions, 510
esophageal cancer, 240(ab)
evaluation of cholangiocarcinoma, 83(ab)
evaluation of primary gallbladder cancer, 473(ab)
false-positive and false-negative findings, lung cancer, 413(ab)
FBP and OSEM reconstruction methods in, 1226(ab)
follow-up of revascularization after myocardial infarction, rats, 704(ab)
^{67}GA blinded comparison, Hodgkin's disease patients, 109(ab)
glucose metabolic changes, traumatic brain injury, 224(ab)
GSO-based whole body scanner, 1194(ab)
hexokinase-II relations, pancreatic cancer, 173
hybrid camera, response to cancer therapies, 1244(ab)
identifying Richters transformation in chronic lymphocytic leukemia, 108(ab)
^{123}I IMP SPECT comparison, dementia with Lewy bodies, 1035(ab)
incidentaloma, 44N(6)
increased thyroid uptake in hypothyroidism, 450(ab)
for induction chemotherapy in non-Hodgkin's lymphoma, 1060(ab)
inflamed joints in rheumatoid arthritis, 138(ab)
initial glucose metabolism and seizure outcome, epilepsy, 983(ab)
injected dose based on body size, higher quality scans and, 1577(ab)
interleaved septa-in/septa-out acquisition protocol, 206(ab)
intraperitoneal metastatic tumor, ovarian cancer, 103(ab)
leukocytes labeled with, biodistribution and dosimetry studies, 1430(ab)
localization of frontal lobe epilepsy, 1167
local/regional evaluation of breast cancer, 44N(11)
long-lasting non-specific uptake in hip arthroplasty, 140(ab)
LS174T carcinoma and *E. coli* infection, rat, 1576(ab)
lung, respiratory motion effects, 208(ab)
lung cancer, extra-thoracic metastases in, 551(ab)
lung metastases, small animal system, 216(ab)
lymph node metastases in medullary thyroid cancer, 66
magnetoencephalography and, temporal lobe epilepsy, 981(ab)
management of lung cancer and, 752
mediastinal staging of non-small cell lung cancer, 550(ab)
metabolic imaging in lung cancer, significance of negative scan, 412(ab)
MET and, pediatric brain, 42N(11)
metastasis or recurrence of gastric cancer, 244(ab)
mismatch in spatial resolution, 45(ab)
modification of management, colorectal cancer, 81(ab)
MRI/CT and, discrepant findings, cervical cancer, 99(ab)
myocardial uptake, respiratory motion effects, 785(ab)
neoadjuvant chemotherapy with gastric cancer, 243(ab)
noninvasive characterization, atherosclerotic plaques, 24(ab)
occult recurrence, colorectal cancer, 82(ab)
in osteoporosis, 42N(11)
outcome in aggressive lymphoma and Hodgkin's disease, 284(ab)
ovarian cancer recurrence, 102(ab)
pathology and survival in gliomas, 400(ab)
perfusion/metabolism match/mismatch, 525(ab)
personality traits and, 44N(11)
PET/CT comparison, staging of lung cancer, 548(ab)
post-probability of malignancy in solitary pulmonary nodules, 1223(ab)
post-therapy surveillance, endometrial cancer, 426(ab)
prediction in lymphoma after stem cell transplant, 283(ab)
prediction of prognosis, aggressive lymphoma and Hodgkin's disease, 1018, 1028
preoperative staging of lung cancer, 549(ab)
previously treated breast cancer, 325
primary auditory regions in deafness, 546(ab)
quantification of glucose metabolism, 964(ab)
quantified metabolic abnormalities and surgical outcome, temporal lobe epilepsy, 542(ab)
radiation therapy treatment planning, lung cancer, 553(ab)
recurrent colorectal cancer, 492
recurrent head and neck cancer, 262(ab)
recurrent or metastatic breast cancer, 267(ab)
response to breast cancer therapy, 34N(10)
semiquantification with SUV, body habitus effects on, 864(ab)
solitary pulmonary nodules, changes of SUV in, 561(ab)
squamous and adenocarcinoma differences, esophagus, 1199(ab)
squamous cell cancer, head and neck, after chemotherapy, 264(ab)
SSCVII squamous cell carcinoma or C3H mammary carcinoma, 940
staging for plasmacytoma, 1059(ab)
staging of bladder cancer, 423(ab)
staging of non-small cell lung cancer, 46N(11)
standardized uptake values in, metabolic changes and, 835(ab)
standardized uptake values in oncology, 1224(ab)
stem-cell transplant outcomes in NHL, 39N(9)
SUV in solitary pulmonary nodules, 566(ab)
symmetrical skeletal muscle uptake, 137(ab)
tabulated summary of literature, 441(le)
therapy monitoring, esophageal cancer, 242(ab)
tongue acupuncture treatment in autism, 304(ab)
tumor characteristics obtained by, for 3D radiation therapy, 107(ab)
uptake in model of inflammation, 658
uptake relations, lung cancer, 1246(ab)
value in breast cancer, 1160(ab)
visual analysis of tumor characteristics, cervical cancer, 100(ab)
volumetric analysis of glioblastoma multiforme, 1667
voxel-classification method for quantitative studies, 359(ab)
whole-body, identification of high-risk myeloma, 1457
whole-body oncologic, non-coronary cardiovascular findings, 773(ab)
whole-body oncology scanning protocols, 884(ab)
whole-body scanning, high-risk myeloma, 111(ab)
FDOPA studies, Parkinson's disease, 1324
^{18}F fallypride
D-amphetamine effects on binding of, baboons, 381(ab)
multiple injection protocol, quantitation of D2 receptors, 203(ab)
^{18}F FCH pharmacokinetics and radiation dosimetry, 92
^{18}F FDG and ^{11}C methionine, in prostate cancer, 46
^{18}F FDOPA
assessment with commercially available synthesis unit, 1519(ab)
brain neoplasms, 405(ab)
^{18}F FECh, development for cancer imaging, 187, 201
^{18}F FEPP and FEPMA, radiotracers for acetylcholinesterase, Alzheimer's disease, 606(ab)
^{18}F FET, recurrence of brain tumors, 403(ab)
^{18}F FLT
mammary, laryngeal and soft tissue tumors, 278(ab)
proliferative activity of non-small cell lung cancer, 277(ab)
^{18}F fluoride, defined disorders of bone metabolism, 135(ab)
^{18}F Fluoro-A85380 nicotinic ligand, biodistribution and radiation dosimetry, 1425(ab)
^{18}F FMAU, DNA synthesis, in tumor patients, 93(ab)
^{18}F FMISO
flow-weighted total input functions, liver, 30(ab)
hypoxia imaging, 367(ab)
primary tumor *versus* lymph node metastases, 266(ab)
patients with tuberculosis therapy, 459(ab)
^{18}F FP, pulmonary fibrosis, rabbit model, 413
^{18}F F-Tyr, whole-body tumor imaging, 280(ab)
^{18}F penciclovir, potential method for monitoring CMV, 1348(ab)
^{18}F sodium fluoride, bone metastases in lung cancer, 1207(ab)
full-ring BGO scanner, 2D and 3D lesion detectability, 204(ab)
gated
left ventricular ejection fraction in small animals, 709(ab)
MRI comparison, measurement of cardiac function, 806
single dose of ^{13}NH$_3$ and gated PET, myocardial blood flow, 999
$H_2{}^{15}O$
and 3D, absolute quantification of myocardial blood flow, 1031, 1041
activation study, apallic patients, 1019(ab)
altered brain activity, 980(ab)
parametric mapping of local renal blood flow, 470
sequential studies, before and after amphetamine, baboon, 1090
high-resolution
dual-layer, image reconstruction for MADPET, 374(ab)
for primate imaging, 925(ab)
scanner, single LSO crystal, small animal imaging, 926(ab)
scanner, with LSO, 927(ab)
HSV1-TK imaging, gene expression, 148(ab)
hybrid cameras, ^{62}Cu-labeled cardiac tracers with, 42(ab)
hybrid CT
equivocal PET lesions in oncology, 115(ab)
inaccurate localization of lesions, 116(ab)
hybrid whole-body, acquisition process, 1573(ab)
hyperemia and cold pressor test, coronary artery vasodilator function in smokers and healthy adults, 185(ab)

hypnosis and, 33N(10)
hypoxia-induced HIF-1α signaling, 250(ab)
image analysis tools in, digital phantoms for evaluation of, 369(ab)
image reconstruction, sinogram restoration filters for, 874(ab)
imaging α4β2 subtype nicotinic acetylcholine receptors, 1433(ab)
imaging of drug distribution after intratumoral injection, malignant gliomas, 1444
imaging of HSV1-*tk* gene expression, comparison of probes for imaging, 1072
improved coincidence timing accuracy in, 934(ab)
^{111}In DTPA, imaging of neuroendocrine tumors, 1391
IndyPET II, initial imaging experience, 214(ab)
initial staging, esophageal cancer, 239(ab)
intermediate septa configurations, comparison of count rate performances, 33(ab)
ischemic cardiomyopathy, flow defect sizes in, left ventricular ejection fraction and, 21(ab)
left bundle branch block, dilative cardiomyopathy and, 20(ab)
left ventricular remodeling and myocardial metabolism, after infarction, 780
lipid lowering therapy, reduction or reversal of CAD, 186(ab)
LSO-based, rest-stress perfusion ^{82}Rb, 811(ab)
M2 selectivity, Alzheimer's disease, 977(ab)
mammography, pixelated NaI(Tl) arrays for, 37(ab)
maximum likelihood expectation maximization image reconstruction, 373(ab)
measurement of serotonin effects, cerebral glucose metabolism, 42N(9)
metabotropic glutamate receptors, 397(ab)
Methods issue devoted to, 35N(10)
modulation of dopamine, chronic neuroleptic treatment, 380(ab)
molecular imaging probes, FDDNP *versus* torsionally modified analogs, Alzheimer's disease, 604(ab)
monitoring of treatment, Alzheimer's disease patients, 227(ab), 228(ab)
monoamine oxidase B, in peripheral organs, 961(ab), 1331
Monte Carlo simulation, standardization and validation, 849(ab)
motion correction in
  accuracy evaluation with optical motion tracking system, 855(ab)
  using event-based rebinning method, 530(ab)
MR registration and, soft-tissue masses, 29(ab)
multitracer, identification of target tissue for gene therapy in glioblastoma, 90(ab)
myocardial blood flow and flow reserve, ischemic cardiomyopathy, 781(ab)
myocardial dihydropyridine binding sites, quantification of, 1227
myocardial fatty acid oxidation, insulin-dependent diabetes, 510(ab)
myocardium, chronic ischemic dysfunction, dogs, 556
^{13}N ammonia
  factor analysis for determination of myocardial blood flow, 188(ab)
  noninvasive quantitation, 524(ab)
  post-stress left ventricular dysfunction, 775(ab)
  ventricular volumes and ejection fraction, CAD patients, 774(ab)
neuroreceptor images, coregistration of, 853(ab)
nicotinic receptors, inhibition of cytochrome P-450 effects, 607(ab)
non-immunogenic reporter gene for, thymidine kinase type 2, 252(ab)
noninvasive, without blood sampling, quantification of glucose metabolism, 966(ab)
nuclear medicine and, 11N(2)
oncology
  image segmentation algorithm for, 837(ab)
  noninvasive extraction of blood time activity, 366(ab)
optical imaging and, cardiac reporter gene expression, 1(ab)
^{15}O water
  CAD, reduction in vasodilator function, myocardial infarction patients, 189(ab)
  coronary evaluation after Kawasaki disease, 47N(8)
  myocardial flow reserve and endothelial function after Kawasaki disease, 1381(ab)
  pre- and post-amphetamine data, baboon, 844(ab)
PARS imaging in tumor, ^{11}C MIQO biodistribution, 1453(ab)
Patlak tumor images revisited, 365(ab)
performance measurements
  NEMA NU 202001 standard, 1398
  small animals, 212(ab)
plasma input function, dynamic FDG PET investigations, 824(ab)
post-reconstruction smoothing of, using nonlinear filtering, 875(ab)
potassium, myocardial uptake and kinetics, 783(ab)
prediction, treatment response in head and neck cancer, 41N(4)
preoperative, ischemic heart disease management, 41N(7)
preventing hyper pileup-prevention, nuclear cameras, 931(ab)
prognostic evaluation of dementia, specificity for, 225(ab)
prostate "suicide" gene and, 33N(10)
in psychiatric disorders, 35N(12)
quantifying choline transporter activity, 393(ab)
quantitation
  image reconstruction, PET in cancer patients, 567(ab)
  simplified kinetic analysis, tumor therapy, 565(ab)
  SUV *versus* actual measurement, rectal cancer, 873(ab)
radiation dosimetry, ^{18}F FETNIM, in cancer studies, 1674
radiosynthesis and, ^{18}F-labeled COX-1 and COX-2 inhibitors, 117
rapid clinical imaging of rCMRO2, rCBF and rOEF, 223(ab)
regional cerebral metabolism, evaluation of early dementia, 253
respiratory gating, FDG, lung cancer, 876
scanners, calibration of, multicenter comparison, 635
selective tracer for serotonin transporters, ^{18}F AFM, 1440(ab)
sentinel node detection, melanoma, 34N(10)
serotonin transporter radioligands, comparison under experimental conditions, 678
serotonin transporters in the limbic system, alcoholism effects, 390(ab)
severe brain damage, 41N(7)
SISCOM correlation, temporal lobe epilepsy, 991
SNM Learning Center, 32N(6)
spatially normalized, SPECT comparison, Alzheimer's disease, 21
spatially variant convolution subtraction scatter correction, animal scanner, 889(ab)
stabilizing of body temperature, small animal imaging, 1574(ab)
striatal uptake of ^{18}F fluoro-L-dopa, diagnosis of Parkinson's disease, 201(ab)
striatal uptake of ^{18}F FPCIT, Parkinson's disease, 202(ab)
TGF-β signal transduction pathway activity, 249(ab)
tracer kinetic modeling in, web-based COM application, 1567(ab)
tumor targeting, *Salmonella typhimurium*, 251(ab)
tumor tracers
  drug-induced modulation of tumor proliferation, 97(ab)
  FLT, identification of functional p53 integrity, tumor cells, 254(ab)
  lesion detection rate and, oncology patients, 562(ab)
TYR and FDG comparison, metastatic lymph node detection in squamous cell cancer, 265(ab)
ultra high-resolution, comparison to MRI/MRS, neural degeneration in Huntington's disease, 220(ab)
uncorrected, attenuation artifact, reducing loss of image quality, 1054
vascular endothelial growth and, 34N(12)
whole-body
  body weight effects on count statistics, 1565(ab)
  five minute routine studies, 36(ab)
  staging of nasopharyngeal cancer, 263(ab)
  whole-body image database, technical development and initial application, 872(ab)
PET/CT. *see* Multimodality imaging
P-glycoprotein
  correlation with FDG PET, multidrug resistance in lung cancer, 1215(ab)
  identification, multidrug resistance, breast tumor, 1119(ab)
  multidrug resistance due to, toremifene modulation of, breast cancer, 519, 526
  substrates, determine multidrug resistance of tumors, 1118(ab)
  transport activity, measured by biodistribution of ^{11}C verapamil PET, 1120(ab)
Pharmacokinetics
  ^{11}C tolulene, effects of vehicle on brain uptake, 158(ab)
  ^{99m}Tc MAG3, morpholinos labeled with, behavior, 485(ab)
  ^{131}I and ^{111}In labeled monoclonal antibodies, interpatient variability, 1261(ab)
  anti-angiogenic drug, dynamic MR and PET relations, 441(ab)
  FK960, PET, conscious monkey, 959(ab)
  pegylated peptides, effects of molecular size on tumor targeting, lymphoma, 334(ab)
Pheochromocytoma, synthesis and uptake of ^{99m}Tc MIBC, 1479(ab)
Photomultiplier tubes (PMT), equalization, using all spectral data, 932(ab)
Picture Archiving Computer System (PACS), regional system, nuclear medicine department as part of, 832(ab)
Pinhole imaging. *see also* SPECT, pinhole
  utility of, foot and ankle, 1601(ab)
Pinhole spiral orbit, improving SPECT sampling, 34(ab)
Pixellated NaI(T1) crystal array, compact detectors based on, small animal imaging, 213(ab)
Plasma clearance, renal, Bayesian regression model for, 762
Plasmacytoma, staging, FDG PET, 1059(ab)
Plasma input function, dynamic FDG PET investigations, cerebral metabolic rate of glucose, 824(ab)
Pleural disease, benign of malignant, FDG PET in differentiation, 583(ab)
Posterior cingulate cortex, Alzheimer's disease, hypoperfusion in, 3D stereotactic surface projection, 984(ab)
Posttraumatic stress disorder (PTSD), peripheral arousal during guided traumatic imagery ia, PET, 1047(ab)
Potassium, K38, myocardial uptake and kinetics, PET, 783(ab)
Practice guidelines, myocardial SPECT detection of CAD, U. S. and European markets, 726(ab)
Precursors, intramolecular protected, for ^{18}F FLT synthesis, 1524(ab)
Prefrontal cortex, chronic dopamine depletion, binding of PET D1 receptor radiotracers and, rat, 379(ab)
γ-Probe, intraoperative guidance, malignant cutaneous melanoma, 811
Probe systems
  antisense
    biological activity of oligonucleotides, 1452(ab)
    ^{99m}Tc oligomers, 501(ab)
  beta microprobe, alternative to PET, small animal brain studies, 921(ab)
  B+-range-sensitive, radiopharmacology in small animals, 227
  gamma-probe guided video assisted thoracoscopic surgery, lung cancer, 411(ab)
  hand-held nuclear medicine, first clinical experience with, 922(ab)
  HSV1-TK PET, FIAU and FHBG comparison, 148(ab)
  ^{123}I/^{125}I IMPY as abeta-plaque imaging agent, Alzheimer's disease, 603(ab)
  intraoperative
    ^{99m}Tc sestamibi SPECT, in parathyroidectomy, 453(ab)
    background rejection capability, FDG-guided surgery, 217(ab)

intraoperative detection, PET tracers, 1136(ab)
intraoperative gamma probes, dead-time effects, 1606(ab)
Promethium-149 DOTATOC, as a radiotherapy agent, 1502(ab)
Prostaglandin $F_{2\alpha}$, 8-epi, oxidation injury induced by radioiodine therapy, 1254
Prostate cancer
advanced, radionuclide therapy of bone metastases, 580(ab)
androgen receptor expressing tumors, ^{99m}Tc testosterone-BFCO conjugate for, 1473(ab)
bone metastases from
cisplatin effects on ^{89}Sr therapy, 79, 87
radionuclide study with ^{186}Re etidronate, 1150
^{14}C acetate, cellular metabolism of, 1099(ab)
^{11}C acetate dynamic PET studies, 425(ab)
^{11}C acetate PET imaging, 181
^{11}C MCG, NAALADase/PSMA, 493(ab)
detection with ^{18}F FLT microPET, 98(ab)
FDG *versus* FCH PET in, 46N(8)
^{18}F FECh PET development for, 187, 201
hormonal therapy, ^{11}C choline in determination of outcome, 421(ab)
hormone refractory, anti-PSMA antibody, radioimmunotherapy, 1190(ab)
HSV-tk reporter gene, ^{18}F FHBG for PET assessment of, 1109(ab)
metabolic activity, combined PET/CT systems, 427(ab)
metastatic, ^{18}F FDG and ^{11}C methionine PET, 46
primary and locally recurrent, ^{11}C acetate PET imaging, 422(ab)
radioimmunotherapy
^{177}Lu DOTA-huJ591, 577(ab)
^{90}Y DOTA-huJ591, 576(ab)
radiotracer imaging, PET-based radiation dosimetry for, 315(ab)
suicide gene, PET and, 33N(10)
Prosthetic joint
infection, antibiotic effects on combined labeled leukocyte/marrow imaging, 297(ab)
painful
FDG as screening test in, 1380(ab)
FDG PET imaging of, 457(ab)
Protein binding mechanism, dyes, localizing the sentinel lymph node, 1377
Protein restriction, during lactation, ^{99m}Tc O_4Na biodistribution and, 89
Pulmonary blood flow
quantitative measurement, normal volunteers, 1401(ab)
regional, PET and radioactive microspheres for assessment of, 1063
Pulmonary edema, acute, regional pulmonary perfusion, 863
Pulmonary embolism
artificial, ventilation/perfusion SPECT for, 640, 648
baseline lung scintigraphy, positive helicoidal CT or venous sonography, 1408(ab)
deep venous thrombosis relations, radionuclide techniques for assessment, 1403(ab)
early diagnosis and management, D-dimers and V/Q scan, 1562(ab)
experimental, radioimaging with ^{99m}Tc labeled monoclonal antibody SZ51, 1399(ab)
imaging after introduction of pulmonary CT angiography, tertiary care center, 1615(ab)
lung scintigraphy, spiral CT angiography, 585(ab)
lung scintigraphy in, 588(ab)
SPECT, planar mode comparison, 586(ab)
ventilation-perfusion lung scintigraphy, Gestalt interpretation, 1317
ventilation-perfusion ratios in, distribution, 1596
V/Q scans, spiral CT and, 587(ab)
Pulmonary fibrosis
idiopathic, nuclear medicine tests in, 1400(ab)
PET imaging, rabbit model, 413
Pulmonary hypertension, lung perfusion in, quantitative analysis, 757, 1402(ab)
Pulmonary nodules
evaluation with FDG PET, 871
mediastinal tumors and, ^{11}C PET, comparison with FDG PET, 275(ab)
Pyelonephritis, acute
color and power Doppler or DMSA scintigraphy in, 27
renal damage in, renal scintigraphy abnormalities, 1384(ab)

Q

Quality assurance, procedures for FDG injection, 1495
Quality control
clinical PET/CT, 1569(ab)
high-resolution PET, for primate imaging, 925(ab)
multicontrast single-chamber hot spheres phantom, PET and SPECT, 940(ab)
performance measurements, animal PET, 212(ab)
phantom proficiency test, Dept. of Veterans Affairs, 816(ab)
^{99m}Tc complexes, structure confirmation with radio-LC-MS, 1517(ab)
^{99m}Tc tetrofosmin, 154(ab)
Quality of life, health-related, ischemia measured by stress imaging, 754(ab)
Quinolone, radiolabeled, evaluation of *S. aureus* prosthetic joint infection, 239

R

RADAR web site, dose information, 28N(5)
Radiation
cognitive decline induced by, 34N(12)
risk statements, 42N(6)
Radiation exposure
chromosome aberration, workers in nuclear medicine centers in Iran, 1602(ab)
chronic low-level, chromosomal aberrations and, 34N(1)
effect on photomultiplier gain, two-dimensional decoding map in PET cameras, 930(ab)
protective radiation devices, evaluation of, 1553(ab)
survey in The Netherlands, 42N(5)
Radiation injury, leukocyte labeling with ^{99m}Tc HMPAO and, 203
Radiation oncology, fusing PET and CT in, 1563(ab)
Radiation probes, intraoperative-type solid-state, localization of thyroid tissue using, 1127(le)
Radiation safety, calculating absorbed dose, radioactive patients, 1241
Radiation shielding, vial and syringe, radiation exposure from ^{90}Y zevalin, 164(ab)
Radiation therapy
3D, lung cancer, FDG PET imaging in, 552(ab)
3D treatment planning, FDG PET in lymphoma, 107(ab)
adjuvant percutaneous, ^{131}I doses and complete ablation of thyroid remnant, 1292(ab)
^{64}Cu radionuclide, ultra-small cyclotron, 1499(ab)
dose escalation, target volumes in, glioblastoma multiforme, 1667
dosimetry, ^{18}F FETNIM, in cancer studies, 1674
external beam, integrated PET/CT scanning, 118(ab)
FDG PET in treatment planning, lung cancer, 553(ab)
^{18}F FET PET, recurrence of brain tumors, 403(ab)
head and neck, automated nonrigid PET/CT registration for, 1230(ab)
^{111}In octreotide, long-term efficacy, 125(ab)
internal, radiolabeling of avidin, intraperitoneally disseminated tumors, 1090(ab)
intravascular, ^{166}Ho DOTA as agent for, 1129(ab)
joint hemorrhage, pediatric hemophilia, 308(ab)
^{177}Lu DOTA-Tyr3 octreotate, somatostatin receptor-positive tumors, 123(ab)
lung, treatment planning with integrated PET/CT scanning, 119(ab)
peptide-receptor
^{90}Y and ^{111}In comparison, 121(ab)
dose to kidneys and tumors, 1271(ab)
small cell lung cancer, mouse, 445(ab)
somatostatin receptor-positive neuroendocrine tumors, 120(ab)
peptide receptor, bone marrow dose results in, 325(ab)
^{149}Pm DOTATOC as agent in, 1502(ab)
radioiodinated quinazolinone derivative, enzyme-mediated insolubilization therapy, 1126(ab)
^{188}Re anti-CD66-mab, pediatric leukemia, 133(ab)
receptor-targeted, medullary thyroid cancer, 126(ab)
response after postprostatectomy PSA relapse, ^{11}capromab prediction, 1188(ab)
safely increased dose, ^{111}In/^{90}Y DOTA-Lym-1, 420(ab)
stereotactic, FDG PET evaluation of treatment response in lung cancer, 1218(ab)
^{99m}Tc HL91 prediction of response to, 1124(ab)
TheraSphere, treatment of unresectable hepatic tumors, 1274(ab)
^{90}Y DPC-A80350, C-NEU oncomouse mammary tumor model, 1080(ab)
Radioactive waste, 40N(7)
Radioactivity, consumer products, fact sheet on, 34N(12)
Radiocolloid, sentinel lymph node biopsy, malignant cutaneous melanoma, 811
Radioimmunoassay, serum concentration of macrophage inhibitor factor, prediction of septic shock, 1356(ab)
Radioimmunoconjugates, preparation, characterization and application, renal cell carcinoma, 1085(ab)
Radioimmunoimaging, operator dependent variation, critical organ dosimetry, 1432(ab)
Radioimmunoscintigraphy
^{11}capromab, response to radiation therapy after postprostatectomy PSA relapse, 1188(ab)
chronic idiopathic thrombocytopenic purpura, accessory spleen, 287(ab)
Radioimmunotherapy
^{131}I tositumomab, patient release after, 354, 364
administration guidelines, non-Hodgkin's lymphoma, 267
affinity enhancement system, 1496(ab)
antiangiogenic therapy with thalidomide and, cognitive effects, human cancer xenografts, 1084
antibody pretargeting, tumor-bearing mice, 1083(ab)
anti-CEA X anti-Hapten bispecific antibody, pretargeting with, 579(ab)
anti-human CEA, transgenic mouse model for, 1368
B-cell non-Hodgkin's lymphoma, 1507
^{213}Bi-labeled anti-CD20-CHX-A-DTPA antibody conjugate, B-lineage NHL, 418(ab)
cancer, 693
CC49 pretarget, new genetically engineered fusion protein, 1264(ab)
dose distributions, normal tissue adjacent to tumors containing ^{131}I or ^{90}Y, 1110
educational initiative for SNM chapters, 29N(11)
gammaglobulin reticuloendothelial system blocking regimens, cancer therapy, 1260(ab)
high-dose ^{131}I, lymphoma and leukemia, 1526(ab)
hormone refractory prostate cancer, anti-PSMA antibody, 1190(ab)
human IgG anti-mouse antibody, B-cell malignancies, 1256(ab)
^{131}I and ^{111}In labeled monoclonal antibodies, pharmacokinetic variability, 1261(ab)
^{131}I anti-CD20, relapsed or refractory non-Hodgkin's lymphoma, 415(ab)
^{131}I Bexxar and cytotoxic chemotherapy, in non-Hodgkin's lymphoma, 417(ab)
^{131}I chTNT, hepatic cancer, 578(ab)
^{131}I-labeled chimeric 81C6 anti-tenascin monoclonal antibody, non-Hodgkin's lymphoma, 1259(ab)
^{131}I monoclonal antibody, antiangiogenic therapy and, colon cancer, 1081(ab)
^{111}In/^{90}Y DOTA-Lym-1, therapeutic index enhancement, lymphoma, 420(ab)
intraperitoneal, ovarian cancer, 1580(ab)
^{111}In Zevalin, biodistribution, nuclear medicine expert panel, 1258(ab)
^{125}I tositumomab
chronic lymphocytic leukemia, 1255(ab)
relapsed/refractory non-Hodgkin's lymphoma, 1257(ab)
^{131}I using FLT3-L cytokine levels, hematologic toxicity correlation, 310(ab)
^{177}Lu- DOTA-huJ591, prostate cancer, 577(ab)
myeloablative, before stem cell transplant, 1263(ab)
myeloablative, mantle cell non-Hodgkin's lymphoma, 414(ab)
non-Hodgkin's lymphoma and, 11N(4)

non-marrow-targeting ^{90}Y-antibody, prediction of myelotoxicity, 1245
ovarian and colon cancer, treatment of tumor xenografts, 1082(ab)
patient-specific dosimetry, peripheral blood stem cell transfusion using, 312(ab)
phage displayed library technology, anti-tag-72 antibody, 1087(ab)
potentiation with response-selective peptide agonist of human C5a, 957
preclinical, breast cancer, mAb and a new residualizing ^{131}I, 556(ab)
preparation, characterization and application, renal cell carcinoma, 1085(ab)
pretarget, anti-CD20 fusion protein, in NHL, 419(ab)
pretargeted, biotin-DOTA conjugate for, 1485(ab)
radiolabeled herceptin, inflammatory breast cancer, 554(ab)
^{186}Re bivatuzumab, head and neck cancer, 575(ab)
reinfusion of cold antibody, non-Hodgkin's lymphoma, 416(ab)
^{186}Re-labeled monoclonal antibody, liver metastases of colon cancer cells, nude mice, 1089(ab)
synergism and antiangiogenic therapy, liver metastasis model, colon cancer cells, 1079(ab)
tumor necrosis therapy, lung cancer, 1265(ab)
^{90}Y DOTA-huJ591, prostate cancer, 576(ab)
Zevalin, non-Hodgkin's lymphoma, infusion symptoms, 1579(ab)

adioiodides
formulation, effects on thyroid uptake, 56
stunning, ^{131}I irradiation, cultured thyroid epithelial cells, 828, 835

adioiodine
remnant ablation, small papillary thyroid cancers, 455(ab)
thioflavin-t derivative, for imaging amyloid in Alzheimer's disease, 1444(ab)
thyroid remnant ablation, recombinant human TSH as preparation for, 1482
in thyrotoxicosis, enhancement by lithium carbonate, 1280(ab)
uptake in dose calculation, Grave's disease, 469(ab)

adioiodine therapy
accumulation thyroid during, in breathing air, 1325(ab)
Grave's disease, antithyroid drug effects, 1293(ab)
healthy thyroid remnants and tumor tissue after, in differentiated thyroid cancer, 1283(ab)
intralumbar injection, radiation dosimetry for, 314(ab)
isotretinoin, metastatic thyroid cancer, 465(ab)
metastatic breast cancer, 428(ab)
molecular biological and pathobiological effects, differentiated thyroid cancer, 292(ab)
optimization of, benign thyroid disease, 1302(ab)
outcome, prediction by FDG uptake, metastatic thyroid cancer, 1331(ab)
oxidation injury induced by, isoprostane 8-Epi-PGF$_{2\alpha}$, 1254
sodium iodide symporter, adenovirus-mediated transfer of, thyroid cancer, 429(ab)
stunning, differentiated thyroid cancer, 1319(ab)
thyroid cancer, improved planning for, 714(le)
thyroid maximum uptake, effective half-life and, Graves' disease patients, 1328(ab)

adioisotopes
after 9/11: Keeping the world supplied, 12N(3)
first commercial shipment, 30N(1)
in restenosis prevention, 32N(10)

adiolabeled antibody therapy
anti-human CEA, transgenic mouse model for, 1368
B-lymphoma cells, cytotoxicity, 560(ab)
cancer treatment, liver, 311(ab)
radiation dose distribution, normal tissue adjacent to tumors, 328(ab)
targeted, cancer, 693
treatment of infection, *C. neoformans*, 299(ab)

adiolanthanides, pretargeting protocols, tumor-bearing mice, 1083(ab)

adiologic technologists, smallpox vaccine for, 32N(12)

adionuclide angiography, ventricular function and hemodynamics, great arteries, 1382(ab)

adionuclides
abnormal uptake, acute myocardial infarction, 15(ab)
alpha-emitting, selective killing of cells, 1086(ab)
long-lived stand-in for technetium, 498(ab)
therapeutic application, verification of a practical model, 1435(ab)
treatment of infection, *C. neoformans*, 299(ab)

Radionuclide therapy
calculating absorbed dose, radioactive patients, 1241
chronic otitis media, paranasal sinusitis and, 298(ab)
intratumoral administration, therapeutic comparison in GW39 tumors, 1127(ab)
^{177}Lu-DOTA,Tyr^3 octreotate, tumor response and side effects, 444(ab)
peptide receptor, intrahepatic tumor growth after partial hepatectomy, 1681
peptide receptors, new advances, 617
^{32}P phosphorous colloid radiosynoviorthesis, pediatric hemophilia, 308(ab)
quantitative SPECT for, 3D absorbed dose calculation method based on, 1101
receptor-targeted scintigraphy and, ^{111}In-labeled DTPA- or DOTA-bombesin, 1650
targeted, conference at Hopkins, 12N(5)
^{90}Y and ^{177}Lu analog combination in, 446(ab)

Radiopeptides, ^{90}Y DOTATOC
neuroendocrine tumor response to, 610
peptide receptor radionuclide therapy with, 617

Radiopeptide therapy, kidney protection during, mice, 1076(ab)

Radiopharmaceutical Dosimetry Seminar, 38N(7)

Radiopharmaceuticals
antisense, drug-targeting technology, Huntington's disease, 948
chemistry
abeta-plaques as imaging agents, 1451(ab)
asymmetric ^{75}Se selenoethers, 491(ab)
^{18}F FLT preparation using a nolsylate precursor, 319(ab)
^{18}F-labeled 7-substituted estradiol derivatives, breast cancer, 1465(ab)
novel iodinated proliferation marker, 1490(ab)
one-step radiosynthesis procedure for ^{18}F FCWAY, 1449(ab)
polymer-bound bases, 492(ab)
^{186}Re-labeled bisphosphonate, metastatic bone pain, 1498(ab)
S-arylcysteine and peptides, reaction with cysteine, 1468(ab)
synthesis of high specific activity ^{18}F FFAU, PET gene imaging, 320(ab)
code recommendations, 27N(7)
compounding guidelines, 37N(11)
development
dendrimer nanocomposites, 490(ab)
^{18}F-labeled MMP inhibitor, 1462(ab)
macromolecular, hydrophilic polyacetals for, 1514(ab)
N,N-dimethyl-2-(2,amino-4-^{18}F fluorophenylthio)benzylamine as imaging agent, 601(ab)
radiolabeled guanine derivatives, breast cancer, 1491(ab)
drug targeting, PET, 609(ab)
electrophilic or nucleophilic substitution, custom manufactured fluorination module, 1522(ab)
gene imaging, cancer gene therapy, 1112(ab)
issues, 19N(1)
nuclear medicine market, 38N(9)
peptide-based, as tumor imaging agents, 1483(ab)
PET dispensing unit, 1518(ab)
receptor-binding
^{111}In labeled *E. coli* ST$_h$ analog, colorectal cancer, 333(ab)
^{111}In-labeled MRI contrast agent, 503(ab)
angiogenesis-targeted protein and its receptor, 437(ab)
vitronectin receptor antagonist, 1495(ab)
receptor-binding, imaging androgen receptor expressing tumors, 1473(ab)
for sentinel node detection, breast cancer, 72(ab)
stabilization, ^{99m}Tc exanetazime labeled leukocytes, 928
targeted lipid soluble, in cancer therapy, 1128(ab)
^{99m}Tc carbonyl complexes, with amine ligands, 1507(ab)
^{99m}Tc exametazime labeled leukocytes, lysis and color dilution process effects, 1531(ab)
^{99m}Tc-labeled blue Ficoll, localization of sentinel node, 1480(ab)
therapeutic and diagnostic, radiation protective devices, 1552(ab)
validation studies, A549 cells, 95(ab)

Radioresistance, 2-nitroimidazole derivatives of cyclam, positive markers of tumor hypoxia, 837

Radoinuclide imaging, bone studies, postmenopausal women, 338

Rain Algorithm, edge-preserving smooth filter with Watershed transform, 845(ab)

Ratio method, FDOPA PET, Parkinson's disease, 1324

Reactive attachment disorder, ^{99m}Tc ECD cerebral perfusion SPECT, children, 1390(ab)

Reactor
Canadian, recommissioned on low-power operation, 30N(12)
high flux, 30N(3)

Receiver operating characteristics (ROC)
localization, lesion detectability, 6 PET platforms, 1545, 1555
myocardial SPECT, 432
^{99m}Tc MIBI scintimammography, quantitative index role in, breast cancer, 1166(ab)
triple-head 360 degree *versus* dual-head 180 degree, SPECT, 190(ab)
voxel-based analysis, cerebral SPECT, 829(ab)

Receptor imaging, schizophrenic patients, flupenthixol, haloperidol and risperidon treatment, 1056(ab)

β-Receptors, binding of ^{18}F 4-FM and ^{123}I MIBG, normotensive and hypertensive rats, 366

Reconstruction, *see* Image reconstruction

Rectal cancer, ^{11}C MET PET, 279(ab)

Red cell mass, ^{51}Cr estimation, in renal transplant recipients, 1073(ab)

Region of interest (ROI), analysis, 363(ab)

Renal artery stenosis, with impaired renal function, losartan and captopril renal scintigraphy comparison, 143(ab)

Renal blood flow, mapping, PET and $H_2{}^{15}O$, 470

Renal cell carcinoma
bone metastases from, FDG PET and ^{99m}Tc MDP in, 44N(11)
pretargeting with bispecific antibodies, targeting with bivalent peptides, 558(ab)
radioimmunoconjugates, preparation, characterization and application, 1085(ab)

Renal disease, end-stage, long-term hemodialysis patients, bone scan, 1375(ab)

Renal output, normal residual activity, renogram in evaluation of, 33

Renography
^{99m}Tc MAG3, graft function and, 32N(10)
captopril
assessment of renal vascular disease, interobserver agreement, 330
split renal function measurement, 142(ab)
diuretic, urinary obstruction in mild hydronephrosis, 1421(ab)
exercise, ^{99m}Tc DTPA, in young hypertensives with negative captopril renograms, 1423(ab)
F+0 diuretic, suspected PUJ obstruction, children, 147(ab)
F-15 diuretic, patient selection criterion, 146(ab)
kidney function effects, output efficiency, 851
MAG$_3$F$_0$ diuretic, ER patients with renal colic and positive helical CT, 145(ab)
normalized residual activity, 33
unilateral multicystic kidney, follow-up renal function, children, 1385(ab)

Reperfusion injury, myocardial, FASTSPECT in detection, rats, 175(ab)

Respiratory burst, neutrophils and, interpretation of ^{18}F FDG PET images, 652

Respiratory distress syndrome, acute pulmonary edema, regional pulmonary perfusion, 863

Respiratory gating, quantifying PET images, lung cancer, 876

Restenosis, smooth cells, ^{188}Re dose-response study, 707(ab)

Revascularization, functional recovery after, myocardial SPECT in prediction of, 759(ab)
Reverse redistribution, pathophysiology of, ^{201}Tl SPECT in myocardial viability, 341(ab)
Rhenium-186, radioimmunotherapy with, liver metastases of colon cancer cells, nude mice, 1089(ab)
Rhenium-186 bivatuzumab, radioimmunotherapy, head and neck cancer, 575(ab)
Rhenium-186 etidronate, bone metastases, prostate cancer, 1150
Rhenium-186 HEDP, therapy, skeletal metastases from prostate cancer, 1272(ab)
Rhenium-186 sulphide, intracavitary therapy, chronic otitis media and paranasal sinusitis, 298(ab)
Rhenium-188
dose-response study, vascular smooth muscle cells, endothelial cells, and myocardial cells, 707(ab)
NIS-expressing tumors, breast cancer, 433(ab)
skin patches, treatment of superficial tumors, 1278(ab)
Rhenium-188 alpha-MSH peptide analogs, tumor to kidney uptake ratio, melanoma, 152(ab)
Rhenium-188 anti-CD66-mab, radiotherapy, pediatric leukemia, 133(ab)
Rhenium-188 HDD, preparation of kit, treatment of liver cancer, 1527(ab)
Rhenium-188 HDD-lipiodol, therapeutic agent, liver cancer, 153(ab)
Rhenium-188 HEDP
posttherapeutic scan in dosimetry after, favorable time, 1439(ab)
treatment, bone metastases from prostate cancer, 581(ab)
Rhenium-188 lipiodol, intrahepatic artery therapy, liver cancer, 1429(ab)
Rhenium-188 P2045, peptide-receptor radiotherapy, small cell lung cancer, 445(ab)
Rhenium-188 pertechenate, continuous low dose rate beta irradiation therapy, Burkitt's lymphoma cell line, 1424(ab)
Rheumatoid arthritis
experimental model, imaging cell death with radiolabeled annexin V, 1359, 1366
inflamed joints in, FDG PET imaging, 138(ab)
infliximab treatment, inflammation imaging with FDG PET, 139(ab)
Richters transformation, FDG PET in identification of, chronic lymphocytic leukemia, 108(ab)
Right ventricular ejection fraction
automatic evaluation by ECG-gated blood pool SPECT, 349(ab)
automatic evaluation with gated blood pool SPECT, 350(ab)
Right ventricular function
automatic evaluation with gated blood pool SPECT, 350(ab)
biventricular dynamic physical phantom, gated SPECT, 172(ab)
gated blood-pool imaging, 806(ab)
prognostic value of, in dilated cardiomyopathy, pediatric, 803(ab)
volume and, gated SPECT blood-pool imaging in, 1558(ab)
Robotic system, ^{18}F FHPG, specific activity of, 160(ab)
Rosiglitazone, effects on endothelial dysfunction, coronary blood flow in insulin-resistant patients, PET, 3(ab)
Rubidium-82
cardiac perfusion imaging, pig heart, 27(ab)
hybrid gamma camera and, effective functional renal volume in small kidneys, 1416(ab)
PET
cardiac imaging, 777(ab)
left main or three vessel coronary disease, 728(ab)
rest/stress perfusion studies, LSO-based stress, 811(ab)
Rutland method, BMIPP dynamic SPECT, myocardial damage, 1286

S

Sacroiliitis, bone scan quantification, 1361(ab)
Salivary glands
^{18}C IAP and FDG accumulation, discrepancy, 1103(ab)
scintigraphy, Sjögren's syndrome, 1342(ab)
Salmonella typhimurium, non-virulent, tumor targeting PET, 251(ab)
Samarium-153 EDTMP, skeletal uptake, prior bisphosphonate infusion and, 1273(ab)
Sarcoidosis, FDG uptake patterns in, 1398(ab)
Sarcoma
FDG PET potential roles in imaging, 1155(ab)
kinetic PET data and VEGF expression in, FDG PET, 91(ab)
Scabs, posttraumatic superficial, ^{131}I false-positive scans due to, 207
Scatter and collimator resolution, ROC evaluation of, ^{99m}Tc myocardial perfusion imaging, 6(ab)
Scatter correction
convolution and triple-energy window spill-down, ^{99m}Tc/^{111}In SPECT, 907(ab)
CT, planar activity quantification, application to ^{131}I, 972
CT-based, attenuation correction in SPECT and, phantom study, 902(ab)
evaluation with striatal phantom, quantitative brain SPECT, 1555(ab)
FBP and OSEM comparison, quantitative dopamine SPECT, 883(ab)
nonuniform attenuation correction and, myocardial SPECT in CAD, 176(ab)
pinhole SPECT, using Monte Carlo simulation, 896(ab)
septal penetration and, narrow beam attenuation correction, 906(ab)
simulation algorithm, 3D PET, 207(ab)
spatially variant convolution subtraction, animal PET scanner, 889(ab)
triple energy window, cross-talk ratio, SPECT, 1570(ab)
triple energy window compensation methods, ^{67}Ga tumor imaging, 194(ab)
Schizophrenia
amphetamine-induced dopamine release, SPECT and ^{123}I IBZM studies, 51(ab)
atypical antipsychotic drugs, occupancy of dopamine D2 receptors by, 50(ab)
dopamine D2 receptor occupancy, antipsychotic drugs, ^{123}I IBZM SPECT, 1556(ab)
dopamine transporter density, ^{99m}Tc TRODAT-1 SPECT, 1057(ab)
neuroleptic treatment, receptor imaging of, 1056(ab)
serotonin receptors in, quantitative analysis with ^{11}C WAY 100635, 52(ab)
treatment with amisulpride, ^{18}F DMFP PET, 1058(ab)
Scintigraphy, granulocyte, fever of unknown origin, 140
Scintimammography
16 x 20 CM^2 CZT gamma camera for, 943(ab)
^{99m}Tc sestamibi compared with MDP and DMSA, in palpable breast lesions, 882
CZT detector for, phantom and patient studies, 1168(ab)
high resolution, breast neoplasm, 909, 916
miniature camera, mounted on upright mammography gantry, 273(ab)
planar and SPECT, ^{99m}Tc tetrofosmin, detection of early stage breast cancer, 1162(ab)
simultaneous cone-beam and parallel-beam SPECT, phantom evaluation, 901(ab)
with SOV gamma camera, occult breast cancer detection, 1169(ab)
^{99m}Tc pertechnetate, sodium iodide symporter expressed in breast cancer, 431(ab)
^{99m}Tc sestamibi
international prospective evaluation, 271(ab)
mammography combination, over 50s, 272(ab)
Sclerosis, systemic, esophageal dysfunction in, 1343(ab)
Sclerotherapy, Plummer's disease, 1317(ab)
Selenium-73 selenoethers, asymmetric, NCA synthesis of, 491(ab)
Sentinel lymph node
biopsies, dyes for, 1377
biopsy, body-outline imaging technique for localization, 1181
head and neck cancer, fine-needle aspiration cytology of, 1585
Sentinel node imaging
biopsy
axillary detection in, tumor size effects, 1171(ab)
breast cancer, German multicenter study, 1170(ab)
minimally invasive approaches, gastric cancer, 1185(ab)
preoperative staging of squamous cell carcinoma, neck, 574(ab)
staging of squamous cell head and neck cancer, 1178(ab)
body-outline imaging technique for localization, in breast surgery, 1181
breast cancer
first lymph node radiodetected in, 73(ab)
internal mammary nodes and diseased axillary nodes, 1174(ab)
intradermal injection and intraoperative isosulfan dye in, 1175(ab)
new radiopharmaceutical for, 72(ab)
Oscar Lambret Center, 1173(ab)
combined SPECT-CT in, lymphoscintigraphy, 572(ab)
CZT intraoperative gamma camera, 945(ab)
detection of micrometastases, melanoma patients, 1182(ab)
dyes for, 1377
endoscopic administration of ^{99m}Tc DTPA-*mannosyl*-dextran, gastric and colorectal, 475(ab)
evaluation of lymphatic drainage, esophagogastric cancer, 241(ab)
fine-needle aspiration cytology, head and neck cancer, 1585
gamma camera, intraoperative use of a small field of view, 923(ab)
internal mammary nodes, breast cancer, 75(ab)
intraoperative, sterile-field imaging, 569(ab)
intraoperative gamma probe-guided, after radiochemotherapy, head and neck cancer, 573(ab)
intraoperative imaging, biopsy in breast cancer, 924(ab)
intraoperative localization, endometrial cancer, 1179(ab)
lymphatic drainage
head and neck cancer, 571(ab)
spread of cutaneous malignant melanoma and, 570(ab)
lymphoscintigraphy, cervical cancer, 1184(ab)
lymphoscintigraphy and intraoperative gamma probe, melanoma, procedure guideline, 1414
mapping in breast cancer
nodular drainage patterns and tumor location, 1177(ab)
subareolar lymphoscintigraphy, 1176(ab)
multifocal/multicentric breast cancer and, 71(ab)
PET, in melanoma, 34N(10)
porphyrin-based agent for detection, 1135(ab)
preoperative localization, combined transmission-emission SPECT, 900(ab)
radioguided biopsy
internal mammary nodes, breast cancer, 76(ab)
local anesthesia and, breast cancer, 77(ab)
malignant cutaneous melanoma, 811
radiolocalization, head and neck cancer, 568(ab)
scintigraphic and sonographic characteristics, cutaneous malignant melanoma, 1183(ab)
scintigraphic mapping, breast cancer, dual-head gamma camera, 899(ab)
^{99m}Tc colloid and blue-dye, endometrial cancer, 1180(ab)
^{99m}Tc dextran, malignant skin lesions, 1181(ab)
^{99m}Tc-labeled blue Ficoll for localization, 1480(ab)
^{99m}Tc-labeled liposomes, rat model of breast cancer, 1137(ab)
Septa design, in PET, comparison of count rate performances, 33(ab)
Septum, wall thickening and motion, after CABG, gated SPECT assessment of, 589
Serotonin, brain synthesis, effects of changes in blood oxygen, α-^{11}C methyl-L-tryptophan and PET, 947(ab)
Serotonin-1A receptors, PET imaging, neuropsychiatric disorders, 292
Serotonin receptors
cortical density, estrogen replacement therapy effects, 1048(ab)
^{11}C WAY-100635, two C-methyl derivatives of, 1445(ab)

human functional imaging, 198(ab)
measurement with ^{11}C (+)McN-5652, in obsessive-compulsive disorder, 54(ab)
in OCD patients, binding in right caudate nucleus, 1046(ab)
one-step radiosynthesis procedure for ^{18}F FCWAY, 1449(ab)
quantitative analysis with ^{11}C WAY 100635, schizophrenia, 52(ab)
reversible parameters, linear methods to reduce bias, 843(ab)
uptake of radiolabeled acid metabolites, monkey brain, 960(ab)
Serotonin transporters
^{11}C McN6562 and DASB, comparison under experimental conditions, 678
biodistribution study of ^{123}I ADAM, conventional tissue dissection and whole body autoradiography, 1436(ab)
bound ^{123}I ADAM in, rabbit brains, SPECT, 1625(ab)
brain, ^{123}I-labeled ADAM as radioligand for, 946(ab)
^{11}C EADAM, radiolabeling and characterization of, PET, 597(ab)
^{11}C MADAM labeled in two different positions for, PET, monkey brain, 596(ab)
^{11}C YP186, synthesis and biological evaluation, 598(ab)
fluorinated ADAM derivative as imaging agent, 600(ab)
Ichise non-invasive plot, PET/SPECT imaging, 842(ab)
limbic system, alcoholism effects, 390(ab)
in OCD patients, ^{123}I β-CIT SPECT studies, 1044(ab), 1045(ab)
PET imaging, ^{11}C ZbRET and ZIET use in, 151(ab)
selective PET tracer for, ^{18}F AFM, 1440(ab)
synthesis of N,N-dimethyl-2-(2,amino-4-^{18}F fluorophenylthio)benzylamine as imaging agent, 601(ab)
Sestamibi scanning, breast cancer, 125(le)
S-factors, murine-specific, potential toxicity, 323(ab)
Sickle cell disease, hemoglobinopathies, bone marrow infarction in, 896
Sigma receptors, scintigraphy, iodobenzamides in suspected breast cancer, 1647
Signal-to-noise ratio, fast, high-resolution, low-dose planar scintigraphy, with coded apertures, 916(ab)
Silicosis, PET imaging of pulmonary fibrosis, rabbit model, 413
Sincalide (Kinevac), shortages lead to inventive measures, 20N(3)
Single photon emission local tomography (SPELT), computer algorithms and phantom studies, 526(ab)
SISCOM, PET correlation, temporal lobe epilepsy, 991
Sjögren's syndrome, salivary gland scintigraphy in, 1342(ab)
Skeletal metastases, ^{223}Ra treatment in, 38N(9)
Skeletal scintigraphy
bone and bone marrow infarction, sickle hemoglobinopathies, 896
diagnosis of acute hematogenous osteomyelitis, children, 1310
Smallpox vaccine, recommended for designated RTs, 32N(12)
Society of Nuclear Medicine (SNM)
2002 annual meeting preview, 20N(4)
Alavi-Mandell Award for 2001, 43N(8)
American Society of Nuclear Cardiology and, joint position statement, 273
Annual Meeting 2002: Los Angeles, 12N(6), 13N(9)
candidate slate for 2002–2003 election, 36N(4)
Clinical Trials Council, nuclear medicine participation, 24N(10)
Clinical Trials Council Preliminary Database of Active Protocols, 10N(11)
commentary response: name change or a bigger challenge, 16N(2)
continuing education opportunities, 34N(10)
Education and Research Foundation (ERF), officers and awardees, 32N(5)
highlights 2002 lecture, Reinventing *Clinical* Nuclear Medicine, 11N(8)
longer residency requirements proposed, 13N(12), 15N(12)
Mid-Winter Educational Symposium, 9N(11)
new tagline announced, 36N(7)
New Year's greetings from the SNM President, 11N(1)
notification of proposed Bylaw change, 29N(4)
Nuclear Medicine Residents Committee, 39N(8)
PET Learning Center, 23N(5), 32N(6)
from the President, 11N(6), 11N(9)
public affairs, 26N(1)
public affairs update, 14N(3), 25N(2), 29N(10), 30N(7), 30N(11), 32N(1), 33N(9), 34N(6), 36N(5), 40N(4)
publishing: online guidelines solicit input, clarify procedures, 22N(10)
Quality Assurance Committee, chest tumor phantom, 25N(11), 31N(6)
Radioimmunotherapy project, 29N(11)
residency program directors organize, 42N(8)
specific guidance on NRC Part 35, 26N(12)
two plenary sessions at annual meeting, 27N(5)
Virginia M. Pappas named SNM Executive Director, 25N(4)
Society of Nuclear Medicine –Technologists Section (SNM-TS)
2002 Fellows, 31N(5)
new curriculum guide, 31N(6)
New Year's greetings from the SNM-TS President, 12N(1)
from the President, 11N(6), 12N(9)
USP DI available on web site, 41N(4)
Sodium iodide symporter
adenovirus transfer of, thyroid cancer, 429(ab)
all-trans retinoic acid effects, thyroid cancer, 484(ab)
anaplastic thyroid cancer cell line expressing, animal model, 430(ab)
astatine and iodine uptake in, cancer cell lines, 432(ab)
gene transfer/radioiodine treatment, intracerebral gliomas, 1094(ab)
monitoring of neural stem cells, 971(ab)
new imaging reporter gene system, 1095(ab)
role in nuclear medicine, 1188
transfer, rat adenocarcinoma, 1096(ab)
tumors expressing, ^{188}Re therapy for, 433(ab)
Soft tissue carcinoma, ^{18}F FLT PET detection, 278(ab)
Soft-tissue mass, PET-MR registration accuracy in, 29(ab)
Soft-tissue tumors
differentiation from bone, ^{201}Tl scintigraphy, radionuclide angiography and planar imaging, 1379(ab)
^{201}Tl and three-phase bone scintigraphy, comparative study, 478(ab)
^{201}Tl scintigraphy for, 1368(ab)
Somatostatin analog, ^{90}Y DOTATOC
neuroendocrine tumor response to, 610
peptide receptor radionuclide therapy with, 617
Somatostatin analog imaging, Hurthle cell carcinoma, thyroid, 1309(ab)
Somatostatin receptor imaging
auger-emitting radiolabeled, anti-angiogenic and anti-tumor effects, 438(ab)
detection of liver metastases, gastroenteropancreatic neuroendocrine tumors, 1206(ab)
internalization, RC-160-induced, NCI-H446 cells, 443(ab)
^{177}Lu-DOTA,Tyr^3 octreotate therapy, tumor response and side effects, 444(ab)
PET, small cell lung cancer, 409(ab)
radiolabeling with metals and halogens, 331(ab)
^{90}Y and ^{177}Lu analogs, for radionuclide therapy, 446(ab)
Somatostatin receptors
binding sites in spleen, metabolic regulation by ^{67}Ga/68 DOTATOC, 1488(ab)
expression, mucoepidermoid carcinoma, MEC-1 and MC3 cells, 1077(ab)
type 2, chimeric gene transfer, noninvasive monitoring of, 406
Somatostatin receptor scintigraphy, ^{99m}Tc P829 compared with ^{111}In pentetreotide, detection of neuroendocrine tumors, 889
Sonography
color and power Doppler, DMSA scintigraphy and, in acute pyelonephritis, 27
versus parathyroid scintigraphy, directing targeted surgery, 1329(ab)
scintigraphy comparison, renal transplantation, 141(ab)
Spatial resolution
image contrast and, triple-head gamma camera with coincidence detection, 928(ab)
mismatch, emission and transmission scans, 45(ab)
SPECT
5IA studies, nicotinic acetylcholine receptors, 975(ab)
accuracy of, effects of acquisition orbits on, 1115
ADHD
before and after methylphenidate, children, 1394(ab)
subtyping with high-resolution HMPAO, 1395(ab)
altropane, bolus-infusion technique for evaluation of dopamine transporters, 836(ab)
Alzheimer's disease, morphologic and functional changes, 304
analytical, 526(ab)
analytic and iterative reconstruction algorithms, 1343
application-specific, breast imaging, 39(ab)
artifacts, dual-head gamma camera and, 285
assessment of post-trauma amnesia, 39N(9)
blood pool
reproducibility of right and left ventricular Fourier phase analysis, 801(ab)
blood-pool
left ventricular function, CAD patients, 804(ab)
bone, detection of early osteonecrosis in femoral head, after renal transplant, 1006
brain. *see also* Cerebral SPECT
computer-aided intrapatient comparison, 715
DAT concentrations in Machado-Joseph disease gene carriers, 153
deep brain stimulation of subthalamic nucleus, in Parkinson's disease, 725
lymphoma in AIDS patients, 31N(3)
ROC-based comparison of methods, 458
during temporary balloon occlusion test and after carotid occlusion, 1616
brain perfusion follow-up, Alzheimer's, treatment with acetylcholinesterase inhibitors, 983
cardiac. *see* Cardiac SPECT
cerebral blood flow studies, children with ADHD, 1624, 1630
clinical application of neuroactivation probe, spatial working memory task, 1426
combined CT system, small animal imaging, 35(ab)
combined transmission-emission, preoperative localization of sentinel node, 900(ab)
comparison with FDG PET, detection of focus in temporal lobe epilepsy, 1040(ab)
cone-beam, 3D reconstruction of, 881(ab)
cone-beam brain, observer study, 1578
continuous blood sampling system, GSO detector assembly for, 933(ab)
cortical GABA function, in acutely detoxified alcohol-dependent patients, 392(ab)
dual-isotope, ^{99m}Tc HMDP, assessment of intraoral squamous cell carcinoma, 1464
dual-isotope imaging
location of anatomical abnormality, 1564(ab)
reducing cross-talk ratio, triple energy window scatter correction in, 1570(ab)
dynamic
changing liver concentration in ^{99m}Tc TEBO imaging, 912(ab)
lesion contrast and reduced liver interference, 522(ab)
parameter bias and reliability trade-off, 831(ab)
reducing bladder artifacts in pelvic images, 196(ab)
spectral analysis, liver function, 470(ab), 471(ab)
ECG-gated, myocardial viability, 337(ab)
FDG, myocardial viability, 820(ab)
^{67}Ga, triple energy window compensation methods, scatter correction, 194(ab)
^{67}Ga citrate, attenuation correction effects on lesion detection, 368(ab)
gated
addition of low-dose dobutamine to, myocardial viability, 339(ab)

after CABG surgery, 589
biventricular dynamic physical phantom, 172(ab)
estimation of end-diastolic pressure, cylindrical heart model, 170(ab)
estimation of left ventricular ejection fraction, 169(ab)
left ventricular ejection fraction without edge detection, in small hearts, 786
gene transfer, 434(ab)
gold pinhole, performance measurement for small animal imaging, 917(ab)
high-resolution
acute MI in rat hearts with ischemia-reperfusion, 933
myocardial ischemia, FASTSPECT in, rats, 175(ab)
neurofocus device for small animal imaging, 936(ab)
high-resolution detector modules, based on high-granularity NaI(Tl) arrays, small animal imaging, 942(ab)
hyperemic stress, coronary flow insufficiency in Kawasaki disease, 733(ab)
^{123}I 5-I-A-85380, quantification of nicotinic acetylcholine receptors, 395(ab)
^{123}I ADAM, in serotonin transporters, rabbit brain, 1625(ab)
ictal, *versus* FDG PET, refractory partial epilepsy, 1031(ab)
ictal-interictal subtraction brain, local normalization areas for epilepsy, 1419
^{123}I FP-CIT, diagnosis of Parkinson's disease, 65(ab)
^{123}I IMP, misery perfusion and, 42N(11)
^{123}I-labeled ADAM, as radioligand for imaging serotonin transporters, 946(ab)
image quality evaluation, improved phantom population for, 31(ab)
image reconstruction, sinogram restoration filters for, 874(ab)
^{111}In βCIT, improvement in routine preparation, 168(ab)
^{111}In compounds, one-detector gamma-gamma perturbed angular correlation technique, 165(ab)
^{111}In DTPA, imaging of neuroendocrine tumors, 1391
^{123}I PE21, Logan's graphical method, dopamine transporters in Parkinson's disease, 221(ab)
^{131}I with MonteCarlo simulation, 3D dose calculation, 1101
knee, early degenerative arthritis, 1371(ab)
lung scan, diagnosis of pulmonary embolism, 586(ab)
lung ventilation/perfusion, artificially embolized pig, 640, 648
Monte Carlo simulation
acceleration using delta scattering, 191(ab)
standardization and validation, 849(ab)
motion correction, head movement in CBF-SPECT, annular gamma camera, 911(ab)
MRI and, mutual-information registration, 160
multipinhole, small animal research, 913(ab)
multisegment slant-hole
design and evaluation, 918(ab)
effects of camera positions in ectomography and, 898(ab)
multispeak, attenuation correction, with CT data, 903(ab)
myocardial, *see* Myocardial SPECT
nicotinic receptors, inhibition of cytochrome P-450 effects, 607(ab)
nonuniform attenuation, image reconstruction with, 1607(ab)
parathyroid scintigraphy, descended superior adenoma, 1310(ab)
pinhole
improving reconstruction through modeling, 378(ab)
improving sampling through spiral orbits, 34(ab)
measurement of extent of myocardial infarction, 174(ab)
versus parallel hole collimator, thyroid, 1294(ab)
penetration and scattering effects, Monte Carlo simulation, 896(ab)
varying acquisition and reconstruction parameters, 870(ab)
pulmonary nodules, respiratory-gated set of images for, 915(ab)
quantitative
for focal ^{131}I activity, 882(ab)
fusion with anatomical CT images, 195(ab)
integrated report generation for, comparison to report dictation, 182(ab)
measurement, pulmonary blood flow, normal volunteers, 1401(ab)
reconstruction of data, direct matrix inversion for, 376(ab)
referral bias in, 44N(5)
simultaneous cone-beam and parallel-beam, phantom evaluation, 901(ab)
single and double-edged pinhole collimators for, imaging of small volumes, 914(ab)
smoothing filter, left ventricular function from, 826(ab)
spatially normalized PET comparison, in Alzheimer's disease, 21
statistical parametric mapping, head injury, 476
stress, CAD and, 41N(4)
^{99m}Tc/^{111}In, convolution and triple-energy window spill-down, 907(ab)
^{99m}Tc/^{123}I dual-isotope, model-based crosstalk compensation in, 193(ab)
^{99m}Tc/^{201}Tl dual-isotope, Monte Carlo simulation, 192(ab)
^{99m}Tc annexin, thallium and, detection of acute myocardial infarction, 11(ab)
^{99m}Tc DMSA, before and after renal transplant, 584
^{99m}Tc ECD, brain lesions, 46N(11)
^{99m}Tc HMPAO, cerebral blood flow measurement, 818(ab)
^{99m}Tc MDP, in patellofemoral pain disorders, 480(ab)
^{99m}Tc MIBI, *versus* double-phase planar, parathyroid adenoma or hyperplasia, 449(ab)
^{99m}Tc phytate colloid, liver and spleen uptake, in cirrhosis, 312
^{99m}Tc sestamibi and furifosmin, multidrug resistance in breast tumor, 1119(ab)
^{99m}Tc TRODAT-1
aging and idiopathic Parkinson's disease, 57(ab)
dopamine transporter levels in major depression, 55(ab)
nigral damage in Wilson's disease, 66(ab)
subtypes of multiple atrophy, Parkinson's disease, 63(ab)
^{99m}Tc TRODAT-1 and ^{123}I IBZM, Parkinson's disease, 59(ab)
^{201}Tl, abnormalities in dilated cardiomyopathy, 451
^{201}Tl, improved attenuation compensation method, 905(ab)
^{201}Tl exercise-redistribution, ischemic dysfunction, 621, 628
triple injection of ECD, cerebrovascular ischemic disease, 577
Spectral analysis, ^{99m}Tc HMPAO SPECT, cerebral blood flow measurement, 818(ab)
Spinal cord, trauma, heterotopic ossification, 346
Spinal fracture, traumatic, bone scan, children, 483(ab)
Spironolactone, cardiac sympathetic nerve activity and, congestive heart failure patients, 1279
Squamous cell carcinoma
FDG imaging, metabolic fate, 1101(ab)
head and neck, FDG PET after chemotherapy, 264(ab)
intraoral, assessment with dual-isotope SPECT, 1464
oral cavity, TYR PET and FDG PET for metastatic lymph node detection, 265(ab)
SSCVII, metabolic fate of FDG, 940
STa, binding to guanylyl cyclase, targeted colon cancer imaging, 392
Standardized uptake value (SUV)
FBP and OSEM reconstruction methods, tumor FDG PET, 1226(ab)
FDG, patient weight and residual dosage effects, 1622(ab)
FDG, stomach, serum glucose level effects, 1339(ab)
FDG PET, metabolic change effects, 835(ab)
oncology, FDG PET meta-analysis, 1224(ab)
semiquantification with, body habitus effects on, 864(ab)
Staphylococcus aureus, prosthetic joint infection, ^{99m}Tc ciprofloxacin evaluation of, 239
Statistically-regulated expectation-maximization (StatREM), reconstruction, PET, 372(ab)
Stem cell transplant. *see* Transplantation
Stereo optical camera, motion correction, SPECT, 910(ab)
Stereotactic surface projection, 3D, posterior cingulate cortex in Alzheimer's disease, 984(ab)
Stochastic resonance, for image enhancement, low count density, 894(ab)
Streptavidin
antibody conjugates, tumor targeting, mouse model, 489(ab)
imaging gene expression, brain, Huntington's disease, 948
Stroke
blood-brain barrier imaging, SPECT, 1003(ab)
recovery, functional imaging in, 42N(9)
Strontium-89, therapy, low-dose cisplatin effects, bone metastases from prostate cancer, 79, 87
ST segment, exercise-induced depression, myocardial SPECT in, 357(ab)
Subarachnoid hemorrhage, cerebral blood flow SPECT, operative indication and prediction of outcome, 1005(ab)
Subthalamic nucleus, deep brain stimulation of, Parkinson's disease, rCBF changes and, 725
Sulesomab, meta-analysis, imaging of infection, 295(ab)
Sulfonic acid group, dyes for localization, sentinel lymph node, 1377
Survivin, inhibition of cell cycle progression, induction of apoptosis and, carcinoma cell line, 257(ab)
Sympathetic denervation, vasospastic angina, SPECT images of, 1476
Sympathetic nerves
cardiac, activity, in hypertrophic cardiomyopathy, ^{123}I MIBG evaluation, 15
cardiac, spironolactone effects, congestive heart failure patients, 1279
Sympathetic neuron, function, MIBG as index of, 1234
Synovectomy, radiation, with ^{166}Ho ferric hydroxide, 1489
Systolic dysfunction, cardiac sympathetic nerve activity and, in hypertrophic cardiomyopathy, ^{123}I MIBG evaluation, 15

T

Target to background ratio, ^{18}F FDG uptake, lung cancer, 370(ab)
Tat protein, cell uptake of antisense DNA and, target cells, 486(ab)
Taxol, chemotherapy, ^{111}In DTPA PEG-annexin V after, 150(ab)
T cells, somatostatin receptor labeling of, hCAR transgenic mouse, 1078(ab)
Technetium-95m, production of silver targets, high energy protons, 498(ab)
Technetium-99m
lipid concentration, in breast cancer tissue, 45N(8)
macroaggregated albumin labeled with, lung perfusion in PPH, 757
morpholinos labeled with
chain length effects on instabilities, 1508(ab)
improved antisense *versus* control accumulations, 501(ab)
tumor pretargeting with, 384
myocardial SPECT, ungated *versus* end-diastolic imaging in, 798(ab)
neurotensin(8–13) pseudopeptide radiolabeled with, 374
peptides labeled with, thrombosis imaging, 502(ab)
recombinant antibody fragment labeled with, tumor imaging, 557(ab)
Technetium -99m AcuTect, negative scans, in patients at risk for deep venous thrombosis, 1413(ab)
Technetium-99m alendronate, in place of other bisphosphonates, in bone imaging, 1364(ab)
Technetium-99m annexin V
acute myocardial infarction, abnormal radiotracer uptake and, 15(ab)
assessment of apoptotic process, myocardial ischemia and reperfusion, 708(ab)
evaluation, sterile inflammation model, 1357(ab)
versus FDG, identification of plaques in atherosclerosis, 2(ab)

hepatic apoptosis, prolonged fasting and refeeding effects, 1335(ab)
Hynic-derivatized, optimization of, 1532(ab)
imaging of apoptosis, experimental myocarditis, 713(ab)
imaging of cranial suture apoptosis, rat model, 1392(ab)
^{111}In antimyosin-antibody comparison, uptake in acute myocardial infarction, 703(ab)
increased organ clearance, 1504(ab)
native and mutant, biodistribution of, 500(ab)
noninvasive targeting, apoptotic macrophages, in CAD, 23(ab)
versus radiolabeled monocyte chemotactic protein-1, atherosclerotic plaque identification, 702(ab)
single-dose chemotherapy
apoptotic tumor response after, 259(ab)
experimental tumor model, 258(ab)
SPECT, thallium and, detection of acute myocardial infarction, 11(ab)
therapeutic tool, in atherosclerosis, 22(ab)
uptake and tumor response, 46N(11)
Technetium-99m anti-intercellular adhesion molecule-1, detection of lung inflammation, rat, 1506(ab)
Technetium-99m antisense DNA, Tat enhanced cell uptake, target cells, 486(ab)
Technetium-99m Apcitide, validity, diagnosis of lower extremity venous thrombosis, 1405(ab)
Technetium-99m BRU-5921, marker of myocardial angiogenesis, ischemic rat model, 26(ab)
Technetium-99m carbonyl complexes, with amine ligands, synthesis and biological evaluation, 1507(ab)
Technetium-99m chelating agents, as potential renal radiopharmaceutical, 1509(ab)
Technetium-99m ciprofloxacin
diagnosis in musculoskeletal infection, 300(ab)
diagnosis in osteomyelitis, 301(ab)
SPECT, FDG PET comparison, orthopedic infections, 477(ab)
uptake, *S. aureus* prosthetic joint infection, 239
Technetium-99m colloid albumin, sentinel node identification, endometrial cancer, 1180(ab)
Technetium-99m complexes
bacterial abscess, sterile inflammation or, 1353(ab)
peptide-based, as tumor imaging agents, 1483(ab)
structure confirmation, with radio-LC-MS, 1517(ab)
Technetium-99m Dac, binding specificity, interleukin-2 receptors, 1472(ab)
Technetium-99m depreotide
analysis of lung nodules, 1209(ab)
detection of infection and inflammation, 296(ab)
mapping of lymphatic drainage, lung cancer, 407(ab)
primary nonpulmonary neoplasms, infections and, 1210(ab)
qualitative analysis, solitary pulmonary nodule, 408(ab)
Technetium-99m dextran, lymphoscintigraphy, malignant skin lesions, 1181(ab)
Technetium-99m D-glucaric acid, scintimammography with, breast cancer clinical trial, 1164(ab)
Technetium-99m DMSA
compared with sestamibi, palpable breast lesions, 882
pH-sensitive, differentiation of cancerous bone metastases, 1130(ab)
SPECT, before and after renal transplant, 584
uptake, breast cancer, calcitonin gene-related peptide and calcitonin effects on, 1167(ab)
uptake in breast cancer, proliferation index (^{67}K), 1163(ab)
Technetium-99m DTPA
exercise renography, young hypertensives with negative captopril renograms, 1423(ab)
F+0 renogram, pelvic ureteric junction obstruction, children, 147(ab)
inhalation imaging, aging effects on pulmonary permeability, 582(ab)
peritoneal excretion, continuous ambulatory peritoneal dialysis patients, 1420(ab)
Technetium-99m DTPA aerosol, ^{67}Ga comparison, interstitial pneumonia, 1404(ab)
Technetium-99m DTPA-mannosyl-dextran
preclinical studies, 1469(ab)
for sentinel node detection, breast cancer, 72(ab)
Technetium-99m EC20, folate-derived, for cancer imaging, 1477(ab)
Technetium-99m EC-angiostatin, radiolabeled, cellular uptake and biodistribution of, 1471(ab)
Technetium-99m EC-C225, primary tumor receptor imaging, epidermal growth factor, 1088(ab)
Technetium-99m ECD
cerebral perfusion SPECT, childhood autism, 1391(ab)
retention of, cerebral cortex slices, rat, 166(ab)
SPECT, brain lesions, 46N(11)
triple injection, delayed effects of acetazolamide, cerebral ischemic disease, 577
Technetium-99m EC-DG, comparison with FDG, tumor targeting, 1102(ab)
Technetium-99m EC-endostatin, imaging angiogenesis with, 435(ab)
Technetium-99m ethyl cysteinate dimer, perfusion SPECT, after vagus nerve stimulation in epilepsy, 733
Technetium-99m exametazime, viability and function, lysis and color dilution process effects, 1531(ab)
Technetium-99m exanetazime, leukocytes labeled with, viability and chemotaxis of, 928
Technetium-99m GHA, SPECT, primary brain tumors receiving radiotherapy, 1011(ab)
Technetium-99m GLA, high-resolution FastSPECT imaging, detecting breast tumor, 1104(ab)
Technetium-99m glucaric acid, opoptotic and oncotic myocardial necrosis, 25(ab)
Technetium-99m GSA
dynamic SPECT, liver function, 470(ab)
liver scintigraphy, fibrosis and regeneration, after hepatectomy, 1341(ab)
regional dynamic hepatocyte function, 1611
Technetium-99m heterocomplexes, asymmetrical nitrodo, cardiac agent, 499(ab)
Technetium-99m HIG, inflammation imaging, in adhesive capsulitis, 482(ab)
Technetium-99m HL91, prediction of response, radiation therapy, 1124(ab)
Technetium-99m HMDP
dual-isotope SPECT, assessment of intraoral squamous cell carcinoma, 1464
MIBI and, detection of bone marrow metastases, 596
three-phase bone scanning, osteomyelitis of the mandible, 1365(ab)
Technetium-99m HMPAO
acetazolamide SPECT, dementia, 538(ab)
acute appendicitis and, children, 48N(11)
autologous *versus* heterologous leukocytes, for infection imaging, 1351(ab)
diagnosis in musculoskeletal infection, 300(ab)
infection imaging, 918, 925
leukocytes, chronic bone and joint infection, 1352(ab)
mixed leukocytes labeled with, chromosomal aberrations in lymphocytes and, 203
spatially normalized PET and SPECT, direct comparison, Alzheimer's disease, 21
SPECT
hypothyroidism, post-thyroidectomy patients, 1028(ab)
major subarachnoid hemorrhage, 1005(ab)
observer variation in interpretation, 1041(ab)
prolonged impaired consciousness and, 1610(ab)
subtyping of ADHD, 1395(ab)
SPECT test balloon occlusion, carotid occlusion, 1007(ab)
Technetium-99m Hynexin, first human evaluation, 255(ab)
Technetium-99m labeled stem cells, imaging of body distribution, infarcted myocardium, 712(ab)
Technetium-99m leukokinin residue, infection/inflammation imaging, 1347(ab)
Technetium-99m liposines, in acute postoperative mediastinitis, 42N(9)
Technetium-99m MAA, intra-arterial chemotherapy, myocutaneous adverse side effects, bone and soft tissue tumors, 1452
Technetium-99m MAEC, preliminary evaluation, renal function, 1422(ab)
Technetium-99m MAG3
clearance, optimizing renal counting method for, 1418(ab)
critical bladder volumes, in neuropathic bladders, 1415(ab)
morpholinos labeled with, pharmacokinetic behavior, 485(ab)
normal extraction fraction values, children, 1383(ab)
renal studies, correlation of MAG3 and creatinine clearances, 1414(ab)
Technetium-99m MCP-1, annexin V and, radionuclide imaging of postischemic inflammation, 396(ab)
Technetium-99m MDP
bone metastases, from renal cell carcinoma, 44N(11)
bone scan, sternal fractures after air bag deployment, 1360(ab)
bone scintigraphy, skeletal tuberculosis, 479(ab)
bone SPECT, in patellofemoral pain disorders, 480(ab)
compared with sestamibi, palpable breast lesions, 882
extraosseous accumulation, mechanism of, 1362(ab)
PET, uptake, primary osteosarcoma, 1012
radionuclide bone studies, in postmenopausal women, 338
skeletal imaging, evaluation of diabetic osteopathy, 1378(ab)
SPECT
detection of precommitted heterotopic ossification, 1373(ab)
early degenerative arthritis, knee, 1371(ab)
Technetium-99m mebrofenin, evaluation of liver disease, rat model of Wilson's disease, 246
Technetium-99m MIBI
abdominal imaging, gastroenteropancreatic tumors, 472(ab)
angina pectoris, before acute myocardial infarction, 16(ab)
beta blockade effects, dipyridamole-induced myocardial ischemia, 180(ab)
comparison with tetraphenylphosphonium, non-small cell lung cancer, 234
double-phase, in hyperparathyroidism, 452(ab)
HMDP and, detection of bone marrow metastases, 596
intraarterial administration, liver malignancies, 1337(ab)
left sided bundle of Kent, quantitative gated SPECT, 797(ab)
myocardial kinetics, heart model of low-flow ischemia, 566
nitrated augmented infusion, myocardial viability, 757(ab)
plastic syringe adsorption of, stability and, 1616(ab)
radioguided surgery
metastases of differentiated thyroid cancer, 293(ab)
primary hyperparathyroidism, 1279(ab)
scintimammography
breast cancer, ROC curve analysis, role of quantitative index in, 1166(ab)
multidetector CT comparison, lymph node metastases in breast cancer, 1165(ab)
SPECT
after CABG surgery, 589
after coronary angioplasty, 745(ab)
attenuation-free, breast scintigraphy, 1578(ab)
breast cancer, 823(ab)
evaluation of pediatric CNS malignancies, 1438
inferior wall artifact in, 714(ab)
uptake degree of, benign and malignant skeletal tumors, 1372(ab)
viral myocarditis, pediatric, 767(ab)
whole-body SPECT, comparison, thyroid cancer, 1312(ab)
Technetium-99m morpholino, pretargeting, conventional tumor targeting and, 1084(ab)
Technetium-99m NOET
regional cardiac activity, comparison to ^{99m}Tc sestamibi, 1559(ab)
sestamibi and, SPECT, defects in same patient, 13(ab)
Technetium-99m O_4Na, biodistribution of, malnutrition during lactation and, 89
Technetium-99m oligonucleotide aptamer, platelet imaging, baboon, 710(ab)
Technetium-99m P829, scintigraphy, compared with ^{111}In pentetreotide, neuroendocrine tumors, 889
Technetium-99m pentetate, aerosol, dose delivery in inhaled chemotherapy, 1208(ab)
Technetium-99m peptide conjugates
bombesin, for tumor imaging, 336(ab)

in vivo biopanning for selection, mice, 335(ab)
Technetium-99m pertechnetate
abdominal scan, children with Henoch Schönlein purpura, 1397(ab)
radiography *versus*, laparoscopic gastric banding, 592(ab)
scintimammography, sodium iodide symporter expressed in breast cancer, 431(ab)
Technetium-99m phytate colloid, liver and spleen uptake, cirrhosis, 312
Technetium-99m PNA-peptide, early detection, breast cancer, 448(ab)
Technetium-99m red blood cells, intestinal bleeding sites, anatomical mapping, 1334(ab)
Technetium-99m sestamibi
arbutamine stress perfusion imaging, coronary artery stenoses, dogs, 664
assessment of toremifene, modulator of multidrug resistance in breast cancer, 519, 526
brain tumors, tumor cell activity in astrocytic tumor, 404(ab)
compared with MDP and DMSA, palpable breast lesions, 882
delayed images, acute myocardial infarction after reperfusion therapy, 1557(ab)
echocardiography and PTCA, in acute myocardial infarction, 8
^{18}F FDG comparison, lung lesions, 410(ab)
gated myocardial SPECT, idiopathic dilated cardiomyopathy, 748(ab)
high-resolution stationary SPECT, acute MI in hearts with ischemia-reperfusion, 933
hyperemic stress SPECT, coronary flow insufficiency in Kawasaki disease, 733(ab)
MDR1 and MDR2 P-glycoprotein genes, 1333(ab)
myocardial scintigraphy, strategies to minimize abdominal activity, 813(ab)
myocardial SPECT, imaging protocols, 178(ab)
Noet and, SPECT, defects in same patient, 13(ab)
parathyroid imaging with, in an endemic goiter area, 1175
pinhole and SPECT imaging, retroesophageal parathyroid lesion, 1282(ab)
prognostic value of washout, locally advanced breast cancer, 745
scintimammography, asymptomatic breast cancer, 1161(ab)
scintimammography, international prospective evaluation, 271(ab)
SPECT
evaluation of pediatric CNS malignancies, 1438
myocardial stunning and subendocardial infarction, dogs, 540
radioguided probe in parathyroidectomy, 453(ab)
tumor uptake, prognosis in osteosarcoma, 129(ab)
Technetium-99m sulfur colloid
cigar smoke particle deposition, lung, study of inhalation, 1412(ab)
ventilation scan, deposition of cigar smoke particles in lung, 1591
Technetium-99m TBIDA, liver trauma and, pediatric, 44N(11)
Technetium-99m TEBO, changing liver concentrations of, dynamic SPECT, 912(ab)
Technetium-99m teboroxime, myocardial kinetics, effects on liver and, 815(ab)
Technetium-99m testosterone-BFCA, imaging, androgen receptor expressing tumors, 1473(ab)
Technetium-99m tetrofosmin
different variants of Kaposi sarcoma, 1156(ab)
dobutamine atropine stress, myocardial perfusion SPECT, in CAD patients, 767
follow-up, breast cancer, 1159(ab)
improved quality control, 154(ab)
myocardial kinetics, cardiac natriuretic peptides and, in chronic heart failure, 14(ab)
planar and SPECT scintimammography, detection of early stage breast cancer, 1162(ab)
plastic syringe adsorption of, stability and, 1616(ab)
scintigraphy, multiple myeloma, 112(ab)
SPECT
cardioprotective effects of intravenous nicorandil, 746(ab)
nicorandil effects after acute myocardial infarction, 747(ab)
Technetium-99m tin colloid, evaluation of lymphatic drainage, esophagogastric cancer, 241(ab)
Technetium-99m tricarbonyl, labeling for triplex forming oligonucleotides, 1505(ab)
Technetium-99m TRODAT-1
and ^{123}I IBZM SPECT, Parkinson's disease, 59(ab)
brain SPECT, DAT binding in Machado-Joseph disease gene carriers, 153
new kit formulation, dopamine transporter imaging agent, 1530(ab)
SPECT
aging and idiopathic Parkinson's disease, 57(ab)
comparison to ^{18}F FDOPA PET in Parkinson's disease, 994(ab)
dopamine transporter levels in major depression, 55(ab)
genetic polymorphisms effects on uptake values of, Parkinson's disease, 67(ab)
hemi-Parkinson's disease, 58(ab)
subtypes of multiple atrophy, Parkinson's disease, 63(ab)
Wilson's disease, 66(ab)
Telenuclear medicine, procedure guideline for, 1410
Testicles, FDG uptake, PET, 856(ab)
Testicular cancer
FDG PET management, prediction of treatment response, 424(ab)
recurrent or residual, FDG with coincidence imaging, 1143(ab)
Tetraphenylphosphonium, accumulation, non-small cell lung cancer, ^{99m}Tc MIBI comparison, 234
Thalamus
alpha rhythm and, PET/EEG simultaneous recording under lorazepam, 543(ab)
^{18}F fallypride displacement in, nicotine- and amphetamine-induced dopamine release, 382(ab)
multiple injection protocol and PET, quantitation of D2 receptors, 203(ab)
muscarinic receptors, estrogen upregulation of, 979(ab)
Thalidomide, antiangiogenic therapy with, radioimmunotherapy and, cognitive effects, human cancer xenografts, 1084
Thallium-201
arbutamine stress perfusion imaging, coronary artery stenoses, dogs, 664
in bone and soft-tissue tumors, 1368(ab)
gated myocardial perfusion imaging, left ventricular ejection fraction and multivessel CAD, 131
gated SPECT
exercise, multivessel coronary artery disease, 443
left ventricular dysfunction, window time for, 788(ab)
myocardial contractile reserve assessment, 338(ab)
myocardial kinetics, heart model of low-flow ischemia, 566
myocardial perfusion study, extracardiac disease detected by, 730(ab)
myocardial SPECT, lung/heart index, SyndromeX patients, 793(ab)
poststent recovery, 40N(11)
rest distribution, recent myocardial infarction, 17(ab)
scintigraphy, fine-needle aspiration biopsy, thyroid lesions, 1308(ab)
sequential imaging, dobutamine echocardiography and, left ventricular ejection fraction after revascularization, 795, 803
SPECT
abnormalities, in dilated cardiomyopathy, 451
detection of bronchioloalveolar lung cancer, 1211(ab)
detection of precommitted heterotopic ossification, after spinal cord injury, 1373(ab)
esophageal cancer and prediction of therapy response, 1200(ab)
reverse redistribution on stress-redistribution, myocardial, 341(ab)
stress-redistribution-reinjection, ischemic dysfunction, 621, 628
transient myocardial stunning in, 345(ab)
uptake, thyroid cancer, TSH effects, 145
Thallium-201 chloride, dual-isotope SPECT, assessment of intraoral squamous cell carcinoma, 1464
Thoracic aortic wall, metabolic activity and calcification, PET/CT, 10(ab)
Thoracic cancer
^{11}C choline and ^{18}F FDG PET in, 167
CT-PET fusion in, 42N(9)
Three-dimensional volume imaging, lesion detectability, full-ring BGO PET scanner, 204(ab)
Thrombocytopenic purpura, chronic idiopathic, splenectomy in, accessory spleen after, 287(ab)
Thrombosis imaging, platelet-rich clot model, baboon, 710(ab)
Thrombus, endovascular detection, atheromatous plaques, 701(ab)
Thymidine analog, tumor imaging agent, metabolic studies in dogs, 94(ab)
Thymidine kinase, activity in A549 cancer cells, FLT uptake as a measure of, 1210
Thymidine kinase type 2, mitochondrial, PET imaging of, 252(ab)
Thymidine phosphorylase, as proliferation-imaging agent, SPECT, 1218
Thyroid
accumulation of radioiodine in, organically bound radioiodine in breathing air, 1325(ab)
autonomous adenoma, imaging with ^{99m}Tc sestamibi/^{123}I subtraction, in an endemic goiter area, 1175
cultured epithelial cells, ^{131}I irradiation in, stunning of iodide transport, 828, 835
dysfunction in Down syndrome, children, 1327(ab)
follicular and nonfollicular lesions, fine-needle aspiration biopsy of, 1308(ab)
localization of tissue using radiation probes, 1127(le)
radioiodide uptake, formulation effects, 56
Thyroid cancer
anaplastic, expressing sodium iodide symporter, 430(ab)
diagnostic whole body scanning with 185 MBq, effect on ^{131}I therapy, 1311(ab)
differentiated
benefit from ^{131}I therapy, 1303(ab)
FDG gamma PET in, 1321(ab)
FDG PET, ^{201}Tl and ^{131}I combination in detection, 1315(ab)
healthy thyroid remnants and tumor tissue after radioiodine therapy, 1283(ab)
high-dose ^{131}I ablation therapy, 1427(ab)
hyperthyroidism in athyreotic patients, 1300(ab)
^{131}I ablation of remnants, dose effects, 1289(ab)
^{131}I sodium therapy, whole-body scan, 1287(ab)
^{131}I SPECT and CT, fusion images, 1291(ab)
loco-regional metastases, radioguided surgery, 293(ab)
pre- and post-treatment whole body scan with ^{131}I, 1323(ab)
radioiodine therapy, 292(ab)
recombinant human thyrotropin in management of, 1301(ab)
stages I and II, aggressive behavior in, 1304(ab)
staging with combined PET/CT systems, 1133(ab)
stunning effects, 1319(ab)
surgery, diagnostic scanning of remnant after, 468(ab)
therapeutic outcome of ^{131}I therapy, 291(ab)
^{201}Tl uptake into primary cell cultures, TSH effects, 145
elevated thyroglobulin, negative iodine scan and, 1318(ab)
FDG PET, ^{99m}Tc MIBI, and ^{131}I scintigraphy, comparison, 1312(ab)
^{123}I and ^{131}I comparison, 632
^{131}I doses, complete ablation of thyroid remnant and, 1292(ab)
imaging, FDG PET, 294(ab)
^{124}I production, PET/CT, 162(ab)
^{123}I scintigraphy at 5 and 24 hours, comparison, 72, 77
^{131}I therapy procedure guidelines for, 856
^{131}I treatment of, hospital discharge, 61
^{123}I whole-body scan, 466(ab)
^{131}I whole-body scanning findings, false-positives in, 207
lesion detectability, attenuation correction in FDG PET, 1284(ab)

long-term survival, 1297(ab)
management, ^{123}I TSH assessment of, 463(ab)
medullary
different imaging modalities, 467(ab)
lymph node metastases in, FDG PET, 66
radiolabeled peptides in, 289(ab)
receptor-targeted radiotherapy for, dose-escalation study, 126(ab)
metastatic
FDG and ^{11}C MET in detection of, 1306(ab)
FDG PET, effects of attenuation correction, 1314(ab)
FDG uptake, outcome by radioiodine and, 1331(ab)
isotretinoin for radioiodine therapy, 465(ab)
MR spectroscopy in, 46N(8)
papillary
ablation in, 455(ab)
camera-based FDG PET, 1316(ab)
poorly differentiated, sodium iodide symporter, adenovirus-mediated transfer of, 429(ab)
radioiodine negative, redifferentiation therapy, FDG PET monitoring of, 1295(ab)
radioiodine therapy, improved planning for, 714(le)
recombinant human TSH, preparation for radioiodine thyroid remnant ablation, 1482
recurrence
^{124}I and FDG PET for localization of, 1286(ab)
^{131}I in diagnostic scanning, 1285(ab)
remnant ablation, high and low doses of ^{131}I, 1320(ab)
sodium iodide symporter role in, 1188
transfected sodium iodide symporter gene expression in, all-trans retinoic acid effects, 484(ab)
tumor metabolism and proliferation, induced hypothyroidism effects, 1322(ab)
well-differentiated, ^{123}I scans for evaluation, 464(ab)
Thyroid disease
benign, optimization of radioiodine therapy, 1302(ab)
^{131}I therapy procedure guidelines for, 856
pinhole *versus* parallel hole collimator SPECT, phantom acquisitions, 1294(ab)
Thyroid hormones, iodine deficiency and consequent hypothyroidism, neonatal hyperbilirubinemia, 1305(ab)
Thyroid-stimulating hormone (TSH)
abnormal levels, ^{123}I scan and uptake in work-up of, 1330(ab)
effects on ^{201}Tl uptake into primary cell cultures, thyroid cancer, 145
^{123}I-labeled, assessment of thyroid cancer, 463(ab)
recombinant, management of differentiated thyroid cancer, 1301(ab)
Thyrotoxicosis, radioiodine efficacy in, enhancement by lithium carbonate, 1280(ab)
Thyrotropin
effects on ^{201}Tl uptake into primary cell cultures, thyroid cancer, 145
recombinant human, preparation for radioiodine thyroid remnant ablation, 1482
Time-of-Flight, improved coincidence timing accuracy in PET, 934(ab)
Tin-117m(4+)DTPA, preparation, therapeutic use, 1497(ab)
Tobacco smoking
cigar smoke particle deposition, ^{99m}Tc sulfur colloid study of smoke inhalation, 1412(ab)
effects on dopamine transporters, ADHD, 1396(ab)
endogenous dopamine release, imaging in mesolimbic and nigro-striatal dopamine systems, 1054(ab)
Toremifene, modulation of multidrug resistance, breast cancer, ^{99m}Tc sestamibi assessment of, 519, 526
Tracer kinetic modeling
alternative in PET studies, Volterra integral equation approach, 529(ab)
Monte Carlo simulation, using dynamic hybrid phantoms, 528(ab)
PET, web-based COM application, 1567(ab)
Transforming growth factor-β, signaling activity, imaging with PET, 249(ab)
Transmission scan time, quantitative evaluation, PET, 886(ab)
Transmission tomography, FDG, mismatch in spatial resolution, 45(ab)
Transplantation
bone marrow, renal function during, 1417(ab)
cardiac
clinical determinants of sympathetic reinnervation, 515(ab)
myocardial reinnervation after, 516(ab)
liver, biliary bicarbonate excretion after, HCO_3 PET, 476(ab)
renal
before and after, ^{99m}Tc DMSA SPECT, 584
differentiation of spurious erythrocytosis in, red cell mass estimation, 1073(ab)
early osteonecrosis of femoral head after, bone SPECT use in, 1006
scintigraphy and Doppler comparison in, 141
stem cell
in lymphoma, FDG PET after chemotherapy, 282(ab)
myeloablative radioimmunotherapy with ^{188}Re anti-CD66-mAb before, 1263(ab)
Treadmill stress testing, ambient exposure from minor spills, duct tape protection, 1551(ab)
Tuberculosis
detection, ^{99m}Tc INH infection imaging, 1349(ab)
diagnosis with FDG and ^{11}C acetate PET, 461(ab)
extrapulmonary, detection by FDG PET, 1350(ab)
skeletal, ^{99m}Tc MDP bone scintigraphy in, 479(ab)
therapy, ^{18}F FMISO PET use in, 459(ab)
Tumor, glucose metabolism, SSCVII squamous cell carcinoma or C3H mammary carcinoma, 940
Tumor detection, noninvasive extraction of blood time activity, PET oncology, 366(ab)
Tumor grading, non-Hodgkin's lymphoma, FDG PET and, 286(ab)
Tumor hypoxia, positive markers of, 2-nitroimidazole derivatives of cyclam, 837
Tumor imaging
biodistribution of ^{11}C MIQO, tumor-bearing rats, 1453(ab)
copper uptake by tumor cells, nitrosipine effects, 1500(ab)
F98 glioma cells, ^{18}F-labeled amino acid transport mechanisms, 1459(ab)
^{18}F FPT as PET tracer for, 1456(ab)
^{99m}Tc complexes for hypoxia, 1476(ab)
^{99m}Tc EC-deoxyglucose, comparison with FDG, 1478(ab)
^{99m}Tc labeled bombesin analogs for, 336(ab)
^{99m}Tc-labeled nitroimidazole analogs for hypoxia, 1475(ab)
^{99m}Tc MNZ-CAA as specific agent for hypoxia, 1474(ab)
^{99m}Tc peptides for, EGFRvIII positive tumors, 335(ab)
uptake of ^{123}I 3-IMT, preloading with amino acids and, 1201, 1207
Tumor pretargeting, ^{99m}Tc-labeled morpholino, mice, 384
Tumor-seeking agents, angiogenesis-targeted protein, receptor and, 437(ab)
Tumor targeting
antibody streptavidin conjugates, mouse model, 489(ab)
anti-CEA antibodies, pretargeting system for ^{90}Y delivery, 559(ab)
bivalent peptides, after pretargeting with a bispecific antibody, 558(ab)
conventional, ^{99m}Tc morpholino pretargeting in mice-A comparison, 1084(ab)
magnetically targeted delivery, ^{90}Y ABz-DOTA, for cancer therapy, 1486(ab)
octreotate, pharmacological properties of, 1528(ab)
Salmonella-based, cancer therapy and imaging, 251(ab)
^{99m}Tc EC-endostatin, imaging angiogenesis with, 435(ab)
^{99m}Tc-labeled antibody fragments, 557(ab)
tumor-associated folate receptor, ^{111}In complexes, 1481(ab)
^{90}Y DPC-A80350, C-NEU oncomouse mammary tumor model, 1080(ab)
^{89}Zr Df-folate, malignant cell lines, 1482(ab)
Tumor-to-background ratio, PET whole-body images, reducing loss of image quality, 1054

U

United States Pharmacopeia (USP)
drug information available on SNM web site, 41N(4)
procedures for FDG injection, quality assurance, 1495
Urinary bladder
neuropathic, critical volumes in, ^{99m}Tc MAG3 scintigraphy, 1415(ab)
vesico-ureteral reflux, radiography for evaluation, girls, 1386(ab)
Urinary tract infection, febrile, DMSA study during, 1419(ab)

V

Vagus nerve stimulation
acute and chronic, perfusion SPECT changes after, epilepsy, 733
refractory epilepsy, dynamic $C^{15}O_2$ PET, 544(ab)
Vascular endothelial growth factor receptors
cellular uptake and biodistribution, ^{99m}Tc EC-angiostatin, 1471(ab)
modified LDL and, monocytes and endothelial cells, 706(ab)
Vascular permeability, radioimmunotherapy in adenocarcinoma, potentiation with C5a agonist, 957
Vascular targeting therapy, with ^{18}F FDG, 440(ab)
Vasculogenesis, inflammatory breast cancer, radioimmunotherapy in, 554(ab)
Vasospasm, ^{123}I BMIPP and MIBG SPECT images, 1476
Venous thrombosis
lower extremity, ^{99m}Tc Apcitide diagnosis of, 1405(ab)
negative ^{99m}Tc AcuTect scans, at risk patients, 1413(ab)
pulmonary embolism relations, radionuclide techniques for assessment, 1403(ab)
Ventilation-perfusion imaging
after introduction of pulmonary CT angiography, tertiary care center, 1615(ab)
dual isotope ^{81M}Kr/^{99m}Tc, practical considerations for, 1411(ab)
lung
diagnosis of pulmonary embolism, 587(ab)
obese patients, 1407(ab)
lung scintigraphy, Gestalt interpretation, 1317
lung SPECT, artificially embolized pigs, 640, 648
ratio, in pulmonary embolism, 1596
registration, lung, comparison with planar, 1561(ab)
SPECT lung, image histogram analysis, 527(ab)
Ventricular dysfunction, low-dose dobutamine gated SPECT ^{201}Tl, myocardial infarction, 338(ab)
Ventricular function, after CABG, gated SPECT assessment of, 589
Ventricular repolarization, exercise training effects, chronic heart failure, 773
Vesico-ureteral reflux, radiography for evaluation, girls, 1386(ab)
Virtual reality, cerebral activation during, H_2O^{15} PET, 1020(ab)
Vitronectin receptor antagonist
DOTA-conjugated nonpeptide, ^{90}Y labeling, 1495(ab)
DPC-A80350, radiation dosimetry of, 1426(ab)
Volume visualization, organ, nuclear imaging procedures, 1568(ab)

W

Watershed transform, edge-preserving smooth filter with, Rain Algorithm, 845(ab)
Whole-body scanning (WBS), ^{131}I, false-positive findings in, 207
Wilson's disease
nigral damage in, ^{99m}Tc TRODAT-1 SPECT study, 66(ab)
rat model, ^{99m}Tc mebrofenin evaluation of liver, 246
Wolfgang Becker: Personal remembrance, 15N(7)
Working memory, clinical application of neuroactivation probe, SPECT, 1426
World Federation of Nuclear Medicine and Biology (WFNMB), programs and tours for 2002, 19N(2)

World Wide Webb (WWW), diagnostic and nuclear medicine image display, 1566(ab)

X

Xenon-133, SPECT, osteoarthritis pain with ROI and SPM methods, 1024(ab)
Xerostomia, after radiotherapy, head and neck cancer, 1288(ab)

Y

Yttrium, DOTATOC and DOTATATE labeled with, biodistribution in neuroendocrine tumors, 442(ab)
Yttrium-86, purification method, 1525(ab)
Yttrium-86 HER, pharmacokinetics of, ovarian cancer model, 555(ab)
Yttrium-90
^{111}In comparison, peptide receptor radionuclide therapy, 121(ab)
morpholino labeled with, comparison with ^{111}In and ^{99m}Tc, 1529(ab)
skin patches, treatment of superficial tumors, 1278(ab)
therapy evaluation, liver cancer, 1553(ab)
in tumors, radiation dose distributions in normal tissue adjacent to, 1110
Yttrium-90 ABz-DOTA, magnetically targeted delivery, cancer therapy, 1486(ab)
Yttrium-90 biotin, pretargeted radioimmunotherapy, 1485(ab)
Yttrium-90 DOTA, increased therapeutic index for RIT, 420(ab)
Yttrium-90 DOTA-huJ591, radioimmunotherapy, prostate cancer, 576(ab)
Yttrium-90 DOTATOC
peptide receptor radionuclide therapy with, 617
tumor response, neuroendocrine tumors, 1266(ab)
tumor response to, neuroendocrine tumors, 610
Yttrium-90 DPC-A80350, therapy, C-NEU oncomouse mammary tumor model, 1080(ab)
Yttrium-90 HER2, uptake studies, MCF-7 and SKBR-3 cell lines, 1494(ab)
Yttrium-90 ibritumomab tiuxetan, radioimmunotherapy, non-Hodgkin's lymphoma, 267
Yttrium-90 lanreotide
biodistribution, ^{111}In octreotide in prediction of, 1268(ab)
given intra-arterially, neuroendocrine tumors, 1270(ab)
therapy, somatostatin receptor-positive tumors, 122(ab)
Yttrium-90 octreotide, ^{177}Lu combination, for radionuclide therapy, 446(ab)
Yttrium-90 SMT487, therapy, somatostatin receptor-positive neuroendocrine tumors, 120(ab)
Yttrium-90 TheraSphere
evaluation of FDG treatment, colorectal liver metastases, 1276(ab)
treatment effectiveness, statistical segmentation, hepatic cancer, 371(ab)
Yttrium-90 zevalin, radiation exposure from, specific via and syringe shields, 164(ab)

Z

Zirconium-89 Df-folate, folate receptor targeting, malignant cell lines, 1482(ab)